<SEC-DOCUMENT>0001104659-25-122536.txt : 20251218
<SEC-HEADER>0001104659-25-122536.hdr.sgml : 20251218
<ACCEPTANCE-DATETIME>20251218160555
ACCESSION NUMBER:		0001104659-25-122536
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		20
FILED AS OF DATE:		20251218
DATE AS OF CHANGE:		20251218

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COGNITION THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001455365
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-292240
		FILM NUMBER:		251583076

	BUSINESS ADDRESS:	
		STREET 1:		2500 WESTCHESTER AVE
		CITY:			PURCHASE
		STATE:			NY
		ZIP:			10577
		BUSINESS PHONE:		412-481-2210

	MAIL ADDRESS:	
		STREET 1:		2500 WESTCHESTER AVE
		CITY:			PURCHASE
		STATE:			NY
		ZIP:			10577

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COGNITION THERAPUTICS INC
		DATE OF NAME CHANGE:	20090204
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>tm2533585-1_s3.htm
<DESCRIPTION>S-3
<TEXT>
<html>
  <head>
    <title>tm2533585-1_s3 - none - 6.8166511s</title>
  </head>
  <body style="margin-left:auto;margin-right:auto;width:595.31pt;">
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:27pt;width:541.31pt;">
        <div style="text-align:center; width:541.31pt; line-height:9.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.45pt;">As filed with the Securities and Exchange Commission on December 18, 2025</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.18pt;"> </font>
        </div>
        <div style="margin-top:-0.2pt; text-align:right; width:541.31pt; line-height:9.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.45pt;">Registration No. 333-&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</font>&#8203;</div>
        <div style="margin-top:2.3pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 2.3pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:1.79pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 1.79pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:5.8pt; text-align:center; width:541.31pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:14pt;">
          <font style="letter-spacing:0.7pt;">UNITED STATES</font>
          <br >
          <font style="letter-spacing:0.7pt;">SECURITIES AND EXCHANGE COMMISSION</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:-2.2pt; text-align:center; width:541.31pt; line-height:9.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.45pt;">Washington, D.C. 20549</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.18pt;"> </font>
        </div>
        <div style="margin-top:5.3pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 40.024%; margin-right: 40.024%; margin-top: 5.3pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:6.8pt; text-align:center; width:541.31pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:14pt;">
          <font style="letter-spacing:0.7pt;">FORM S-3</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:0.79pt; text-align:center; width:541.31pt; line-height:9.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.45pt;">REGISTRATION STATEMENT</font>
          <br >
          <font style="letter-spacing:0.45pt;">UNDER</font>
          <br >
          <font style="letter-spacing:0.45pt;">THE SECURITIES ACT OF 1933</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.18pt;"> </font>
        </div>
        <div style="margin-top:5.3pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 40.024%; margin-right: 40.024%; margin-top: 5.3pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:6.8pt; text-align:center; width:541.31pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:14pt;">
          <font style="letter-spacing:0.7pt;">Cognition Therapeutics, Inc.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:-0.2pt; text-align:center; width:541.31pt; line-height:8.5pt;font-size:8pt;">
          <font style="letter-spacing:-0.032pt;">(Exact name of Registrant as specified in its charter)</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="margin-top:5.29pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 40.024%; margin-right: 40.024%; margin-top: 5.28999999999999pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <table style="width:541.31pt;height:28pt;margin-top:4.30000000000001pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:9pt;">
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:9pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.53pt 0pt 0.5pt 0pt; width:264.66pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.45pt;">Delaware</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.53pt 0pt 0.5pt 0pt; width:264.65pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.45pt;">13-4365359</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11.25pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:264.66pt;">
              <div style="text-align:center; line-height:8pt;">
                <font style="letter-spacing:-0.032pt;">(State or other jurisdiction of</font>
                <br >
                <font style="letter-spacing:-0.032pt;">incorporation or organization) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:264.65pt;">
              <div style="text-align:center; line-height:9pt;">
                <font style="letter-spacing:-0.032pt;">(I.R.S. Employer</font>
                <br >
                <font style="letter-spacing:-0.032pt;">Identification No.)</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:4pt; text-align:center; width:541.31pt; line-height:9.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.45pt;">2500 Westchester Ave.</font>
          <br >
          <font style="letter-spacing:0.45pt;">Purchase, NY 10577</font>
          <br >
          <font style="letter-spacing:0.45pt;">(412) 481-2210</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.18pt;"> </font>
        </div>
        <div style="margin-top:-1.2pt; text-align:center; width:541.31pt; line-height:8.5pt;font-size:8pt;">
          <font style="letter-spacing:-0.032pt;">(Address, including zip code, and telephone number, including area code, of Registrant&#8217;s principal executive offices)</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="margin-top:6.3pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 40.024%; margin-right: 40.024%; margin-top: 6.30000000000001pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:5.8pt; text-align:center; width:541.31pt; line-height:9.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.45pt;">Lisa Ricciardi</font>
          <br >
          <font style="letter-spacing:0.45pt;">President and Chief Executive Officer</font>
          <br >
          <font style="letter-spacing:0.45pt;">Cognition Therapeutics, Inc.</font>
          <br >
          <font style="letter-spacing:0.45pt;">2500 Westchester Ave.</font>
          <br >
          <font style="letter-spacing:0.45pt;">Purchase, NY 10577</font>
          <br >
          <font style="letter-spacing:0.45pt;">(412) 481-2210</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.18pt;"> </font>
        </div>
        <div style="margin-top:-1.2pt; text-align:center; width:541.31pt; line-height:8.5pt;font-size:8pt;">
          <font style="letter-spacing:-0.032pt;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="margin-top:5.3pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 40.024%; margin-right: 40.024%; margin-top: 5.30000000000001pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:5.79pt; text-align:center; width:541.31pt; line-height:9.5pt;font-style:italic;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.45pt;">Copies to:</font><font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.18pt;"> </font>
        </div>
        <div style="margin-top:4pt; text-align:center; width:541.31pt; line-height:9.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.45pt;">Rachael M. Bushey, Esq.</font>
          <br >
          <font style="letter-spacing:0.45pt;">Justin Platt, Esq.</font>
          <br >
          <font style="letter-spacing:0.45pt;">Goodwin Procter LLP</font>
          <br >
          <font style="letter-spacing:0.45pt;">3025 John F Kennedy Blvd</font>
          <br >
          <font style="letter-spacing:0.45pt;">Philadelphia, PA 19104</font>
          <br >
          <font style="letter-spacing:0.45pt;">(445) 207-7800</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.18pt;"> </font>
        </div>
        <div style="margin-top:5.3pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 40.024%; margin-right: 40.024%; margin-top: 5.29999999999995pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:5.8pt; width:541.31pt; line-height:9.5pt;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="font-weight:bold;letter-spacing:0.45pt;">Approximate date of commencement of proposed sale to the public</font><font style="font-family:Arial, Helvetica, sans-serif;letter-spacing:-0.036pt;">: From time to time after the effective date of this Registration Statement.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.18pt;"> </font>
        </div>
        <div style="margin-top:3pt; width:541.31pt; line-height:9.5pt;">
          <font style="letter-spacing:-0.036pt;">If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. </font><font style="letter-spacing:-0.342pt;">&#9744;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.18pt;"> </font>
        </div>
        <div style="margin-top:3pt; width:541.31pt; line-height:9.5pt;">
          <font style="letter-spacing:-0.036pt;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act of 1933, as amended, or the Securities Act, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. </font><font style="letter-spacing:-0.342pt;">&#9746;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.18pt;"> </font>
        </div>
        <div style="margin-top:3pt; width:541.31pt; line-height:9.5pt;">
          <font style="letter-spacing:-0.036pt;">If this Form is filed to register additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;</font><font style="letter-spacing:-0.342pt;">&#9744; </font>
        </div>
        <div style="margin-top:3pt; width:541.31pt; line-height:9.5pt;">
          <font style="letter-spacing:-0.036pt;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. </font><font style="letter-spacing:-0.342pt;">&#9744;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.18pt;"> </font>
        </div>
        <div style="margin-top:3pt; width:541.31pt; line-height:9.5pt;">
          <font style="letter-spacing:-0.036pt;">If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule&#160;462(e) under the Securities Act, check the following box. </font><font style="letter-spacing:-0.342pt;">&#9744;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.18pt;"> </font>
        </div>
        <div style="margin-top:3pt; width:541.31pt; line-height:9.5pt;">
          <font style="letter-spacing:-0.036pt;">If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule&#160;413(b) under the Securities Act, check the following box. </font><font style="letter-spacing:-0.342pt;">&#9744;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.18pt;"> </font>
        </div>
        <div style="margin-top:3pt; width:541.31pt; line-height:9.5pt;">
          <font style="letter-spacing:-0.036pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.18pt;"> </font>
        </div>
        <table style="width:501.31pt;margin-left:20pt;margin-top:3.79999999999995pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9pt;">
          <tr style="line-height:8.97000000000003pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.53pt 0pt 0.5pt 0pt; width:244.66pt;">
              <div style=" float:left; line-height:9pt; text-align:left; width:108pt;white-space:nowrap;">
                <font style="letter-spacing:-0.036pt;">Large accelerated filer</font>
                <br >
              </div>
              <div style=" line-height:9pt; text-align:left; margin-left:108pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:-0.342pt;">&#9744; </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.53pt 0pt 0.5pt 0pt; width:244.65pt;">
              <div style=" float:left; line-height:9pt; text-align:left; width:132pt;white-space:nowrap;">
                <font style="letter-spacing:-0.036pt;">Accelerated filer</font>
                <br >
              </div>
              <div style=" line-height:9pt; text-align:left; margin-left:132pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:-0.342pt;">&#9744; </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11.34pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0.45pt 0pt 0.5pt 0pt; width:244.66pt;">
              <div style=" float:left; line-height:9pt; text-align:left; width:108pt;white-space:nowrap;">
                <font style="letter-spacing:-0.036pt;">Non-accelerated filer</font>
                <br >
              </div>
              <div style=" line-height:9pt; text-align:left; margin-left:108pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:-0.342pt;">&#9746; </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0.45pt 0pt 0.5pt 0pt; width:244.65pt;">
              <div style=" float:left; line-height:9pt; text-align:left; width:132pt;white-space:nowrap;">
                <font style="letter-spacing:-0.036pt;">Smaller reporting company</font>
                <br >
              </div>
              <div style=" line-height:9pt; text-align:left; margin-left:132pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:-0.342pt;">&#9746; </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
              <div style=" float:left; line-height:9pt; margin-top:2.37pt; margin-bottom:0pt; text-align:left; width:132pt;white-space:nowrap;">
                <font style="letter-spacing:-0.036pt;">Emerging growth company</font>
                <br >
              </div>
              <div style=" margin-top:2.37pt; margin-bottom:0pt; line-height:9pt; text-align:left; margin-left:132pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:-0.342pt;">&#9746;</font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:6pt; width:541.31pt; line-height:9.5pt;">
          <font style="letter-spacing:-0.036pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act. </font><font style="letter-spacing:-0.342pt;">&#9744;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.18pt;"> </font>
        </div>
        <div style="margin-top:3pt; width:541.31pt; line-height:9.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.45pt;">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine.</font>
        </div>
        <div style="margin-top:3.29pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 3.29000000000008pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:1.8pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 1.79999999999995pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">EXPLANATORY NOTE</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:18pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">This registration statement contains two prospectuses:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">a base prospectus, which covers the offering, issuance and sale by us of up to $300,000,000 in the aggregate of our common stock, preferred stock, debt securities, warrants to purchase our common stock, preferred stock or debt securities, subscription rights to purchase our common stock, preferred stock or debt securities and/or&#160;units consisting of some or all of these securities; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">a sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering price of $75,000,000 of our common stock that may be issued and sold under a sales agreement dated December </font><font style="letter-spacing:-0.361pt;">18</font><font style="letter-spacing:-0.038pt;">, 2025, with Jefferies LLC, or Jefferies.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">The base prospectus immediately follows this explanatory note. Under our base prospectus included in the shelf registration statement, we may offer shares of our common stock having an aggregate offering price of up to $300,000,000. The specific terms of any securities to be offered pursuant to the base prospectus will be specified in a prospectus supplement to the base prospectus. The sales agreement prospectus immediately follows the base prospectus. Upon termination of the sales agreement with Jefferies, any portion of the $75,000,000 included in the sales agreement offering prospectus that remains unsold pursuant to the sales agreement will be available for sale in other offerings pursuant to the base prospectus and a corresponding prospectus supplement, and if no shares are sold under the sales agreement, the full $75,000,000 of securities not sold may be sold in other offerings pursuant to the base prospectus and a corresponding prospectus supplement.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="position:relative;overflow:hidden;min-height:775.71pt;page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="position:absolute;top:738.85pt;left:48.64pt;height:30pt;width:706.02pt;transform-origin:0pt -0pt;transform:rotate(-90deg) translate(0%, 0%);">
        <div style="width:706pt; line-height:9.5pt;color:#F7505F;font-size:8pt;">
          <font style="letter-spacing:-0.032pt;">The information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</font><font style="color:#000000;letter-spacing:-0.304pt;"> </font>
          <br >
        </div>
      </div>
      <div style="margin-top:27.85pt;min-height:706pt;margin-bottom:21.86pt;margin-left:87.66pt;width:456pt;">
        <div style="text-align:right; width:456pt; line-height:12.5pt;color:#F7505F;">
          <font style="text-transform:uppercase;letter-spacing:-0.38pt;">Subject to Completion, dated December 18, 2025.</font>&#8203;</div>
        <div style="margin-top:6pt; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.5pt;">PROSPECTUS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:18.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:16pt;">
          <font style="letter-spacing:0.8pt;">$300,000,000</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;font-size:10pt;">&#8203;<font style="letter-spacing:0.2pt;"> </font></font>
        </div>
        <div style="position:relative;margin-top:14.5pt; text-align:center; width:456pt;">
          <img src="lg_cognition-4c.jpg" alt="[MISSING IMAGE: lg_cognition-4c.jpg]" height="80" width="321" >
        </div>
        <div style="margin-top:17.5pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:16pt;">
          <font style="letter-spacing:0.8pt;">Common Stock</font>
          <br >
          <font style="letter-spacing:0.8pt;">Preferred Stock</font>
          <br >
          <font style="letter-spacing:0.8pt;">Debt Securities</font>
          <br >
          <font style="letter-spacing:0.8pt;">Warrants</font>
          <br >
          <font style="letter-spacing:0.8pt;">Units</font>
          <br >
          <font style="letter-spacing:0.8pt;">Subscription Rights</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;font-size:10pt;">&#8203;<font style="letter-spacing:0.2pt;"> </font></font>
        </div>
        <div style="margin-top:6pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.04pt;">We may offer and sell up to $300,000,000 in the aggregate of the securities identified above from time to time in one or more offerings, separately or together in any combination, in one or more classes or series, in amounts, at prices and on terms to be determined at the time of any such offering. This prospectus provides you with a general description of the securities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.04pt;">Each time we offer and sell securities, we will provide a supplement to this prospectus that contains specific information about the offering and the amounts, prices and terms of the securities. The prospectus supplement may also add, update or change information contained in this prospectus with respect to that offering. You should carefully read this prospectus and the applicable prospectus supplement before you invest in any of our securities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.04pt;">We may offer and sell the securities described in this prospectus and any prospectus supplement to or through one or more underwriters, dealers and agents, or directly to purchasers, or through a combination of these methods. If any underwriters, dealers or agents are involved in the sale of any of the securities, their names and any applicable purchase price, fee, commission or discount arrangement between or among them will be set forth, or will be calculable from the information set forth, in the applicable prospectus supplement. See the sections of this prospectus entitled &#8220;About this Prospectus&#8221; and &#8220;Plan of Distribution&#8221; for more information. No securities may be sold without delivery of this prospectus and the applicable prospectus supplement describing the method and terms of the offering of such securities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.5pt;">We are an &#8220;emerging growth company&#8221; and &#8220;smaller reporting company&#8221; under the federal securities laws and, as such, are subject to reduced public company reporting requirements. See &#8220;About the Company-Implications of Being an Emerging Growth Company and Smaller Reporting Company.&#8221;</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.5pt;">INVESTING IN OUR SECURITIES INVOLVES RISKS. SEE THE &#8220;RISK FACTORS&#8221; ON PAGE <a href="#tRIFA">10</a> OF THIS PROSPECTUS AND ANY SIMILAR SECTION CONTAINED IN THE APPLICABLE PROSPECTUS SUPPLEMENT OR IN ANY DOCUMENTS INCORPORATED BY REFERENCE HEREIN AND THEREIN CONCERNING FACTORS YOU SHOULD CONSIDER BEFORE INVESTING IN OUR SECURITIES.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.04pt;">Our common stock is listed on The Nasdaq Capital Market, or Nasdaq, under the symbol &#8220;CGTX.&#8221; On December </font><font style="letter-spacing:-0.38pt;">16</font><font style="letter-spacing:-0.04pt;">, 2025, the last reported sale price of our common stock on Nasdaq was $</font><font style="letter-spacing:-0.38pt;">1.52</font><font style="letter-spacing:-0.04pt;"> per share.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.5pt;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</font>
        </div>
        <div style="margin-top:11pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:10.5pt; text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.5pt;">The date of this prospectus is&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2025</font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:346pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;margin-top:0pt;border-collapse: collapse;border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <tr style="line-height:10pt;min-height:23.75pt;height:23.75pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:11.5pt 0pt 2.5pt 0pt; width:423pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.5pt;">Table of Contents</font><font style="font-size:8pt;">&#8203;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:423pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">page</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tATP"><font style="letter-spacing:-0.361pt;">A</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">BOUT</font><font style="letter-spacing:-0.361pt;"> T</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">HIS</font><font style="letter-spacing:-0.361pt;"> P</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">ROSPECTUS</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.695pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tATP">1</a></font><a href="#tATP"> </a>
            </td>
            <td style="padding:0pt;padding-left:4.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tWYCF"><font style="letter-spacing:-0.361pt;">W</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">HERE</font><font style="letter-spacing:-0.361pt;"> Y</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">OU</font><font style="letter-spacing:-0.361pt;"> C</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">AN</font><font style="letter-spacing:-0.361pt;"> F</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">IND</font><font style="letter-spacing:-0.361pt;"> M</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">ORE</font><font style="letter-spacing:-0.361pt;"> I</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">NFORMATION</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.695pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tWYCF">2</a></font><a href="#tWYCF"> </a>
            </td>
            <td style="padding:0pt;padding-left:4.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tIOCI"><font style="letter-spacing:-0.361pt;">I</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">NCORPORATION</font><font style="letter-spacing:-0.361pt;"> </font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">OF</font><font style="letter-spacing:-0.361pt;"> C</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">ERTAIN</font><font style="letter-spacing:-0.361pt;"> I</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">NFORMATION</font><font style="letter-spacing:-0.361pt;"> </font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">BY</font><font style="letter-spacing:-0.361pt;"> R</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">EFERENCE</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.695pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tIOCI">3</a></font><a href="#tIOCI"> </a>
            </td>
            <td style="padding:0pt;padding-left:4.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCNRF"><font style="letter-spacing:-0.361pt;">C</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">AUTIONARY</font><font style="letter-spacing:-0.361pt;"> N</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">OTE</font><font style="letter-spacing:-0.361pt;"> R</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">EGARDING</font><font style="letter-spacing:-0.361pt;"> F</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">ORWARD</font><font style="letter-spacing:-0.361pt;">-L</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">OOKING</font><font style="letter-spacing:-0.361pt;"> S</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">TATEMENTS</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.695pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tCNRF">4</a></font><a href="#tCNRF"> </a>
            </td>
            <td style="padding:0pt;padding-left:4.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tATC"><font style="letter-spacing:-0.361pt;">A</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">BOUT</font><font style="letter-spacing:-0.361pt;"> T</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">HE</font><font style="letter-spacing:-0.361pt;"> C</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">OMPANY</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.695pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tATC">6</a></font><a href="#tATC"> </a>
            </td>
            <td style="padding:0pt;padding-left:4.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tRIFA"><font style="letter-spacing:-0.361pt;">R</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">ISK</font><font style="letter-spacing:-0.361pt;"> F</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">ACTORS</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.695pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tRIFA">10</a></font><a href="#tRIFA"> </a>
            </td>
            <td style="padding:0pt;padding-left:4.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUOP"><font style="letter-spacing:-0.361pt;">U</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">SE</font><font style="letter-spacing:-0.361pt;"> </font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">OF</font><font style="letter-spacing:-0.361pt;"> P</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">ROCEEDS</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.695pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tUOP">11</a></font><a href="#tUOP"> </a>
            </td>
            <td style="padding:0pt;padding-left:4.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOCS"><font style="letter-spacing:-0.361pt;">D</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">ESCRIPTION</font><font style="letter-spacing:-0.361pt;"> </font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">OF</font><font style="letter-spacing:-0.361pt;"> C</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">APITAL</font><font style="letter-spacing:-0.361pt;"> S</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">TOCK</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.695pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tDOCS">12</a></font><a href="#tDOCS"> </a>
            </td>
            <td style="padding:0pt;padding-left:4.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDODS"><font style="letter-spacing:-0.361pt;">D</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">ESCRIPTION OF</font><font style="letter-spacing:-0.361pt;"> D</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">EBT</font><font style="letter-spacing:-0.361pt;"> S</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">ECURITIES</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.695pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tDODS">16</a></font><a href="#tDODS"> </a>
            </td>
            <td style="padding:0pt;padding-left:4.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOW"><font style="letter-spacing:-0.361pt;">D</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">ESCRIPTION</font><font style="letter-spacing:-0.361pt;"> </font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">OF</font><font style="letter-spacing:-0.361pt;"> W</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">ARRANTS</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.695pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tDOW">23</a></font><a href="#tDOW"> </a>
            </td>
            <td style="padding:0pt;padding-left:4.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOU"><font style="letter-spacing:-0.361pt;">D</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">ESCRIPTION</font><font style="letter-spacing:-0.361pt;"> </font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">OF</font><font style="letter-spacing:-0.361pt;"> U</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">NITS</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.695pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tDOU">25</a></font><a href="#tDOU"> </a>
            </td>
            <td style="padding:0pt;padding-left:4.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOOS"><font style="letter-spacing:-0.361pt;">D</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">ESCRIPTION</font><font style="letter-spacing:-0.361pt;"> </font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">OF</font><font style="letter-spacing:-0.361pt;"> O</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">UR</font><font style="letter-spacing:-0.361pt;"> S</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">UBSCRIPTION</font><font style="letter-spacing:-0.361pt;"> R</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">IGHTS</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.695pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tDOOS">26</a></font><a href="#tDOOS"> </a>
            </td>
            <td style="padding:0pt;padding-left:4.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tGLSE"><font style="letter-spacing:-0.361pt;">G</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">LOBAL</font><font style="letter-spacing:-0.361pt;"> S</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">ECURITIES</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.695pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tGLSE">27</a></font><a href="#tGLSE"> </a>
            </td>
            <td style="padding:0pt;padding-left:4.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPOD"><font style="letter-spacing:-0.361pt;">P</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">LAN OF</font><font style="letter-spacing:-0.361pt;"> D</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">ISTRIBUTION</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.695pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tPOD">31</a></font><a href="#tPOD"> </a>
            </td>
            <td style="padding:0pt;padding-left:4.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLEMA"><font style="letter-spacing:-0.361pt;">L</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">EGAL</font><font style="letter-spacing:-0.361pt;"> M</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">ATTERS</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.695pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tLEMA">33</a></font><a href="#tLEMA"> </a>
            </td>
            <td style="padding:0pt;padding-left:4.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="border-bottom:0.75pt solid #000000; ;padding:3pt 0pt 12pt 0pt; width:423pt;text-align:left;">
              <a href="#tEXP"><font style="letter-spacing:-0.361pt;">E</font><font style="text-transform:lowercase;letter-spacing:-0.361pt;">XPERTS</font></a>
            </td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.695pt;width:0pt;border-bottom:0.75pt solid #000000; ;">&#8203;</td>
            <td style="padding:3pt 0pt 12pt 0pt;border-bottom:0.75pt solid #000000; ; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 12pt 0pt;border-bottom:0.75pt solid #000000; ; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tEXP">34</a></font>
            </td>
            <td style="padding:0pt;padding-left:4.695pt;width:0pt;border-bottom:0.75pt solid #000000; ;">&#8203;</td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.036pt;">i</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tATP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:30pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">ABOUT THIS PROSPECTUS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">This prospectus is part of a registration statement that we filed with the U.S. Securities and Exchange Commission, or the SEC, using a &#8220;shelf&#8221; registration process. By using a shelf registration statement, we may sell securities from time to time in any combination and in one or more offerings up to a total dollar amount of $300,000,000 as described in this prospectus.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">This prospectus provides you only with a general description of the securities that we may offer. Each time that we offer and sell securities, we will provide a prospectus supplement to this prospectus that contains specific information about the securities being offered and sold and the specific terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement or free writing prospectus may also add, update or change information contained or incorporated by reference in this prospectus with respect to that offering. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement or free writing prospectus, you should rely on the prospectus supplement or free writing prospectus, as applicable. Before purchasing any securities, you should carefully read both this prospectus and the applicable prospectus supplement (and any applicable free writing prospectuses), together with the additional information described under the headings &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Certain Information by Reference&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">We have not authorized anyone to provide you with any information or to make any representations other than those contained in, or incorporated by reference in, this prospectus, any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for and can provide no assurance as to the reliability of any other information that others may give you. We will not make an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus and any applicable prospectus supplement is accurate only as of the date on its respective cover, that the information appearing in any applicable free writing prospectus is accurate only as of the date of that free writing prospectus, and that any information incorporated by reference herein and therein is accurate only as of the date of the document incorporated by reference, unless we indicate otherwise. Our business, financial condition, results of operations and prospects may have changed since those dates.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">When we refer to &#8220;Cognition,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and the &#8220;Company&#8221; in this prospectus, we mean Cognition Therapeutics, Inc., and its wholly owned subsidiary unless otherwise specified. When we refer to &#8220;you,&#8221; we mean the potential holders of the applicable series of securities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">&#8220;Cognition Therapeutics,&#8221; the &#8220;Cognition Therapeutics&#8221; logo, and other trademarks, trade names, or service marks of Cognition Therapeutics, Inc. appearing in this prospectus, any prospectus supplement and any free writing prospectus are the property of Cognition Therapeutics, Inc. All other trademarks, trade names, and service marks appearing in this prospectus, any prospectus supplement and any free writing prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus may be referred to without the </font><font style=" position:relative; bottom:4pt;font-size:7pt;letter-spacing:-0.266pt;">&#174;</font><font style="letter-spacing:-0.038pt;"> and </font><font style="letter-spacing:-0.361pt;">&#8482;</font><font style="letter-spacing:-0.038pt;"> symbols, but such references should not be construed as any indicator that their respective owners will not assert their rights thereto. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tWYCF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:458pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">WHERE YOU CAN FIND MORE INFORMATION</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">This prospectus is part of the registration statement on Form S-3 filed with the SEC under the Securities Act of 1933, as amended, or the Securities Act, and does not contain all the information set forth in the registration statement. Whenever a reference is made in this prospectus to any of our contracts, agreements or other documents, the reference may not be complete and you should refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated herein by reference for a copy of such contract, agreement or other document.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">We are currently subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and in accordance therewith file periodic reports, proxy statements and other information with the SEC. Our SEC filings are available to you on the SEC&#8217;s website at http://www.sec.gov and in the &#8220;Investors&#8221; section of our website at www.cogrx.com. Our website and the information contained on that site, or connected to that site, are not incorporated into and are not a part of this prospectus. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tIOCI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:110pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">The SEC allows us to &#8220;incorporate by reference&#8221; information from other documents that we file with it, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we filed with the SEC prior to the date of this prospectus, while information that we file later with the SEC will automatically update and supersede the information in this prospectus. We incorporate by reference into this prospectus and the registration statement of which this prospectus is a part the information or documents listed below that we have filed with the SEC:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">Our <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1455365/000155837025003341/cgtx-20241231x10k.htm">Annual Report on Form 10-K for the year ended December&#160;31, 2024 filed with the SEC on March&#160;20, 2025</a>, and the information specifically incorporated by reference into our Annual Report on Form 10-K for the year ended December&#160;31, 2024 from our <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1455365/000110465925040193/tm252486-4_def14a.htm">Definitive Proxy Statement on Form DEF&#160;14-A, filed with the SEC on April&#160;28, 2025</a></font><font style="letter-spacing:-0.361pt;">;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">Our Quarterly Reports on Form 10-Q for the fiscal quarters ended March&#160;31, 2025, June&#160;30, 2025 and September&#160;30, 2025, filed with the SEC on <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1455365/000155837025006612/cgtx-20250331x10q.htm">May&#160;7, 2025</a></font><font style="letter-spacing:-0.361pt;">, </font><font style="letter-spacing:-0.038pt;"><a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1455365/000155837025010771/cgtx-20250630x10q.htm">August&#160;7, 2025</a> and <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1455365/000110465925107402/cgtx-20250930x10q.htm">November&#160;6, 2025</a></font><font style="letter-spacing:-0.361pt;">, </font><font style="letter-spacing:-0.038pt;">respectively;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">Our Current Reports on Form 8-K filed with the SEC on <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1455365/000110465925006732/tm254703d1_8k.htm">January&#160;28, 2025</a></font><font style="letter-spacing:-0.361pt;">, </font><font style="letter-spacing:-0.038pt;"><a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1455365/000110465925017178/tm257579d1_8k.htm">February&#160;26, 2025</a></font><font style="letter-spacing:-0.361pt;">, </font><font style="letter-spacing:-0.038pt;"><a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1455365/000110465925022969/tm258979d1_8k.htm">March&#160;12, 2025</a></font><font style="letter-spacing:-0.361pt;">, </font><font style="letter-spacing:-0.038pt;"><a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1455365/000110465925045886/tm2514313d1_8k.htm">May&#160;8, 2025, </a><a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1455365/000110465925055089/tm2516681d1_8k.htm">June&#160;2, 2025</a></font><font style="letter-spacing:-0.361pt;">, </font><font style="letter-spacing:-0.038pt;"><a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1455365/000110465925055717/tm2516905d1_8k.htm">June&#160;3, 2025</a></font><font style="letter-spacing:-0.361pt;">, </font><font style="letter-spacing:-0.038pt;"><a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1455365/000110465925061142/tm2518439d2_8k.htm">June&#160;20, 2025</a></font><font style="letter-spacing:-0.361pt;">, </font><font style="letter-spacing:-0.038pt;"><a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1455365/000110465925083059/tm2524388d1_8k.htm">August&#160;26, 2025</a></font><font style="letter-spacing:-0.361pt;">, </font><font style="letter-spacing:-0.038pt;"><a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1455365/000110465925084845/tm2524576d2_8k.htm">August&#160;28, 2025</a> and <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1455365/000110465925089737/tm2525997d1_8k.htm">September&#160;15, 2025</a> (in each case other than any portions thereof deemed furnished and not filed); and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">The description of our common stock contained in our registration statement on <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921123625/tm2113659d20_8a12b.htm">Form 8-A (File No. 001-40886) filed with the SEC on October&#160;6, 2021</a>, under the Exchange Act, including any amendment or report filed for the purpose of updating such description.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">We also incorporate by reference any future filings (other than any filings or portions of such reports that are not deemed &#8220;filed&#8221; under the Exchange Act in accordance with the Exchange Act and applicable SEC rules, including Current Reports furnished under Item&#160;2.02 or Item&#160;7.01 of Form 8-K and exhibits furnished on such form that are related to such items unless such Form 8-K expressly provides to the contrary) made with the SEC pursuant to Sections&#160;13(a), 13(c), 14 or 15(d) of the Exchange Act, including those made after the date of the initial filing of the registration statement of which this prospectus is a part and prior to the effectiveness of the registration statement, until we file a post-effective amendment that indicates the termination of the offering of the securities made by this prospectus, and will become a part of this prospectus from the date that such documents are filed with the SEC. Information in such future filings updates and supplements the information provided in this prospectus. Any statements in any such future filings will automatically be deemed to modify and supersede any information in any document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference to the extent that statements in the later filed document modify or replace such earlier statements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">We will furnish without charge to you, on written or oral request, a copy of any or all of the documents incorporated by reference in this prospectus, including exhibits to these documents. You should direct any requests for documents to Cognition Therapeutics, Inc., Attn: Chief Executive Officer, 2500 Westchester Ave., Purchase, New York 10577.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tCNRF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">This prospectus, any applicable prospectus supplement and the documents incorporated by reference may contain forward-looking statements within the meaning of Section&#160;27A of the Securities Act and Section&#160;21E of the Exchange Act, about us and our subsidiary. These forward-looking statements are intended to be covered by the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact, and can be identified by the use of forward-looking terminology such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;potential,&#8221; &#8220;seek,&#8221; &#8220;evaluate,&#8221; &#8220;pursue,&#8221; &#8220;continue,&#8221; &#8220;design,&#8221; &#8220;impact,&#8221; &#8220;affect,&#8221; &#8220;forecast,&#8221; &#8220;target,&#8221; &#8220;outlook,&#8221; &#8220;initiative,&#8221; &#8220;objective,&#8221; &#8220;designed,&#8221; &#8220;priorities,&#8221; &#8220;goal,&#8221; or the negative thereof or comparable terminology. Forward-looking statements include, but are not limited to, statements concerning:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">our ability to raise additional capital to fund our operations and continue the development of our current and future product candidates;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">our ability to maintain the listing of our common stock on The Nasdaq Capital Market;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the clinical nature of our business and our ability to successfully and in a timely manner advance our current and future product candidates through our ongoing and future clinical trials, preclinical studies and development activities;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">our ability to generate revenue from future product sales and our ability to achieve and maintain profitability;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the accuracy of our projections and estimates regarding our expenses, capital requirements, cash utilization, and need for additional financing;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the expected uses of our existing cash and cash equivalents and the sufficiency of such resources to fund our planned operations;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the extent to which health epidemics and other outbreaks of communicable diseases, geopolitical turmoil, including the ongoing global and regional conflicts or increased trade restrictions between the United States, Russia, China, and other countries, social unrest, political instability, terrorism, or other acts of war could ultimately impact our business, including our ongoing and future clinical trials, preclinical studies and development activities;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">our dependence on the success of zervimesine (CT1812), our lead product candidate;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the novelty of our approach to targeting the &#963;-2 (sigma-2) receptor, or S2R, complex to treat age-related degenerative diseases and disorders, and the challenges we will face due to the novel nature of such approach;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the success of competing therapies that are or become available;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the initiation, progress, success, cost, and timing of our ongoing and future clinical trials, preclinical studies and development activities;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">our ability to obtain and maintain regulatory clearance of CT1812 for clinical trials under investigational new drug, or IND, applications and any future IND applications for any of our other product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the performance of third parties in connection with the development of our product candidates, including third parties conducting our future clinical trials as well as third-party suppliers and manufacturers;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">our ability to attract and retain strategic collaborators with development, regulatory, and commercialization expertise;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:180.5pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the size and growth of the potential markets for our product candidates and our ability to serve those markets;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">regulatory developments and approval pathways in the United States and foreign countries for our product candidates;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the potential scope and value of our intellectual property and proprietary rights;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">our ability, and the ability of any future licensors, to obtain, maintain, defend, and enforce intellectual property and proprietary rights protecting our product candidates, and our ability to develop and commercialize our product candidates without infringing, misappropriating, or otherwise violating the intellectual property or proprietary rights of third parties;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">risks associated with global political changes and global economic conditions, including inflation, tariffs, or uncertainty caused by political violence and unrest, including ongoing global and regional conflicts;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">developments relating to our competitors and our industry; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">other risks and uncertainties, including those described under the caption &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2024, as such risk factors have been amended, supplemented or superseded from time to time by our subsequent periodic reports we file with the SEC.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">We have based these forward-looking statements largely on our current expectations, estimates, forecasts, and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this prospectus, we cannot guarantee that the future results, levels of activity, performance, or events and circumstances reflected in the forward-looking statements will be achieved or occur at all. You should refer to the section titled &#8220;Risk factors&#8221; this prospectus, any applicable prospectus supplement and the documents we incorporate by reference herein and therein for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">You should read this prospectus, any applicable prospectus supplement and the documents incorporated by reference herein and therein completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in this prospectus by these cautionary statements. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tATC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">ABOUT THE COMPANY</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Overview</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">We are a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (&#8220;CNS&#8221;) and retina. Currently available therapies for these diseases are limited, with few Alzheimer&#8217;s disease treatments, two approved treatments for geographic atrophy (&#8220;GA&#8221;) secondary to dry age-related macular degeneration (&#8220;dAMD&#8221;) and no approved treatments for dementia with Lewy bodies (&#8220;DLB&#8221;). Our goal is to develop disease-modifying treatments for people with these degenerative disorders by initially leveraging our expertise in the &#963;-2 (sigma-2) receptor (&#8220;S2R&#8221;), which is expressed by multiple cell types, including neuronal synapses, and acts as a key regulator of cellular damage commonly associated with certain age-related degenerative diseases of the CNS and retina.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">Our lead candidate for the treatment of age-related degenerative diseases is zervimesine (CT1812). Data indicates that zervimesine antagonizes the binding and toxicity of amyloid beta oligomers via targeting the S2R complex and represents a mechanism that is functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. Clinical results support this hypothesis, and our clinical trial findings provide evidence that the displacement of oligomers from synapses via zervimesine engagement with the S2R results in improved synapse function.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">Top-line results from the Phase&#160;2 COG0201 SHINE study were reported in July&#160;2024 with additional data reported in October&#160;2024. An end-of-Phase&#160;2 meeting was conducted on July&#160;9, 2025 to review the results of the SHINE study and Cognition&#8217;s proposed plan for a Phase&#160;3 clinical program with the U.S. Food and Drug Administration (&#8220;FDA&#8221;). Formal minutes were provided by the FDA in August&#160;2025 confirming our Phase&#160;3 clinical program plan.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">SHINE was a randomized, double-blind, placebo-controlled trial that enrolled 153 adults with mild-to-moderate Alzheimer&#8217;s disease. Participants were evenly randomized into two zervimesine dose groups (100&#160;mg or 300 mg) and one placebo group, who were dosed daily for six&#160;months. Endpoints included safety and biomarker evidence of disease modification as well as cognitive function, as measured by ADAS-Cog 11. SHINE met its primary endpoints of safety and tolerability.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">A prespecified analysis conducted on SHINE results identified plasma p-tau217 as a biomarker that may predict participants with mild-to-moderate Alzheimer&#8217;s disease likely to respond to zervimesine therapy. Participants treated with zervimesine (pooled 100 mg and 300 mg) who had baseline levels of plasma p-tau217 below the median of 1.0 pg/mL experienced a 95% reduction of cognitive decline at week 26 as measured by ADAS-Cog 11 relative to placebo-treated participants. P-tau217 is an important biomarker that reflects total brain amyloid and tau pathology.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">In the overall modified intent-to-treat population in SHINE, participants treated with once-daily oral zervimesine experienced less cognitive decline than those treated with placebo. As measured with ADAS-Cog 11, zervimesine-treated participants (pooled 100 mg and 300 mg) experienced a mean 38% slowing of decline at six&#160;months from baseline compared to placebo-treated participants. This difference did not achieve statistical significance. These results are comparable in magnitude to what was achieved with currently approved monoclonal antibody treatments, with the convenience of once-daily oral administration. There were consistent trends favoring zervimesine in other cognitive measures: ADAS-Cog 13, cognitive composite, mini-mental state exam, or MMSE; as well as in functional measures of activities of daily living (ADCS-ADL) and of clinical global impression of change (ADCS-CGIC).</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">In the overall study population, participants treated with zervimesine for six&#160;months had reductions in plasma biomarkers associated with Alzheimer&#8217;s disease processes compared to placebo participants. Further analysis showed that the individuals with below-median plasma p-Tau217 experienced a pronounced reduction in these key plasma biomarkers compared to placebo. Significant reductions were observed in the level of glial fibrillary acidic protein (GFAP), a protein associated with neuroinflammation. Neurofilament light, a protein associated with neurodegeneration was also reduced in participants treated with zervimesine compared to placebo. Similarly, amyloid beta monomers (A&beta;) and p-Tau217, which are proteins that build up in patients with Alzheimer&#8217;s disease, were lower in participants treated with zervimesine for six&#160;months compared to placebo-treated individuals. These findings were presented at the AD/PD</font><font style="letter-spacing:-0.361pt;">&#8482;</font><font style="letter-spacing:-0.038pt;"> 2025 Alzheimer&#8217;s &amp; Parkinson&#8217;s Diseases Conference in April&#160;2025.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.038pt;">Top-line results from the Phase&#160;2 COG1201 SHIMMER study were presented at the International Lewy Body Dementia Conference (ILBDC) in January&#160;2025 and at the Alzheimer&#8217;s Association International Conference (AAIC) in July&#160;2025. The study enrolled 130 participants with mild-to-moderate DLB who were randomized evenly to one of three dose groups: two treated with once-daily oral zervimesine (100 mg or 300 mg) and one treated with placebo. To be eligible, participants were between 50 and 80&#160;years of age, received a diagnosis of probable DLB, and had a MMSE score of between 18 and 27. The study met its primary endpoints of safety and tolerability.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.038pt;">Zervimesine-treated DLB patients scored an average of 86% better than placebo-treated patients on the neuropsychiatric inventory (NPIA-L or NPI-12) at the end of the study. This tool describes the frequency and severity of 12 behavioral symptoms including hallucinations, delusions and anxiety. Compared to placebo-treated participants, those treated with zervimesine performed an average of 52% better on the ADCS-ADL scale, a measure of activities of daily living; an average of 91% better on the CAF, a measure of cognitive fluctuations; an average of 62% better on the Unified Parkinson&#8217;s Disease Rating Scale (UPDRS) Part&#160;III, a measure of motor function such as gait, balance, and tremor.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.038pt;">In June&#160;2025, Cognition received an anonymous philanthropic donation to substantially fund an expanded access program (&#8220;EAP&#8221;) for people with DLB. The EAP will be open to eligible SHIMMER participants who completed the Phase&#160;2 study as well as additional patients with a diagnosis of mild-to-moderate DLB who meet the criteria for this program. Participants will be provided with 100 mg of oral zervimesine to take daily for approximately one year. Eight U.S. sites, all of which were active in the SHIMMER study, were selected to participate in the EAP.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.038pt;">Top-line results from the Phase&#160;2 COG2201 MAGNIFY study of zervimesine in adults with GA secondary to dry AMD were reported in May&#160;2025. The MAGNIFY study was voluntarily concluded in January&#160;2025 after approximately 100 of the planned 246 participants were enrolled to allow the Company to focus its resources on clinical programs in Alzheimer&#8217;s disease and DLB. Top-line results show zervimesine-treated participants had 29% slower GA lesion growth (by slope analysis) on average and at 18&#160;months their lesions were 28% smaller compared to placebo. The GA lesion reduction is comparable to what was reported with currently approved complement inhibitors. Notable differences between the intravitreal complement inhibitors and zervimesine treatment included the convenience of once-daily oral administration and no conversion from dry AMD to choroidal neovascularization (or &#8220;CNV&#8221;), which is a risk factor of treatment with intravitreal complement inhibitors.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.038pt;">A &#8220;segment&#8221; analysis was also conducted to determine the change in GA lesion growth between six-month treatment periods. This analysis shows that the reduction in GA lesion growth increased after 12&#160;months of treatment. The change in lesion growth between 12 and 18&#160;months was 52.7% slower in zervimesine-treated versus placebo-treated participants. The change in ellipsoid zone area, a biomarker of GA progression, also trended in favor of zervimesine treatment compared to placebo. The thickness and integrity of the ellipsoid zone has been correlated with photoreceptor health and visual acuity. Importantly, this effect was also observed to widen over time.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.038pt;">In the above three Phase&#160;2 studies, zervimesine was observed to be generally well tolerated. The average age of participants was approximately 75&#160;years. Among the 238 participants treated with zervimesine, there were 23&#160;incidents of transient treatment-emergent elevations in the liver function test (&#8220;LFT&#8221;) that were greater than 3xULN (9.6%) during the treatment period. Of these incidents, ten occurred in the SHINE study, nine in the SHIMMER study and four in the MAGNIFY study. In these participants, the elevated liver enzymes subsided after cessation of drug with no evidence of permanent liver injury. Overall, adverse events (AEs) were well balanced between treatment and placebo arms; serious AEs occurred at a comparable or higher rate in placebo-treated participants than in those treated with zervimesine in the above studies. Twenty-eight zervimesine-treated (11.8%) and 11 placebo-treated (4.6%) participants discontinued from these studies due to treatment-emergent adverse events.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.038pt;">The above Overview covers only the most recently concluded studies in each indication. The following table highlights findings from these and subsequent clinical programs:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <table style="width:456pt;margin-top:10.5pt;border-collapse: collapse;border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; font-style:normal;font-weight:bold;font-variant:normal;text-transform:uppercase;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:9.833pt 0pt 1.667pt 0pt; width:80pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">Indication </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:9.833pt 0pt 1.667pt 0pt; width:48pt;">
              <div style="text-align:center;">
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">Study </font>
                <br >
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">Identifier </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:9.833pt 0pt 1.667pt 0pt; width:72pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">NCT Number </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:9.833pt 0pt 1.667pt 0pt; width:48pt;">
              <div style="text-align:center;">
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">Clinical </font>
                <br >
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">Phase </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:9.833pt 0pt 1.667pt 0pt; width:48pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">Status </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:9.833pt 0pt 1.667pt 0pt; width:120pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">Key Findings </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:0pt;" colspan="16">
              <font style="letter-spacing:0.475pt;">Alzheimer&#8217;s Disease (AD)</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:80pt;">
              <font style="letter-spacing:-0.038pt;">MCI-early </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;white-space:normal;">
              <font style="letter-spacing:-0.361pt;">COG0203 (START) </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:72pt;">
              <font style="letter-spacing:-0.361pt;">NCT05531656 </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;">
              <div style="font-style:italic;">Phase&#160;2</div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;">
              <font style="letter-spacing:-0.038pt;">ongoing </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:120pt;white-space:normal;">
              <font style="letter-spacing:-0.038pt;">Up to 540 participants with MCI or early AD. This study has completed enrollment. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:80pt;">
              <font style="letter-spacing:-0.038pt;">mild-moderate </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;white-space:normal;">
              <font style="letter-spacing:-0.361pt;">COG0201 (SHINE) </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:72pt;">
              <font style="letter-spacing:-0.361pt;">NCT03507790 </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;white-space:normal;">
              <div style="font-style:italic;">Phase&#160;2 (n=153)</div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;">
              <font style="letter-spacing:-0.038pt;">complete </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:120pt;white-space:normal;">
              <font style="letter-spacing:-0.038pt;">Participants treated with zervimesine experienced a cognitive benefit compared to placebo </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:80pt;">
              <font style="letter-spacing:-0.038pt;">mild-moderate </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;white-space:normal;">
              <font style="letter-spacing:-0.361pt;">COG0202 (SEQUEL) </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:72pt;">
              <font style="letter-spacing:-0.361pt;">NCT04735536 </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;white-space:normal;">
              <div style="font-style:italic;">Phase&#160;2 (n=16)</div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;">
              <font style="letter-spacing:-0.038pt;">complete </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:120pt;white-space:normal;">
              <font style="letter-spacing:-0.038pt;">Participants treated with zervimesine exhibited improvement across prespecified EEG parameters </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:80pt;">
              <font style="letter-spacing:-0.038pt;">mild-moderate </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;white-space:normal;">
              <font style="letter-spacing:-0.361pt;">COG0105 (SPARC) </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:72pt;">
              <font style="letter-spacing:-0.361pt;">NCT03493282 </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;white-space:normal;">
              <div style="font-style:italic;">Phase&#160;1 (n=23)</div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;">
              <font style="letter-spacing:-0.038pt;">complete </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:120pt;white-space:normal;">
              <font style="letter-spacing:-0.038pt;">Treatment with zervimesine was assessed using various imaging modalities, including PET imaging and volumetric MRI (vMRI) </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:80pt;">
              <font style="letter-spacing:-0.038pt;">mild-moderate </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;white-space:normal;">
              <font style="letter-spacing:-0.361pt;">COG0104 (SNAP) </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:72pt;">
              <font style="letter-spacing:-0.361pt;">NCT03522129 </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;white-space:normal;">
              <div style="font-style:italic;">Phase&#160;1 (n=3)</div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;">
              <font style="letter-spacing:-0.038pt;">complete </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:120pt;white-space:normal;">
              <font style="letter-spacing:-0.038pt;">Confirmed preclinical findings showing an increase in A&beta; oligomers in CSF, suggesting increased off-rate from receptors </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:0pt;" colspan="16">
              <font style="letter-spacing:0.475pt;">Dementia with Lewy Bodies (DLB)</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:80pt;">
              <font style="letter-spacing:-0.038pt;">mild-moderate </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;white-space:normal;">
              <font style="letter-spacing:-0.361pt;">COG1201 (SHIMMER) </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:72pt;">
              <font style="letter-spacing:-0.361pt;">NCT05225415 </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;white-space:normal;">
              <div style="font-style:italic;">Phase&#160;2 (n=130)</div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;">
              <font style="letter-spacing:-0.038pt;">complete </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:120pt;white-space:normal;">
              <font style="letter-spacing:-0.038pt;">Participants treated with zervimesine experienced benefits across behavioral, functional, cognitive and motor scales </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:80pt;">
              <font style="letter-spacing:-0.038pt;">Mild-moderate </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;white-space:normal;">
              <font style="letter-spacing:-0.361pt;">COG1202 (EAP) </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:72pt;">
              <font style="letter-spacing:-0.361pt;">NCT06961760 </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;">
              <div style="font-style:italic;">n/a</div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;">
              <font style="letter-spacing:-0.038pt;">ongoing </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:120pt;white-space:normal;">
              <font style="letter-spacing:-0.038pt;">Initially, the EAP will accommodate approximately 30 individuals with DLB. Currently, fully enrolled. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:0pt;" colspan="16">
              <font style="letter-spacing:0.475pt;">Geographic Atrophy Secondary to Dry AMD</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="border-bottom:0.75pt solid #000000; ;padding:1.333pt 0pt 12pt 0pt; width:80pt;">
              <font style="letter-spacing:-0.361pt;">GA </font>
            </td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:4pt;">&#8203;</td>
            <td style="border-bottom:0.75pt solid #000000; ;padding:1.333pt 0pt 12pt 0pt; width:48pt;white-space:normal;">
              <font style="letter-spacing:-0.361pt;">COG2201 (MAGNIFY) </font>
            </td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:4pt;">&#8203;</td>
            <td style="border-bottom:0.75pt solid #000000; ;padding:1.333pt 0pt 12pt 0pt; width:72pt;">
              <font style="letter-spacing:-0.361pt;">NCT05893537 </font>
            </td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:4pt;">&#8203;</td>
            <td style="border-bottom:0.75pt solid #000000; ;padding:1.333pt 0pt 12pt 0pt; width:48pt;white-space:normal;">
              <div style="font-style:italic;">Phase&#160;2 (n=100)</div>
            </td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:4pt;">&#8203;</td>
            <td style="border-bottom:0.75pt solid #000000; ;padding:1.333pt 0pt 12pt 0pt; width:48pt;">
              <font style="letter-spacing:-0.038pt;">concluded </font>
            </td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:4pt;">&#8203;</td>
            <td style="border-bottom:0.75pt solid #000000; ;padding:1.333pt 0pt 12pt 0pt; width:120pt;white-space:normal;">
              <font style="letter-spacing:-0.038pt;">Participants treated with zervimesine experienced slower growth of their GA lesions over the course of the study</font>
            </td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.69pt; width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Corporate Information</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.038pt;">We were incorporated under the laws of the State of Delaware on August&#160;21, 2007. Our principal executive offices are located at 2500 Westchester Ave., Purchase, NY 10577, and our telephone number is 412-481-2210. Our corporate website address is www.cogrx.com. Information contained on, or accessible through, our website shall not be deemed incorporated into and is not a part of this prospectus or the registration statement of which it forms a part. We have included our website in this prospectus solely as an inactive textual reference.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:254.5pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Implications of Being an Emerging Growth Company and Smaller Reporting Company</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the Jobs Act. We will remain an emerging growth company until the earliest of (1)&#160;December&#160;31, 2026, (2)&#160;the beginning of the first fiscal year after our annual gross revenue is $1.235&#160;billion or more, (3)&#160;the date on which we have, during the previous three-year period, issued more than $1.0&#160;billion in non-convertible debt securities and (4)&#160;as of the end of any fiscal year in which the market value of our common stock held by non-affiliates exceeded $700&#160;million as of the end of the second quarter of that fiscal year.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">For as long as we remain an &#8220;emerging growth company,&#8221; we may take advantage of certain exemptions from various reporting requirements that are applicable to public companies that are not &#8220;emerging growth companies&#8221; including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation and financial statements in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote to approve executive compensation and shareholder approval of any golden parachute payments not previously approved. We will take advantage of these reporting exemptions until we are no longer an &#8220;emerging growth company.&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">The JOBS Act provides that an &#8220;emerging growth company&#8221; can take advantage of an extended transition period for complying with new or revised accounting standards. We have irrevocably elected not to avail ourselves of this exemption and, therefore, we are subject to the same new or revised accounting standards as other public companies that are not &#8220;emerging growth companies.&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">We are also a &#8220;smaller reporting company,&#8221; as defined in Item&#160;10(f)(1) of Regulation&#160;S-K. We will remain a smaller reporting company until the last day of the fiscal year in which (i)&#160;the market value of our common stock held by non-affiliates exceeds $250&#160;million as of the end of that year&#8217;s second fiscal quarter, or (ii)&#160;our annual revenues exceeded $100&#160;million during such completed fiscal year and the market value of our common stock held by non-affiliates exceeds $700&#160;million as of the end of that year&#8217;s second fiscal quarter. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal&#160;years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tRIFA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:430pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">RISK FACTORS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">Investing in any of our securities involves significant risks. Before making an investment decision, in addition to the other information contained in or incorporated by reference in this prospectus and any prospectus supplement, you should carefully consider the specific risks set forth under the heading &#8220;Risk Factors&#8221; in our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC, as such risk factors may be amended, supplemented or superseded from time to time by other reports we file with the SEC, including subsequent Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, and the risk factors described under the caption &#8220;Risk Factors&#8221; in any applicable prospectus supplement. See &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Certain Information by Reference.&#8221; If any of these risks actually occurs, our business, results of operations and financial condition could suffer. In that case, the trading price of our securities could decline, and you could lose all or part of your investment. Additional risks and uncertainties not currently known to us, or that we currently believe are immaterial, may also adversely affect our business, operating results and financial condition and the value of an investment in our securities. In addition, past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUOP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:478pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">USE OF PROCEEDS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">We will retain broad discretion over the use of the net proceeds from the sale of the securities offered hereby. Except as described in any applicable prospectus supplement or in any free writing prospectuses that we may authorize to be provided to you in connection with a specific offering, we currently intend to use the net proceeds from the sale of the securities offered hereby for general corporate purposes. General corporate purposes may include, without limitation, research and development and clinical development costs to support the advancement of our current or future product candidates; working capital; capital expenditures; and other general corporate purposes. We may temporarily invest the net proceeds in a variety of capital preservation instruments, including short-term, investment-grade, interest-bearing instruments and U.S. government securities, or may hold such proceeds as cash, until they are used for their stated purpose. We have not determined the amount of net proceeds to be used specifically for such purposes. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDOCS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">DESCRIPTION OF CAPITAL STOCK</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;font-style:italic;">The following description of our capital stock is not complete and may not contain all the information you should consider before investing in our capital stock. This description is summarized from, and qualified in its entirety by reference to, our third amended and restated certificate of incorporation and our amended and restated bylaws, which have been publicly filed with the SEC. See &#8220;Where You Can Find More Information.&#8221; For a complete description, you should refer to our third amended and restated certificate of incorporation and amended and restated bylaws, copies of which are incorporated by reference as exhibits to the registration statement of which this prospectus is a part.<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">General</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">Under our third amended and restated certificate of incorporation, our authorized capital stock consists of 250,000,000 shares of common stock, par value $0.001 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share. As of September&#160;30, 2025, we had 88,268,078 shares of common stock outstanding, and no shares of preferred stock outstanding.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Common Stock</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Voting</font><font style="letter-spacing:-0.038pt;">.&nbsp;&nbsp;&nbsp;Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Our stockholders do not have cumulative voting rights in the election of directors. The affirmative vote of holders of at least 66</font><font style=" position:relative; bottom:2.53pt;font-size:6.65pt;letter-spacing:-0.253pt;">2</font><font style="letter-spacing:-0.361pt;">&#8725;</font><font style="font-size:6.65pt;letter-spacing:-0.253pt;">3</font><font style="letter-spacing:-0.038pt;">% of the voting power of all of the then-outstanding shares of capital stock, voting as a single class, will be required to amend certain provisions of our third amended and restated certificate of incorporation, including the provisions relating to amending our amended and restated bylaws, procedures for our stockholder meetings, the classified board, director liability, and exclusive forum for proceedings.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Dividends</font><font style="letter-spacing:-0.038pt;">.&nbsp;&nbsp;&nbsp;Subject to preferences that may be applicable to any then outstanding preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Liquidation and Dissolution</font><font style="letter-spacing:-0.038pt;">.&nbsp;&nbsp;&nbsp;In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the holders of any then outstanding shares of preferred stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Other Rights and Restrictions</font><font style="letter-spacing:-0.038pt;">.&nbsp;&nbsp;&nbsp;Holders of our common stock have no preemptive, conversion or subscription rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the future.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Listing</font><font style="letter-spacing:-0.038pt;">.&nbsp;&nbsp;&nbsp;Our common stock is listed on The Nasdaq Capital Market under the symbol &#8220;CGTX.&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Transfer Agent and Registrar</font><font style="letter-spacing:-0.038pt;">.&nbsp;&nbsp;&nbsp;The transfer agent and registrar for our common stock is EQ Equiniti Trust Company, LLC.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Preferred Stock</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">Under our third amended and restated certificate of incorporation, our board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in our control that may otherwise benefit holders of our common stock and may </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">adversely affect the market price of the common stock and the voting and other rights of the holders of common stock. We have no current plans to issue any shares of preferred stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Anti-Takeover Provisions of Delaware Law and Our Charter Documents</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Certificate of Incorporation and Bylaws</font><font style="letter-spacing:-0.038pt;">.&nbsp;&nbsp;&nbsp;Among other things, our third amended and restated certificate of incorporation and amended and restated bylaws:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">provide that the authorized number of directors may be changed only by resolution of our board of directors;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">provide that our board of directors is classified into three classes of directors;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">provide that, subject to the rights of any series of preferred stock to elect directors, directors may only be removed for cause, which removal may be effected, subject to any limitation imposed by law, by the holders of at least 66</font><font style=" position:relative; bottom:2.53pt;font-size:6.65pt;letter-spacing:-0.253pt;">2</font><font style="letter-spacing:-0.361pt;">&#8725;</font><font style="font-size:6.65pt;letter-spacing:-0.253pt;">3</font><font style="letter-spacing:-0.038pt;">% of the voting power of all of our then-outstanding shares of the capital stock entitled to vote generally at an election of directors;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent or electronic transmission;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder&#8217;s notice;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">provide that special meetings of our stockholders may be called only by the chairman of our board of directors, our chief executive officer or by our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">do not provide for cumulative voting rights, therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">The amendment of any of these provisions would require approval by the holders of at least 66</font><font style=" position:relative; bottom:2.53pt;font-size:6.65pt;letter-spacing:-0.253pt;">2</font><font style="letter-spacing:-0.361pt;">&#8725;</font><font style="font-size:6.65pt;letter-spacing:-0.253pt;">3</font><font style="letter-spacing:-0.038pt;">% of the voting power of all of our then-outstanding common stock entitled to vote generally in the election of directors, voting together as a single class.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">The combination of these provisions makes it more difficult for our stockholders to replace our board of directors as well as for another party to obtain control of us by replacing our board of directors. Because our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change our control.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to reduce our vulnerability to hostile takeovers and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of delaying changes in our control or management. As a consequence, these provisions may also inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts. We believe that the benefits of these provisions, including increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure our company, outweigh the disadvantages of discouraging takeover proposals, because negotiation of takeover proposals could result in an improvement of their terms. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Section&#160;203 of the Delaware General Corporation Law</font><font style="letter-spacing:-0.038pt;">.&nbsp;&nbsp;&nbsp;We are subject to Section&#160;203 of the DGCL, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three&#160;years after the date that such stockholder became an interested stockholder, with the following exceptions:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (i)&#160;by persons who are directors and also officers and (ii)&#160;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66</font><font style=" position:relative; bottom:2.53pt;font-size:6.65pt;letter-spacing:-0.253pt;">2</font><font style="letter-spacing:-0.361pt;">&#8725;</font><font style="font-size:6.65pt;letter-spacing:-0.253pt;">3</font><font style="letter-spacing:-0.038pt;">% of the outstanding voting stock that is not owned by the interested stockholder.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">In general, Section&#160;203 defines a &#8220;business combination&#8221; to include the following:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">any merger or consolidation involving the corporation and the interested stockholder;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits by or through the corporation.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">In general, Section&#160;203 defines an &#8220;interested stockholder&#8221; as an entity or person who, together with the person&#8217;s affiliates and associates, beneficially owns, or within three&#160;years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">The statute could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may discourage attempts to acquire us even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above the prevailing market price.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">A Delaware corporation may &#8220;opt out&#8221; of these provisions with an express provision in its certificate of incorporation. We have not opted out of these provisions, which may as a result, discourage or prevent mergers or other takeover or change of control attempts of us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Choice of Forum</font><font style="letter-spacing:-0.038pt;">.&nbsp;&nbsp;&nbsp;Our third amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware (or, if and only if, the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if, all such state courts lack subject matter jurisdiction, the United States District Court for the District of Delaware) and any appellate court therefrom shall be the sole and exclusive forum for the following claims or causes of action brought under Delaware statutory or common law: (1)&#160;any derivative claim or action brought on our behalf; (2)&#160;any claim or cause of action asserting a breach of fiduciary duty by any of our current or former directors, officers or other employees; (3)&#160;any claim or cause of action asserting a claim against us arising out of, or pursuant to, the DGCL, our third amended and restated certificate of incorporation or our amended and restated bylaws; (4)&#160;any claim or cause of action seeking to interpret, apply, enforce or determine the validity of our third amended and restated certificate of incorporation or our amended and restated bylaws (including any right, obligation, or remedy thereunder); (5)&#160;any claim or cause of action as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware; or (6)&#160;any claim or cause of action asserting a claim against us or any of our current or former directors, officers or other employees, that is governed by the internal affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court having </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">personal jurisdiction over the indispensable parties named as defendants. The aforementioned provision will not apply to claims or causes of action brought to enforce a duty or liability created by the Securities Act, the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">In addition, our third amended and restated certificate of incorporation further provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America will be the exclusive forum, to the fullest extent permitted by law, for resolving any complaint asserting a cause or causes of action arising under the Securities Act, including all causes of action asserted against any defendant to such complaint. The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with one or more actions or proceedings described above, a court could find the choice of forum provisions contained in our third amended and restated certificate of incorporation to be inapplicable or unenforceable.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Limitations of Liability and Indemnification</font><font style="letter-spacing:-0.038pt;">.&nbsp;&nbsp;&nbsp;Our third amended and restated certificate of incorporation and our amended and restated bylaws limit our directors&#8217; liability and may indemnify our directors and officers to the fullest extent permitted under the DGCL. The DGCL provides that directors of a corporation will not be personally liable for monetary damages for breach of their fiduciary duties as directors, except for liability for:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.71pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">any breach of the director&#8217;s duty of loyalty to us or our stockholders;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.7pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.7pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">any unlawful payment of dividends or unlawful stock repurchases or redemptions as provided in Section&#160;174 of the DGCL; or</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.7pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">any transaction from which the director derived an improper benefit.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">The DGCL and our amended and restated bylaws provide that we will, in certain situations, indemnify our directors and officers and may indemnify other employees and other agents, to the fullest extent permitted by law.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">We have entered into indemnification agreements with our directors and officers. These indemnification agreements may require us, among other things, to indemnify our directors and officers for some expenses, including attorneys&#8217; fees, judgments, penalties, fines and settlement amounts incurred by a director or officer in any action or proceeding arising out of his or her service as one of our directors or officers, or any of our subsidiaries or any other company or enterprise to which the person provides services at our request. Subject to certain limitations, our indemnification agreements also require us to advance expenses incurred by our directors, officers and key employees for the defense of any action for which indemnification is required or permitted.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">We maintain a directors&#8217; and officers&#8217; insurance policy pursuant to which our directors and officers are insured against liability for actions taken in their capacities as directors and officers. We believe that these provisions in our third amended and restated certificate of incorporation, our amended and restated bylaws and these indemnification agreements are necessary to attract and retain qualified persons as directors and officers.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">The limitation of liability and indemnification provisions in our third amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and our stockholders. Further, a stockholder&#8217;s investment may be adversely affected to the extent that we pay the costs of settlement and damage awards against directors and officers as required by these indemnification provisions.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">At present, there is no material pending litigation or proceeding involving any of our directors, officers or employees for which indemnification is sought and we are not aware of any threatened material litigation that may result in claims for indemnification.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or control persons, in the opinion of the SEC, such indemnification is against public policy, as expressed in the Securities Act, and is therefore unenforceable.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDODS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">DESCRIPTION OF DEBT SECURITIES</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">The following description, together with the additional information we include in any applicable prospectus supplement or free writing prospectus, summarizes certain general terms and provisions of the debt securities that we may offer under this prospectus. When we offer to sell a particular series of debt securities, we will describe the specific terms of the series in a supplement to this prospectus. We will also indicate in the supplement to what extent the general terms and provisions described in this prospectus apply to a particular series of debt securities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">We may issue debt securities either separately, or together with, or upon the conversion or exercise of or in exchange for, other securities described in this prospectus. Debt securities may be our senior, senior subordinated or subordinated obligations and, unless otherwise specified in a supplement to this prospectus, the debt securities will be our direct, unsecured obligations and may be issued in one or more series.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">The debt securities will be issued under an indenture between us and a third party to be identified therein, as trustee. We have summarized select portions of the indenture below. The summary is not complete. The form of the indenture has been filed as an exhibit to the registration statement and you should read the indenture for provisions that may be important to you. Capitalized terms used in the summary and not defined herein have the meanings specified in the indenture.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">As used in this section only, &#8220;Cognition,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221; refer to Cognition Therapeutics, Inc., excluding its wholly owned subsidiary, unless expressly stated or the context otherwise requires.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">General</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">The terms of each series of debt securities will be established by or pursuant to a resolution of our board of directors and set forth or determined in the manner provided in a resolution of our board of directors, in an officer&#8217;s certificate or by a supplemental indenture. The particular terms of each series of debt securities will be described in a prospectus supplement relating to such series (including any pricing supplement or term sheet).</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">We can issue an unlimited amount of debt securities under the indenture that may be issued in one or more series with the same or various maturities, at par, at a premium, or at a discount. We will set forth in a prospectus supplement (including any pricing supplement or term sheet) relating to any series of debt securities being offered, the aggregate principal amount and the following terms of the debt securities, if applicable:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the title and ranking of the debt securities (including the terms of any subordination provisions);</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the price or prices (expressed as a&#160;percentage of the principal amount) at which we will sell the debt securities;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">any limit on the aggregate principal amount of the debt securities;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the date or dates on which the principal of the securities of the series is payable;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the rate or rates (which may be fixed or variable) per annum or the method used to determine the rate or rates (including any commodity, commodity index, stock exchange index or financial index) at which the debt securities will bear interest, the date or dates from which interest will accrue, the date or dates on which interest will commence and be payable and any regular record date for the interest payable on any interest payment date;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the place or places where principal of, and interest, if any, on the debt securities will be payable (and the method of such payment), where the securities of such series may be surrendered for registration of transfer or exchange, and where notices and demands to us in respect of the debt securities may be delivered;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the period or periods within which, the price or prices at which and the terms and conditions upon which we may redeem the debt securities;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">any obligation we have to redeem or purchase the debt securities pursuant to any sinking fund or analogous provisions or at the option of a holder of debt securities and the period or periods within</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">which, the price or prices at which and in the terms and conditions upon which securities of the series shall be redeemed or purchased, in whole or in part, pursuant to such obligation;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the dates on which and the price or prices at which we will repurchase debt securities at the option of the holders of debt securities and other detailed terms and provisions of these repurchase obligations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.21pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the denominations in which the debt securities will be issued, if other than denominations of $1,000 and any integral multiple thereof;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.2pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">whether the debt securities will be issued in the form of certificated debt securities or global debt securities;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.21pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the portion of principal amount of the debt securities payable upon declaration of acceleration of the maturity date, if other than the principal amount;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.2pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the currency of denomination of the debt securities, which may be United States Dollars or any foreign currency, and if such currency of denomination is a composite currency, the agency or organization, if any, responsible for overseeing such composite currency;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.2pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the designation of the currency, currencies or currency&#160;units in which payment of principal of, premium, if any, and interest on the debt securities will be made;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.21pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">if payments of principal of, premium, if any, or interest on the debt securities will be made in one or more currencies or currency&#160;units other than that or those in which the debt securities are denominated, the manner in which the exchange rate with respect to these payments will be determined;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.2pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the manner in which the amounts of payment of principal of, premium, if any, or interest on the debt securities will be determined, if these amounts may be determined by reference to an index based on a currency or currencies or by reference to a commodity, commodity index, stock exchange index or financial index;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.2pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">any provisions relating to any security provided for the debt securities;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.2pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">any addition to, deletion of or change in the Events of Default described in this prospectus or in the indenture with respect to the debt securities and any change in the acceleration provisions described in this prospectus or in the indenture with respect to the debt securities;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.2pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">any addition to, deletion of or change in the covenants described in this prospectus or in the indenture with respect to the debt securities;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.21pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">any depositaries, interest rate calculation agents, exchange rate calculation agents or other agents with respect to the debt securities;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.2pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the provisions, if any, relating to conversion or exchange of any debt securities of such series, including if applicable, the conversion or exchange price and period, provisions as to whether conversion or exchange will be mandatory, the events requiring an adjustment of the conversion or exchange price and provisions affecting conversion or exchange;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.2pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">any other terms of the debt securities, which may supplement, modify or delete any provision of the indenture as it applies to that series, including any terms that may be required under applicable law or regulations or advisable in connection with the marketing of the securities; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.21pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">whether any of our direct or indirect subsidiaries will guarantee the debt securities of that series, including the terms of subordination, if any, of such guarantees.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">We may issue debt securities that provide for an amount less than their stated principal amount to be due and payable upon declaration of acceleration of their maturity pursuant to the terms of the indenture. We will provide you with information on the United States federal income tax considerations and other special considerations applicable to any of these debt securities in the applicable prospectus supplement.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">If we denominate the purchase price of any of the debt securities in a foreign currency or currencies or a foreign currency unit or&#160;units, or if the principal of and any premium and interest on any series of debt securities is payable in a foreign currency or currencies or a foreign currency unit or&#160;units, we will provide you with information on the restrictions, elections, general tax considerations, specific terms and other information with respect to that issue of debt securities and such foreign currency or currencies or foreign currency unit or&#160;units in the applicable prospectus supplement.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Transfer and Exchange</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">Each debt security will be represented by either one or more global securities registered in the name of The Depository Trust Company, or DTC, or a nominee of DTC (we will refer to any debt security represented by a </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">global debt security as a &#8220;book-entry debt security&#8221;), or a certificate issued in definitive registered form (we will refer to any debt security represented by a certificated security as a &#8220;certificated debt security&#8221;) as set forth in the applicable prospectus supplement. Except as set forth under the heading &#8220;Global Debt Securities and Book-Entry System&#8221; below, book-entry debt securities will not be issuable in certificated form.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">Certificated Debt Securities. You may transfer or exchange certificated debt securities at any office we maintain for this purpose in accordance with the terms of the indenture. No service charge will be made for any transfer or exchange of certificated debt securities, but we may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection with a transfer or exchange.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">You may effect the transfer of certificated debt securities and the right to receive the principal of, premium and interest on certificated debt securities only by surrendering the certificate representing those certificated debt securities and either reissuance by us or the trustee of the certificate to the new holder or the issuance by us or the trustee of a new certificate to the new holder.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">Global Debt Securities and Book-Entry System. Each global debt security representing book-entry debt securities will be deposited with, or on behalf of, DTC, and registered in the name of DTC or a nominee of DTC. Please see &#8220;Global Securities.&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Covenants</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">We will set forth in the applicable prospectus supplement any restrictive covenants applicable to any issue of debt securities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">No Protection in the Event of a Change of Control</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">Unless we state otherwise in the applicable prospectus supplement, the debt securities will not contain any provisions which may afford holders of the debt securities protection in the event we have a change in control or in the event of a highly leveraged transaction (whether or not such transaction results in a change in control) which could adversely affect holders of debt securities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Consolidation, Merger and Sale of Assets</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">We may not consolidate with or merge with or into, or convey, transfer or lease all or substantially all of our properties and assets to any person (a &#8220;successor person&#8221;) unless:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">we are the surviving entity or the successor person (if other than Cognition) is a corporation, partnership, trust or other entity organized and validly existing under the laws of any U.S. domestic jurisdiction and expressly assumes our obligations on the debt securities and under the indenture; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.91pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">immediately after giving effect to the transaction, no Default (defined as any event which is, or after notice or passage of time or both would be, an Event of Default) or Event of Default, shall have occurred and be continuing.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">Notwithstanding the above, any of our subsidiaries may consolidate with, merge into or transfer all or part of its properties to us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Events of Default</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">Event of Default&#8221; means with respect to any series of debt securities, any of the following:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">default in the payment of any interest upon any debt security of that series when it becomes due and payable, and continuance of such default for a period of 30&#160;days (unless the entire amount of the payment is deposited by us with the trustee or with a paying agent prior to the expiration of the 30-day period);</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">default in the payment of principal of any security of that series at its maturity;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">default in the performance or breach of any other covenant or warranty by us in the indenture (other than a covenant or warranty that has been included in the indenture solely for the benefit of a series of debt securities other than that series), which default continues uncured for a period of 60&#160;days after we receive written notice from the trustee or Cognition and the trustee receive written notice from the holders of not less than 25% in principal amount of the outstanding debt securities of that series as provided in the indenture;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">certain voluntary or involuntary events of bankruptcy, insolvency or reorganization of Cognition; or</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">any other Event of Default provided with respect to debt securities of that series that is described in the applicable prospectus supplement.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">No Event of Default with respect to a particular series of debt securities (except as to certain events of bankruptcy, insolvency or reorganization) necessarily constitutes an Event of Default with respect to any other series of debt securities. The occurrence of certain Events of Default or an acceleration under the indenture may constitute an event of default under certain indebtedness of ours or our subsidiaries outstanding from time to time.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">We will provide the trustee written notice of any Default or Event of Default within 30&#160;days of becoming aware of the occurrence of such Default or Event of Default, which notice will describe in reasonable detail the status of such Default or Event of Default and what action we are taking or propose to take in respect thereof.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">If an Event of Default with respect to debt securities of any series at the time outstanding occurs and is continuing, then the trustee or the holders of not less than 25% in principal amount of the outstanding debt securities of that series may, by a notice in writing to us (and to the trustee if given by the holders), declare to be due and payable immediately the principal of (or, if the debt securities of that series are discount securities, that portion of the principal amount as may be specified in the terms of that series) and accrued and unpaid interest, if any, on all debt securities of that series. In the case of an Event of Default resulting from certain events of bankruptcy, insolvency or reorganization, the principal (or such specified amount) of and accrued and unpaid interest, if any, on all outstanding debt securities will become and be immediately due and payable without any declaration or other act on the part of the trustee or any holder of outstanding debt securities. At any time after a declaration of acceleration with respect to debt securities of any series has been made, but before a judgment or decree for payment of the money due has been obtained by the trustee, the holders of a majority in principal amount of the outstanding debt securities of that series may rescind and annul the acceleration if all Events of Default, other than the non-payment of accelerated principal and interest, if any, with respect to debt securities of that series, have been cured or waived as provided in the indenture. We refer you to the prospectus supplement relating to any series of debt securities that are discount securities for the particular provisions relating to acceleration of a portion of the principal amount of such discount securities upon the occurrence of an Event of Default.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">The indenture provides that the trustee may refuse to perform any duty or exercise any of its rights or powers under the indenture unless the trustee receives indemnity satisfactory to it against any cost, liability or expense which might be incurred by it in performing such duty or exercising such right or power. Subject to certain rights of the trustee, the holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee or exercising any trust or power conferred on the trustee with respect to the debt securities of that series.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">No holder of any debt security of any series will have any right to institute any proceeding, judicial or otherwise, with respect to the indenture or for the appointment of a receiver or trustee, or for any remedy under the indenture, unless:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">that holder has previously given to the trustee written notice of a continuing Event of Default with respect to debt securities of that series; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the holders of not less than 25% in principal amount of the outstanding debt securities of that series have made written request, and offered indemnity or security satisfactory to the trustee, to the trustee to institute the proceeding as trustee, and the trustee has not received from the holders of not less than a majority in principal amount of the outstanding debt securities of that series a direction inconsistent with that request and has failed to institute the proceeding within 60&#160;days.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">Notwithstanding any other provision in the indenture, the holder of any debt security will have an absolute and unconditional right to receive payment of the principal of, premium and any interest on that debt security on or after the due dates expressed in that debt security and to institute suit for the enforcement of payment. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">The indenture requires us, within 120&#160;days after the end of our fiscal year, to furnish to the trustee a statement as to compliance with the indenture. If a Default or Event of Default occurs and is continuing with respect to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">the securities of any series and if it is known to a responsible officer of the trustee, the trustee shall mail to each securityholder of the securities of that series notice of a Default or Event of Default within 90&#160;days after it occurs or, if later, after a responsible officer of the trustee has knowledge of such Default or Event of Default. The indenture provides that the trustee may withhold notice to the holders of debt securities of any series of any Default or Event of Default (except in payment on any debt securities of that series) with respect to debt securities of that series if the trustee determines in good faith that withholding notice is in the interest of the holders of those debt securities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Modification and Waiver</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">We and the trustee may modify, amend or supplement the indenture or the debt securities of any series without the consent of any holder of any debt security:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.29pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">to cure any ambiguity, defect or inconsistency;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.3pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">to comply with covenants in the indenture described above under the heading &#8220;Consolidation, Merger and Sale of Assets&#8221;;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.3pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">to provide for uncertificated securities in addition to or in place of certificated securities;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.3pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">to add guarantees with respect to debt securities of any series or secure debt securities of any series;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.3pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">to surrender any of our rights or powers under the indenture;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.29pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">to add covenants or events of default for the benefit of the holders of debt securities of any series;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.3pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">to comply with the procedures of the applicable depositary;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.3pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">to make any change that does not adversely affect the rights of any holder of debt securities;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.3pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">to provide for the issuance of and establish the form and terms and conditions of debt securities of any series as permitted by the indenture;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.3pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">to effect the appointment of a successor trustee with respect to the debt securities of any series and to add to or change any of the provisions of the indenture to provide for or facilitate administration by more than one trustee;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.3pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">to conform the terms of the indenture (insofar as it applies to any series of debt securities issued under the indenture) or the terms of the debt securities of any series issued under the indenture to the description thereof contained in any prospectus, prospectus supplement or similar offering document used in connection with the initial offering and sale of such debt securities to investors in a public or private offering; or</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.3pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">to comply with requirements of the SEC in order to effect or maintain the qualification of the indenture under the Trust Indenture Act.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">We may also modify and amend the indenture with the consent of the holders of at least a majority in principal amount of the outstanding debt securities of each series affected by the modifications or amendments. We may not make any modification or amendment without the consent of the holders of each affected debt security then outstanding if that amendment will:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.19pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">reduce the amount of debt securities whose holders must consent to an amendment, supplement or waiver;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.2pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">reduce the rate of or extend the time for payment of interest (including default interest) on any debt security;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.2pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">reduce the principal of or premium on or change the fixed maturity of any debt security or reduce the amount of, or postpone the date fixed for, the payment of any sinking fund or analogous obligation with respect to any series of debt securities;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.2pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">reduce the principal amount of discount securities payable upon acceleration of maturity;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.2pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">waive a default in the payment of the principal of, premium or interest on any debt security (except a rescission of acceleration of the debt securities of any series by the holders of at least a majority in aggregate principal amount of the then outstanding debt securities of that series and a waiver of the payment default that resulted from such acceleration);</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">make the principal of or premium or interest on any debt security payable in currency other than that stated in the debt security;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.7pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">make any change to certain provisions of the indenture relating to, among other things, the right of holders of debt securities to receive payment of the principal of, premium and interest on those debt securities and to institute suit for the enforcement of any such payment and to waivers or amendments; or</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.7pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">waive a redemption payment with respect to any debt security.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">Except for certain specified provisions, the holders of at least a majority in principal amount of the outstanding debt securities of any series may on behalf of the holders of all debt securities of that series waive our compliance with provisions of the indenture. The holders of a majority in principal amount of the outstanding debt securities of any series may on behalf of the holders of all the debt securities of such series waive any past default under the indenture with respect to that series and its consequences, except a default in the payment of the principal of, premium or any interest on any debt security of that series; provided, however, that the holders of a majority in principal amount of the outstanding debt securities of any series may rescind an acceleration and its consequences, including any related payment default that resulted from the acceleration.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Defeasance of Debt Securities and Certain Covenants in Certain Circumstances</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Legal Defeasance</font><font style="letter-spacing:-0.038pt;">.&nbsp;&nbsp;&nbsp;The indenture provides that, unless otherwise provided by the terms of the applicable series of debt securities, we may be discharged from any and all obligations in respect of the debt securities of any series (subject to certain exceptions). We will be so discharged upon the irrevocable deposit with the trustee, in trust, of money and/or U.S. government obligations or, in the case of debt securities denominated in a single currency other than U.S. Dollars, government obligations of the government that issued or caused to be issued such currency, that, through the payment of interest and principal in accordance with their terms, will provide money or U.S. government obligations in an amount sufficient in the opinion of a nationally recognized firm of independent public accountants or investment bank to pay and discharge each installment of principal, premium and interest on and any mandatory sinking fund payments in respect of the debt securities of that series on the stated maturity of those payments in accordance with the terms of the indenture and those debt securities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">This discharge may occur only if, among other things, we have delivered to the trustee an opinion of counsel stating that we have received from, or there has been published by, the United States Internal Revenue Service a ruling or, since the date of execution of the indenture, there has been a change in the applicable United States federal income tax law, in either case to the effect that, and based thereon such opinion shall confirm that, the holders and beneficial owners of the debt securities of that series will not recognize income, gain or loss for United States federal income tax purposes as a result of the deposit, defeasance and discharge and will be subject to United States federal income tax on the same amounts and in the same manner and at the same times as would have been the case if the deposit, defeasance and discharge had not occurred.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Defeasance of Certain Covenants</font><font style="letter-spacing:-0.038pt;">.&nbsp;&nbsp;&nbsp;The indenture provides that, unless otherwise provided by the terms of the applicable series of debt securities, upon compliance with certain conditions:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">we may omit to comply with the covenant described under the heading &#8220;Consolidation, Merger and Sale of Assets&#8221; and certain other covenants set forth in the indenture, as well as any additional covenants which may be set forth in the applicable prospectus supplement; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">any omission to comply with those covenants will not constitute a Default or an Event of Default with respect to the debt securities of that series, or covenant defeasance.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">The conditions include:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">depositing with the trustee money and/or U.S. government obligations or, in the case of debt securities denominated in a single currency other than U.S. Dollars, government obligations of the government that issued or caused to be issued such currency, that, through the payment of interest and principal in accordance with their terms, will provide money in an amount sufficient in the opinion of a nationally recognized firm of independent public accountants or investment bank to pay and discharge each installment of principal of, premium and interest on and any mandatory sinking fund payments in respect of the debt securities of that series on the stated maturity of those payments in accordance with the terms of the indenture and those debt securities; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:152.5pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">delivering to the trustee an opinion of counsel to the effect that we have received from, or there has been published by, the United States Internal Revenue Service a ruling or, since the date of execution of the indenture, there has been a change in the applicable United States federal income tax law, in either case to the effect that, and based thereon such opinion shall confirm that, the holders and beneficial owners of the debt securities of that series will not recognize income, gain or loss for United States federal income tax purposes as a result of the deposit and related covenant defeasance and will be subject to United States federal income tax on the same amounts and in the same manner and at the same times as would have been the case if the deposit and related covenant defeasance had not occurred.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">No Personal Liability of Directors, Officers, Employees or Securityholders</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">None of our past, present or future directors, officers, employees or securityholders, as such, will have any liability for any of our obligations under the debt securities or the indenture or for any claim based on, or in respect or by reason of, such obligations or their creation. By accepting a debt security, each holder waives and releases all such liability. This waiver and release is part of the consideration for the issue of the debt securities. However, this waiver and release may not be effective to waive liabilities under U.S. federal securities laws, and it is the view of the SEC that such a waiver is against public policy.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Governing Law</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">The indenture and the debt securities, including any claim or controversy arising out of or relating to the indenture or the debt securities, will be governed by the laws of the State of New York.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">The indenture will provide that we, the trustee and the holders of the debt securities (by their acceptance of the debt securities) irrevocably waive, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to the indenture, the debt securities or the transactions contemplated thereby.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">The indenture will provide that any legal suit, action or proceeding arising out of or based upon the indenture or the transactions contemplated thereby may be instituted in the federal courts of the United States of America located in the City of New York or the courts of the State of New York in each case located in the City of New York, and we, the trustee and the holder of the debt securities (by their acceptance of the debt securities) irrevocably submit to the non-exclusive jurisdiction of such courts in any such suit, action or proceeding. The indenture will further provide that service of any process, summons, notice or document by mail (to the extent allowed under any applicable statute or rule of court) to such party&#8217;s address set forth in the indenture will be effective service of process for any suit, action or other proceeding brought in any such court. The indenture will further provide that we, the trustee and the holders of the debt securities (by their acceptance of the debt securities) irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the courts specified above and irrevocably and unconditionally waive and agree not to plead or claim any such suit, action or other proceeding has been brought in an inconvenient forum.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDOW">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">DESCRIPTION OF WARRANTS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">We may issue warrants for the purchase of shares of our common stock or preferred stock or of debt securities. We may issue warrants independently or together with other securities, and the warrants may be attached to or separate from any offered securities. Each series of warrants will be issued under a separate warrant agreement to be entered into between us and the investors or a warrant agent. The following summary of material provisions of the warrants and warrant agreements are subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable to a particular series of warrants. The terms of any warrants offered under a prospectus supplement may differ from the terms described below. We urge you to read the applicable prospectus supplement and any related free writing prospectus, as well as the complete warrant agreements and warrant certificates that contain the terms of the warrants.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">The particular terms of any issue of warrants will be described in the prospectus supplement relating to the issue. Those terms may include:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the number of shares of common stock or preferred stock purchasable upon the exercise of warrants to purchase such shares and the price at which such number of shares may be purchased upon such exercise;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the designation, stated value and terms (including, without limitation, liquidation, dividend, conversion and voting rights) of the series of preferred stock purchasable upon exercise of warrants to purchase preferred stock;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the principal amount of debt securities that may be purchased upon exercise of a debt warrant and the exercise price for the warrants, which may be payable in cash, securities or other property;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the date, if any, on and after which the warrants and the related debt securities, preferred stock or common stock will be separately transferable;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the terms of any rights to redeem or call the warrants;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreement and the warrants;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the date on which the right to exercise the warrants will commence and the date on which the right will expire;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">United States federal income tax consequences applicable to the warrants; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">any additional terms of the warrants, including terms, procedures, and limitations relating to the exchange, exercise and settlement of the warrants.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">Holders of equity warrants will not be entitled to:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">vote, consent or receive dividends;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">receive notice as stockholders with respect to any meeting of stockholders for the election of our directors or any other matter; or</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">exercise any rights as our stockholders.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">Each warrant will entitle its holder to purchase the principal amount of debt securities or the number of shares of preferred stock or common stock at the exercise price set forth in, or calculable as set forth in, the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the specified time on the expiration date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">A holder of warrant certificates may exchange them for new warrant certificates of different denominations, present them for registration of transfer and exercise them at the corporate trust office of the warrant agent or any other office indicated in the applicable prospectus supplement. Until any warrants to purchase debt </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:456.5pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">securities are exercised, the holder of the warrants will not have any rights of holders of the debt securities that can be purchased upon exercise, including any rights to receive payments of principal, premium or interest on the underlying debt securities or to enforce covenants in the applicable indenture. Until any warrants to purchase common stock or preferred stock are exercised, the holders of the warrants will not have any rights of holders of the underlying common stock or preferred stock, including any rights to receive dividends or payments upon any liquidation, dissolution or winding up on the common stock or preferred stock, if any.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">Prospective purchasers of warrants should be aware that special United States federal income tax, accounting and other considerations may be applicable to instruments such as warrants. The applicable prospectus supplement will describe such considerations, to the extent they are material, as they apply generally to purchasers of such warrants.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">As of September&#160;30, 2025, we had outstanding warrants to purchase an aggregate of 514,500 shares of our common stock, with an exercise price of $2.78 per share. These warrants may be exercised at any time from time to time, in whole or in part, commencing on March&#160;1, 2026 and expiring on August&#160;27, 2030. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDOU">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:238pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">DESCRIPTION OF UNITS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">We may issue&#160;units consisting of any combination of the other types of securities offered under this prospectus in one or more series. We may evidence each series of&#160;units by unit certificates that we will issue under a separate agreement. We may enter into unit agreements with a unit agent. Each unit agent will be a bank or trust company that we select. We will indicate the name and address of the unit agent in the applicable prospectus supplement relating to a particular series of&#160;units.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">The following description, together with the additional information included in any applicable prospectus supplement, summarizes the general features of the&#160;units that we may offer under this prospectus. You should read any prospectus supplement and any free writing prospectus that we may authorize to be provided to you related to the series of&#160;units being offered, as well as the complete unit agreements that contain the terms of the&#160;units. Specific unit agreements will contain additional important terms and provisions and we will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from another report that we file with the SEC, the form of each unit agreement relating to&#160;units offered under this prospectus.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">If we offer any&#160;units, certain terms of that series of&#160;units will be described in the applicable prospectus supplement, including, without limitation, the following, as applicable:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the designation and terms of the&#160;units and of the securities comprising the&#160;units, including whether and under what circumstances those securities may be held or transferred separately;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">any provisions of the governing unit agreement;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the price or prices at which such&#160;units will be issued;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the applicable United States federal income tax considerations relating to the&#160;units;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">any provisions for the issuance, payment, settlement, transfer or exchange of the&#160;units or of the securities comprising the&#160;units; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">any other terms of the&#160;units and of the securities comprising the&#160;units.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">The provisions described in this section, as well as those described under &#8220;Description of Capital Stock,&#8221; &#8220;Description of Debt Securities&#8221; and &#8220;Description of Warrants&#8221; will apply to the securities included in each unit, to the extent relevant and as may be updated in any prospectus supplements. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDOOS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:574pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">DESCRIPTION OF OUR SUBSCRIPTION RIGHTS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
          <font style="letter-spacing:-0.038pt;">As specified in any applicable prospectus supplement, we may issue subscription rights consisting of one or more debt securities, shares of preferred stock, shares of common stock or any combination of such securities. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-family:Arial, Helvetica, sans-serif;">
          <font style="letter-spacing:-0.342pt;">26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tGLSE">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">GLOBAL SECURITIES</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Book-Entry, Delivery and Form</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">Unless we indicate differently in any applicable prospectus supplement or free writing prospectus, the securities initially will be issued in book-entry form and represented by one or more global notes or global securities, or, collectively, global securities. The global securities will be deposited with, or on behalf of, The Depository Trust Company, New York, New York, as depositary, or DTC, and registered in the name of Cede &amp; Co., the nominee of DTC. Unless and until it is exchanged for individual certificates evidencing securities under the limited circumstances described below, a global security may not be transferred except as a whole by the depositary to its nominee or by the nominee to the depositary, or by the depositary or its nominee to a successor depositary or to a nominee of the successor depositary.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">DTC has advised us that it is:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.29pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">a limited-purpose trust company organized under the New York Banking Law;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.3pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">a &#8220;banking organization&#8221; within the meaning of the New York Banking Law;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.3pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">a member of the Federal Reserve System;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.3pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">a &#8220;clearing corporation&#8221; within the meaning of the New York Uniform Commercial Code; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.3pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">a &#8220;clearing agency&#8221; registered pursuant to the provisions of Section&#160;17A of the Exchange Act.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">DTC holds securities that its participants deposit with DTC. DTC also facilitates the settlement among its participants of securities transactions, such as transfers and pledges, in deposited securities through electronic computerized book-entry changes in participants&#8217; accounts, thereby eliminating the need for physical movement of securities certificates. &#8220;Direct participants&#8221; in DTC include securities brokers and dealers, including underwriters, banks, trust companies, clearing corporations and other organizations. DTC is a wholly-owned subsidiary of The Depository Trust &amp; Clearing Corporation, or DTCC. DTCC is the holding company for DTC, National Securities Clearing Corporation and Fixed Income Clearing Corporation, all of which are registered clearing agencies. DTCC is owned by the users of its regulated subsidiaries. Access to the DTC system is also available to others, which we sometimes refer to as indirect participants, that clear through or maintain a custodial relationship with a direct participant, either directly or indirectly. The rules applicable to DTC and its participants are on file with the SEC.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">Purchases of securities under the DTC system must be made by or through direct participants, which will receive a credit for the securities on DTC&#8217;s records. The ownership interest of the actual purchaser of a security, which we sometimes refer to as a beneficial owner, is in turn recorded on the direct and indirect participants&#8217; records. Beneficial owners of securities will not receive written confirmation from DTC of their purchases. However, beneficial owners are expected to receive written confirmations providing details of their transactions, as well as periodic statements of their holdings, from the direct or indirect participants through which they purchased securities. Transfers of ownership interests in global securities are to be accomplished by entries made on the books of participants acting on behalf of beneficial owners. Beneficial owners will not receive certificates representing their ownership interests in the global securities, except under the limited circumstances described below.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">To facilitate subsequent transfers, all global securities deposited by direct participants with DTC will be registered in the name of DTC&#8217;s partnership nominee, Cede &amp; Co., or such other name as may be requested by an authorized representative of DTC. The deposit of securities with DTC and their registration in the name of Cede &amp; Co. or such other nominee will not change the beneficial ownership of the securities. DTC has no knowledge of the actual beneficial owners of the securities. DTC&#8217;s records reflect only the identity of the direct participants to whose accounts the securities are credited, which may or may not be the beneficial owners. The participants are responsible for keeping account of their holdings on behalf of their customers.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">So long as the securities are in book-entry form, you will receive payments and may transfer securities only through the facilities of the depositary and its direct and indirect participants. We will maintain an office or agency in the location specified in the prospectus supplement for the applicable securities, where notices and demands in respect of the securities and the indenture may be delivered to us and where certificated securities may be surrendered for payment, registration of transfer or exchange.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">27</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">Conveyance of notices and other communications by DTC to direct participants, by direct participants to indirect participants and by direct participants and indirect participants to beneficial owners will be governed by arrangements among them, subject to any legal requirements in effect from time to time.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">Redemption notices will be sent to DTC. If less than all of the securities of a particular series are being redeemed, DTC&#8217;s practice is to determine by lot the amount of the interest of each direct participant in the securities of such series to be redeemed.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">Neither DTC nor Cede &amp; Co. (or such other DTC nominee) will consent or vote with respect to the securities. Under its usual procedures, DTC will mail an omnibus proxy to us as soon as possible after the record date. The omnibus proxy assigns the consenting or voting rights of Cede &amp; Co. to those direct participants to whose accounts the securities of such series are credited on the record date, identified in a listing attached to the omnibus proxy.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">So long as securities are in book-entry form, we will make payments on those securities to the depositary or its nominee, as the registered owner of such securities, by wire transfer of immediately available funds. If securities are issued in definitive certificated form under the limited circumstances described below and unless if otherwise provided in the description of the applicable securities herein or in the applicable prospectus supplement, we will have the option of making payments by check mailed to the addresses of the persons entitled to payment or by wire transfer to bank accounts in the United States designated in writing to the applicable trustee or other designated party at least 15&#160;days before the applicable payment date by the persons entitled to payment, unless a shorter period is satisfactory to the applicable trustee or other designated party.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">Redemption proceeds, distributions and dividend payments on the securities will be made to Cede &amp; Co., or such other nominee as may be requested by an authorized representative of DTC. DTC&#8217;s practice is to credit direct participants&#8217; accounts upon DTC&#8217;s receipt of funds and corresponding detail information from us on the payment date in accordance with their respective holdings shown on DTC records. Payments by participants to beneficial owners will be governed by standing instructions and customary practices, as is the case with securities held for the account of customers in bearer form or registered in &#8220;street name.&#8221; Those payments will be the responsibility of participants and not of DTC or us, subject to any statutory or regulatory requirements in effect from time to time. Payment of redemption proceeds, distributions and dividend payments to Cede &amp; Co., or such other nominee as may be requested by an authorized representative of DTC, is our responsibility, disbursement of payments to direct participants is the responsibility of DTC, and disbursement of payments to the beneficial owners is the responsibility of direct and indirect participants.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">Except under the limited circumstances described below, purchasers of securities will not be entitled to have securities registered in their names and will not receive physical delivery of securities. Accordingly, each beneficial owner must rely on the procedures of DTC and its participants to exercise any rights under the securities and the indenture.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">The laws of some jurisdictions may require that some purchasers of securities take physical delivery of securities in definitive form. Those laws may impair the ability to transfer or pledge beneficial interests in securities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">DTC may discontinue providing its services as securities depositary with respect to the securities at any time by giving reasonable notice to us. Under such circumstances, in the event that a successor depositary is not obtained, securities certificates are required to be printed and delivered.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">As noted above, beneficial owners of a particular series of securities generally will not receive certificates representing their ownership interests in those securities. However, if:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">DTC notifies us that it is unwilling or unable to continue as a depositary for the global security or securities representing such series of securities or if DTC ceases to be a clearing agency registered under the Exchange Act at a time when it is required to be registered and a successor depositary is not appointed within 90&#160;days of the notification to us or of our becoming aware of DTC&#8217;s ceasing to be so registered, as the case may be;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">we determine, in our sole discretion, not to have such securities represented by one or more global securities; or</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">28</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">an Event of Default has occurred and is continuing with respect to such series of securities, we will prepare and deliver certificates for such securities in exchange for beneficial interests in the global securities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">Any beneficial interest in a global security that is exchangeable under the circumstances described in the preceding sentence will be exchangeable for securities in definitive certificated form registered in the names that the depositary directs. It is expected that these directions will be based upon directions received by the depositary from its participants with respect to ownership of beneficial interests in the global securities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">We have obtained the information in this section and elsewhere in this prospectus concerning DTC and DTC&#8217;s book-entry system from sources that are believed to be reliable, but we take no responsibility for the accuracy of this information.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Euroclear and Clearstream</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">If so provided in the applicable prospectus supplement, you may hold interests in a global security through Clearstream Banking, S.A., which we refer to as &#8220;Clearstream,&#8221; or Euroclear Bank SA/NV, as operator of the Euroclear System, which we refer to as &#8220;Euroclear,&#8221; either directly if you are a participant in Clearstream or Euroclear or indirectly through organizations which are participants in Clearstream or Euroclear. Clearstream and Euroclear will hold interests on behalf of their respective participants through customers&#8217; securities accounts in the names of Clearstream and Euroclear, respectively, on the books of their respective U.S. depositaries, which in turn will hold such interests in customers&#8217; securities accounts in such depositaries&#8217; names on DTC&#8217;s books.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">Clearstream and Euroclear are securities clearance systems in Europe. Clearstream and Euroclear hold securities for their respective participating organizations and facilitate the clearance and settlement of securities transactions between those participants through electronic book-entry changes in their accounts, thereby eliminating the need for physical movement of certificates.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">Payments, deliveries, transfers, exchanges, notices and other matters relating to beneficial interests in global securities owned through Euroclear or Clearstream must comply with the rules and procedures of those systems. Transactions between participants in Euroclear or Clearstream, on one hand, and other participants in DTC, on the other hand, are also subject to DTC&#8217;s rules and procedures.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">Investors will be able to make and receive through Euroclear and Clearstream payments, deliveries, transfers and other transactions involving any beneficial interests in global securities held through those systems only on days when those systems are open for business. Those systems may not be open for business on days when banks, brokers and other institutions are open for business in the United States.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">Cross-market transfers between participants in DTC, on the one hand, and participants in Euroclear or Clearstream, on the other hand, will be effected through DTC in accordance with the DTC&#8217;s rules on behalf of Euroclear or Clearstream, as the case may be, by their respective U.S. depositaries; however, such cross-market transactions will require delivery of instructions to Euroclear or Clearstream, as the case may be, by the counterparty in such system in accordance with the rules and procedures and within the established deadlines (European time) of such system. Euroclear or Clearstream, as the case may be, will, if the transaction meets its settlement requirements, deliver instructions to its U.S. depositary to take action to effect final settlement on its behalf by delivering or receiving interests in the global securities through DTC, and making or receiving payment in accordance with normal procedures for same-day fund settlement. Participants in Euroclear or Clearstream may not deliver instructions directly to their respective U.S. depositaries.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">Due to time zone differences, the securities accounts of a participant in Euroclear or Clearstream purchasing an interest in a global security from a direct participant in DTC will be credited, and any such crediting will be reported to the relevant participant in Euroclear or Clearstream, during the securities settlement processing day (which must be a business day for Euroclear or Clearstream) immediately following the settlement date of DTC. Cash received in Euroclear or Clearstream as a result of sales of interests in a global security by or through a participant in Euroclear or Clearstream to a direct participant in DTC will be received with value on the settlement date of DTC but will be available in the relevant Euroclear or Clearstream cash account only as of the business day for Euroclear or Clearstream following DTC&#8217;s settlement date.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">29</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:470.5pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Other</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">The information in this section of this prospectus concerning DTC, Clearstream, Euroclear and their respective book-entry systems has been obtained from sources that we believe to be reliable, but we do not take responsibility for this information. This information has been provided solely as a matter of convenience. The rules and procedures of DTC, Clearstream and Euroclear are solely within the control of those organizations and could change at any time. Neither we nor the trustee nor any agent of ours or of the trustee has any control over those entities and none of us takes any responsibility for their activities. You are urged to contact DTC, Clearstream and Euroclear or their respective participants directly to discuss those matters. In addition, although we expect that DTC, Clearstream and Euroclear will perform the foregoing procedures, none of them is under any obligation to perform or continue to perform such procedures and such procedures may be discontinued at any time. Neither we nor any agent of ours will have any responsibility for the performance or nonperformance by DTC, Clearstream and Euroclear or their respective participants of these or any other rules or procedures governing their respective operations. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">30</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPOD">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">PLAN OF DISTRIBUTION</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">We may sell the securities from time to time pursuant to underwritten public offerings, &#8220;at the market offerings,&#8221; negotiated transactions, block trades or a combination of these methods or through underwriters or dealers, through agents and/or directly to one or more purchasers. The securities may be distributed from time to time in one or more transactions:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">at a fixed price or prices, which may be changed;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">at market prices prevailing at the time of sale;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">at prices related to such prevailing market prices;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">in &#8220;at-the-market offerings&#8221; &#8203;(as defined in Rule&#160;415 under the Securities Act);</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">at negotiated prices; or</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">through any method permitted by applicable law and described in a prospectus supplement.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">Each time that we sell securities covered by this prospectus, we will provide a prospectus supplement or supplements that will describe the method of distribution and set forth the terms and conditions of the offering of such securities, including the offering price of the securities and the proceeds to us, if applicable.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">Offers to purchase the securities being offered by this prospectus may be solicited directly. Agents may also be designated to solicit offers to purchase the securities from time to time. Any agent involved in the offer or sale of our securities will be identified in a prospectus supplement.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">If a dealer is utilized in the sale of the securities being offered by this prospectus, the securities will be sold to the dealer, as principal. The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">If an underwriter is utilized in the sale of the securities being offered by this prospectus, an underwriting agreement will be executed with the underwriter at the time of sale and the name of any underwriter will be provided in the prospectus supplement that the underwriter will use to make resales of the securities to the public. In connection with the sale of the securities, we or the purchasers of securities for whom the underwriter may act as agent, may compensate the underwriter in the form of underwriting discounts or commissions. The underwriter may sell the securities to or through dealers, and those dealers may receive compensation in the form of discounts, concessions or commissions from the underwriters and/or commissions from the purchasers for which they may act as agent. Unless otherwise indicated in a prospectus supplement, an agent will be acting on a best efforts basis and a dealer will purchase securities as a principal, and may then resell the securities at varying prices to be determined by the dealer.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">Any compensation paid to underwriters, dealers or agents in connection with the offering of the securities, and any discounts, concessions or commissions allowed by underwriters to participating dealers will be provided in the applicable prospectus supplement. Underwriters, dealers and agents participating in the distribution of the securities may be deemed to be underwriters within the meaning of the Securities Act, and any discounts and commissions received by them and any profit realized by them on resale of the securities may be deemed to be underwriting discounts and commissions. We may enter into agreements to indemnify underwriters, dealers and agents against civil liabilities, including liabilities under the Securities Act, or to contribute to payments they may be required to make in respect thereof and to reimburse those persons for certain expenses.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">Any common stock will be listed on The Nasdaq Capital Market, or Nasdaq, but any other securities may or may not be listed on a national securities exchange.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">To facilitate the offering of securities, and to the extent permitted by and in accordance with Regulation&#160;M under the Exchange Act, certain persons participating in the offering may engage in transactions that stabilize, maintain or otherwise affect the price of the securities. This may include over-allotments or short sales of the securities, which involve the sale by persons participating in the offering of more securities than were sold to them. In these circumstances, these persons would cover such over-allotments or short positions by making purchases in the open market or by exercising their over-allotment option, if any. In addition, these persons may stabilize or maintain the price of the securities by bidding for or purchasing securities in the open </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">31</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">market or by imposing penalty bids, whereby selling concessions allowed to dealers participating in the offering may be reclaimed if securities sold by them are repurchased in connection with stabilization transactions. The effect of these transactions may be to stabilize or maintain the market price of the securities at a level above that which might otherwise prevail in the open market. These transactions may be discontinued at any time.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">To the extent permitted by and in accordance with Regulation&#160;M under the Exchange Act, any underwriters who are qualified market makers on Nasdaq may engage in passive market making transactions in the securities on Nasdaq during the business day prior to the pricing of an offering, before the commencement of offers or sales of the securities. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive market maker&#8217;s bid, however, the passive market maker&#8217;s bid must then be lowered when certain purchase limits are exceeded.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">If indicated in the applicable prospectus supplement, underwriters or other persons acting as agents may be authorized to solicit offers by institutions or other suitable purchasers to purchase the securities at the public offering price set forth in the prospectus supplement, pursuant to delayed delivery contracts providing for payment and delivery on the date or dates stated in the prospectus supplement. These purchasers may include, among others, commercial and savings banks, insurance companies, pension funds, investment companies and educational and charitable institutions. Delayed delivery contracts will be subject to the condition that the purchase of the securities covered by the delayed delivery contracts will not at the time of delivery be prohibited under the laws of any jurisdiction in the United States to which the purchaser is subject. The underwriters and agents will not have any responsibility with respect to the validity or performance of these contracts.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">We may engage in &#8220;at-the-market offerings&#8221; into an existing trading market in accordance with Rule&#160;415(a)(4) under the Securities Act. In addition, we may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement so indicates, in connection with those derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party may use securities pledged by us or borrowed from us or others to settle those sales or to close out any related open borrowings of stock, and may use securities received from us in settlement of those derivatives to close out any related open borrowings of stock. The third party in such sale transactions will be an underwriter and, if not identified in this prospectus, will be named in the applicable prospectus supplement (or a post-effective amendment). In addition, we may otherwise loan or pledge securities to a financial institution or other third party that in turn may sell the securities short using this prospectus and an applicable prospectus supplement. Such financial institution or other third party may transfer its economic short position to investors in our securities or in connection with a concurrent offering of other securities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">The specific terms of any lock-up provisions in respect of any given offering will be described in the applicable prospectus supplement.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">The underwriters, dealers and agents may engage in transactions with us, or perform services for us, in the ordinary course of business for which they receive compensation.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">No securities may be sold under this prospectus without delivery, in paper format or in electronic format, or both, of the applicable prospectus supplement describing the method and terms of the offering.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">Under Rule&#160;15c6-1 of the Exchange Act, trades in the secondary market generally are required to settle in one business day, unless the parties to any such trade expressly agree otherwise. The applicable prospectus supplement may provide that the original issue date for your securities may be more than one scheduled business day after the trade date for your securities. Accordingly, in such a case, if you wish to trade securities on any date prior to the first business day before the original issue date for your securities, you will be required, by virtue of the fact that your securities initially are expected to settle in more than one scheduled business day after the trade date for your securities, to make alternative settlement arrangements to prevent a failed settlement.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">The anticipated date of delivery of offered securities will be set forth in the applicable prospectus supplement relating to each offer. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">32</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tLEMA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:550pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">LEGAL MATTERS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
          <font style="letter-spacing:-0.038pt;">Goodwin Procter LLP, Philadelphia, Pennsylvania, will pass upon certain legal matters relating to the issuance and sale of the securities offered hereby on behalf of Cognition Therapeutics, Inc. Additional legal matters may be passed upon for us or any underwriters, dealers or agents by counsel that we will name in the applicable prospectus supplement. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-family:Arial, Helvetica, sans-serif;">
          <font style="letter-spacing:-0.342pt;">33</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tEXP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:526pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">EXPERTS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
          <font style="letter-spacing:-0.038pt;">The consolidated financial statements of Cognition Therapeutics, Inc. appearing in Cognition Therapeutics, Inc.&#8217;s <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1455365/000155837025003341/cgtx-20241231x10k.htm">Annual Report (Form 10-K) for the year ended December&#160;31, 2024</a></font><font style="letter-spacing:-0.361pt;">,</font><font style="letter-spacing:-0.038pt;"> have been audited by Ernst &amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon, included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-family:Arial, Helvetica, sans-serif;">
          <font style="letter-spacing:-0.342pt;">34</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7.42pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 3.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:39pt; text-align:center; width:456pt; line-height:18.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:16pt;">
          <font style="letter-spacing:0.8pt;">$300,000,000</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;font-size:9.5pt;">&#8203;<font style="letter-spacing:0.19pt;"> </font></font>
        </div>
        <div style="position:relative;margin-top:74.5pt; text-align:center; width:456pt;">
          <img src="lg_cognition-4c.jpg" alt="[MISSING IMAGE: lg_cognition-4c.jpg]" height="80" width="321" >
        </div>
        <div style="margin-top:42pt; text-align:center; width:456pt; line-height:18.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:16pt;">
          <font style="letter-spacing:0.8pt;">Common Stock </font>
          <br >
          <font style="letter-spacing:0.8pt;">Preferred Stock</font>
          <br >
          <font style="letter-spacing:0.8pt;">Debt Securities</font>
          <br >
          <font style="letter-spacing:0.8pt;">Warrants</font>
          <br >
          <font style="letter-spacing:0.8pt;">Units</font>
          <br >
          <font style="letter-spacing:0.8pt;">Subscription Rights</font><font style="font-weight:normal;text-transform:uppercase;font-family:Times New Roman, Times, serif ;letter-spacing:0.32pt;"> </font>
        </div>
        <div style="margin-top:46.667pt; text-align:center; width:456pt;">
          <div style="margin-left: 31.579%; margin-right: 31.579%; margin-top: 46.6666666666667pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12pt;">
          <font style="text-transform:uppercase;letter-spacing:0.6pt;">PROSPECTUS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;font-size:10pt;">&#8203;<font style="letter-spacing:0.2pt;"> </font></font>
        </div>
        <div style="margin-top:13.333pt; text-align:center; width:456pt;">
          <div style="margin-left: 31.579%; margin-right: 31.579%; margin-top: 13.3333333333333pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:149pt; text-align:center; width:456pt; line-height:13.5pt;font-family:Arial, Helvetica, sans-serif;font-size:11pt;">
          <font style="letter-spacing:-0.418pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2025</font>
        </div>
        <div style="margin-top:86.483pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 86.4833333333335pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 3.5pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
    <div style="position:relative;overflow:hidden;min-height:775.71pt;page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="position:absolute;top:738.85pt;left:48.64pt;height:30pt;width:706.02pt;transform-origin:0pt -0pt;transform:rotate(-90deg) translate(0%, 0%);">
        <div style="width:706pt; line-height:9.5pt;color:#F7505F;font-size:8pt;">
          <font style="letter-spacing:-0.032pt;">The information in this prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</font><font style="color:#000000;letter-spacing:-0.304pt;"> </font>
          <br >
        </div>
      </div>
      <div style="margin-top:27.85pt;min-height:706pt;margin-bottom:21.86pt;margin-left:87.66pt;width:456pt;">
        <div style="text-align:right; width:456pt; line-height:12.5pt;color:#F7505F;">
          <font style="text-transform:uppercase;letter-spacing:-0.38pt;">Subject to Completion, dated December 18, 2025</font>&#8203;</div>
        <div style="margin-top:6pt; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">PROSPECTUS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:8.4pt; text-align:center; width:456pt;">
          <img src="lg_cognition-4c.jpg" alt="[MISSING IMAGE: lg_cognition-4c.jpg]" height="80" width="321" >
        </div>
        <div style="margin-top:11.3pt; text-align:center; width:456pt; line-height:18.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:16pt;">
          <font style="letter-spacing:0.8pt;">$75,000,000</font>
        </div>
        <div style="margin-top:27pt; text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.5pt;">Common Stock</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.04pt;">We have entered into an Open Market Sale Agreement</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:-0.285pt;">SM</font><font style="letter-spacing:-0.04pt;"> , or Sales Agreement, with Jefferies LLC, or the Sales Agent, relating to the sale of shares of our common stock, par value $0.001 per share, offered by this prospectus. In accordance with the terms of the Sales Agreement, under this prospectus, we may offer and sell shares of our common stock having an aggregate offering price of up to $75,000,000 from time to time through or to the Sales Agent, as sales agent or principal.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.04pt;">Our common stock is traded on The Nasdaq Capital Market under the symbol &#8220;CGTX.&#8221; On December&#160;</font><font style="letter-spacing:-0.38pt;">16, </font><font style="letter-spacing:-0.04pt;">2025, the last reported sale price of our common stock was $</font><font style="letter-spacing:-0.38pt;">1.52</font><font style="letter-spacing:-0.04pt;"> per share.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.04pt;">Sales of our common stock, if any, under this prospectus will be made in negotiated transactions, including block trades, or sales deemed to be an &#8220;at the market offering&#8221; as defined in Rule&#160;415(a)(4) under the Securities Act of 1933, as amended, or the Securities Act. The Sales Agent is not required to sell any specific amount of securities but will use commercially reasonable efforts consistent with their normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of The Nasdaq Stock Market LLC on mutually agreed terms between the Sales Agent and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.04pt;">The compensation to the Sales Agent for sales of our common stock sold pursuant to the Sales Agreement will be equal to 3.0% of the aggregate gross proceeds of any shares of our common stock sold under the Sales Agreement. In connection with the sale of our common stock on our behalf, the Sales Agent will be deemed to be an &#8220;underwriter&#8221; within the meaning of the Securities Act and the compensation paid to the Sales Agent will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to the Sales Agent with respect to certain liabilities, including liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended, or the Exchange Act. See &#8220;Plan of Distribution&#8221; beginning on page </font><font style="letter-spacing:-0.38pt;">21</font><font style="letter-spacing:-0.04pt;"> for additional information regarding the compensation payable to the Sales Agent.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.5pt;">We are an &#8220;emerging growth company&#8221; and &#8220;smaller reporting company&#8221; under the federal securities laws and, as such, are subject to reduced public company reporting requirements. See &#8220;Prospectus Summary&#8201;-&#8201;Implications of Being an Emerging Growth Company.&#8221;</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.5pt;">Investing in our common stock involves a high degree of risk. See &#8220;Risk Factors&#8221; beginning on page <a href="#tRIFA1">8</a> of this prospectus and the &#8220;Risk Factors&#8221; section contained in the documents incorporated by reference in this prospectus before investing in our common stock.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.5pt;">NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:18.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:16pt;">
          <font style="letter-spacing:0.8pt;">Jefferies</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.32pt;"> </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.04pt;">The date of this prospectus is &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;, 2025</font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="TOC2">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:318pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;margin-top:0pt;border-collapse: collapse;border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <tr style="line-height:10pt;min-height:23.75pt;height:23.75pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:11.5pt 0pt 2.5pt 0pt; width:423pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.5pt;">TABLE OF CONTENTS</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:423pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">Page</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <font style="letter-spacing:0.475pt;">Prospectus</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tATP1"><font style="letter-spacing:-0.038pt;">About This Prospectus </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tATP1">1</a></font><a href="#tATP1"> </a>
            </td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPRSU"><font style="letter-spacing:-0.038pt;">Prospectus Summary </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tPRSU">2</a></font><a href="#tPRSU"> </a>
            </td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tTHOF"><font style="letter-spacing:-0.038pt;">The Offering </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tTHOF">6</a></font><a href="#tTHOF"> </a>
            </td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tRIFA1"><font style="letter-spacing:-0.038pt;">Risk Factors </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tRIFA1">8</a></font><a href="#tRIFA1"> </a>
            </td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSNRF"><font style="letter-spacing:-0.038pt;">Special Note Regarding Forward-Looking Statements </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tSNRF">11</a></font><a href="#tSNRF"> </a>
            </td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUOP1"><font style="letter-spacing:-0.038pt;">Use of Proceeds </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tUOP1">13</a></font><a href="#tUOP1"> </a>
            </td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDIPO"><font style="letter-spacing:-0.038pt;">Dividend Policy </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tDIPO">14</a></font><a href="#tDIPO"> </a>
            </td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDIF1"><font style="letter-spacing:-0.038pt;">Dilution </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tDIF1">15</a></font><a href="#tDIF1"> </a>
            </td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOCS1"><font style="letter-spacing:-0.038pt;">Description of Capital Stock </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tDOCS1">17</a></font><a href="#tDOCS1"> </a>
            </td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPOD1"><font style="letter-spacing:-0.038pt;">Plan of Distribution </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tPOD1">21</a></font><a href="#tPOD1"> </a>
            </td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLEMA1"><font style="letter-spacing:-0.038pt;">Legal Matters </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tLEMA1">23</a></font><a href="#tLEMA1"> </a>
            </td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXP1"><font style="letter-spacing:-0.038pt;">Experts </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tEXP1">24</a></font><a href="#tEXP1"> </a>
            </td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tWYCF1"><font style="letter-spacing:-0.038pt;">Where You Can Find More Information </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tWYCF1">25</a></font><a href="#tWYCF1"> </a>
            </td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tIBR"><font style="letter-spacing:-0.038pt;">Incorporation by Reference </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tIBR">26</a></font><a href="#tIBR"> </a>
            </td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXIN"><font style="letter-spacing:-0.038pt;">Exhibit Index </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tEXIN">II-2</a></font><a href="#tEXIN"> </a>
            </td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 1.5pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSIG"><font style="letter-spacing:-0.038pt;">Signatures </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tSIG">II-5</a></font><a href="#tSIG"> </a>
            </td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="border-bottom:0.75pt solid #000000; ;padding:3pt 0pt 12pt 0pt; width:423pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPOA"><font style="letter-spacing:-0.038pt;">Power of Attorney </font></a>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;border-bottom:0.75pt solid #000000; ;">&#8203;</td>
            <td style="padding:3pt 0pt 12pt 0pt;border-bottom:0.75pt solid #000000; ; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 12pt 0pt;border-bottom:0.75pt solid #000000; ; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.361pt;"><a href="#tPOA">II-5</a></font>
            </td>
            <td style="padding:0pt;padding-left:2.855pt;width:0pt;border-bottom:0.75pt solid #000000; ;">&#8203;</td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.036pt;">i</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tATP1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:78pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">ABOUT THIS PROSPECTUS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">This prospectus is part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission, or the SEC, using a &#8220;shelf&#8221; registration process. Under this shelf registration process, we may from time to time sell shares of our common stock having an aggregate offering price of up to $75,000,000 under this prospectus at prices and on terms to be determined by market conditions at the time of the offering. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">This prospectus describes the terms of this offering of common stock and also adds to and updates information contained in the documents incorporated by reference into this prospectus. To the extent there is a conflict between the information contained in this prospectus, on the one hand, and the information contained in any document incorporated by reference into this prospectus that was filed with the SEC before the date of this prospectus, on the other hand, you should rely on the information in this prospectus. If any statement in one of these documents is inconsistent with a statement in another document having a later date &#8212; for example, a document incorporated by reference into this prospectus that was filed after the date of this prospectus &#8212; the statement in the document having the later date modifies or supersedes the earlier statement.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">We have not, and the Sales Agent has not, authorized anyone to provide you with any information other than that contained or incorporated by reference in this prospectus or any accompanying prospectus supplement or related free writing prospectus to which we have referred you. Neither we nor the Sales Agent take any responsibility for, and can provide no assurance as to the reliability of, any other information others may give you. We are not, and the Sales Agent is not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted or in which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. You should assume that the information appearing in this prospectus, the documents incorporated by reference herein and any free writing prospectus that we have authorized for use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have changed since those dates. You should read this prospectus, the documents incorporated by reference herein and any free writing prospectus that we have authorized for use in connection with this offering, in their entirety before making an investment decision.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">When we refer to &#8220;Cognition,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and the &#8220;Company&#8221; in this prospectus, we mean Cognition Therapeutics, Inc., and its wholly owned subsidiary unless otherwise specified.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">&#8220;Cognition Therapeutics&#8221; the &#8220;Cognition Therapeutics&#8221; logo, and other trademarks, trade names, or service marks of Cognition Therapeutics, Inc. appearing in this prospectus are the property of Cognition Therapeutics, Inc. All other trademarks, trade names, and service marks appearing in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus may be referred to without the </font><font style=" position:relative; bottom:4pt;font-size:7pt;letter-spacing:-0.266pt;">&#174;</font><font style="letter-spacing:-0.038pt;"> and </font><font style="letter-spacing:-0.361pt;">&#8482;</font><font style="letter-spacing:-0.038pt;"> symbols, but such references should not be construed as any indicator that their respective owners will not assert their rights thereto.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tPRSU">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
            <font style="text-transform:uppercase;letter-spacing:0.5pt;">PROSPECTUS SUMMARY</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:18pt; width:456pt; line-height:11.5pt;font-style:italic;">This summary highlights selected information contained elsewhere in this prospectus and in the documents we incorporate by reference. This summary does not contain all of the information you should consider before making an investment decision. You should read this entire prospectus carefully, especially the risks of investing in our common stock discussed under &#8220;Risk Factors&#8221; beginning on page <a href="#tRIFA1">8</a> of this prospectus, along with our consolidated financial statements and notes to those consolidated financial statements and the other information incorporated by reference in this prospectus.<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
          <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
            <font style="letter-spacing:0.475pt;">Overview</font><font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="margin-top:2pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.038pt;">We are a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (&#8220;CNS&#8221;) and retina. Currently available therapies for these diseases are limited, with few Alzheimer&#8217;s disease treatments, two approved treatments for geographic atrophy (&#8220;GA&#8221;) secondary to dry age-related macular degeneration (&#8220;dAMD&#8221;) and no approved treatments for dementia with Lewy bodies (&#8220;DLB&#8221;). Our goal is to develop disease-modifying treatments for people with these degenerative disorders by initially leveraging our expertise in the &#963;-2 (sigma-2) receptor (&#8220;S2R&#8221;), which is expressed by multiple cell types, including neuronal synapses, and acts as a key regulator of cellular damage commonly associated with certain age-related degenerative diseases of the CNS and retina.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.038pt;">Our lead candidate for the treatment of age-related degenerative diseases is zervimesine (CT1812). Data indicates that zervimesine antagonizes the binding and toxicity of amyloid beta oligomers via targeting the S2R complex and represents a mechanism that is functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. Clinical results support this hypothesis, and our clinical trial findings provide evidence that the displacement of oligomers from synapses via zervimesine engagement with the S2R results in improved synapse function.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.038pt;">Top-line results from the Phase&#160;2 COG0201 SHINE study were reported in July&#160;2024 with additional data reported in October&#160;2024. An end-of-Phase&#160;2 meeting was conducted on July&#160;9, 2025 to review the results of the SHINE study and Cognition&#8217;s proposed plan for a Phase&#160;3 clinical program with the U.S. Food and Drug Administration (&#8220;FDA&#8221;). Formal minutes were provided by the FDA in August&#160;2025 confirming our Phase&#160;3 clinical program plan.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.038pt;">SHINE was a randomized, double-blind, placebo-controlled trial that enrolled 153 adults with mild-to-moderate Alzheimer&#8217;s disease. Participants were evenly randomized into two zervimesine dose groups (100&#160;mg or 300 mg) and one placebo group, who were dosed daily for six&#160;months. Endpoints included safety and biomarker evidence of disease modification as well as cognitive function, as measured by ADAS-Cog 11. SHINE met its primary endpoints of safety and tolerability.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.038pt;">A prespecified analysis conducted on SHINE results identified plasma p-tau217 as a biomarker that may predict participants with mild-to-moderate Alzheimer&#8217;s disease likely to respond to zervimesine therapy. Participants treated with zervimesine (pooled 100 mg and 300 mg) who had baseline levels of plasma p-tau217 below the median of 1.0 pg/mL experienced a 95% reduction of cognitive decline at week 26 as measured by ADAS-Cog 11 relative to placebo-treated participants. P-tau217 is an important biomarker that reflects total brain amyloid and tau pathology.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.038pt;">In the overall modified intent-to-treat population in SHINE, participants treated with once-daily oral zervimesine experienced less cognitive decline than those treated with placebo. As measured with ADAS-Cog 11, zervimesine-treated participants (pooled 100 mg and 300 mg) experienced a mean 38% slowing of decline at six&#160;months from baseline compared to placebo-treated participants. This difference did not achieve statistical significance. These results are comparable in magnitude to what was achieved with currently approved monoclonal antibody treatments, with the convenience of once-daily oral administration. There were consistent trends favoring zervimesine in other cognitive measures: ADAS-Cog 13, cognitive composite, mini-mental state exam, or MMSE; as well as in functional measures of activities of daily living (ADCS-ADL) and of clinical global impression of change (ADCS-CGIC).</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.038pt;">In the overall study population, participants treated with zervimesine for six&#160;months had reductions in plasma biomarkers associated with Alzheimer&#8217;s disease processes compared to placebo participants. Further analysis </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.361pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.038pt;">showed that the individuals with below-median plasma p-Tau217 experienced a pronounced reduction in these key plasma biomarkers compared to placebo. Significant reductions were observed in the level of glial fibrillary acidic protein (GFAP), a protein associated with neuroinflammation. Neurofilament light, a protein associated with neurodegeneration was also reduced in participants treated with zervimesine compared to placebo. Similarly, amyloid beta monomers (A&beta;) and p-Tau217, which are proteins that build up in patients with Alzheimer&#8217;s disease, were lower in participants treated with zervimesine for six&#160;months compared to placebo-treated individuals. These findings were presented at the AD/PD</font><font style="letter-spacing:-0.361pt;">&#8482;</font><font style="letter-spacing:-0.038pt;"> 2025 Alzheimer&#8217;s &amp; Parkinson&#8217;s Diseases Conference in April&#160;2025.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.038pt;">Top-line results from the Phase&#160;2 COG1201 SHIMMER study were presented at the International Lewy Body Dementia Conference (ILBDC) in January&#160;2025 and at the Alzheimer&#8217;s Association International Conference (AAIC) in July&#160;2025. The study enrolled 130 participants with mild-to-moderate DLB who were randomized evenly to one of three dose groups: two treated with once-daily oral zervimesine (100 mg or 300 mg) and one treated with placebo. To be eligible, participants were between 50 and 80&#160;years of age, received a diagnosis of probable DLB, and had a MMSE score of between 18 and 27. The study met its primary endpoints of safety and tolerability.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.038pt;">Zervimesine-treated DLB patients scored an average of 86% better than placebo-treated patients on the neuropsychiatric inventory (NPIA-L or NPI-12) at the end of the study. This tool describes the frequency and severity of 12 behavioral symptoms including hallucinations, delusions and anxiety. Compared to placebo-treated participants, those treated with zervimesine performed an average of 52% better on the ADCS-ADL scale, a measure of activities of daily living; an average of 91% better on the CAF, a measure of cognitive fluctuations; an average of 62% better on the Unified Parkinson&#8217;s Disease Rating Scale (UPDRS) Part&#160;III, a measure of motor function such as gait, balance, and tremor.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.038pt;">In June&#160;2025, Cognition received an anonymous philanthropic donation to substantially fund an expanded access program (&#8220;EAP&#8221;) for people with DLB. The EAP will be open to eligible SHIMMER participants who completed the Phase&#160;2 study as well as additional patients with a diagnosis of mild-to-moderate DLB who meet the criteria for this program. Participants will be provided with 100 mg of oral zervimesine to take daily for approximately one year. Eight U.S. sites, all of which were active in the SHIMMER study, were selected to participate in the EAP.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.038pt;">Top-line results from the Phase&#160;2 COG2201 MAGNIFY study of zervimesine in adults with GA secondary to dry AMD were reported in May&#160;2025. The MAGNIFY study was voluntarily concluded in January&#160;2025 after approximately 100 of the planned 246 participants were enrolled to allow the Company to focus its resources on clinical programs in Alzheimer&#8217;s disease and DLB. Top-line results show zervimesine-treated participants had 29% slower GA lesion growth (by slope analysis) on average and at 18&#160;months their lesions were 28% smaller compared to placebo. The GA lesion reduction is comparable to what was reported with currently approved complement inhibitors. Notable differences between the intravitreal complement inhibitors and zervimesine treatment included the convenience of once-daily oral administration and no conversion from dry AMD to choroidal neovascularization (or &#8220;CNV&#8221;), which is a risk factor of treatment with intravitreal complement inhibitors.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.038pt;">A &#8220;segment&#8221; analysis was also conducted to determine the change in GA lesion growth between six-month treatment periods. This analysis shows that the reduction in GA lesion growth increased after 12&#160;months of treatment. The change in lesion growth between 12 and 18&#160;months was 52.7% slower in zervimesine-treated versus placebo-treated participants. The change in ellipsoid zone area, a biomarker of GA progression, also trended in favor of zervimesine treatment compared to placebo. The thickness and integrity of the ellipsoid zone has been correlated with photoreceptor health and visual acuity. Importantly, this effect was also observed to widen over time.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.038pt;">In the above three Phase&#160;2 studies, zervimesine was observed to be generally well tolerated. The average age of participants was approximately 75&#160;years. Among the 238 participants treated with zervimesine, there were 23 incidents of transient treatment-emergent elevations in the liver function test (&#8220;LFT&#8221;) that were greater than 3xULN (9.6%) during the treatment period. Of these incidents, ten occurred in the SHINE study, nine in the SHIMMER study and four in the MAGNIFY study. In these participants, the elevated liver enzymes subsided after cessation of drug with no evidence of permanent liver injury. Overall, adverse events (AEs) were well </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.361pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-bottom:33.5pt; margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.038pt;">balanced between treatment and placebo arms; serious AEs occurred at a comparable or higher rate in placebo-treated participants than in those treated with zervimesine in the above studies. Twenty-eight zervimesine-treated (11.8%) and 11 placebo-treated (4.6%) participants discontinued from these studies due to treatment-emergent adverse events.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.038pt;">The above Overview covers only the most recently concluded studies in each indication. The following table highlights findings from these and subsequent clinical programs:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <table style="width:456pt;margin-top:10.5pt;border-collapse: collapse;border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; font-style:normal;font-weight:bold;font-variant:normal;text-transform:uppercase;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:8pt;">
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:8pt;">
              <td style="border-bottom:1px solid #000000;padding:9.833pt 0pt 1.667pt 0pt; width:80pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="text-transform:uppercase;letter-spacing:0.4pt;">Indication </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:9.833pt 0pt 1.667pt 0pt; width:48pt;">
                <div style="text-align:center;">
                  <font style="text-transform:uppercase;letter-spacing:0.4pt;">Study </font>
                  <br >
                  <font style="text-transform:uppercase;letter-spacing:0.4pt;">Identifier </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:9.833pt 0pt 1.667pt 0pt; width:72pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="text-transform:uppercase;letter-spacing:0.4pt;">NCT Number </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:9.833pt 0pt 1.667pt 0pt; width:48pt;">
                <div style="text-align:center;">
                  <font style="text-transform:uppercase;letter-spacing:0.4pt;">Clinical </font>
                  <br >
                  <font style="text-transform:uppercase;letter-spacing:0.4pt;">Phase </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:9.833pt 0pt 1.667pt 0pt; width:48pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="text-transform:uppercase;letter-spacing:0.4pt;">Status </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:9.833pt 0pt 1.667pt 0pt; width:120pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="text-transform:uppercase;letter-spacing:0.4pt;">Key Findings </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:9.5pt;">
              <td style="padding:2.75pt 0pt 1.5pt 0pt; width:0pt;" colspan="16">
                <font style="letter-spacing:0.475pt;">Alzheimer&#8217;s Disease (AD)</font>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:80pt;text-align:left;">
                <font style="letter-spacing:-0.038pt;">MCI-early </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;white-space:normal;">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.361pt;">COG0203 (START) </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:72pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.361pt;">NCT05531656 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;">
                <div style="text-align:center;font-style:italic;">Phase&#160;2</div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.038pt;">ongoing </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:120pt;white-space:normal;text-align:left;">
                <font style="letter-spacing:-0.038pt;">Up to 540 participants with MCI or early AD. This study has completed enrollment. </font>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:80pt;text-align:left;">
                <font style="letter-spacing:-0.038pt;">mild-moderate </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;white-space:normal;">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.361pt;">COG0201 (SHINE) </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:72pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.361pt;">NCT03507790 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;white-space:normal;">
                <div style="text-align:center;font-style:italic;">Phase&#160;2 (n=153)</div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.038pt;">complete </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:120pt;white-space:normal;text-align:left;">
                <font style="letter-spacing:-0.038pt;">Participants treated with zervimesine experienced a cognitive benefit compared to placebo </font>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:80pt;text-align:left;">
                <font style="letter-spacing:-0.038pt;">mild-moderate </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;white-space:normal;">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.361pt;">COG0202 (SEQUEL) </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:72pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.361pt;">NCT04735536 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;white-space:normal;">
                <div style="text-align:center;font-style:italic;">Phase&#160;2 (n=16)</div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.038pt;">complete </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:120pt;white-space:normal;text-align:left;">
                <font style="letter-spacing:-0.038pt;">Participants treated with zervimesine exhibited improvement across prespecified EEG parameters </font>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:80pt;text-align:left;">
                <font style="letter-spacing:-0.038pt;">mild-moderate </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;white-space:normal;">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.361pt;">COG0105 (SPARC) </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:72pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.361pt;">NCT03493282 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;white-space:normal;">
                <div style="text-align:center;font-style:italic;">Phase&#160;1 (n=23)</div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.038pt;">complete </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:120pt;white-space:normal;text-align:left;">
                <font style="letter-spacing:-0.038pt;">Treatment with zervimesine was assessed using various imaging modalities, including PET imaging and volumetric MRI (vMRI) </font>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:80pt;text-align:left;">
                <font style="letter-spacing:-0.038pt;">mild-moderate </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;white-space:normal;">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.361pt;">COG0104 (SNAP) </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:72pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.361pt;">NCT03522129 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;white-space:normal;">
                <div style="text-align:center;font-style:italic;">Phase&#160;1 (n=3)</div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.038pt;">complete </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:120pt;white-space:normal;text-align:left;">
                <font style="letter-spacing:-0.038pt;">Confirmed preclinical findings showing an increase in A&beta; oligomers in CSF, suggesting increased off-rate from receptors </font>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:9.5pt;">
              <td style="padding:3pt 0pt 1.5pt 0pt; width:0pt;" colspan="16">
                <font style="letter-spacing:0.475pt;">Dementia with Lewy Bodies (DLB)</font>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:80pt;text-align:left;">
                <font style="letter-spacing:-0.038pt;">mild-moderate </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;white-space:normal;">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.361pt;">COG1201 (SHIMMER) </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:72pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.361pt;">NCT05225415 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;white-space:normal;">
                <div style="text-align:center;font-style:italic;">Phase&#160;2 (n=130)</div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.038pt;">complete </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:120pt;white-space:normal;text-align:left;">
                <font style="letter-spacing:-0.038pt;">Participants treated with zervimesine experienced benefits across behavioral, functional, cognitive and motor scales </font>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:80pt;text-align:left;">
                <font style="letter-spacing:-0.038pt;">Mild-moderate </font>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;white-space:normal;">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.361pt;">COG1202 (EAP) </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:72pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.361pt;">NCT06961760 </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;">
                <div style="text-align:center;font-style:italic;">n/a</div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:48pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.038pt;">ongoing </font>
                </div>
              </td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:0pt; width:4pt;">&#8203;</td>
              <td style="padding:1.333pt 0pt 0.667pt 0pt; width:120pt;white-space:normal;text-align:left;">
                <font style="letter-spacing:-0.038pt;">Initially, the EAP will accommodate approximately 30 individuals with DLB. Currently, fully enrolled. </font>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:9.5pt;">
              <td style="padding:3pt 0pt 1.5pt 0pt; width:0pt;" colspan="16">
                <font style="letter-spacing:0.475pt;">Geographic Atrophy Secondary to Dry AMD</font>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
              <td style="border-bottom:0.75pt solid #000000; ;padding:1.333pt 0pt 12pt 0pt; width:80pt;text-align:left;">
                <font style="letter-spacing:-0.361pt;">GA </font>
              </td>
              <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:4pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:4pt;">&#8203;</td>
              <td style="border-bottom:0.75pt solid #000000; ;padding:1.333pt 0pt 12pt 0pt; width:48pt;white-space:normal;">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.361pt;">COG2201 (MAGNIFY) </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:4pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:4pt;">&#8203;</td>
              <td style="border-bottom:0.75pt solid #000000; ;padding:1.333pt 0pt 12pt 0pt; width:72pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.361pt;">NCT05893537 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:4pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:4pt;">&#8203;</td>
              <td style="border-bottom:0.75pt solid #000000; ;padding:1.333pt 0pt 12pt 0pt; width:48pt;white-space:normal;">
                <div style="text-align:center;font-style:italic;">Phase&#160;2 (n=100)</div>
              </td>
              <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:4pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:4pt;">&#8203;</td>
              <td style="border-bottom:0.75pt solid #000000; ;padding:1.333pt 0pt 12pt 0pt; width:48pt;">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.038pt;">concluded </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:4pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:4pt;">&#8203;</td>
              <td style="border-bottom:0.75pt solid #000000; ;padding:1.333pt 0pt 12pt 0pt; width:120pt;white-space:normal;text-align:left;">
                <font style="letter-spacing:-0.038pt;">Participants treated with zervimesine experienced slower growth of their GA lesions over the course of the study</font>
              </td>
              <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:0pt;">&#8203;</td>
            </tr>
          </table>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.361pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
            <font style="letter-spacing:0.5pt;">Corporate Information</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:2pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.038pt;">We were incorporated under the laws of the State of Delaware on August&#160;21, 2007. Our primary executive offices are located at 2500 Westchester Ave., Purchase, NY 10577, and our telephone number is 412-481-2210. Our corporate website is www.cogrx.com. The information contained on, or accessible through, our website is not incorporated by reference into this prospectus, and you should not consider any information contained in, or that can be accessed through, our website as part of this prospectus or in deciding whether to purchase our common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
            <font style="letter-spacing:0.5pt;">Implications of Being an Emerging Growth Company and Smaller Reporting Company</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:2pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.038pt;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We will remain an emerging growth company until the earliest of (1)&#160;December&#160;31, 2026, (2)&#160;the beginning of the first fiscal year after our annual gross revenue is $1.235&#160;billion or more, (3)&#160;the date on which we have, during the previous three-year period, issued more than $1.0&#160;billion in non-convertible debt securities and (4)&#160;as of the end of any fiscal year in which the market value of our common stock held by non-affiliates exceeded $700&#160;million as of the end of the second quarter of that fiscal year.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.038pt;">For as long as we remain an &#8220;emerging growth company,&#8221; we may take advantage of certain exemptions from various reporting requirements that are applicable to public companies that are not &#8220;emerging growth companies&#8221; including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation and financial statements in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote to approve executive compensation and shareholder approval of any golden parachute payments not previously approved. We will take advantage of these reporting exemptions until we are no longer an &#8220;emerging growth company.&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.038pt;">The JOBS Act provides that an &#8220;emerging growth company&#8221; can take advantage of an extended transition period for complying with new or revised accounting standards. We have irrevocably elected not to avail ourselves of this exemption and, therefore, we are subject to the same new or revised accounting standards as other public companies that are not &#8220;emerging growth companies.&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.038pt;">We are also a &#8220;smaller reporting company,&#8221; as defined in Item&#160;10(f)(1) of Regulation&#160;S-K. We will remain a smaller reporting company until the last day of the fiscal year so long as either (i)&#160;the market value of our common stock held by non-affiliates exceeds $250&#160;million as of the end of that year&#8217;s second fiscal quarter, or (ii)&#160;our annual revenues exceeded $100&#160;million during such completed fiscal year and the market value of our common stock held by non-affiliates exceeds $700&#160;million as of the end of that year&#8217;s second fiscal quarter. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal&#160;years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.361pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tTHOF">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
            <font style="text-transform:uppercase;letter-spacing:0.5pt;">THE OFFERING</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:12pt; line-height:11.5pt;">
              <font style="letter-spacing:-0.038pt;">Common stock offered by us </font>
            </div>
          </div>
          <div style="margin-left:180pt; margin-top:-11.5pt; width:276pt; line-height:12pt;">
            <font style="letter-spacing:-0.038pt;">Shares of our common stock having an aggregate offering price of up to $75,000,000</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:18pt; line-height:11.5pt;">
              <font style="letter-spacing:-0.038pt;">Manner of offering </font>
            </div>
          </div>
          <div style="margin-left:180pt; margin-top:-11.5pt; width:276pt; line-height:12pt;">
            <font style="letter-spacing:-0.038pt;">&#8220;At the market offering&#8221; that may be made from time to time through or to, at our option, the Sales Agent, as sales agent or principal. See &#8220;Plan of Distribution.&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:18pt; line-height:11.5pt;">
              <font style="letter-spacing:-0.038pt;">Common stock to be outstanding immediately after this offering </font>
            </div>
          </div>
          <div style="margin-left:180pt; margin-top:-11.5pt; width:276pt; line-height:12pt;">
            <font style="letter-spacing:-0.361pt;">137,610,183</font><font style="letter-spacing:-0.038pt;"> shares, assuming the sale of </font><font style="letter-spacing:-0.361pt;">49,342,105</font><font style="letter-spacing:-0.038pt;"> shares of our common stock in this offering at a price of $</font><font style="letter-spacing:-0.361pt;">1.52</font><font style="letter-spacing:-0.038pt;"> per share, which was the last reported sale price on The Nasdaq Capital Market on December&#160;16, 2025. The actual number of shares issued and outstanding will vary based on the sales price of our common stock under this offering.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:18pt; line-height:11.5pt;">
              <font style="letter-spacing:-0.038pt;">Use of proceeds </font>
            </div>
          </div>
          <div style="margin-left:180pt; margin-top:-11.5pt; width:276pt; line-height:12pt;">
            <font style="letter-spacing:-0.038pt;">We currently intend to use the net proceeds of this offering primarily for general corporate purposes, which may include funding research, clinical development, process development and manufacturing of our product candidates, working capital and capital expenditures. See &#8220;Use of Proceeds.&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:18pt; line-height:11.5pt;">
              <font style="letter-spacing:-0.038pt;">Risk factors </font>
            </div>
          </div>
          <div style="margin-left:180pt; margin-top:-11.5pt; width:276pt; line-height:12pt;">
            <font style="letter-spacing:-0.038pt;">An investment in our common stock involves a high degree of risk. See &#8220;Risk Factors&#8221; beginning on page </font><font style="letter-spacing:-0.361pt;"><a href="#tRIFA1">8</a></font><font style="letter-spacing:-0.038pt;"> of this prospectus and the similarly titled sections in the documents incorporated by reference into this prospectus.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:18pt; line-height:11.5pt;">
              <font style="letter-spacing:-0.038pt;">Nasdaq Capital Market symbol </font>
            </div>
          </div>
          <div style="margin-left:180pt; margin-top:-11.5pt; width:276pt; line-height:12pt;">
            <font style="letter-spacing:-0.361pt;">CGTX</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="margin-top:18pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.038pt;">The number of shares of our common stock to be outstanding immediately after this offering is based on 88,268,078 shares of our common stock outstanding as of September&#160;30, 2025, and excludes as of such date:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
            <font style="letter-spacing:-0.361pt;">&#9642;</font>
            <br >
          </div>
          <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:-0.038pt;">3,366,840 shares of our common stock issuable upon the exercise of stock options outstanding as of September&#160;30, 2025, at a weighted-average exercise price of $5.66 per share;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
            <font style="letter-spacing:-0.361pt;">&#9642;</font>
            <br >
          </div>
          <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:-0.038pt;">2,652,182 shares of our common stock issuable upon the vesting and settlement of outstanding restricted stock&#160;units and performance restricted stock&#160;units as of September&#160;30, 2025;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
            <font style="letter-spacing:-0.361pt;">&#9642;</font>
            <br >
          </div>
          <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:-0.038pt;">4,257,146 shares of our common stock available for future issuance under our 2021 Equity Incentive Plan;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
            <font style="letter-spacing:-0.361pt;">&#9642;</font>
            <br >
          </div>
          <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:-0.038pt;">209,532 shares of our common stock available for future issuance under our Employee Stock Purchase Plan;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
            <font style="letter-spacing:-0.361pt;">&#9642;</font>
            <br >
          </div>
          <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:-0.038pt;">514,500 shares of our common stock issuable upon the exercise of warrants to purchase shares of common stock with an exercise price of $2.78 per share that we issued in connection with our August&#160;2025 underwritten offering; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
            <font style="letter-spacing:-0.361pt;">&#9642;</font>
            <br >
          </div>
          <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:-0.361pt;">464,443</font><font style="letter-spacing:-0.038pt;"> shares of our common stock sold since September&#160;30, 2025 pursuant to our sales agreement with B. Riley Securities, Inc. for net proceeds of approximately $0.8&#160;million. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.361pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <font style="letter-spacing:-0.038pt;">Unless otherwise indicated, all information in this prospectus assumes the following:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <font style="letter-spacing:-0.361pt;">&#9642;</font>
            <br >
          </div>
          <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:52pt;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:-0.038pt;">no exercise of the outstanding stock options or warrants described above;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <font style="letter-spacing:-0.361pt;">&#9642;</font>
            <br >
          </div>
          <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:52pt;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:-0.038pt;">no settlement of unvested restricted stock&#160;units and performance restricted stock&#160;units described above; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <font style="letter-spacing:-0.361pt;">&#9642;</font>
            <br >
          </div>
          <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:52pt;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:-0.038pt;">no exercise of the outstanding warrants described above.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <font style="letter-spacing:-0.361pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-family:Arial, Helvetica, sans-serif;">
          <font style="letter-spacing:-0.342pt;">7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tRIFA1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">RISK FACTORS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;font-style:italic;">An investment in our common stock involves a high degree of risk. Before deciding whether to invest in our common stock, you should carefully consider the risks described below and those discussed under the Section captioned &#8220;Risk Factors&#8221; contained in our most recent Annual Report on Form 10-K and in our most recent Quarterly Reports on Form 10-Q, as well as any amendments thereto reflected in subsequent filings with the SEC, which are incorporated by reference into this prospectus in their entirety, together with other information in this prospectus, the documents incorporated by reference herein, and any free writing prospectus that we may authorize for use in connection with a specific offering. If any of these risks actually occurs, our business, financial condition, results of operations or cash flow could be harmed. This could cause the trading price of our common stock to decline, resulting in a loss of all or part of your investment.<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Risks Related to This Offering</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.475pt;">Management will have broad discretion as to the use of the proceeds from this offering, and we may not use the proceeds effectively.</font><font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">Our management will have broad discretion with respect to the use of proceeds of this offering, including for any of the purposes described in the section of this prospectus entitled &#8220;Use of Proceeds.&#8221; You will be relying on the judgment of our management regarding the application of the proceeds of this offering. The results and effectiveness of the use of proceeds are uncertain, and we could spend the proceeds in ways that you do not agree with or that do not improve our results of operations or enhance the value of our common stock. Our failure to apply these funds effectively could harm our business, delay the development of our product candidates and cause the price of our common stock to decline.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.475pt;">You will experience immediate dilution in the book value per share of the common stock purchased in the offering.</font><font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">The shares sold in this offering, if any, will be sold from time to time at various prices. However, we expect that the offering price of our common stock will be substantially higher than the net tangible book value per share of our outstanding common stock. See the section entitled &#8220;Dilution&#8221; in this prospectus for a more detailed discussion of the dilution you will incur if you purchase common stock in this offering. In addition, the exercise of outstanding stock options or warrants may result in further dilution of your investment.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.475pt;">You may experience future dilution as a result of future equity offerings.</font><font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">To raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock at prices that may not be the same as the price per share in this offering. We may sell shares or other securities in any other offering at a price per share that is less than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common stock, or securities convertible or exchangeable into common stock, in future transactions may be higher or lower than the price per share paid by investors in this offering.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.475pt;">The trading price of the shares of our common stock could be highly volatile, and purchasers of our common stock could incur substantial losses.</font><font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">Our stock price is likely to be volatile. The stock market in general and the market for stock of biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our common stock may be influenced by those factors discussed in this &#8220;Risk Factors&#8221; section and in similar sections incorporated by reference herein, as well as other factors, including:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the commencement, enrollment, or results of our current and future preclinical studies and clinical trials, and the results of trials of our competitors or those of other companies in our market sector;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">regulatory approval of our product candidates, or limitations to specific label indications or patient populations for its use, or changes or delays in the regulatory review process;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">regulatory developments in the United States and foreign countries;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">changes in the structure of healthcare payment systems, especially in light of current reforms to the United States healthcare system;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the success or failure of our efforts to acquire, license, or develop additional product candidates;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.01pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">innovations or new products developed by us or our competitors;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, or capital commitments;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.01pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">manufacturing, supply or distribution delays or shortages;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.01pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">any changes to our relationship with manufacturers, suppliers, licensors, future collaborators, or other strategic partners;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">achievement of expected product sales and profitability;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.01pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">variations in our financial results or those of companies that are perceived to be similar to us;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.01pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">market conditions in the biopharmaceutical sector and issuance of securities analysts&#8217; reports or recommendations;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">trading volume of our common stock;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.01pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">an inability to obtain additional funding;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.01pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">sales of our stock by insiders and stockholders;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">additions or departures of key personnel;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.01pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">our ability to maintain our listing on The Nasdaq Capital Market;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">intellectual property, product liability, or other litigation against us;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.01pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">general economic, industry and market conditions, including with respect to the financial markets in the United States and worldwide resulting from inflation, global health crises such as the COVID-19 pandemic and ongoing global and regional conflicts; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.01pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the use of proceeds from this offering</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">These broad market and industry factors may decrease the market price of our common stock, regardless of our actual operating performance.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">In addition, in the past, stockholders have initiated class action lawsuits against biopharmaceutical companies following periods of volatility in the market prices of these companies&#8217; stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management&#8217;s attention and resources, which could have a material adverse effect on our business, financial condition, and results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.475pt;">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.</font><font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amount of our common stock in the public market, the market price of our common stock could decline significantly.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">Shares issued upon the exercise of stock options, warrants, or shares issued upon vesting of our restricted stock&#160;units pr performance stock&#160;units outstanding under our equity incentive plans or pursuant to future awards granted under those plans will become available for sale in the public market to the extent permitted by the provisions of applicable vesting schedules and Rule&#160;144 and Rule&#160;701 under the Securities Act.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.475pt;">The actual number of shares we will issue under the Sales Agreement, at any one time or in total, is uncertain.</font><font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">Subject to certain limitations in the Sales Agreement and compliance with applicable law, we have the discretion to deliver a placement notice to the Sales Agent at any time throughout the term of the Sales Agreement. The number of shares that are sold by the Sales Agent after delivering a placement notice will fluctuate based on the market price of the common shares during the sales period and limits we set with the Sales Agent. Because the price per share of each share sold will fluctuate based on the market price of our common stock during the sales period, it is not possible at this stage to predict the number of shares that will be ultimately issued.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.475pt;">The common stock offered hereby will be sold in &#8220;at the market offerings,&#8221; and investors who buy shares at different times will likely pay different prices.</font><font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">Investors who purchase shares in this offering at different times will likely pay different prices, and accordingly may experience different levels of dilution and different outcomes in their investment results. We will have </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:568.5pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
          <font style="letter-spacing:-0.038pt;">discretion, subject to market demand and the terms of the Sales Agreement, to vary the timing, prices and number of shares sold in this offering. In addition, subject to the final determination by our board of directors or any restrictions we may place in any applicable placement notice, there is no minimum or maximum sales price for shares to be sold in this offering. Investors may experience a decline in the value of the shares they purchase in this offering as a result of sales made at prices lower than the prices they paid. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-family:Arial, Helvetica, sans-serif;">
          <font style="letter-spacing:-0.342pt;">10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tSNRF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">This prospectus and the documents incorporated by reference herein contain forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this prospectus or the documents incorporated herein by reference regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;potential,&#8221; &#8220;seek,&#8221; &#8220;evaluate,&#8221; &#8220;pursue,&#8221; &#8220;continue,&#8221; &#8220;design,&#8221; &#8220;impact,&#8221; &#8220;affect,&#8221; &#8220;forecast,&#8221; &#8220;target,&#8221; &#8220;outlook,&#8221; &#8220;initiative,&#8221; &#8220;objective,&#8221; &#8220;designed,&#8221; &#8220;priorities,&#8221; &#8220;goal,&#8221; or the negative of such terms and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">The forward-looking statements in this prospectus and the documents incorporated herein by reference include, among other things, statements about:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.3pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">our ability to raise additional capital to fund our operations and continue the development of our current and future product candidates;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.3pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">our ability to maintain the listing of our common stock on The Nasdaq Capital Market;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.3pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.3pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the clinical nature of our business and our ability to successfully and in a timely manner advance our current and future product candidates through our ongoing and future clinical trials, preclinical studies and development activities;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.3pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.29pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">our ability to generate revenue from future product sales and our ability to achieve and maintain profitability;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.3pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the accuracy of our projections and estimates regarding our expenses, capital requirements, cash utilization, and need for additional financing;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.3pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the expected uses of our existing cash and cash equivalents and the sufficiency of such resources to fund our planned operations;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.2pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the extent to which health epidemics and other outbreaks of communicable diseases, geopolitical turmoil, including the ongoing global and regional conflicts or increased trade restrictions between the United States, Russia, China, and other countries, social unrest, political instability, terrorism, or other acts of war could ultimately impact our business, including our ongoing and future clinical trials, preclinical studies and development activities;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.2pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">our dependence on the success of zervimesine (CT1812), our lead product candidate;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.2pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the novelty of our approach to targeting the &#963;-2 (sigma-2) receptor, or S2R, complex to treat age-related degenerative diseases and disorders, and the challenges we will face due to the novel nature of such approach;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.19pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the success of competing therapies that are or become available;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.2pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the initiation, progress, success, cost, and timing of our ongoing and future clinical trials, preclinical studies and development activities;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.2pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">our ability to obtain and maintain regulatory clearance of CT1812 for clinical trials under investigational new drug, or IND, applications and any future IND applications for any of our other product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.2pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the performance of third parties in connection with the development of our product candidates, including third parties conducting our future clinical trials as well as third-party suppliers and manufacturers;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.2pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">our ability to attract and retain strategic collaborators with development, regulatory, and commercialization expertise;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:152.5pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the size and growth of the potential markets for our product candidates and our ability to serve those markets;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">regulatory developments and approval pathways in the United States and foreign countries for our product candidates;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the potential scope and value of our intellectual property and proprietary rights;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">our ability, and the ability of any future licensors, to obtain, maintain, defend, and enforce intellectual property and proprietary rights protecting our product candidates, and our ability to develop and commercialize our product candidates without infringing, misappropriating, or otherwise violating the intellectual property or proprietary rights of third parties;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">risks associated with global political changes and global economic conditions, including inflation, tariffs, or uncertainty caused by political violence and unrest, including ongoing global and regional conflicts;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">developments relating to our competitors and our industry; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">other risks and uncertainties, including those described under the caption &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2024, as such risk factors have been amended, supplemented or superseded from time to time by our subsequent periodic reports we file with the SEC.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">We have based these forward-looking statements largely on our current expectations, estimates, forecasts, and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained or incorporated by reference in this prospectus, we cannot guarantee that the future results, levels of activity, performance, or events and circumstances reflected in the forward-looking statements will be achieved or occur at all. You should refer to the section titled &#8220;Risk Factors&#8221; this prospectus, any applicable prospectus supplement and the documents we incorporate by reference herein and therein for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">You should read this prospectus, any applicable prospectus supplement and the documents incorporated by reference herein and therein completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in this prospectus by these cautionary statements. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tUOP1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:346pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">USE OF PROCEEDS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">We may issue and sell shares of our common stock having aggregate gross sales proceeds of up to $75,000,000 from time to time (before deducting sales agent commissions and expenses). Because there is no minimum offering amount required to be sold in connection with this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. There can be no assurance that we will sell any shares under or fully utilize the Sales Agreement with the Sales Agent as a source of financing.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">We currently intend to use any net proceeds from the sale of shares of common stock under this prospectus primarily to fund research, clinical development, process development and manufacturing of our product candidates, working capital, capital expenditures and other general corporate purposes.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">These expected uses represent our intentions based upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve. The amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress of our development, the status of and results from clinical trials, as well as any new collaborations that we may enter into with third parties for our product candidates, and any unforeseen cash needs. As a result, our management will have broad discretion in the application of the net proceeds from this offering, and investors will be relying on the judgment of our management regarding the application of the net proceeds from this offering.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">Pending their use, we plan to invest the net proceeds from this offering in short- and medium-term, interest-bearing obligations, investment-grade instruments, certificates of deposit, or direct or guaranteed obligations of the United States government. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tDIPO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:514pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">DIVIDEND POLICY</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
          <font style="letter-spacing:-0.038pt;">We have never declared or paid any cash dividends on our common stock, and we do not currently intend to pay any cash dividends on our capital stock in the foreseeable future. We currently intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination to pay dividends on our common stock will be made at the discretion of our board of directors and will depend on various factors, including applicable laws, our results of operations, financial condition, future prospects, anticipated cash needs, plans for expansion and any other factors deemed relevant by our board of directors. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-family:Arial, Helvetica, sans-serif;">
          <font style="letter-spacing:-0.342pt;">14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tDIF1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:17.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.475pt;">DILUTION</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between the price per share of our common stock you pay in this offering and the as adjusted net tangible book value per share of our common stock after this offering.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">Our net tangible book value as of September&#160;30, 2025 was $36.5&#160;million, or $0.41 per share of our common stock. Net tangible book value per share as of September&#160;30, 2025 is equal to our total tangible assets minus total liabilities, all divided by the number of shares of common stock outstanding as of September&#160;30, </font><font style="letter-spacing:-0.361pt;">2025.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">After giving effect to the sale of $75,000,000 of shares of our common stock in this offering at an assumed offering price of $</font><font style="letter-spacing:-0.361pt;">1.52</font><font style="letter-spacing:-0.038pt;"> per share, the last reported sale price of our common stock on The Nasdaq Capital Market on December&#160;16, 2025, and after deducting estimated offering commissions and expenses payable by us, our adjusted net tangible book value would have been approximately $</font><font style="letter-spacing:-0.361pt;">109.0</font><font style="letter-spacing:-0.038pt;"> million, or $</font><font style="letter-spacing:-0.361pt;">0.79</font><font style="letter-spacing:-0.038pt;"> per share of common stock, as of September&#160;30, 2025. This represents an immediate increase in net tangible book value of approximately $</font><font style="letter-spacing:-0.361pt;">0.38</font><font style="letter-spacing:-0.038pt;"> per share to existing stockholders and an immediate dilution of approximately </font><font style="letter-spacing:-0.361pt;">$0.73</font><font style="letter-spacing:-0.038pt;"> per share to investors in this offering. The following table illustrates this calculation on a per share basis. </font>
        </div>
        <table style="width:456pt;margin-top:10.5pt;border-collapse: collapse;border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:11.5pt 0pt 0.5pt 0pt; width:379.78pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.038pt;">Assumed public offering price per share </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:11.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:11.5pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">1.52 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:379.78pt;text-align:left;">
              <div style="margin-left:9.5pt;">
                <font style="letter-spacing:-0.038pt;">Net tangible book value per share at September&#160;30, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">0.41 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:379.78pt;white-space:normal;text-align:left;">
              <div style="margin-left:19pt; text-indent:-9.5pt;">
                <font style="letter-spacing:-0.038pt;">Increase in net tangible book value per share attributable to new investors purchasing shares in this offering </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">0.38 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:379.78pt;white-space:normal;text-align:left;">
              <div style="margin-left:9.5pt; text-indent:-9.5pt;">
                <font style="letter-spacing:-0.038pt;">As adjusted net tangible book value per share as of September&#160;30, 2025, after giving effect to this offering </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">0.79 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:0pt;">&#8203;</td>
            <td style="border-bottom:0.75pt solid #000000; ;padding:3pt 0pt 12pt 0pt; width:379.78pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.038pt;">Dilution per share to new investors purchasing shares in this offering </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:0.75pt solid #000000; ;">&#8203;</td>
            <td style="padding:0pt 0pt 12pt 0pt;border-bottom:0.75pt solid #000000; ; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 12pt 0pt;border-bottom:0.75pt solid #000000; ; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:0.75pt solid #000000; ;">&#8203;</td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:0.75pt solid #000000; ;">&#8203;</td>
            <td style="padding:3pt 0pt 12pt 0pt;border-bottom:0.75pt solid #000000; ; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 12pt 0pt;border-bottom:0.75pt solid #000000; ; min-width:21.75pt; text-align:right; white-space:nowrap;">0.73</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:0.75pt solid #000000; ;">&#8203;</td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:7.5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">The table above assumes for illustrative purposes that an aggregate of </font><font style="letter-spacing:-0.361pt;">49,342,105</font><font style="letter-spacing:-0.038pt;"> shares of our common stock are sold at an assumed offering price of $</font><font style="letter-spacing:-0.361pt;">1.52</font><font style="letter-spacing:-0.038pt;"> per share, the last reported sale price of our common stock on The Nasdaq Capital Market on December&#160;16, 2025, for aggregate gross proceeds of $75,000,000. The shares sold in this offering, if any, will be sold from time to time at various prices. An increase of $1.00 per share in the price at which the shares are sold from the assumed offering price of $</font><font style="letter-spacing:-0.361pt;">1.52</font><font style="letter-spacing:-0.038pt;"> per share, the last reported price of our common stock on The Nasdaq Capital Market on December&#160;16, 2025, assuming $75,000,000 of shares of our common stock is sold at that price, would increase our adjusted net tangible book value per share after the offering to $</font><font style="letter-spacing:-0.361pt;">0.92</font><font style="letter-spacing:-0.038pt;"> per share and would increase the dilution in net tangible book value per share to new investors in this offering to $</font><font style="letter-spacing:-0.361pt;">1.60</font><font style="letter-spacing:-0.038pt;"> per share, after deducting commissions and estimated aggregate offering expenses payable by us. A decrease of $1.00 per share in the price at which the shares are sold from the assumed offering price of $</font><font style="letter-spacing:-0.361pt;">1.52</font><font style="letter-spacing:-0.038pt;"> per share, the last reported price of our common stock on The Nasdaq Capital Market on December&#160;16, 2025, assuming $75,000,000 of shares of our common stock is sold at that price, would increase our adjusted net tangible book value per share after the offering to </font><font style="letter-spacing:-0.361pt;">$0.47</font><font style="letter-spacing:-0.038pt;"> per share and the dilution in net tangible book value per share to new investors participating in this offering would be $</font><font style="letter-spacing:-0.361pt;">0.05</font><font style="letter-spacing:-0.038pt;"> per share, after deducting commissions and estimated aggregate offering expenses payable by us. This information is supplied for illustrative purposes only.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">The table and calculations above are based on 88,268,078 shares outstanding as of September&#160;30, 2025 and exclude as of that date:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">3,366,840 shares of our common stock issuable upon the exercise of outstanding stock options as of September&#160;30, 2025, with a weighted-average exercise price of $5.66 per share;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">2,652,182 shares of our common stock issuable upon the vesting and settlement of outstanding restricted stock&#160;units and performance restricted stock&#160;units as of September&#160;30, 2025; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:428.5pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">4,257,146 shares of our common stock reserved for future issuance under our 2021 Plan plus any annual increases in the number of shares of common stock reserved for future issuance under the 2021 Plan;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">209,532 shares of our common stock reserved for future issuance under our ESPP plus any annual increases in the number of shares of common stock reserved for future issuance under the ESPP;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">514,500 shares of our common stock issuable upon the exercise of warrants to purchase shares of common stock with an exercise price of $2.78 per share that we issued in connection with our August&#160;2025 underwritten offering; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.361pt;">464,443</font><font style="letter-spacing:-0.038pt;"> shares of our common stock sold since September&#160;30, 2025 pursuant to our sales agreement with B. Riley Securities, Inc. for net proceeds of approximately $0.8&#160;million.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">To the extent that any outstanding options are exercised, you will experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of such securities may result in further dilution to our stockholders.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tDOCS1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">DESCRIPTION OF CAPITAL STOCK</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">The following description of our capital stock is not complete and may not contain all the information you should consider before investing in our capital stock. This description is summarized from, and qualified in its entirety by reference to, our third amended and restated certificate of incorporation and our amended and restated bylaws, which have been publicly filed with the SEC. See &#8220;Where You Can Find More Information.&#8221; For a complete description, you should refer to our third amended and restated certificate of incorporation and amended and restated bylaws, copies of which are incorporated by reference as exhibits to the registration statement of which this prospectus is a part.<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">General</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">Under our third amended and restated certificate of incorporation, our authorized capital stock consists of 250,000,000 shares of common stock, par value $0.001 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share. As of September&#160;30, 2025, we had 88,268,078 shares of common stock outstanding, and no shares of preferred stock outstanding.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Common Stock</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Voting</font><font style="letter-spacing:-0.038pt;">.&nbsp;&nbsp;&nbsp;Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Our stockholders do not have cumulative voting rights in the election of directors. The affirmative vote of holders of at least 66</font><font style=" position:relative; bottom:2.53pt;font-size:6.65pt;letter-spacing:-0.253pt;">2</font><font style="letter-spacing:-0.361pt;">&#8725;</font><font style="font-size:6.65pt;letter-spacing:-0.253pt;">3</font><font style="letter-spacing:-0.038pt;">% of the voting power of all of the then-outstanding shares of capital stock, voting as a single class, will be required to amend certain provisions of our third amended and restated certificate of incorporation, including the provisions relating to amending our amended and restated bylaws, procedures for our stockholder meetings, the classified board, director liability, and exclusive forum for proceedings.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Dividends</font><font style="letter-spacing:-0.038pt;">.&nbsp;&nbsp;&nbsp;Subject to preferences that may be applicable to any then outstanding preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Liquidation and Dissolution</font><font style="letter-spacing:-0.038pt;">.&nbsp;&nbsp;&nbsp;In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the holders of any then outstanding shares of preferred stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Other Rights and Restrictions</font><font style="letter-spacing:-0.038pt;">.&nbsp;&nbsp;&nbsp;Holders of our common stock have no preemptive, conversion or subscription rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the future.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Listing</font><font style="letter-spacing:-0.038pt;">.&nbsp;&nbsp;&nbsp;Our common stock is listed on The Nasdaq Capital Market under the symbol &#8220;CGTX.&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Transfer Agent and Registrar</font><font style="letter-spacing:-0.038pt;">.&nbsp;&nbsp;&nbsp;The transfer agent and registrar for our common stock is EQ Equiniti Trust Company, LLC.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Preferred Stock</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">Under our third amended and restated certificate of incorporation, our board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in our control that may otherwise benefit holders of our common stock and may adversely affect the market price of the common stock and the voting and other rights of the holders of common stock. We have no current plans to issue any shares of preferred stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Anti-Takeover Provisions of Delaware Law and Our Charter Documents</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Certificate of Incorporation and Bylaws</font><font style="letter-spacing:-0.038pt;">.&nbsp;&nbsp;&nbsp;Among other things, our third amended and restated certificate of incorporation and amended and restated bylaws:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.99pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">provide that the authorized number of directors may be changed only by resolution of our board of directors;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.99pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">provide that our board of directors is classified into three classes of directors;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.99pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">provide that, subject to the rights of any series of preferred stock to elect directors, directors may only be removed for cause, which removal may be effected, subject to any limitation imposed by law, by the holders of at least 66</font><font style=" position:relative; bottom:2.53pt;font-size:6.65pt;letter-spacing:-0.253pt;">2</font><font style="letter-spacing:-0.361pt;">&#8725;</font><font style="font-size:6.65pt;letter-spacing:-0.253pt;">3</font><font style="letter-spacing:-0.038pt;">% of the voting power of all of our then-outstanding shares of the capital stock entitled to vote generally at an election of directors;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.99pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent or electronic transmission;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.99pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder&#8217;s notice;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.99pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">provide that special meetings of our stockholders may be called only by the chairman of our board of directors, our chief executive officer or by our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.99pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">do not provide for cumulative voting rights, therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">The amendment of any of these provisions would require approval by the holders of at least 66</font><font style=" position:relative; bottom:2.53pt;font-size:6.65pt;letter-spacing:-0.253pt;">2</font><font style="letter-spacing:-0.361pt;">&#8725;</font><font style="font-size:6.65pt;letter-spacing:-0.253pt;">3</font><font style="letter-spacing:-0.038pt;">% of the voting power of all of our then-outstanding common stock entitled to vote generally in the election of directors, voting together as a single class.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">The combination of these provisions makes it more difficult for our stockholders to replace our board of directors as well as for another party to obtain control of us by replacing our board of directors. Because our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change our control.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to reduce our vulnerability to hostile takeovers and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of delaying changes in our control or management. As a consequence, these provisions may also inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts. We believe that the benefits of these provisions, including increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure our company, outweigh the disadvantages of discouraging takeover proposals, because negotiation of takeover proposals could result in an improvement of their terms.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Section&#160;203 of the Delaware General Corporation Law</font><font style="letter-spacing:-0.038pt;">.&nbsp;&nbsp;&nbsp;We are subject to Section&#160;203 of the DGCL, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">for a period of three&#160;years after the date that such stockholder became an interested stockholder, with the following exceptions:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.2pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.2pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (i)&#160;by persons who are directors and also officers and (ii)&#160;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="width:456pt;">
          <div style="margin-left:20pt; margin-top:4pt; line-height:12pt;">
            <font style="letter-spacing:-0.361pt;">&#9642;</font>
          </div>
        </div>
        <div style="margin-left:32pt; margin-top:-12pt; width:424pt; line-height:12pt;">
          <font style="letter-spacing:-0.361pt;">&#8226;</font><font style="letter-spacing:-0.038pt;"> on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66</font><font style=" position:relative; bottom:2.53pt;font-size:6.65pt;letter-spacing:-0.253pt;">2</font><font style="letter-spacing:-0.361pt;">&#8725;</font><font style="font-size:6.65pt;letter-spacing:-0.253pt;">3</font><font style="letter-spacing:-0.038pt;">% of the outstanding voting stock that is not owned by the interested stockholder.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">In general, Section&#160;203 defines a &#8220;business combination&#8221; to include the following:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.09pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">any merger or consolidation involving the corporation and the interested stockholder;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits by or through the corporation.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">In general, Section&#160;203 defines an &#8220;interested stockholder&#8221; as an entity or person who, together with the person&#8217;s affiliates and associates, beneficially owns, or within three&#160;years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">The statute could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may discourage attempts to acquire us even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above the prevailing market price.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">A Delaware corporation may &#8220;opt out&#8221; of these provisions with an express provision in its certificate of incorporation. We have not opted out of these provisions, which may as a result, discourage or prevent mergers or other takeover or change of control attempts of us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Choice of Forum</font><font style="letter-spacing:-0.038pt;">.&nbsp;&nbsp;&nbsp;Our third amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware (or, if and only if, the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if, all such state courts lack subject matter jurisdiction, the United States District Court for the District of Delaware) and any appellate court therefrom shall be the sole and exclusive forum for the following claims or causes of action brought under Delaware statutory or common law: (1)&#160;any derivative claim or action brought on our behalf; (2)&#160;any claim or cause of action asserting a breach of fiduciary duty by any of our current or former directors, officers or other employees; (3)&#160;any claim or cause of action asserting a claim against us arising out of, or pursuant to, the DGCL, our third amended and restated certificate of incorporation or our amended and restated bylaws; (4)&#160;any claim or cause of action seeking to interpret, apply, enforce or determine the validity of our third amended and restated certificate of incorporation or our amended and restated bylaws (including any right, obligation, or remedy thereunder); (5)&#160;any claim or cause of action as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware; or (6)&#160;any claim or cause of action asserting a claim against us or any of our current or former directors, officers or other employees, that is governed by the internal affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court having personal jurisdiction over the indispensable parties named as defendants. The aforementioned provision will </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">not apply to claims or causes of action brought to enforce a duty or liability created by the Securities Act, the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">In addition, our third amended and restated certificate of incorporation further provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America will be the exclusive forum, to the fullest extent permitted by law, for resolving any complaint asserting a cause or causes of action arising under the Securities Act, including all causes of action asserted against any defendant to such complaint. The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with one or more actions or proceedings described above, a court could find the choice of forum provisions contained in our third amended and restated certificate of incorporation to be inapplicable or unenforceable.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Limitations of Liability and Indemnification</font><font style="letter-spacing:-0.038pt;">.&nbsp;&nbsp;&nbsp;Our third amended and restated certificate of incorporation and our amended and restated bylaws limit our directors&#8217; liability and may indemnify our directors and officers to the fullest extent permitted under the DGCL. The DGCL provides that directors of a corporation will not be personally liable for monetary damages for breach of their fiduciary duties as directors, except for liability for:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">any breach of the director&#8217;s duty of loyalty to us or our stockholders;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">any unlawful payment of dividends or unlawful stock repurchases or redemptions as provided in Section&#160;174 of the DGCL; or</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">any transaction from which the director derived an improper benefit.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">The DGCL and our amended and restated bylaws provide that we will, in certain situations, indemnify our directors and officers and may indemnify other employees and other agents, to the fullest extent permitted by law.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">We have entered into indemnification agreements with our directors and officers. These indemnification agreements may require us, among other things, to indemnify our directors and officers for some expenses, including attorneys&#8217; fees, judgments, penalties, fines and settlement amounts incurred by a director or officer in any action or proceeding arising out of his or her service as one of our directors or officers, or any of our subsidiaries or any other company or enterprise to which the person provides services at our request. Subject to certain limitations, our indemnification agreements also require us to advance expenses incurred by our directors, officers and key employees for the defense of any action for which indemnification is required or permitted.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">We maintain a directors&#8217; and officers&#8217; insurance policy pursuant to which our directors and officers are insured against liability for actions taken in their capacities as directors and officers. We believe that these provisions in our third amended and restated certificate of incorporation, our amended and restated bylaws and these indemnification agreements are necessary to attract and retain qualified persons as directors and officers.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">The limitation of liability and indemnification provisions in our third amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and our stockholders. Further, a stockholder&#8217;s investment may be adversely affected to the extent that we pay the costs of settlement and damage awards against directors and officers as required by these indemnification provisions.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">At present, there is no material pending litigation or proceeding involving any of our directors, officers or employees for which indemnification is sought and we are not aware of any threatened material litigation that may result in claims for indemnification.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or control persons, in the opinion of the SEC, such indemnification is against public policy, as expressed in the Securities Act, and is therefore unenforceable.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tPOD1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">PLAN OF DISTRIBUTION</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">We have entered into an Open Market Sale Agreement</font><font style=" position:relative; bottom:4pt;font-size:7pt;letter-spacing:-0.266pt;">SM</font><font style="letter-spacing:-0.038pt;">, or Sales Agreement, with Jefferies, under which we may offer and sell up to $75,000,000 of our shares of common stock from time to time through or to Jefferies acting as sales agent or principal. Sales of our shares of common stock, if any, under this prospectus and the accompanying base prospectus will be made by any method that is deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) under the Securities Act.</font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">Each time we wish to issue and sell our shares of common stock under the Sales Agreement, we will notify Jefferies of the number of shares to be issued, the dates on which such sales are anticipated to be made, any limitation on the number of shares to be sold in any one day and any minimum price below which sales may not be made. Once we have so instructed Jefferies, unless Jefferies declines to accept the terms of such notice, Jefferies has agreed to use its commercially reasonable efforts consistent with its normal trading and sales practices to sell such shares up to the amount specified on such terms. The obligations of Jefferies under the Sales Agreement to sell our shares of common stock are subject to a number of conditions that we must meet.</font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">The settlement of sales of shares between us and Jefferies is generally anticipated to occur on the first trading day following the date on which the sale was made. Sales of our shares of common stock as contemplated in this prospectus will be settled through the facilities of The Depository Trust Company or by such other means as we and Jefferies may agree upon. There is no arrangement for funds to be received in an escrow, trust or similar arrangement.</font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">We will pay Jefferies a commission of 3.0% of the aggregate gross proceeds we receive from each sale of our shares of common stock. Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. In addition, we have agreed to reimburse Jefferies for the fees and disbursements of its counsel, payable upon execution of the Sales Agreement, in an amount not to exceed $100,000, in addition to certain ongoing disbursements of its legal counsel. We estimate that the total expenses for the offering, excluding any commissions or expense reimbursement payable to Jefferies under the terms of the Sales Agreement, will be approximately $</font><font style="letter-spacing:-0.361pt;">300,000</font><font style="letter-spacing:-0.038pt;">. The remaining sale proceeds, after deducting any other transaction fees, will equal our net proceeds from the sale of such shares.</font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">Jefferies will provide written confirmation to us before the open on The Nasdaq Capital Market on the day following each day on which our shares of common stock are sold under the Sales Agreement. Each confirmation will include the number of shares sold on that day, the aggregate gross proceeds of such sales and the proceeds to us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">In connection with the sale of our shares of common stock on our behalf, Jefferies may be deemed to be an &#8220;underwriter&#8221; within the meaning of the Securities Act, and the compensation of Jefferies will be deemed to be underwriting commissions or discounts. We have agreed to indemnify Jefferies against certain civil liabilities, including liabilities under the Securities Act. We have also agreed to contribute to payments Jefferies may be required to make in respect of such liabilities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">The offering of our shares of common stock pursuant to the Sales Agreement will terminate upon the earlier of (i) the sale of all shares of common stock subject to the Sales Agreement and (ii) the termination of the Sales Agreement as permitted therein. We and Jefferies may each terminate the Sales Agreement at any time upon ten days&#8217; prior notice.</font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">This summary of the material provisions of the Sales Agreement does not purport to be a complete statement of its terms and conditions. A copy of the Sales Agreement is filed as an exhibit to a current report on Form&#160;8-K filed under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and incorporated by reference in this prospectus.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">Jefferies and its affiliates may in the future provide various investment banking, commercial banking, financial advisory and other financial services for us and our affiliates, for which services they may in the future receive customary fees. In the course of its business, Jefferies may actively trade our securities for its </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:560.5pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
          <font style="letter-spacing:-0.038pt;">own account or for the accounts of customers, and, accordingly, Jefferies may at any time hold long or short positions in such securities.</font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
          <font style="letter-spacing:-0.038pt;">A prospectus supplement and the accompanying prospectus in electronic format may be made available on a website maintained by Jefferies, and Jefferies may distribute the prospectus supplement and the accompanying prospectus electronically. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-family:Arial, Helvetica, sans-serif;">
          <font style="letter-spacing:-0.342pt;">22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tLEMA1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:562pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">LEGAL MATTERS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
          <font style="letter-spacing:-0.038pt;">The validity of the common stock being offered in this offering will be passed upon for us by Goodwin Procter LLP, Philadelphia, Pennsylvania. The Sales Agent is being represented by Duane Morris LLP, New York, New York, in connection with this offering. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-family:Arial, Helvetica, sans-serif;">
          <font style="letter-spacing:-0.342pt;">23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tEXP1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:538pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">EXPERTS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
          <font style="letter-spacing:-0.038pt;">The consolidated financial statements of Cognition Therapeutics, Inc. appearing in Cognition Therapeutics, Inc.&#8217;s <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1455365/000155837025003341/cgtx-20241231x10k.htm">Annual Report (Form 10-K) for the year ended December&#160;31, 2024</a></font><font style="letter-spacing:-0.361pt;">,</font><font style="letter-spacing:-0.038pt;"> have been audited by Ernst &amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon, included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-family:Arial, Helvetica, sans-serif;">
          <font style="letter-spacing:-0.342pt;">24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tWYCF1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:514pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">WHERE YOU CAN FIND MORE INFORMATION</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
          <font style="letter-spacing:-0.038pt;">The SEC maintains an Internet website at http://www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. You may access the registration statement, of which this prospectus forms a part, at the SEC&#8217;s Internet website. Our reports on Forms 10-K, 10-Q and 8-K, and amendments to those reports filed pursuant to Section&#160;13(a) or 15(d) of the Exchange Act, are also available for download, free of charge, as soon as reasonably practicable after these reports are filed with the SEC, at our website at www.cogrx.com. The content contained in, or that can be accessed through, our website is not incorporated by reference and is not a part of this prospectus. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-family:Arial, Helvetica, sans-serif;">
          <font style="letter-spacing:-0.342pt;">25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tIBR">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:110pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">INCORPORATION BY REFERENCE</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">The SEC allows us to &#8220;incorporate by reference&#8221; information from other documents that we file with it, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we filed with the SEC prior to the date of this prospectus, while information that we file later with the SEC will automatically update and supersede the information in this prospectus. We incorporate by reference into this prospectus and the registration statement of which this prospectus is a part the information or documents listed below that we have filed with the SEC:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">Our <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1455365/000155837025003341/cgtx-20241231x10k.htm">Annual Report on Form 10-K for the year ended December&#160;31, 2024 filed with the SEC on March&#160;20, 2025</a>, and the information specifically incorporated by reference into our Annual Report on Form 10-K for the year ended December&#160;31, 2024 from our <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1455365/000110465925040193/tm252486-4_def14a.htm">Definitive Proxy Statement on Form&#160;DEF&#160;14-A, filed with the SEC on April&#160;28, 2025</a></font><font style="letter-spacing:-0.361pt;">;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">Our Quarterly Reports on Form 10-Q for the fiscal quarters ended March&#160;31, 2025, June&#160;30, 2025 and September&#160;30, 2025, filed with the SEC on <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1455365/000155837025006612/cgtx-20250331x10q.htm">May&#160;7, 2025</a></font><font style="letter-spacing:-0.361pt;">, </font><font style="letter-spacing:-0.038pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1455365/000155837025010771/cgtx-20250630x10q.htm">August&#160;7, 2025</a> and <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1455365/000110465925107402/cgtx-20250930x10q.htm">November&#160;6, 2025</a></font><font style="letter-spacing:-0.361pt;">, </font><font style="letter-spacing:-0.038pt;">respectively;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">our Current Reports on Form 8-K filed with the SEC on <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1455365/000110465925006732/tm254703d1_8k.htm">January&#160;28, 2025</a></font><font style="letter-spacing:-0.361pt;">, </font><font style="letter-spacing:-0.038pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1455365/000110465925017178/tm257579d1_8k.htm">February&#160;26, 2025</a></font><font style="letter-spacing:-0.361pt;">, </font><font style="letter-spacing:-0.038pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1455365/000110465925022969/tm258979d1_8k.htm">March&#160;12, 2025</a></font><font style="letter-spacing:-0.361pt;">, </font><font style="letter-spacing:-0.038pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1455365/000110465925045886/tm2514313d1_8k.htm">May&#160;8, 2025</a></font><font style="letter-spacing:-0.361pt;">, </font><font style="letter-spacing:-0.038pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1455365/000110465925055089/tm2516681d1_8k.htm">June&#160;2, 2025</a></font><font style="letter-spacing:-0.361pt;">, </font><font style="letter-spacing:-0.038pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1455365/000110465925055717/tm2516905d1_8k.htm">June&#160;3, 2025</a></font><font style="letter-spacing:-0.361pt;">, </font><font style="letter-spacing:-0.038pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1455365/000110465925061142/tm2518439d2_8k.htm">June&#160;20, 2025</a></font><font style="letter-spacing:-0.361pt;">, </font><font style="letter-spacing:-0.038pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1455365/000110465925083059/tm2524388d1_8k.htm">August&#160;26, 2025</a></font><font style="letter-spacing:-0.361pt;">, </font><font style="letter-spacing:-0.038pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1455365/000110465925084845/tm2524576d2_8k.htm">August&#160;28, 2025</a>, and <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1455365/000110465925089737/tm2525997d1_8k.htm">September&#160;15, 2025</a> (in each case other than any portions thereof deemed furnished and not filed); and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">The description of our common stock contained in our registration statement on <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1455365/000110465921123625/tm2113659d20_8a12b.htm">Form 8-A (File No. 001-40886) filed with the SEC on October&#160;6, 2021</a>, under the Exchange Act, including any amendment or report filed for the purpose of updating such description.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">We also incorporate by reference any future filings (other than any filings or portions of such reports that are not deemed &#8220;filed&#8221; under the Exchange Act in accordance with the Exchange Act and applicable SEC rules, including current reports furnished under Item&#160;2.02 or Item&#160;7.01 of Form 8-K and exhibits furnished on such form that are related to such items unless such Form 8-K expressly provides to the contrary) made with the SEC pursuant to Sections&#160;13(a), 13(c), 14 or 15(d) of the Exchange Act, including those made after the date of the initial filing of the registration statement of which this prospectus is a part and prior to the effectiveness of the registration statement, until we file a post-effective amendment that indicates the termination of the offering of the securities made by this prospectus and will become a part of this prospectus from the date that such documents are filed with the SEC. Information in such future filings updates and supplements the information provided in this prospectus. Any statements in any such future filings will automatically be deemed to modify and supersede any information in any document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference to the extent that statements in the later filed document modify or replace such earlier statements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">We will furnish without charge to you, on written or oral request, a copy of any or all of the documents incorporated by reference in this prospectus, including exhibits to these documents. You should direct any requests for documents to Cognition Therapeutics, Inc., Attn: Chief Executive Officer, 2500 Westchester Ave., Purchase, New York 10577.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 3.3pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:73.51pt; text-align:center; width:456pt; line-height:18.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:16pt;">
          <font style="text-transform:uppercase;letter-spacing:0.8pt;">$75,000,000</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.32pt;"> </font>
        </div>
        <div style="position:relative;margin-top:38.5pt; text-align:center; width:456pt;">
          <img src="lg_cognition-4c.jpg" alt="[MISSING IMAGE: lg_cognition-4c.jpg]" height="80" width="321" >
        </div>
        <div style="margin-top:41.01pt; text-align:center; width:456pt; line-height:18.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:16pt;">
          <font style="text-transform:uppercase;letter-spacing:0.8pt;">Common Stock</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.32pt;"> </font>
        </div>
        <div style="margin-top:82.667pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 82.6666666666667pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:16.6pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12pt;">
          <font style="text-transform:uppercase;letter-spacing:0.6pt;">PROSPECTUS</font>
        </div>
        <div style="margin-top:13.333pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 13.3333333333333pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:110.71pt; text-align:center; width:456pt; line-height:18.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:16pt;">
          <font style="text-transform:uppercase;letter-spacing:0.8pt;">Jefferies</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.32pt;"> </font>
        </div>
        <div style="margin-top:108pt; text-align:center; width:456pt; line-height:13.5pt;font-family:Arial, Helvetica, sans-serif;font-size:11pt;">
          <font style="letter-spacing:-0.418pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2025</font>
        </div>
        <div style="margin-top:73.143pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 73.1433333333334pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 3.29999999999995pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">PART II</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">INFORMATION NOT REQUIRED IN PROSPECTUS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2.3pt; width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Item&#160;14.&nbsp;&nbsp;&nbsp;Other Expenses of Issuance and Distribution.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">The following is an estimate of the expenses (all of which are to be paid by the registrant) that we may incur in connection with the securities being registered hereby, other than the SEC registration fee.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <table style="width:456pt;margin-top:10.5pt;border-collapse: collapse;border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:11.5pt 0pt 0.5pt 0pt; width:406.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.038pt;">SEC registration fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:11.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:11.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">41,430</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:406.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.038pt;">FINRA filing fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">0</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:406.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.038pt;">Fees and expenses of the trustee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;"><font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:9pt;"></font><font style=" position:relative; bottom:3pt;font-size:6pt;">(1)</font> </font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:406.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.038pt;">Printing expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;"><font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:9pt;"></font><font style=" position:relative; bottom:3pt;font-size:6pt;">(1)</font> </font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:406.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.038pt;">Legal fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;"><font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:9pt;"></font><font style=" position:relative; bottom:3pt;font-size:6pt;">(1)</font> </font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:406.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.038pt;">Accounting fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;"><font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:9pt;"></font><font style=" position:relative; bottom:3pt;font-size:6pt;">(1)</font> </font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:406.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.038pt;">Blue Sky, qualification fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;"><font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:9pt;"></font><font style=" position:relative; bottom:3pt;font-size:6pt;">(1)</font> </font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:406.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.038pt;">Transfer agent fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;"><font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:9pt;"></font><font style=" position:relative; bottom:3pt;font-size:6pt;">(1)</font> </font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2.25pt 0pt; width:406.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.038pt;">Miscellaneous </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;"><font style="font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:9pt;"></font><font style=" position:relative; bottom:3pt;font-size:6pt;">(1)</font> </font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 3pt 0pt; width:406.28pt;text-align:left;">
              <font style="letter-spacing:0.475pt;">Total</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-2.14pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt;border-bottom:3pt double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;"><font style="font-size:9pt;"></font><font style=" position:relative; bottom:3pt;font-size:6pt;">(1)</font>
              </font>
            </td>
            <td style="padding:0pt;padding-left:-2.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:7.5pt;line-height:7.5pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="9">&#8203;</td>
          </tr>
        </table>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:8.3pt; margin-top:4.3pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;font-size:7pt;">
          <font style=" position:relative; bottom:2.75pt;font-size:5.5pt;letter-spacing:-0.209pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:4.3pt; margin-bottom:0pt; line-height:8.3pt; text-align:left; margin-left:12pt;font-size:7pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.028pt;">These fees are calculated based on the securities offered and the number of issuances and accordingly cannot be estimated at this time.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.14pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Item&#160;15.&nbsp;&nbsp;&nbsp;Indemnification of Directors and Officers.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">As permitted by Section&#160;102 of the DGCL, we have adopted provisions in our third amended and restated certificate of incorporation and amended and restated bylaws that limit or eliminate the personal liability of our directors for a breach of their fiduciary duty of care as a director. The duty of care generally requires that, when acting on behalf of the corporation, directors exercise an informed business judgment based on all material information reasonably available to them. Consequently, a director will not be personally liable to us or our stockholders for monetary damages for breach of fiduciary duty as a director, except for liability for:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">any breach of the director&#8217;s duty of loyalty to us or our stockholders;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">any act related to unlawful stock repurchases, redemptions or other distributions or payment of dividends; or</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">any transaction from which the director derived an improper personal benefit.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">These limitations of liability do not affect the availability of equitable remedies such as injunctive relief or rescission. Our third amended and restated certificate of incorporation also authorizes us to indemnify our officers, directors and other agents to the fullest extent permitted under Delaware law.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">As permitted by Section&#160;145 of the DGCL, our amended and restated bylaws provide that:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">we may indemnify our directors, officers and employees to the fullest extent permitted by the DGCL, subject to limited exceptions;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">we may advance expenses to our directors, officers and employees in connection with a legal proceeding to the fullest extent permitted by the DGCL, subject to limited exceptions; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:12pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">&#9642;</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:32pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">the rights provided in our amended and restated bylaws are not exclusive.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">Our third amended and restated certificate of incorporation and our amended and restated bylaws provide for the indemnification provisions described above and elsewhere herein. We have entered or will enter into, and intend to continue to enter into, separate indemnification agreements with our directors and officers that may be broader than the specific indemnification provisions contained in the DGCL. These indemnification agreements generally require us, among other things, to indemnify our officers and directors against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct. These indemnification agreements also generally require us to advance any expenses </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">II-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tEXIN">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">incurred by the directors or officers as a result of any proceeding against them as to which they could be indemnified. These indemnification provisions and the indemnification agreements may be sufficiently broad to permit indemnification of our officers and directors for liabilities, including reimbursement of expenses incurred, arising under the Securities Act.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">We have purchased and currently intend to maintain insurance on behalf of each and every person who is or was a director or officer of the Company against any loss arising from any claim asserted against him or her and incurred by him or her in any such capacity, subject to certain exclusions.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Item&#160;16.&nbsp;&nbsp;&nbsp;Exhibits.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:4pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">(a)</font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;font-style:italic;">Exhibits<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font></div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">EXHIBIT INDEX</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;margin-top:20.5pt;border-collapse: collapse;border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; font-style:normal;font-weight:bold;font-variant:normal;text-transform:uppercase;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:9.833pt 0pt 1.667pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">Exhibit </font>
                <br >
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">Number </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:9.833pt 0pt 1.667pt 0pt; width:408pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">Exhibit&#160;Description </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="margin-left:11.61pt;letter-spacing:-0.361pt;">1.1* </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:408pt;text-align:left;">
              <font style="letter-spacing:-0.038pt;">Form of Underwriting Agreement. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:-0.038pt;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="margin-left:11.61pt;letter-spacing:-0.361pt;">1.2 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:408pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="tm2533585d2_ex1-2.htm">Open Market Sale Agreement</a><font style=" position:relative; bottom:4pt;font-size:6pt;letter-spacing:-0.266pt;"><a style="-sec-extract:exhibit" href="tm2533585d2_ex1-2.htm">SM</a></font><a style="-sec-extract:exhibit" href="tm2533585d2_ex1-2.htm">, dated December </a><font style="letter-spacing:-0.361pt;"><a style="-sec-extract:exhibit" href="tm2533585d2_ex1-2.htm">18</a></font><a style="-sec-extract:exhibit" href="tm2533585d2_ex1-2.htm">, 2025, by and between the registrant and Jefferies LLC (filed herewith).</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="margin-left:11.61pt;letter-spacing:-0.361pt;">3.1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:408pt;white-space:normal;text-align:left;">
              <div style="letter-spacing:-0.038pt;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921126265/tm2130061d1_ex3-1.htm">Third Amended and Restated Certificate of Incorporation (incorporated by reference to exhibit 3.1 of the Company&#8217;s Current Report on Form 8-K filed on October&#160;14, 2021).</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="margin-left:11.61pt;letter-spacing:-0.361pt;">3.2 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:408pt;white-space:normal;text-align:left;">
              <div style="letter-spacing:-0.038pt;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000155837023008117/cgtx-20230331xex3d1.htm">Second Amended and Restated Bylaws (incorporated by reference to exhibit 3.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on May&#160;4, 2023).</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="margin-left:11.61pt;letter-spacing:-0.361pt;">3.3 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:408pt;white-space:normal;text-align:left;">
              <div style="letter-spacing:-0.038pt;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000155837025003341/cgtx-20241231xex3d3.htm">Amendment to the Second Amended and Restated Bylaws (incorporated by reference to exhibit&#160;3.3 of the Company&#8217;s Annual Report on Form 10-K filed on March&#160;20, 2025).</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:-0.038pt;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="margin-left:11.61pt;letter-spacing:-0.361pt;">4.1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:408pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921122299/tm2113659d19_ex4-1.htm">Specimen Common Stock Certificate of Registrant (incorporated by reference to exhibit 4.1 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-257999) filed October 4</a><font style="letter-spacing:-0.361pt;"><a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921122299/tm2113659d19_ex4-1.htm">, 2021).</a></font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="margin-left:11.61pt;letter-spacing:-0.361pt;">4.2* </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:408pt;text-align:left;">
              <font style="letter-spacing:-0.038pt;">Form of Preferred Stock Certificate. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="margin-left:11.61pt;letter-spacing:-0.361pt;">4.3* </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:408pt;text-align:left;">
              <font style="letter-spacing:-0.038pt;">Certificate of Designations of Preferred Stock. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="margin-left:11.61pt;letter-spacing:-0.361pt;">4.4 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:408pt;text-align:left;">
              <div style="letter-spacing:-0.038pt;">
                <a style="-sec-extract:exhibit" href="tm2533585d2_ex4-4.htm">Form of Indenture (filed herewith).</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="margin-left:11.61pt;letter-spacing:-0.361pt;">4.5* </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:408pt;text-align:left;">
              <font style="letter-spacing:-0.038pt;">Form of Debt Security. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="margin-left:11.61pt;letter-spacing:-0.361pt;">4.6* </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:408pt;text-align:left;">
              <font style="letter-spacing:-0.038pt;">Form of Warrant. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="margin-left:11.61pt;letter-spacing:-0.361pt;">4.7* </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:408pt;text-align:left;">
              <font style="letter-spacing:-0.038pt;">Form of Purchase Contract Agreement. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="margin-left:11.61pt;letter-spacing:-0.361pt;">4.8* </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:408pt;text-align:left;">
              <font style="letter-spacing:-0.038pt;">Form of Unit Agreement. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="margin-left:11.61pt;letter-spacing:-0.361pt;">4.9* </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:408pt;text-align:left;">
              <font style="letter-spacing:-0.038pt;">Form of Unit. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="margin-left:11.61pt;letter-spacing:-0.361pt;">4.10* </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:408pt;text-align:left;">
              <font style="letter-spacing:-0.038pt;">Form of Subscription Rights Agreement. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="margin-left:11.61pt;letter-spacing:-0.361pt;">5.1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:408pt;text-align:left;">
              <div style="letter-spacing:-0.038pt;">
                <a style="-sec-extract:exhibit" href="tm2533585d2_ex5-1.htm">Opinion of Goodwin Procter LLP (filed herewith).</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="margin-left:11.61pt;letter-spacing:-0.361pt;">5.2 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:408pt;text-align:left;">
              <div style="letter-spacing:-0.038pt;">
                <a style="-sec-extract:exhibit" href="tm2533585d2_ex5-2.htm">Opinion of Goodwin Procter LLP relating to the sales agreement prospectus (filed herewith).</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="margin-left:5.8pt;letter-spacing:-0.361pt;">23.1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:408pt;text-align:left;">
              <div style="letter-spacing:-0.038pt;">
                <a style="-sec-extract:exhibit" href="tm2533585d2_ex23-1.htm">Consent of Ernst &amp; Young LLP (filed herewith).</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="margin-left:5.8pt;letter-spacing:-0.361pt;">23.2 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:408pt;text-align:left;">
              <div style="letter-spacing:-0.038pt;">
                <a style="-sec-extract:exhibit" href="tm2533585d2_ex5-1.htm">Consent of Goodwin Procter LLP (included in Exhibit&#160;5.1).</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="margin-left:5.8pt;letter-spacing:-0.361pt;">23.3 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:408pt;text-align:left;">
              <div style="letter-spacing:-0.038pt;">
                <a style="-sec-extract:exhibit" href="tm2533585d2_ex5-2.htm">Consent of Goodwin Procter LLP (included in Exhibit&#160;5.2).</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="margin-left:5.8pt;letter-spacing:-0.361pt;">24.1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.5pt 0pt; width:408pt;text-align:left;">
              <div style="letter-spacing:-0.038pt;">
                <a href="#tPOA">Power of Attorney (included on the signature page).</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="margin-left:5.8pt;letter-spacing:-0.361pt;">25.1** </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.333pt 0pt 0.667pt 0pt; width:408pt;white-space:normal;text-align:left;">
              <font style="letter-spacing:-0.038pt;">Statement of Eligibility on Form T-1 under the Trust Indenture Act of 1939, as amended, of the trustee, as trustee under the indenture filed herewith. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:0pt;">&#8203;</td>
            <td style="border-bottom:0.75pt solid #000000; ;padding:3pt 0pt 12pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.361pt;">107 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="border-bottom:0.75pt solid #000000; ;padding:3pt 0pt 12pt 0pt; width:408pt;text-align:left;">
              <div style="letter-spacing:-0.038pt;">
                <a style="-sec-extract:exhibit" href="tm2533585d1_ex-filingfees.htm">Filing Fee Table (filed herewith).</a>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:8.3pt; margin-top:3.21pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:7pt;">
          <font style="letter-spacing:-0.266pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:3.21pt; margin-bottom:0pt; line-height:8.3pt; text-align:left; margin-left:20pt;font-size:7pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.028pt;">To be filed, if necessary, by amendment or incorporated by reference as an exhibit to a report pursuant to Section&#160;13(a), 13(c) or 15(d) of the Exchange Act in connection with the offering of specific securities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.14pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:8.3pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:7pt;">
          <font style="letter-spacing:-0.266pt;">**</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:8.3pt; text-align:left; margin-left:20pt;font-size:7pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.028pt;">To be filed in accordance with the requirements of Section&#160;305(b)(2) of the Trust Indenture Act of 1939 and Rule&#160;5b-3 thereunder. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">II-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:0.5pt;">Item&#160;17.&nbsp;&nbsp;&nbsp;Undertakings.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.038pt;">(a)</font>
          <br >
        </div>
        <div style=" margin-top:3.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">The undersigned registrant hereby undertakes:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:7.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.038pt;">(i)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">To include any prospectus required by Section&#160;10(a)(3) of the Securities Act;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:7.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.038pt;">(ii)</font>
          <br >
        </div>
        <div style=" margin-top:7.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in the volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule&#160;424(b) if, in the aggregate, the changes in volume and price represent no more than 20&#160;percent change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.038pt;">(iii)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; </font><font style="font-style:italic;">provided</font><font style="letter-spacing:-0.361pt;">, </font><font style="font-style:italic;">however</font><font style="letter-spacing:-0.038pt;">, that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section&#160;13 or Section&#160;15(d) of the Exchange Act that are incorporated by reference in the registration statement or is contained in a form of prospectus filed pursuant to Rule&#160;424(b) that is part of the registration statement.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial </font><font style="font-style:italic;">bona fide</font><font style="letter-spacing:-0.038pt;"> offering thereof.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">That, for the purpose of determining liability under the Securities Act to any purchaser:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:7.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.038pt;">(i)</font>
          <br >
        </div>
        <div style=" margin-top:7.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">Each prospectus filed by the registrant pursuant to Rule&#160;424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:7.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.038pt;">(ii)</font>
          <br >
        </div>
        <div style=" margin-top:7.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">Each prospectus required to be filed pursuant to Rule&#160;424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule&#160;430B relating to an offering made pursuant to Rule&#160;415(a)(1)(i), (vii), or (x)&#160;for the purpose of providing the information required by Section&#160;10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule&#160;430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial </font><font style="font-style:italic;">bona fide</font><font style="letter-spacing:-0.038pt;"> offering thereof. </font><font style="font-style:italic;">Provided</font><font style="letter-spacing:-0.361pt;">, </font><font style="font-style:italic;">however</font><font style="letter-spacing:-0.038pt;">, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">II-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:116.5pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:40pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.361pt;">(6)</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.038pt;">(i)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule&#160;424;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.038pt;">(ii)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.038pt;">(iii)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.038pt;">(iv)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.038pt;">(b)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant&#8217;s annual report pursuant to Section&#160;13(a) or Section&#160;15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section&#160;15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial </font><font style="font-style:italic;">bona fide</font><font style="letter-spacing:-0.038pt;"> offering thereof.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.038pt;">(h)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.038pt;">(j)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">The undersigned registrant hereby undertakes to file an application for the purpose of determining the eligibility of the trustee to act under subsection (a)&#160;of Section&#160;310 of the Trust Indenture Act (the &#8220;Act&#8221;) in accordance with the rules and regulations prescribed by the SEC under section 305(b)(2) of the Act.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">II-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style=" width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tSIG">&#8203;</a><a name="tPOA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:12.5pt;">
          <font style="letter-spacing:0.625pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">SIGNATURES</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.038pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Purchase, State of New York, on this </font><font style="letter-spacing:-0.361pt;">18</font><font style="letter-spacing:-0.038pt;">th day of December&#160;2025.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-left:240pt; margin-top:17pt; text-align:justify; width:216pt; line-height:12pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;">
          <font style="letter-spacing:0.475pt;">Cognition Therapeutics, Inc.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style=" float:left; margin-left:240pt; line-height:12pt; margin-top:14.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.038pt;">By:</font>
          <br >
        </div>
        <div style=" margin-top:14.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:260pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">/s/ Lisa Ricciardi </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="white-space:nowrap; margin-left:260pt; margin-top:2.667pt; width:196pt;">
          <div style="margin-left: 0pt; width: 196pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-left:260pt; margin-top:3pt; margin-bottom:0pt; text-align:left; width:31pt;white-space:nowrap;">
          <font style="letter-spacing:-0.038pt;">Name:</font>
          <br >
        </div>
        <div style=" margin-top:3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:291pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">Lisa Ricciardi</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:260pt; line-height:12pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:31pt;white-space:nowrap;">
          <font style="letter-spacing:-0.038pt;">Title:</font>
          <br >
        </div>
        <div style=" margin-top:0pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:291pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.038pt;">Chief Executive Officer and President</font>
          <br >
          <font style="letter-spacing:-0.361pt;">(</font><font style="font-style:italic;">Principal Executive Officer</font><font style="letter-spacing:-0.361pt;">)</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;font-family:Arial Narrow, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:0.5pt;">POWER OF ATTORNEY</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">We, the undersigned officers and directors of Cognition Therapeutics, Inc., hereby severally constitute and appoint each of Lisa Ricciardi and John Doyle our true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution in her or him for her or him and in her or his name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as she or he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or her or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.038pt;">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.19pt;"> </font>
        </div>
        <table style="width:456pt;height:273pt;margin-top:8.5pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:uppercase;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;min-height:21.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial Narrow, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:11.5pt 0pt 2.5pt 0pt; width:154.8pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">Signature </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:11.5pt 0pt 2.5pt 0pt; width:192pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">Title </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:11.5pt 0pt 2.5pt 0pt; width:85.2pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="text-transform:uppercase;letter-spacing:0.4pt;">Date </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:49.75pt; white-space:normal;text-align:center;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:18.583pt 0pt 0.5pt 0pt; width:154.8pt;vertical-align:top;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.038pt;">/s/ Lisa Ricciardi</font>
              </div>
              <div style="margin-top:2.667pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 154.8pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:3pt; text-align:center;">
                <font style="letter-spacing:-0.038pt;">Lisa Ricciardi </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:18.583pt 0pt 0.5pt 0pt; width:192pt;text-align:justify;">
              <div>
                <font style="letter-spacing:-0.038pt;">Chief Executive Officer, President and Director </font><font style="letter-spacing:-0.361pt;">(</font><font style="font-style:italic;">Principal Executive Officer</font><font style="letter-spacing:-0.361pt;">) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:18.583pt 0pt 0.5pt 0pt; width:85.2pt;white-space:nowrap;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.038pt;">December </font><font style="letter-spacing:-0.361pt;">18, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:36.5pt; white-space:normal;text-align:center;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:5.833pt 0pt 0.5pt 0pt; width:154.8pt;vertical-align:top;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.038pt;">/s/ John Doyle </font>
              </div>
              <div style="margin-top:2.667pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 154.8pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:3pt; text-align:center;">
                <font style="letter-spacing:-0.038pt;">John Doyle </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1px 0pt; width:192pt;text-align:justify;">
              <div>
                <font style="letter-spacing:-0.038pt;">Chief Financial Officer (</font><font style="font-style:italic;">Principal Financial and Accounting Officer</font><font style="letter-spacing:-0.361pt;">) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1px 0pt; width:85.2pt;white-space:nowrap;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.038pt;">December </font><font style="letter-spacing:-0.361pt;">18, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:36.5pt; white-space:nowrap;text-align:center;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:5.833pt 0pt 0.5pt 0pt; width:154.8pt;white-space:normal;vertical-align:top;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.038pt;">/s/ Jack A. Khattar</font>
              </div>
              <div style="margin-top:2.667pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 154.8pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:3pt; text-align:center;">
                <font style="letter-spacing:-0.038pt;">Jack A. Khattar </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1px 0pt; width:192pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.038pt;">Director (Chairman of the Board) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1px 0pt; width:85.2pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.038pt;">December </font><font style="letter-spacing:-0.361pt;">18, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:36.5pt; white-space:nowrap;text-align:center;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:5.833pt 0pt 0.5pt 0pt; width:154.8pt;white-space:normal;vertical-align:top;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.038pt;">/s/ Aaron G. L. Fletcher, Ph.D. </font>
              </div>
              <div style="margin-top:2.667pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 154.8pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:3pt; text-align:center;">
                <font style="letter-spacing:-0.038pt;">Aaron G. L. Fletcher, Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1px 0pt; width:192pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.038pt;">Director </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1px 0pt; width:85.2pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.038pt;">December </font><font style="letter-spacing:-0.361pt;">18, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:36.5pt; white-space:nowrap;text-align:center;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:5.833pt 0pt 0.5pt 0pt; width:154.8pt;white-space:normal;vertical-align:top;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.038pt;">/s/ Brett P. Monia, Ph.D. </font>
              </div>
              <div style="margin-top:2.667pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 154.8pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:3pt; text-align:center;">
                <font style="letter-spacing:-0.038pt;">Brett P. Monia, Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1px 0pt; width:192pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.038pt;">Director </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1px 0pt; width:85.2pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.038pt;">December </font><font style="letter-spacing:-0.361pt;">18, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:36.5pt; white-space:nowrap;text-align:center;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:5.833pt 0pt 0.5pt 0pt; width:154.8pt;white-space:normal;vertical-align:top;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.038pt;">/s/ Ellen B. Richstone </font>
              </div>
              <div style="margin-top:2.667pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 154.8pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:3pt; text-align:center;">
                <font style="letter-spacing:-0.038pt;">Ellen B. Richstone </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1px 0pt; width:192pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.038pt;">Director </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1px 0pt; width:85.2pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.038pt;">December </font><font style="letter-spacing:-0.361pt;">18, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:12pt;white-space:nowrap;text-align:center;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:5.833pt 0pt 0.5pt 0pt; width:154.8pt;white-space:normal;vertical-align:top;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.038pt;">/s/ Peggy Wallace </font>
              </div>
              <div style="margin-top:2.667pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 154.8pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:3pt; text-align:center;">
                <font style="letter-spacing:-0.038pt;">Peggy Wallace </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1px 0pt; width:192pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.038pt;">Director </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1px 0pt; width:85.2pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.038pt;">December </font><font style="letter-spacing:-0.361pt;">18, 2025</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.361pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:-0.342pt;">II-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.2
<SEQUENCE>2
<FILENAME>tm2533585d2_ex1-2.htm
<DESCRIPTION>EXHIBIT 1.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0; font-size: 10pt"><B>Exhibit 1.2</B></P>

<P STYLE="margin: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>OPEN MARKET SALE
AGREEMENT<SUP>SM</SUP></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt">December&nbsp;18,
2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">JEFFERIES LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">520 Madison Avenue</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">New York, New York 10022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Ladies and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Cognition
Therapeutics,&nbsp;Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), proposes, subject to the terms and conditions stated
herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the &ldquo;<B>Agent</B>&rdquo;),
shares of the Company&rsquo;s common stock, par value $0.001 per share (the &ldquo;<B>Common Shares</B>&rdquo;), on the terms set forth
in this agreement (this &ldquo;<B>Agreement</B>&rdquo;). In the event that the Company has no subsidiaries, or only one subsidiary, then
all references herein to &ldquo;subsidiaries&rdquo; of the Company shall be deemed to refer to no subsidiary, or such single subsidiary,
<I>mutatis mutandis</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;DEFINITIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Certain
Definitions</U>. For purposes of this Agreement, capitalized terms used herein and not otherwise defined shall have the following respective
meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Affiliate</B>&rdquo;
of a Person means another Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under
common control with, such first- mentioned Person. The term &ldquo;control&rdquo; (including the terms &ldquo;controlling,&rdquo; &ldquo;controlled
by&rdquo; and &ldquo;under common control with&rdquo;) means the possession, direct or indirect, of the power to direct or cause the
direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Agency
Period</B>&rdquo; means the period commencing on the date of this Agreement and expiring on the earliest to occur of (x)&nbsp;the date
on which the Agent shall have placed the Maximum Program Amount pursuant to this Agreement and (y)&nbsp;the date this Agreement is terminated
pursuant to <U>&lrm;Section&nbsp;7</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Commission</B>&rdquo;
means the U.S. Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Exchange
Act</B>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations of the Commission thereunder
(the &ldquo;<B>Securities Act Regulations</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Floor
Price</B>&rdquo; means the minimum price set by the Company in the Issuance Notice below which the Agent shall not sell Shares during
the applicable period set forth in the Issuance Notice, which may be adjusted by the Company at any time during the period set forth
in the Issuance Notice by delivering written notice of such change to the Agent and which in no event shall be less than $1.00 without
the prior written consent of the Agent, which may be withheld in the Agent&rsquo;s sole discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>SM</SUP> &ldquo;Open Market Sale Agreement&rdquo; is a service
mark of Jefferies LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Governmental
Authority</B>&rdquo; means (i)&nbsp;any federal, provincial, state, local, municipal, national or international government or governmental
authority, regulatory or administrative agency, governmental commission, department, board, bureau, agency or instrumentality, court,
tribunal, arbitrator or arbitral body (public or private); (ii)&nbsp;any self-regulatory organization; or (iii)&nbsp;any political subdivision
of any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Issuance
Amount</B>&rdquo; means the aggregate Sales Price of the Shares to be sold by the Agent pursuant to any Issuance Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Issuance
Notice</B>&rdquo; means a written notice delivered to the Agent by the Company in accordance with this Agreement in the form attached
hereto as Exhibit&nbsp;A that is executed by its Chief Executive Officer, President or Chief Financial Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Issuance
Notice Date</B>&rdquo; means any Trading Day during the Agency Period that an Issuance Notice is delivered pursuant to &lrm;<U>Section&nbsp;3(b)(i)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Issuance
Price</B>&rdquo; means the Sales Price less the Selling Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Law</B>&rdquo;
means any and all laws, including all federal, state, local, municipal, national or foreign statutes, codes, ordinances, guidelines,
decrees, rules, regulations and by-laws and all judicial, arbitral, administrative, ministerial, departmental or regulatory judgments,
orders, directives, decisions, rulings or awards or other requirements of any Governmental Authority, binding on or affecting the person
referred to in the context in which the term is used and rules, regulations and policies of any stock exchange on which securities of
the Company are listed for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Maximum
Program Amount</B>&rdquo; means Common Shares with an aggregate Sales Price of the lesser of (a)&nbsp;the number or dollar amount of
Common Shares registered under the effective Registration Statement (defined below) pursuant to which the offering is being made, (b)&nbsp;the
number of authorized but unissued Common Shares (less Common Shares issuable upon exercise, conversion or exchange of any outstanding
securities of the Company or otherwise reserved from the Company&rsquo;s authorized capital stock), (c)&nbsp;the number or dollar amount
of Common Shares permitted to be sold under Form&nbsp;S-3 (including General Instruction I.B.6 thereof, if applicable), or (d)&nbsp;the
number or dollar amount of Common Shares for which the Company has filed a Prospectus (defined below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Person</B>&rdquo;
means an individual or a corporation, partnership, limited liability company, trust, incorporated or unincorporated association, joint
venture, joint stock company, governmental authority or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Principal
Market</B>&rdquo; means the Nasdaq Capital Market or such other national securities exchange on which the Common Shares, including any
Shares, are then listed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B><U>Rule&nbsp;164</U></B>,&rdquo;
 &ldquo;<B><U>Rule&nbsp;405</U></B>,&rdquo; &ldquo;<B><U>Rule&nbsp;415</U></B>,&rdquo; &ldquo;<B><U>Rule&nbsp;424</U></B>,&rdquo; &ldquo;<B><U>Rule&nbsp;424(b)</U></B>,&rdquo;
 &ldquo;<B><U>Rule&nbsp;430B</U></B>,&rdquo; and &ldquo;<B><U>Rule&nbsp;433</U></B>&rdquo; refer to such rules&nbsp;under the Securities
Act Regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Sales
Price</B>&rdquo; means the actual sale execution price of each Share placed by the Agent pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Securities
Act</B>&rdquo; means the Securities Act of 1933, as amended, and the rules&nbsp;and regulations of the Commission thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Selling
Commission</B>&rdquo; means three percent 3.0% of the gross proceeds of Shares sold pursuant to this Agreement, or as otherwise agreed
between the Company and the Agent with respect to any Shares sold pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Settlement
Date</B>&rdquo; means the first business day following each Trading Day during the period set forth in the Issuance Notice on which Shares
are sold pursuant to this Agreement, when the Company shall deliver to the Agent the amount of Shares sold on such Trading Day and the
Agent shall deliver to the Company the Issuance Price received on such sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Shares</B>&rdquo;
shall mean the Company&rsquo;s Common Shares issued or issuable pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Trading
Day</B>&rdquo; means any day on which the Principal Market is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;REPRESENTATIONS
AND WARRANTIES OF THE COMPANY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company represents and warrants to, and agrees with, the Agent that, unless such representation, warranty or agreement specifies otherwise,
as of (1)&nbsp;the date of this Agreement, (2)&nbsp;each Issuance Notice Date, (3)&nbsp;each Settlement Date, (4)&nbsp;each Triggering
Event Date (as defined below) with respect to which the Company is obligated to deliver a certificate pursuant to Section&nbsp;4(o)&nbsp;and
(5)&nbsp;each Time of Sale (each of the times referenced above is referred to herein as a &ldquo;<B>Representation Date</B>&rdquo;),
except as may be disclosed in the Prospectus (including any documents incorporated by reference therein and any supplements thereto)
on or before a Representation Date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Registration
Statement and Prospectus</U>. The Company and the transactions contemplated by this Agreement meet the requirements for and comply with
the applicable conditions set forth in Form&nbsp;S-3 (including General Instructions I.A and I.B) under the Securities Act. The Registration
Statement has been or will be filed with the Commission and has been or will be declared effective by the Commission under the Securities
Act prior to the issuance of any Placement Notices by the Company. As of each Time of Sale (as defined below), the Registration Statement
is effective. The Prospectus Supplement will name the Agent as the agent in the section entitled &ldquo;Plan of Distribution.&rdquo;
The Company has not received, and has no notice of, any order of the Commission preventing or suspending the use of the Registration
Statement, or threatening or instituting proceedings for that purpose. The Registration Statement and the offer and sale of Shares as
contemplated hereby meet the requirements of Rule&nbsp;415 under the Securities Act and comply in all material respects with said Rule.
Any statutes, regulations, contracts or other documents that are required to be described in the Registration Statement or the Prospectus
or to be filed as exhibits to the Registration Statement have been so described or filed. Copies of the Registration Statement, the Prospectus,
and any such amendments or supplements and all documents incorporated by reference therein that were filed with the Commission on or
prior to the date of this Agreement have been delivered, or are available through EDGAR, to the Agent and its counsel. The Company has
not distributed and, prior to the later to occur of each Settlement Date and completion of the distribution of the Shares, will not distribute
any offering material in connection with the offering or sale of the Shares other than the Registration Statement and the Prospectus
and any Free Writing Prospectus (as defined below) to which the Agent has consented (such consent not to be unreasonably withheld, conditioned
or delayed). The Common Shares are registered pursuant to Section&nbsp;12(b)&nbsp;of the Exchange Act and is currently listed on the
Principal Market under the trading symbol &ldquo;CGTX.&rdquo; The Company has taken no action designed to, or likely to have the effect
of, terminating the registration of the Common Shares under the Exchange Act, delisting the Common Shares from the Principal Market,
nor has the Company received any notification that the Commission or the Principal Market is contemplating terminating such registration
or listing. To the Company&rsquo;s knowledge, it is in compliance with all applicable listing requirements of the Principal Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Misstatement or Omission</U>. The Registration Statement, when it became or becomes effective, and the Prospectus, and any amendment
or supplement thereto, on the date of such Prospectus or amendment or supplement, conformed and will conform in all material respects
with the requirements of the Securities Act. At each Settlement Date, the Registration Statement and the Prospectus, as of such date,
will conform in all material respects with the requirements of the Securities Act. The Registration Statement, when it became or becomes
effective, did not, and will not, contain an untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary to make the statements therein not misleading. The Prospectus and any amendment and supplement thereto, on the date
thereof and at each Time of Sale, did not or will not include an untrue statement of a material fact or omit to state a material fact
necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. The documents incorporated
by reference in the Prospectus or any Prospectus Supplement did not, and any further documents filed and incorporated by reference therein
will not, when filed with the Commission, contain an untrue statement of a material fact or omit to state a material fact required to
be stated in such document or necessary to make the statements in such document, in light of the circumstances under which they were
made, not misleading. The foregoing shall not apply to statements in, or omissions from, any such document made in reliance upon, and
in conformity with, information furnished to the Company by the Agent in writing specifically for use in the preparation thereof, it
being understood and agreed that the only such information furnished by the Agent to the Company consists of &ldquo;Agent Information&rdquo;
as defined below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Conformity
with the Securities Act and Exchange Act</U>. The Registration Statement, the Prospectus, any Free Writing Prospectus or any amendment
or supplement thereto, and the documents incorporated by reference in the Registration Statement, the Prospectus or any amendment or
supplement thereto, when such documents were or are filed with the Commission under the Securities Act or the Exchange Act or became
or become effective under the Securities Act, as the case may be, conformed or will conform in all material respects with the requirements
of the Securities Act and the Exchange Act, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Emerging
Growth Company</U>. From the time of initial confidential submission of the Registration Statement to the Commission (or, if earlier,
the first date on which the Company engaged directly or through any person authorized to act on its behalf in any Section&nbsp;5(d)&nbsp;Written
Communication or Section&nbsp;5(d)&nbsp;Oral Communication) through the date hereof, the Company has been and is an &ldquo;emerging growth
company,&rdquo; as defined in Section&nbsp;2(a)&nbsp;of the Securities Act (an &ldquo;<B>Emerging Growth Company</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Financial
Information</U>. The consolidated financial statements of the Company included or incorporated by reference in the Registration Statement,
the Prospectus and the Free Writing Prospectuses, if any, together with the related notes and schedules, present fairly, in all material
respects, the consolidated financial position of the Company and the Subsidiaries (as defined below) as of the dates indicated and the
consolidated results of operations, cash flows and changes in stockholders&rsquo; equity of the Company for the periods specified and
have been prepared in compliance with the requirements of the Securities Act and Exchange Act and in conformity with U.S. Generally Accepted
Accounting Principles (&ldquo;<B>GAAP</B>&rdquo;) applied on a consistent basis during the periods involved except as may be expressly
stated in the related notes thereto; there are no financial statements (historical or pro forma) that are required to be included or
incorporated by reference in the Registration Statement, or the Prospectus that are not included or incorporated by reference as required;
the Company and the Subsidiaries (as defined below) do not have any material liabilities or obligations, direct or contingent (including
any off-balance sheet obligations), not described in the Registration Statement (excluding the exhibits thereto), and the Prospectus;
and all disclosures contained or incorporated by reference in the Registration Statement, the Prospectus and the Free Writing Prospectuses,
if any, regarding &ldquo;non-GAAP financial measures&rdquo; (as such term is defined by the rules&nbsp;and regulations of the Commission)
comply in all material respects with Regulation G of the Exchange Act and Item 10 of Regulation S-K under the Securities Act, to the
extent applicable. The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration
Statement and the Prospectus fairly presents the information called for in all material respects and has been prepared in accordance
with the Commission&rsquo;s rules&nbsp;and guidelines applicable thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Conformity
with EDGAR Filing</U>. The Prospectus delivered to the Agent for use in connection with the sale of the Shares pursuant to this Agreement
will be identical to the versions of the Prospectus created to be transmitted to the Commission for filing via EDGAR, except to the extent
permitted by Regulation S-T.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Organization</U>.
The Company and each of its Subsidiaries (defined below) are duly organized, validly existing as a corporation and in good standing under
the Laws of their respective jurisdictions of organization. The Company and each of its Subsidiaries are duly licensed or qualified as
a foreign corporation for transaction of business and in good standing under the Laws of each other jurisdiction in which their respective
ownership or lease of property or the conduct of their respective businesses requires such license or qualification, and have all corporate
power and authority necessary to own or hold their respective properties and to conduct their respective businesses as described in the
Registration Statement and the Prospectus, except where the failure to be so qualified or in good standing or have such power or authority
would not, individually or in the aggregate, have a material adverse effect or would reasonably be expected to have a material adverse
effect on or affecting the assets, business, operations, earnings, properties, condition (financial or otherwise), prospects, stockholders&rsquo;
equity or results of operations of the Company and the Subsidiaries taken as a whole, or prevent or materially interfere with the consummation
of the transactions contemplated hereby (a &ldquo;<B>Material Adverse Effect</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Subsidiaries</U>.
The subsidiaries set forth in Exhibit&nbsp;21.1 of the Company&rsquo;s most recently filed Form&nbsp;10-K (collectively, the &ldquo;<B>Subsidiaries</B>&rdquo;),
are the Company&rsquo;s only significant subsidiaries (as such term is defined in Rule&nbsp;1-02 of Regulation S-X promulgated by the
Commission). Except as set forth in the Registration Statement and in the Prospectus, the Company owns, directly or indirectly, all of
the equity interests of the Subsidiaries free and clear of any lien, charge, security interest, encumbrance, right of first refusal or
other restriction, and all the equity interests of the Subsidiaries are validly issued and are fully paid, nonassessable and free of
preemptive and similar rights. No Subsidiary is currently prohibited, directly or indirectly, from paying any dividends to the Company,
from making any other distribution on such Subsidiary&rsquo;s capital stock, from repaying to the Company any loans or advances to such
Subsidiary from the Company or from transferring any of such Subsidiary&rsquo;s property or assets to the Company or any other Subsidiary
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Violation or Default</U>. Neither the Company nor any of its Subsidiaries is (i)&nbsp;in violation of its charter or by-laws or similar
organizational documents; (ii)&nbsp;in default, and no event has occurred that, with notice or lapse of time or both, would constitute
such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of
trust, loan agreement or other agreement or instrument to which the Company or any of its Subsidiaries is a party or by which the Company
or any of its Subsidiaries is bound or to which any of the property or assets of the Company or any of its Subsidiaries are subject;
or (iii)&nbsp;in violation of any Law of any Governmental Authority, except, in the case of each of clauses (ii)&nbsp;and (iii)&nbsp;above,
for any such violation or default that would not, individually or in the aggregate, have a Material Adverse Effect. To the Company&rsquo;s
knowledge, no other party under any material contract or other agreement to which it or any of its Subsidiaries is a party is in default
in any respect thereunder where such default would have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Material Adverse Effect</U>. Subsequent to the respective dates as of which information is given in the Registration Statement, the Prospectus
and the Free Writing Prospectuses, if any (including any document deemed incorporated by reference therein), there has not been (i)&nbsp;any
Material Adverse Effect or the occurrence of any development that the Company reasonably expects will result in a Material Adverse Effect,
(ii)&nbsp;any transaction which is material to the Company and the Subsidiaries taken as a whole, (iii)&nbsp;any obligation or liability,
direct or contingent (including any off-balance sheet obligations), incurred by the Company or any Subsidiary, which is material to the
Company and the Subsidiaries taken as a whole, (iv)&nbsp;any material change in the capital stock or outstanding long-term indebtedness
of the Company or any of its Subsidiaries or (v)&nbsp;any dividend or distribution of any kind declared, paid or made on the capital
stock of the Company or any Subsidiary, other than in each case above in the ordinary course of business or as otherwise disclosed in
the Registration Statement or Prospectus (including any document incorporated by reference therein).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Capitalization</U>.
The issued and outstanding shares of capital stock of the Company have been validly issued, are fully paid and nonassessable and, other
than as disclosed in the Registration Statement or the Prospectus, are not subject to any preemptive rights, rights of first refusal
or similar rights. The Company has an authorized, issued and outstanding capitalization as set forth in the Registration Statement and
the Prospectus as of the dates referred to therein (other than the grant of additional options or other equity awards under the Company&rsquo;s
existing equity incentive plans, or changes in the number of outstanding Common Shares of the Company due to the issuance of shares upon
the exercise or conversion of securities exercisable for, or convertible into, Common Shares outstanding on the date hereof) and such
authorized capital stock conforms in all material respects to the description thereof set forth in the Registration Statement and the
Prospectus. The description of the securities of the Company in the Registration Statement and the Prospectus is complete and accurate
in all material respects. Except as disclosed in or contemplated by the Registration Statement or the Prospectus, as of the date referred
to therein, the Company does not have outstanding any options to purchase, or any rights or warrants to subscribe for, or any securities
or obligations convertible into, or exchangeable for, or any contracts or commitments to issue or sell, any shares of capital stock or
other securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Authorization;
Enforceability</U>. The Company has full legal right, power and authority to enter into this Agreement and perform the transactions contemplated
hereby. This Agreement has been duly authorized, executed and delivered by the Company and is a legal, valid and binding agreement of
the Company enforceable in accordance with its terms, except to the extent that enforceability may be limited by bankruptcy, insolvency,
reorganization, moratorium or similar Laws affecting creditors&rsquo; rights generally and by general equitable principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Authorization
of Shares</U>. The Shares, when issued and delivered pursuant to the terms approved by the board of directors of the Company or a duly
authorized committee thereof, or a duly authorized executive committee, against payment therefor as provided herein, will be duly and
validly authorized and issued and fully paid and nonassessable, free and clear of any pledge, lien, encumbrance, security interest or
other claim, including any statutory or contractual preemptive rights, resale rights, rights of first refusal or other similar rights,
and will be registered pursuant to Section&nbsp;12 of the Exchange Act. The Shares, when issued, will conform in all material respects
to the description thereof set forth in or incorporated into the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Consents Required</U>. No consent, approval, authorization, order, registration or qualification of or with any Governmental Authority
is required for the execution, delivery and performance by the Company of this Agreement, the issuance and sale by the Company of the
Shares, except for such consents, approvals, authorizations, orders and registrations or qualifications as may be required under applicable
state securities Laws or Laws of the Financial Industry Regulatory Authority (&ldquo;<B>FINRA</B>&rdquo;) or the Principal Market in
connection with the sale of the Shares by the Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Preferential Rights</U>. Except as set forth in the Registration Statement and the Prospectus, (i)&nbsp;no person, as such term is defined
in Rule&nbsp;1-02 of Regulation S-X promulgated under the Securities Act (each, a &ldquo;<U>Person</U>&rdquo;), has the right, contractual
or otherwise, to cause the Company to issue or sell to such Person any Common Shares or shares of any other capital stock or other securities
of the Company, (ii)&nbsp;no Person has any preemptive rights, resale rights, rights of first refusal, rights of co-sale, or any other
rights (whether pursuant to a &ldquo;poison pill&rdquo; provision or otherwise) to purchase any Common Shares or shares of any other
capital stock or other securities of the Company, (iii)&nbsp; no Person has the right to act as an underwriter or as a financial advisor
to the Company in connection with the offer and sale of the Common Shares offered pursuant to this Agreement, and (iv)&nbsp;no Person
has the right, contractual or otherwise, to require the Company to register under the Securities Act any Common Shares or shares of any
other capital stock or other securities of the Company, or to include any such shares or other securities in the Registration Statement
or the offering contemplated thereby, whether as a result of the filing or effectiveness of the Registration Statement or the sale of
the Shares as contemplated thereby or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(p)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Independent
Public Accounting Firm</U>. Ernst&nbsp;&amp; Young LLP (the &ldquo;<B>Accountant</B>&rdquo;), whose report on the consolidated financial
statements of the Company is filed with the Commission as part of the Company&rsquo;s most recent Annual Report on Form&nbsp;10-K filed
with the Commission and incorporated by reference into the Registration Statement and the Prospectus, are and, during the periods covered
by their report, were an independent registered public accounting firm within the meaning of the Securities Act and the Public Company
Accounting Oversight Board (United States). To the Company&rsquo;s knowledge, the Accountant is not in violation of the auditor independence
requirements of the Sarbanes-Oxley Act of 2002 (the &ldquo;<B>Sarbanes-Oxley Act</B>&rdquo;) with respect to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(q)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Enforceability
of Agreements</U>. To the Company&rsquo;s knowledge, all agreements between the Company and third parties expressly referenced in the
Prospectus are legal, valid and binding obligations of the Company enforceable in accordance with their respective terms, except to the
extent that (i)&nbsp;enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar Laws affecting creditors&rsquo;
rights generally and by general equitable principles and (ii)&nbsp;the indemnification provisions of certain agreements may be limited
by federal or state securities Laws or public policy considerations in respect thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(r)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Litigation</U>. There is no action, suit, proceeding, inquiry, arbitration, investigation, litigation or governmental proceeding pending
or, to the Company&rsquo;s knowledge, threatened against, or involving the Company or, to the Company&rsquo;s knowledge, any executive
officer or director that is required to be disclosed in the Prospectus and the Registration Statement which has not been disclosed therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(s)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Possession
of Licenses and Permits</U>. The Company (A)&nbsp;possesses the licenses, permits, certificates, authorizations, consents and approvals
(collectively, &ldquo;<B>Governmental Licenses</B>&rdquo;) issued by the appropriate governmental entities necessary to conduct its business
as currently conducted as described in the Prospectus and the Registration Statement, and (B)&nbsp;has obtained all necessary Governmental
Licenses from other persons necessary to conduct its business, except, in each case of clauses (A)&nbsp;and (B), (i)&nbsp;as described
in the Prospectus and the Registration Statement or (ii)&nbsp;to the extent that any failure to possess any Governmental Licenses, provide
any notice, make any filing, or obtain any Governmental Licenses would not, individually or in the aggregate, reasonably be expected
to have a Material Adverse Effect; none of the Company or any of its Subsidiaries is in violation of, or in default under, any Governmental
License, except as would not reasonably be expected to have a Material Adverse Effect. All of the Governmental Licenses are valid and
in full force and effect, except when the invalidity of such Governmental Licenses or the failure of such Governmental Licenses to be
in full force and effect would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Company
has not received any written notice of proceedings relating to the revocation or modification of any Governmental Licenses which, individually
or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(t)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Health
Care Authorizations</U>. The Company has submitted and possesses, or qualifies for applicable exemptions to, such valid and current registrations,
listings, approvals, clearances, licenses, certificates, authorizations or permits and supplements or amendments thereto (collectively,
 &ldquo;<B>Health Care Authorizations</B>&rdquo;) issued or required by the appropriate local, state, federal, national, supranational
or other foreign regulatory agencies or bodies (collectively, &ldquo;<B>Health Regulatory Agencies</B>&rdquo;) necessary to conduct its
business as described in the Registration Statement and the Prospectus, including, without limitation, all such Health Care Authorizations
required by the U.S. Food and Drug Administration (the &ldquo;<B>FDA</B>&rdquo;), the Australian Therapeutic Goods Administration (&ldquo;<B>TGA</B>&rdquo;),
the Department of Health and Human Services, the European Commission, the European Medicines Agency (the &ldquo;<B>EMA</B>&rdquo;) or
any other Health Regulatory Agencies engaged in the regulation of Biologics (as defined in the Public Health Service Act of 1944, as
amended (42 U.S.C. 6A et seq.)), except as would not be reasonably expected to result in a Material Adverse Effect. The Company has not
received any written notice of proceedings, or have any knowledge of any threatened proceedings, relating to the revocation or modification
of, or non-compliance with, any such Health Care Authorization, except where such revocation, modification or non-compliance would not
result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(u)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Compliance
with Health Care Laws</U>. The Company is, and has been, in compliance with all applicable Health Care Laws, and has not engaged in activities
which are, as applicable, cause for false claims liability, civil penalties, or mandatory or permissive exclusion from Medicare, Medicaid
or any other state, federal or national health care program, except where such noncompliance, false claims liability or civil penalties
would not reasonably be expected to, singly or in the aggregate, result in a Material Adverse Effect. For purposes of this Agreement,
 &ldquo;<B>Health Care Laws</B>&rdquo; means all health care laws applicable to the Company, including, but not limited to: the Federal
Food, Drug, and Cosmetic Act (21 U.S.C. Section&nbsp;301 et seq.), the Anti-Kickback Statute (42 U.S.C. Section&nbsp;1320a-7b(b)), the
Civil Monetary Penalties Law (42 U.S.C. &sect; 1320a-7a), the Physician Payments Sunshine Act (42 U.S.C. &sect; 1320a-7h), the Civil
False Claims Act (31 U.S.C. Section&nbsp;3729 et seq.), the criminal False Claims Law (42 U.S.C. &sect; 1320a-7b(a)), all criminal laws
relating to health care fraud and abuse, including but not limited to 18 U.S.C. Sections 286 and 287, and the health care fraud criminal
provisions under the U.S. Health Insurance Portability and Accountability Act of 1996 (&ldquo;<B>HIPAA</B>&rdquo;) (42 U.S.C. Section&nbsp;1320d
et seq.), the exclusion laws (42 U.S.C. &sect; 1320a-7), Basic Health and Human Services Policy for Protection of Human Research Subjects
 &quot;Common Rule&quot; as codified and enforced by the Department of Health and Human Services in 45 C.F.R. part 46 and enforced by
FDA under 21 C.F.R. part 50, Laboratory Animal Welfare Act of 1966, HIPAA, as amended by the Health Information Technology for Economic
and Clinical Health Act (42 U.S.C. Section&nbsp;17921 et seq.), Medicare (Title XVIII of the Social Security Act), Medicaid (Title XIX
of the Social Security Act), any and all other applicable comparable local, state, federal, national, supranational and foreign health
care laws and the regulations promulgated pursuant to such laws, each as amended from time to time. The Company has not received written
notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator
or governmental or regulatory authority or third party alleging that any product operation or activity is in material violation of any
Health Care Laws, and, to the knowledge of the Company, no such claim, action, suit, proceeding, hearing, enforcement, investigation,
arbitration or other action is threatened. The Company has not received any written notice of adverse filing, warning letter, untitled
letter or other correspondence or notice from the FDA, the European Commission, the EMA, the TGA or any other Health Regulatory Agencies,
or any other court or arbitrator, alleging or asserting material noncompliance with the Health Care Laws. The Company is not a party
to and has no ongoing reporting obligations pursuant to any corporate integrity agreements, deferred prosecution agreements, monitoring
agreements, consent decrees, settlement orders, plans of correction or similar agreements with or imposed by any governmental or regulatory
authority. Additionally, neither the Company, nor, to the knowledge of the Company, any of its employees, officers or directors has been
excluded, suspended or debarred from participation in any U.S. federal health care program or human research study or trial or, to the
knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably
be expected to result in debarment, suspension or exclusion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Research
Studies and Trials</U>. (A)&nbsp;The research studies and trials conducted by or, to the Company's knowledge, on behalf of, or sponsored
by, the Company, or in which the Company has participated, that are described in the Registration Statement or the Prospectus, or the
results of which are referred to in the Registration Statement or the Prospectus, as applicable, were and, if still pending, are being,
conducted in all material respects in accordance with applicable experimental protocols, procedures and controls pursuant to, where applicable,
accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company
and all applicable statutes, rules&nbsp;and regulations of the FDA, National Institute of Health Department of Health and Human Services,
the European Commission, the EMA, the TGA and any other Health Regulatory Agencies to which it is subject; (B)&nbsp;the descriptions
of the results of such studies and trials contained in the Registration Statement or the Prospectus do not contain any misstatement of
a material fact or omit to state a material fact necessary to make such statements not misleading; (C)&nbsp;the Company has no knowledge
of any research studies or trials not described in the Registration Statement and the Prospectus the results of which reasonably call
into question in any material respect the results of the research studies and trials described in the Registration Statement or the Prospectus;
(D)&nbsp;the Company has not received any notices or correspondence from the FDA, the European Commission, the EMA, the TGA or any Health
Regulatory Agency or any institutional review board or comparable authority requiring or threatening the premature termination, suspension,
material modification or clinical hold of any research studies or trials conducted by or on behalf of, or sponsored by, the Company or
in which the Company has participated that are described in the Registration Statement or the Prospectus, and, to the Company's knowledge,
there are no reasonable grounds for the same; (E)&nbsp;there has not been any violation of applicable Law or regulation by the Company
in any of its product development efforts, submissions or reports to the FDA, the European Commission, the EMA, the TGA or any other
Health Regulatory Agency that could reasonably be expected to require investigation, corrective action or result in enforcement action,
except where such violation would not, singly or in the aggregate, result in a Material Adverse Effect; and (F)&nbsp;the research studies
and clinical trials of Company are being conducted in an ethical and human manner under state, national or supra-national applicable
Laws that are either equal or more stringent than applicable Laws and regulations enforced by the Department of Health and Human Services
and FDA governing human, animal or non-human primate research participants and test subjects and such studies and the clinical trials
are conducted, where applicable, under the auspices of a neutral and independent Institutional Animal Care and Use Committee or institutional
review board and applicable state, national, or supra national agencies responsible for oversight.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(w)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Health
Care Products Manufacturing</U>. The manufacture of the Company's products by or, to the knowledge of the Company, on behalf of the Company
is being conducted in compliance with all applicable Health Care Laws, including, without limitation, the FDA&rsquo;s regulation pertaining
to Biologics at 21 CFR Part&nbsp;600, and, to the extent applicable, the respective counterparts thereof promulgated by the European
Commission, the EMA, TGA or other Health Regulatory Agencies. Except as disclosed in the Registration Statement and the Prospectus, the
Company has not had any manufacturing site (whether owned by the Company or, to the knowledge of the Company, that of a third party manufacturer
for the Company's products) subject to an FDA, European Commission, EMA, TGA or other Health Regulatory Agency shutdown or import or
export prohibition, nor received any written FDA, European Commission, EMA or other Health Regulatory Agency &ldquo;warning letters,&rdquo;
or &ldquo;untitled letters&rdquo;&quot; alleging or asserting material noncompliance with any applicable Health Care Laws, requests to
make material changes to the Company's products, processes or operations, or similar written correspondence or notice from the FDA, the
European Commission, the EMA, the TGA or other Health Regulatory Agency alleging or asserting material noncompliance with any applicable
Health Care Laws, other than those that have been satisfactorily addressed and/or closed with the FDA, the European Commission, the EMA
or other Health Regulatory Agency. To the knowledge of the Company, none of the FDA, the European Commission, the EMA, the TGA or any
other Health Regulatory Agency is considering such action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(x)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Possession
of Intellectual Property</U>. The Company owns or possesses all licenses or other rights to use all patents, trademarks, service marks,
trade names, copyrights, software and design licenses, trade secrets, manufacturing processes, other intangible property rights and know-how
as are necessary for the conduct of its business as described in the Prospectus and the Registration Statement (collectively, &ldquo;<B>Intellectual
Property</B>&rdquo;), except where the failure to own or possess such Intellectual Property would not reasonably be expected to have
a Material Adverse Effect. The Company has not received written notice of any infringement of or conflict with (and the Company does
not know of any such infringement of or conflict with) any asserted rights of others with respect to any Intellectual Property used by
the Company that would reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(y)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Company
IT Systems</U>. The Company owns or has a valid right to access and use all computer systems, networks, hardware, software, databases,
websites and equipment used to process, store, maintain and operate data, information and functions necessary for the conduct of its
business (the &ldquo;<B>Company IT Systems</B>&rdquo;), except where the failure to own or have the right to access the Company IT Systems
would not reasonably be expected to have a Material Adverse Effect. The Company IT Systems are adequate for, and operate and perform
in all material respects as required in connection with, the operation of the business of the Company as currently conducted except as
would not be reasonably expected, individually or in the aggregate, to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(z)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Market
Capitalization</U>. At the time the Registration Statement was or will be originally declared effective, and at the time the Company&rsquo;s
most recent Annual Report on Form&nbsp;10-K was filed with the Commission, the Company met or will meet the then applicable requirements
for the use of Form&nbsp;S-3 under the Securities Act, including, but not limited to, General Instruction I.B.1 of Form&nbsp;S-3. The
Company is not a shell company (as defined in Rule&nbsp;405 under the Securities Act) and has not been a shell company for at least 12
calendar months previously and if it has been a shell company at any time previously, has filed current Form&nbsp;10 information (as
defined in Instruction I.B.6 of Form&nbsp;S-3) with the Commission at least 12 calendar months previously reflecting its status as an
entity that is not a shell company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(aa)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>FINRA
Matters</U>. All of the information provided to the Agent or to counsel for the Agent by the Company, its counsel, its officers and directors
and the holders of any securities (debt or equity) or options to acquire any securities of the Company in connection with the offering
of the Shares is true, complete, correct and compliant with FINRA&rsquo;s rules&nbsp;and any letters, filings or other supplemental information
provided to FINRA pursuant to FINRA Rules&nbsp;is true, complete and correct.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(bb)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Material Defaults</U>. Neither the Company nor any of the Subsidiaries has defaulted on any installment on indebtedness for borrowed
money or on any rental on one or more long-term leases, which defaults, individually or in the aggregate, would have a Material Adverse
Effect. The Company has not filed a report pursuant to Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Exchange Act since the filing of
its last Annual Report on Form&nbsp;10-K, indicating that it (i)&nbsp;has failed to pay any dividend or sinking fund installment on preferred
stock or (ii)&nbsp;has defaulted on any installment on indebtedness for borrowed money or on any rental on one or more long-term leases,
which defaults, individually or in the aggregate, would have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(cc)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Certain
Market Activities</U>. Neither the Company nor any of its Subsidiaries has taken, directly or indirectly, any action designed to or that
might cause or result in stabilization or manipulation of the price of the Shares or of any &ldquo;reference security&rdquo; (as defined
in Rule&nbsp;100 of Regulation M under the Exchange Act (&ldquo;<B>Regulation M</B>&rdquo;)) with respect to the Common Shares, whether
to facilitate the sale or resale of the Shares or otherwise, and has taken no action which would directly or indirectly violate Regulation
M.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(dd)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Broker/Dealer
Relationships</U>. Neither the Company nor any of the Subsidiaries (i)&nbsp;is required to register as a &ldquo;broker&rdquo; or &ldquo;dealer&rdquo;
in accordance with the provisions of the Exchange Act or (ii)&nbsp;directly or indirectly through one or more intermediaries, controls
or is a &ldquo;person associated with a member&rdquo; or &ldquo;associated person of a member&rdquo; (within the meaning set forth in
the FINRA Manual).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ee)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Reliance</U>. The Company has not relied upon the Agent or legal counsel for the Agent for any legal, tax or accounting advice in connection
with the offering and sale of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ff)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Payment
of Taxes</U>. Except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect or where
such matters are the result of a pending bona fide dispute with taxing authorities, (A)&nbsp;the Company has accurately prepared and
timely filed all federal, state, foreign and other tax returns or other statements that are or were required to be filed by it, if any,
and has paid or made provision for the payment of all taxes, assessments, governmental or other similar charges, including without limitation,
all sales and use taxes and all taxes which it is obligated to withhold from amounts owing to employees, creditors and third parties,
with respect to the periods covered by such tax returns (whether or not such amounts are shown as due on any tax return), (B)&nbsp;no
deficiency assessment with respect to a proposed adjustment of the Company's federal, state, local or foreign taxes is pending or, to
the Company&rsquo;s knowledge threatened, (C)&nbsp;since the date of the most recent audited financial statements, the Company has not
incurred any liability for taxes other than in the ordinary course of its business, and (D)&nbsp;there is no tax lien, whether imposed
by any federal, state, foreign or other taxing authority, outstanding against the assets, properties or business of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(gg)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Title
to Property</U>. The Company has legal and valid title to all assets and properties described as owned by it in the Prospectus and the
Registration Statement (whether through fee ownership, mineral estates or similar rights of ownership), in each case free and clear of
all liens, except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, and any real
property or personal property held under lease by the Company is held under a lease that is valid, existing and enforceable by the Company
with such exceptions as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, and the
Company has not received any written notice of any material claim that is adverse to the rights of the Company under any lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(hh)&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Environmental Laws</U>. Except as set forth in the Registration Statement or the Prospectus, (A)&nbsp;the
Company is not in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or rule&nbsp;of
common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree
or judgment, relating to pollution or protection of human health, the environment (including, without limitation, ambient air, surface
water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the
release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum
products, asbestos-containing materials or mold (collectively, &ldquo;<B>Hazardous Materials</B>&rdquo;) or to the manufacture, processing,
distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, &ldquo;<B>Environmental
Laws</B>&rdquo;), except for those violations that would not reasonably be expected, individually or in the aggregate, to have a Material
Adverse Effect, (B)&nbsp;the Company has all permits, authorizations and approvals required under any applicable Environmental Laws and
is in compliance in all material respects with their requirements, (C)&nbsp;there are no pending or, to the Company&rsquo;s knowledge,
threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or
violation, investigations or proceedings relating to any Environmental Law against the Company, and (D)&nbsp;to the Company's knowledge,
there are no events or circumstances that would reasonably be expected to form the basis of an order for clean-up or remediation, or
an action, suit or proceeding by any private party or governmental body or agency, against or affecting the Company relating to Hazardous
Materials or any Environmental Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Disclosure
Controls</U>. The Company and each of its Subsidiaries maintain systems of internal accounting controls sufficient to provide reasonable
assurance that (i)&nbsp;transactions are executed in accordance with management&rsquo;s general or specific authorizations; (ii)&nbsp;transactions
are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability;
(iii)&nbsp;access to assets is permitted only in accordance with management&rsquo;s general or specific authorization; and (iv)&nbsp;the
recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with
respect to any differences. The Company&rsquo;s internal control over financial reporting is effective and the Company is not aware of
any material weaknesses in its internal control over financial reporting (other than as set forth in the Prospectus). Since the date
of the latest audited financial statements of the Company included in the Prospectus, there has been no change in the Company&rsquo;s
internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s
internal control over financial reporting (other than as set forth in the Prospectus). The Company has established disclosure controls
and procedures (as defined in Exchange Act Rules&nbsp;13a-15 and 15d-15) for the Company and designed such disclosure controls and procedures
to ensure that material information relating to the Company and each of its Subsidiaries is made known to the certifying officers by
others within those entities, particularly during the period in which the Company&rsquo;s Annual Report on Form&nbsp;10-K or Quarterly
Report on Form&nbsp;10-Q, as the case may be, is being prepared. The Company&rsquo;s certifying officers have evaluated the effectiveness
of the Company&rsquo;s disclosure controls and procedures as of a date within 90 days prior to the filing date of the Form&nbsp;10-K
for the fiscal year most recently ended (such date, the &ldquo;<B>Evaluation Date</B>&rdquo;). The Company presented in its Form&nbsp;10-K
for the fiscal year most recently ended the conclusions of the certifying officers about the effectiveness of the disclosure controls
and procedures based on their evaluations as of the Evaluation Date and the disclosure controls and procedures are effective. Since the
Evaluation Date, there have been no significant changes in the Company&rsquo;s internal controls over financial reporting (as such term
is defined in Item 307(b)&nbsp;of Regulation S-K under the Securities Act) or, to the Company&rsquo;s knowledge, in other factors that
could significantly affect the Company&rsquo;s internal controls.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(jj)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Sarbanes-Oxley</U>.
There is and has been no failure on the part of the Company or any of the Company&rsquo;s directors or officers, in their capacities
as such, to comply in all material respects with any applicable provisions of the Sarbanes-Oxley Act and the rules&nbsp;and regulations
promulgated thereunder. Each of the principal executive officer and the principal financial officer of the Company (or each former principal
executive officer of the Company and each former principal financial officer of the Company as applicable) has made all certifications
required by Sections 302 and 906 of the Sarbanes-Oxley Act with respect to all reports, schedules, forms, statements and other documents
required to be filed by it or furnished by it to the Commission. For purposes of the preceding sentence, &ldquo;principal executive officer&rdquo;
and &ldquo;principal financial officer&rdquo; shall have the meanings given to such terms in the Sarbanes-Oxley Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(kk)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Finder&rsquo;s
Fees</U>. Neither the Company nor any of the Subsidiaries has incurred any liability for any finder&rsquo;s fees, brokerage commissions
or similar payments in connection with the transactions herein contemplated, except as may otherwise exist with respect to the Agent
pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ll)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Employment
Laws Compliance</U>. The Company has not violated, or received any notice of any violation with respect to, any law, rule, regulation,
order, decree or judgment applicable to it and its business, including those relating to transactions with affiliates, environmental,
safety or similar laws, federal or state laws relating to discrimination in the hiring, promotion or pay of employees, federal or state
wages and hours law, the Employee Retirement Income Security Act of 1974, as amended, or the rules&nbsp;and regulations promulgated thereunder,
except for those violations that would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(mm)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Investment
Company Act</U>. Neither the Company nor any of the Subsidiaries is or, after giving effect to the offering and sale of the Shares, will
be an &ldquo;investment company&rdquo; or an entity &ldquo;controlled&rdquo; by an &ldquo;investment company,&rdquo; as such terms are
defined in the Investment Company Act of 1940, as amended (the &ldquo;<B>Investment Company Act</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(nn)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Money
Laundering Laws</U>. The Company has not, and to the Company&rsquo;s knowledge, none of the officers or directors of the Company have,
and, to the Company's knowledge, none of the Company&rsquo;s employees or agents purporting to act on behalf of the Company, as applicable,
have made any payment of funds of the Company or received or retained any funds in violation of any law, rule&nbsp;or regulation relating
to the &ldquo;know your customer&rdquo; and anti-money laundering laws of any jurisdiction (collectively, the &ldquo;<B>Money Laundering
Laws</B>&rdquo;) and no action, suit or proceeding by or before any governmental entity involving the Company with respect to the Money
Laundering Laws is pending or to the Company&rsquo;s knowledge, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(oo)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Off-Balance
Sheet Arrangements</U>. There are no transactions, arrangements and other relationships between and/or among the Company, and/or any
of its affiliates and any unconsolidated entity, including, but not limited to, any structured finance, special purpose or limited purpose
entity (each, an &ldquo;<B>Off-Balance Sheet Transaction</B>&rdquo;) that would reasonably be expected to affect materially the Company&rsquo;s
liquidity or the availability of or requirements for its capital resources, including those Off-Balance Sheet Transactions described
in the Commission&rsquo;s Statement about Management&rsquo;s Discussion and Analysis of Financial Conditions and Results of Operations
(Release Nos. 33-8056; 34-45321; FR-61), required to be described in the Prospectus which have not been described as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(pp)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Underwriter
Agreements</U>. The Company is not a party to any agreement with an agent or underwriter for any other &ldquo;at the market&rdquo; or
continuous equity transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(qq)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>ERISA</U>.
To the knowledge of the Company, each material employee benefit plan, within the meaning of Section&nbsp;3(3)&nbsp;of the Employee Retirement
Income Security Act of 1974, as amended (&ldquo;<B>ERISA</B>&rdquo;), that is maintained, administered or contributed to by the Company
or any of its affiliates for employees or former employees of the Company and any of its Subsidiaries has been maintained in material
compliance with its terms and the requirements of any applicable statutes, orders, rules&nbsp;and regulations, including but not limited
to ERISA and the Internal Revenue Code of 1986, as amended (the &ldquo;<B>Code</B>&rdquo;); no prohibited transaction, within the meaning
of Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code, has occurred which would result in a material liability to the Company
with respect to any such plan excluding transactions effected pursuant to a statutory or administrative exemption; and for each such
plan that is subject to the funding rules&nbsp;of Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA, no &ldquo;accumulated funding
deficiency&rdquo; as defined in Section&nbsp;412 of the Code has been incurred, whether or not waived, and the fair market value of the
assets of each such plan (excluding for these purposes accrued but unpaid contributions) exceeds the present value of all benefits accrued
under such plan determined using reasonable actuarial assumptions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(rr)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Forward-Looking
Statements</U>. Each financial or operational projection or other &ldquo;forward-looking statement&rdquo; (as defined by Section&nbsp;27A
of the Securities Act or Section&nbsp;21E of the Exchange Act) contained in the Registration Statement or the Prospectus (i)&nbsp;was
so included by the Company in good faith and with reasonable basis after due consideration by the Company of the underlying assumptions,
estimates and other applicable facts and circumstances and (ii)&nbsp;is accompanied by meaningful cautionary statements identifying those
factors that could cause actual results to differ materially from those in such forward-looking statement. No such statement was made
with the knowledge of an executive officer or director of the Company that was false or misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ss)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Agent
Purchases</U>. The Company acknowledges and agrees that the Agent has informed the Company that the Agent may, to the extent permitted
under the Securities Act and the Exchange Act, purchase and sell Common Shares for its own account while this Agreement is in effect,
<I>provided</I>, that the Company shall not be deemed to have authorized or consented to any such purchases or sales by the Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(tt)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Margin
Rules</U>. Neither the issuance, sale and delivery of the Shares nor the application of the proceeds thereof by the Company as described
in the Registration Statement and the Prospectus will violate Regulation T, U or X of the Board of Governors of the Federal Reserve System
or any other regulation of such Board of Governors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(uu)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Insurance</U>.
The Company carries, or is covered by, insurance (issued by insurers of recognized financial responsibility) in such amounts and covering
such risks as is appropriate for the conduct of its entire business and the value of its assets, all of which insurance is in full force
and effect in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(vv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Status
Under the Securities Act</U>. The Company was not and is not an ineligible issuer as defined in Rule&nbsp;405 under the Securities Act
at the times specified in Rules&nbsp;164 and 433 under the Securities Act in connection with the offering of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ww)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Misstatement or Omission in a Free Writing Prospectus</U>. Each Free Writing Prospectus, as of its issue date and as of each Time of
Sale, did not, does not and will not include any information that conflicted, conflicts or will conflict with the information contained
in the Registration Statement or the Prospectus, including any incorporated document deemed to be a part thereof that has not been superseded
or modified. The foregoing sentence does not apply to statements in or omissions from any Free Writing Prospectus based upon and in conformity
with written information furnished to the Company by the Agent specifically for use therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(xx)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Conflicts</U>. Neither the execution of this Agreement, nor the issuance, offering or sale of the Shares, nor the consummation of any
of the transactions contemplated herein and therein, nor the compliance by the Company with the terms and provisions hereof and thereof
will conflict with, or will result in a breach of, any of the terms and provisions of, or has constituted or will constitute a default
under, or has resulted in or will result in the creation or imposition of any lien, charge or encumbrance upon any property or assets
of the Company pursuant to the terms of any contract or other agreement to which the Company may be bound or to which any of the property
or assets of the Company is subject, except (i)&nbsp;such conflicts, breaches or defaults as may have been waived and (ii)&nbsp;such
conflicts, breaches and defaults that would not have a Material Adverse Effect; nor will such action result (x)&nbsp;in any violation
of the provisions of the organizational or governing documents of the Company, or (y)&nbsp;in any material violation of the provisions
of any statute or any order, rule&nbsp;or regulation applicable to the Company or of any Governmental Authority having jurisdiction over
the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(yy)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>OFAC</U>.
The Company is not, and, to the Company&rsquo;s knowledge, none of its Subsidiaries, directors, officers, agents or employees nor any
agent, Affiliate or other person acting on behalf of the Company or any of its Subsidiaries are currently the target of or reasonably
likely to become the target of any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the
Treasury (&ldquo;<B>OFAC</B>&rdquo;) or the U.S. Department of State, the United Nations Security Council, the European Union, His Majesty&rsquo;s
Treasury of the United Kingdom, or other relevant sanctions authority (collectively, &ldquo;<B>Sanctions</B>&rdquo;); nor is the Company
or any of its Subsidiaries located, organized or resident in a country or territory that is the subject or the target of Sanctions, including,
without limitation, the Crimea Region of Ukraine, the so-called Donetsk People&rsquo;s Republic, the so-called Luhansk People&rsquo;s
Republic, Cuba,&nbsp;Iran, North Korea, and Syria; and the Company will not directly or indirectly use the proceeds of the offering of
the Shares hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other
person or entity, for the purpose of financing the activities of any person, or in any country or territory, that at the time of such
financing, is the subject or the target of Sanctions or in any other manner that will result in a violation by any person (including
any person participating in the transaction whether as underwriter, advisor, investor or otherwise) of applicable Sanctions. For the
past five years, the Company and its Subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or
transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with
any Sanctioned Country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(zz)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Stock
Transfer Taxes</U>. On each Settlement Date, all stock transfer or other taxes (other than income taxes) which are required to be paid
in connection with the sale and transfer of the Shares to be sold hereunder will be, or will have been, fully paid or provided for by
the Company and all laws imposing such taxes will be or will have been fully complied with.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(aaa)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Statistical
and Market-Related Data</U>.&nbsp; All statistical, demographic and market-related data included in the Registration Statement and Prospectus
are based on or derived from sources that the Company believes to be reliable and accurate or represent the Company&rsquo;s good faith
estimates that are made on the basis of data derived from such sources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(bbb)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Stock
Exchange Listing</U>. The Shares are registered pursuant to Section&nbsp;12(b)&nbsp;or 12(g)&nbsp;of the Exchange Act and are listed
on The NASDAQ Capital Market (&ldquo;<B>NASDAQ</B>&rdquo;), and the Company has taken no action designed to, or likely to have the effect
of, terminating the registration of the Shares under the Exchange Act or delisting the Shares from NASDAQ, nor has the Company received
any notification that the Commission or NASDAQ is contemplating terminating such registration or listing. To the Company&rsquo;s knowledge,
it is in compliance with all applicable listing requirements of NASDAQ.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ccc)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Related-Party
Transactions</U>. There are no business relationships or related-party transactions involving the Company or any of its Subsidiaries
or any other person required to be described in the Registration Statement or the Prospectus that have not been described as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ddd)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>FINRA
Matters</U>. All of the information provided to the Agent or to counsel for the Agent by the Company, its counsel, its officers and directors
and the holders of any securities (debt or equity) or options to acquire any securities of the Company in connection with the offering
of the Shares is true, complete, correct and compliant with FINRA&rsquo;s rules&nbsp;and any letters, filings or other supplemental information
provided to FINRA pursuant to FINRA Rules&nbsp;is true, complete and correct.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(eee)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Cybersecurity</U>.
The Company and its Subsidiaries&rsquo; information technology assets and equipment, computers, systems, networks, hardware, software,
websites, applications, and databases (collectively, &ldquo;<B>IT Systems</B>&rdquo;) are adequate for, and operate and perform in all
material respects as required in connection with the operation of the business of the Company as currently conducted, free and clear
of known material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company and its Subsidiaries have
implemented and maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards
designed to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security
of all IT Systems and data, including all &ldquo;Personal Data&rdquo; (defined below) and all sensitive, confidential or regulated data
(&ldquo;<B>Confidential Data</B>&rdquo;) used in connection with their businesses. &ldquo;Personal Data&rdquo; means (i)&nbsp;a natural
person&rsquo;s name, street address, telephone number, e-mail address, photograph, social security number or tax identification number,
driver&rsquo;s license number, passport number, credit card number, bank information, or customer or account number; (ii)&nbsp;any information
which would qualify as &ldquo;personally identifying information&rdquo; under the Federal Trade Commission Act, as amended; (iii)&nbsp;&ldquo;personal
data&rdquo; as defined by the European Union General Data Protection Regulation (&ldquo;<B>GDPR</B>&rdquo;) (EU 2016/679); (iv)&nbsp;any
information which would qualify as &ldquo;protected health information&rdquo; under HIPAA; (v)&nbsp;any &ldquo;personal information&rdquo;
as defined by the California Consumer Privacy Act (&ldquo;<B>CCPA</B>&rdquo;); and (vi)&nbsp;any other piece of information that allows
the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified
person&rsquo;s health or sexual orientation. There have been no material breaches, violations, outages or unauthorized uses of or accesses
to same, except for those that have been remedied without material cost or liability or the duty to notify any other person, nor any
incidents under internal review or investigations relating to the same. The Company and its Subsidiaries are presently in material compliance
with all applicable Laws or statutes and all judgments, orders, rules&nbsp;and regulations of any court or arbitrator or governmental
or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems, Confidential
Data, and Personal Data and to the protection of such IT Systems, Confidential Data, and Personal Data from unauthorized use, access,
misappropriation or modification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(fff)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Compliance
with Data Privacy Laws</U>. The Company and its Subsidiaries are, and at all prior times during the last three (3)&nbsp;years were, in
material compliance with all applicable state and federal data privacy and security laws and regulations, including without limitation
HIPAA, CCPA, and GDPR (collectively, the &ldquo;<B>Privacy Laws</B>&rdquo;). To ensure compliance with the Privacy Laws, the Company
has in place, complies with, and takes appropriate steps to ensure compliance in all material respects with their policies and procedures
relating to data privacy and security and the collection, storage, use, processing, disclosure, handling, and analysis of Personal Data
and Confidential Data (the &ldquo;<B>Policies</B>&rdquo;). The Company has at all times made all disclosures to users or customers required
by applicable Laws and regulatory rules&nbsp;or requirements, and none of such disclosures made or contained in any Policy have been
inaccurate or in violation of any applicable Laws and regulatory rules&nbsp;or requirements in any material respect. The Company further
certifies that neither it nor any subsidiary: (i)&nbsp;has received notice of any actual or potential liability under or relating to,
or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably be
expected to result in any such notice; (ii)&nbsp;is currently conducting or paying for, in whole or in part, any investigation, remediation,
or other corrective action pursuant to any Privacy Law; or (iii)&nbsp;is a party to any order, decree, or agreement that imposes any
obligation or liability under any Privacy Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ggg)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Anti-Corruption
and Anti-Bribery Laws</U>. Neither the Company nor any of its Subsidiaries nor any director, officer, or employee of the Company or any
of its Subsidiaries, nor to the knowledge of the Company, any agent, Affiliate or other person acting on behalf of the Company or any
of its Subsidiaries has, in the course of its actions for, or on behalf of, the Company or any of its Subsidiaries (i)&nbsp;used any
corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (ii)&nbsp;made
or taken any act in furtherance of an offer, promise, or authorization of any direct or indirect unlawful payment or benefit to any foreign
or domestic government official or employee, including of any government-owned or controlled entity or public international organization,
or any political party, party official, or candidate for political office; (iii)&nbsp;violated or is in violation of any provision of
the U.S. Foreign Corrupt Practices Act of 1977, as amended (the &ldquo;<B>FCPA</B>&rdquo;), the UK Bribery Act 2010, or any other applicable
anti-bribery or anti-corruption law; or (iv)&nbsp;made, offered, authorized, requested, or taken an act in furtherance of any unlawful
bribe, rebate, payoff, influence payment, kickback or other unlawful payment or benefit. The Company and its Subsidiaries and, to the
knowledge of the Company, the Company&rsquo;s Affiliates have conducted their respective businesses in compliance with the FCPA and have
instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued
compliance therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Any
certificate signed by any officer or representative of the Company or any of its Subsidiaries and delivered to the Agent or counsel for
the Agent in connection with an issuance of Shares shall be deemed a representation and warranty by the Company to the Agent as to the
matters covered thereby on the date of such certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company acknowledges that the Agent and, for purposes of the opinions to be delivered pursuant to <U>Section&nbsp;4(o)</U>&nbsp;hereof,
counsel to the Company and counsel to the Agent, will rely upon the accuracy and truthfulness of the foregoing representations and hereby
consents to such reliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;ISSUANCE
AND SALE OF COMMON SHARES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Sale
of Securities</U>. On the basis of the representations, warranties and agreements herein contained, but subject to the terms and conditions
herein set forth, the Company and the Agent agree that the Company may from time to time seek to sell Shares through the Agent, acting
as sales agent, or directly to the Agent, acting as principal, as follows, with an aggregate Sales Price of up to the Maximum Program
Amount, based on and in accordance with Issuance Notices as the Company may deliver, during the Agency Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Mechanics
of Issuances</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Issuance
Notice</U>. Upon the terms and subject to the conditions set forth herein, on any Trading Day during the Agency Period on which the conditions
set forth in &lrm;<U>Section&nbsp;5(a)</U>&nbsp;and <U>Section&nbsp;5(b)</U>&nbsp;shall have been satisfied, the Company may exercise
its right to request an issuance of Shares by delivering to the Agent an Issuance Notice; provided, however, that (A)&nbsp;in no event
may the Company deliver an Issuance Notice to the extent that the sum of (x)&nbsp;the aggregate Sales Price of the requested Issuance
Amount, plus (y)&nbsp;the aggregate Sales Price of all Shares issued under all previous Issuance Notices effected pursuant to this Agreement,
would exceed the Maximum Program Amount; and (B)&nbsp;prior to delivery of any Issuance Notice, the period set forth for any previous
Issuance Notice shall have expired or been terminated. An Issuance Notice shall be considered delivered on the Trading Day that it is
received by e-mail to the persons set forth in Schedule A hereto and confirmed by the Company by telephone (including a voicemail message
to the persons so identified), with the understanding that, with adequate prior written notice, the Agent may modify the list of such
persons from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Agent
Efforts</U>. Upon the terms and subject to the conditions set forth in this Agreement, upon the receipt of an Issuance Notice, the Agent
will use its commercially reasonable efforts consistent with its normal sales and trading practices to place the Shares with respect
to which the Agent has agreed to act as sales agent, subject to, and in accordance with the information specified in, the Issuance Notice,
unless the sale of the Shares described therein has been suspended, cancelled or otherwise terminated in accordance with the terms of
this Agreement. For the avoidance of doubt, the parties to this Agreement may modify an Issuance Notice at any time provided they both
agree in writing to any such modification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Method
of Offer and Sale</U>. The Shares may be offered and sold (A)&nbsp;in negotiated transactions with the consent of the Company or (B)&nbsp;by
any other method permitted by law deemed to be an &ldquo;<B>at the market offering</B>&rdquo; as defined in Rule&nbsp;415(a)(4)&nbsp;under
the Securities Act, including in each case block transactions, sales made directly on the Principal Market or sales made into any other
existing trading market of the Common Shares. Nothing in this Agreement shall be deemed to require either party to agree to the method
of offer and sale specified in the preceding sentence, and (except as specified in clause (A)&nbsp;above) the method of placement of
any Shares by the Agent shall be at the Agent&rsquo;s discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Confirmation
to the Company</U>. If acting as sales agent hereunder, the Agent will provide written confirmation to the Company no later than the
opening of the Trading Day next following the Trading Day on which it has placed Shares hereunder setting forth the number of Shares
sold on such Trading Day, the corresponding Sales Price and the Issuance Price payable to the Company in respect thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Settlement</U>.
Each issuance of Shares will be settled on the applicable Settlement Date for such issuance of Shares and, subject to the provisions
of &lrm;<U>Section&nbsp;5</U>, on or before each Settlement Date, the Company will, or will cause its transfer agent to, electronically
transfer the Shares being sold by crediting the Agent or its designee&rsquo;s account at The Depository Trust Company through its Deposit/Withdrawal
At Custodian (DWAC) System, or by such other means of delivery as may be mutually agreed upon by the parties hereto and, upon receipt
of such Shares, which in all cases shall be freely tradable, transferable, registered shares in good deliverable form, the Agent will
deliver, by wire transfer of immediately available funds, the related Issuance Price in same day funds delivered to an account designated
by the Company prior to the Settlement Date. The Company may sell Shares to the Agent as principal at a price agreed upon at each relevant
time Shares are sold pursuant to this Agreement (each, a &ldquo;<B>Time of Sale</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Suspension
or Termination of Sales</U>. Consistent with standard market settlement practices, the Company or the Agent may, upon notice to the other
party hereto in writing or by telephone (confirmed immediately by verifiable e-mail), suspend any sale of Shares, and the period set
forth in an Issuance Notice shall immediately terminate; provided, however, that (A)&nbsp;such suspension and termination shall not affect
or impair either party&rsquo;s obligations with respect to any Shares placed or sold hereunder prior to the receipt of such notice; (B)&nbsp;if
the Company suspends or terminates any sale of Shares after the Agent confirms such sale to the Company, the Company shall still be obligated
to comply with &lrm;<U>Section&nbsp;3(b)(v)</U>&nbsp;with respect to such Shares; and (C)&nbsp;if the Company defaults in its obligation
to deliver Shares on a Settlement Date, the Company agrees that it will hold the Agent harmless against any loss, claim, damage or expense
(including, without limitation, penalties, interest and reasonable legal fees and expenses), as incurred, arising out of or in connection
with such default by the Company. The parties hereto acknowledge and agree that, in performing its obligations under this Agreement,
the Agent may borrow Common Shares from stock lenders in the event that the Company has not delivered Shares to settle sales as required
by subsection (v)&nbsp;above, and may use the Shares to settle or close out such borrowings. The Company agrees that no such notice shall
be effective against the Agent unless it is made to the persons identified in writing by the Agent pursuant to <U>Section&nbsp;3(b)(i)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(vii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Guarantee of Placement, Etc</U>. The Company acknowledges and agrees that (A)&nbsp;there can be no assurance that the Agent will be successful
in placing Shares; (B)&nbsp;the Agent will incur no liability or obligation to the Company or any other Person if it does not sell Shares;
and (C)&nbsp;the Agent shall be under no obligation to purchase Shares on a principal basis pursuant to this Agreement, except as otherwise
specifically agreed by the Agent and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(viii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Material
Non-Public Information</U>. Notwithstanding any other provision of this Agreement, the Company and the Agent agree that the Company shall
not deliver any Issuance Notice to the Agent, and the Agent shall not be obligated to place any Shares, during any period in which the
Company is in possession of material non-public information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Fees</U>.
As compensation for services rendered, the Company shall pay to the Agent, on the applicable Settlement Date, the Selling Commission
for the applicable Issuance Amount (including with respect to any suspended or terminated sale pursuant to <U>Section&nbsp;3(b)(vi)</U>)
by the Agent deducting the Selling Commission from the applicable Issuance Amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Expenses</U>.
The Company agrees to pay all costs, fees and expenses incurred in connection with the performance of its obligations hereunder and in
connection with the transactions contemplated hereby, including without limitation (i)&nbsp;all expenses incident to the issuance and
delivery of the Shares (including all printing and engraving costs); (ii)&nbsp;all fees and expenses of the registrar and transfer agent
of the Shares; (iii)&nbsp;all necessary issue, transfer and other stamp taxes in connection with the issuance and sale of the Shares;
(iv)&nbsp;all fees and expenses of the Company&rsquo;s counsel, independent public or certified public accountants and other advisors;
(v)&nbsp;all costs and expenses incurred in connection with the preparation, printing, filing, shipping and distribution of the Registration
Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Prospectus, any Free Writing
Prospectus (as defined below) prepared by or on behalf of, used by, or referred to by the Company, and all amendments and supplements
thereto, and this Agreement; (vi)&nbsp;all filing fees, attorneys&rsquo; fees and expenses incurred by the Company or the Agent in connection
with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any part of the Shares for
offer and sale under the state securities or blue sky laws or the provincial securities laws of Canada, and, if requested by the Agent,
preparing and printing a &ldquo;<B>Blue Sky Survey</B>&rdquo; or memorandum and a &ldquo;Canadian wrapper&rdquo;, and any supplements
thereto, advising the Agent of such qualifications, registrations, determinations and exemptions; (vii)&nbsp;the reasonable fees and
disbursements of the Agent&rsquo;s counsel, including the reasonable fees and expenses of counsel for the Agent in connection with, FINRA
review, if any, and approval of the Agent&rsquo;s participation in the offering and distribution of the Shares; (viii)&nbsp;the filing
fees incident to FINRA review, if any; (ix)&nbsp;the costs and expenses of the Company relating to investor presentations on any &ldquo;road
show&rdquo; undertaken in connection with the marketing of the offering of the Shares, including, without limitation, expenses associated
with the preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics,
fees and expenses of any consultants engaged in connection with the road show presentations with the prior approval of the Company, travel
and lodging expenses of the representatives, employees and officers of the Company and of the Agent and any such consultants, and the
cost of any aircraft chartered in connection with the road show; and (x)&nbsp;the fees and expenses associated with listing the Shares
on the Principal Market. The fees and disbursements of Agent&rsquo;s counsel pursuant to subsections (vi)&nbsp;and (vii)&nbsp;above shall
not exceed (A)&nbsp;$100,000 in connection with the execution of this Agreement, (B)&nbsp;$25,000 in connection with each Triggering
Event Date (as defined below) involving the filing of a Form&nbsp;10-K on which the Company is required to provide a certificate pursuant
to <U>Section&nbsp;4(o)</U>&nbsp;and (C)&nbsp;$15,000 in connection with each other Triggering Event Date (as defined below) on which
the Company is required to provide a certificate pursuant to <U>Section&nbsp;4(o)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;ADDITIONAL
COVENANTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company covenants and agrees with the Agent as follows, in addition to any other covenants and agreements made elsewhere in this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Exchange
Act Compliance</U>. During the Agency Period, the Company shall (i)&nbsp;file, on a timely basis, with the Commission all reports and
documents required to be filed under Section&nbsp;13, 14 or 15 of the Exchange Act in the manner and within the time periods required
by the Exchange Act; and (ii)&nbsp;either (A)&nbsp;include in its quarterly reports on Form&nbsp;10-Q and its annual reports on Form&nbsp;10-K,
a summary detailing, for the relevant reporting period, (1)&nbsp;the number of Shares sold through the Agent pursuant to this Agreement
and (2)&nbsp;the net proceeds received by the Company from such sales or (B)&nbsp;prepare a prospectus supplement containing, or include
in such other filing permitted by the Securities Act or Exchange Act (each an &ldquo;<B>Interim Prospectus Supplement</B>&rdquo;), such
summary information and, at least once a quarter and subject to this <U>Section&nbsp;4</U>, file such Interim Prospectus Supplement pursuant
to Rule&nbsp;424(b)&nbsp;under the Securities Act (and within the time periods required by Rule&nbsp;424(b)&nbsp;and Rule&nbsp;430B under
the Securities Act)).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Securities
Act Compliance</U>. After the date of this Agreement, the Company shall promptly advise the Agent in writing (i)&nbsp;of the receipt
of any comments of, or requests for additional or supplemental information from, the Commission in relation to the Registration Statement
or the Prospectus; (ii)&nbsp;of the time and date of any filing of any post-effective amendment to the Registration Statement, any Rule&nbsp;462(b)&nbsp;Registration
Statement or any amendment or supplement to the Prospectus or any Free Writing Prospectus; (iii)&nbsp;of the time and date that any post-effective
amendment to the Registration Statement or any Rule&nbsp;462(b)&nbsp;Registration Statement becomes effective; and (iv)&nbsp;of the issuance
by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto,
any Rule&nbsp;462(b)&nbsp;Registration Statement or any amendment or supplement to the Prospectus or of any order preventing or suspending
the use of any Free Writing Prospectus or the Prospectus, or of any proceedings to remove, suspend or terminate from listing or quotation
the Common Shares from any securities exchange upon which they are listed for trading or included or designated for quotation, or of
the threatening or initiation of any proceedings for any of such purposes. If the Commission shall enter any such stop order at any time,
the Company will use its reasonable best efforts to obtain the lifting of such order as soon as practicable. Additionally, the Company
agrees that it shall comply with the provisions of Rule&nbsp;424(b)&nbsp;and Rule&nbsp;433, as applicable, under the Securities Act and
will use its reasonable efforts to confirm that any filings made by the Company under such Rule&nbsp;424(b)&nbsp;or Rule&nbsp;433 were
received in a timely manner by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Amendments
and Supplements to the Prospectus and Other Securities Act Matters</U>. If any event shall occur or condition exist as a result of which
it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue statement of a material fact
or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus
is delivered to a purchaser, not misleading, or if in the opinion of the Agent or counsel for the Agent it is otherwise necessary to
amend or supplement the Prospectus to comply with applicable law, including the Securities Act, the Company agrees (subject to <U>Section&nbsp;4(d)</U>&nbsp;and
<U>Section&nbsp;4(f)</U>) to promptly prepare, file with the Commission and furnish at its own expense to the Agent, amendments or supplements
to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not include an untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus
is delivered to a purchaser, be misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law including
the Securities Act. Neither the Agent&rsquo;s consent to, or delivery of, any such amendment or supplement shall constitute a waiver
of any of the Company&rsquo;s obligations under <U>Section&nbsp;4(d)</U>&nbsp;and <U>Section&nbsp;4(f)</U>. Notwithstanding the foregoing,
the Company shall not be required to file such amendment or supplement if there is no pending Issuance Notice and the Company believes
that it is in its best interest not to file such amendment or supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Agent&rsquo;s
Review of Proposed Amendments and Supplements</U>. Prior to amending or supplementing the Registration Statement (including any registration
statement filed under Rule&nbsp;462(b)&nbsp;under the Securities Act) or the Prospectus (excluding any amendment or supplement through
incorporation of any report filed under the Exchange Act), the Company shall furnish to the Agent for review, a reasonable amount of
time prior to the proposed time of filing or use thereof, a copy of each such proposed amendment or supplement insofar as such proposed
amendment or supplement relates to the transactions contemplated in this Agreement, and the Company shall not file or use any such proposed
amendment or supplement without the Agent&rsquo;s prior consent, and to file with the Commission within the applicable period specified
in Rule&nbsp;424(b)&nbsp;under the Securities Act any prospectus required to be filed pursuant to such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Use
of Free Writing Prospectus</U>. Neither the Company nor the Agent has prepared, used, referred to or distributed, or will prepare, use,
refer to or distribute, without the other party&rsquo;s prior written consent, any &ldquo;written communication&rdquo; that constitutes
a &ldquo;free writing prospectus&rdquo; as such terms are defined in Rule&nbsp;405 under the Securities Act with respect to the offering
contemplated by this Agreement (any such free writing prospectus being referred to herein as a &ldquo;<B>Free Writing Prospectus</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Free
Writing Prospectuses</U>. The Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed time of
filing or use thereof, a copy of each proposed Free Writing Prospectus or any amendment or supplement thereto to be prepared by or on
behalf of, used by, or referred to by the Company and the Company shall not file, use or refer to any proposed free writing prospectus
or any amendment or supplement thereto without the Agent&rsquo;s consent, which shall not be unreasonably withheld, conditioned or delayed.
The Company shall furnish to the Agent, without charge, as many copies of any Free Writing Prospectus prepared by or on behalf of, or
used by the Company, as the Agent may reasonably request. If at any time when a prospectus is required by the Securities Act (including,
without limitation, pursuant to Rule&nbsp;173(d)) to be delivered in connection with sales of the Shares (but in any event if at any
time through and including the date of this Agreement) there occurred or occurs an event or development as a result of which any Free
Writing Prospectus prepared by or on behalf of, used by, or referred to by the Company conflicted or would conflict with the information
contained in the Registration Statement or included or would include an untrue statement of a material fact or omitted or would omit
to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at that subsequent
time, not misleading, the Company shall promptly amend or supplement such Free Writing Prospectus to eliminate or correct such conflict
or so that the statements in such free writing prospectus as so amended or supplemented will not include an untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing
at such subsequent time, not misleading, as the case may be; provided, however, that prior to amending or supplementing any such free
writing prospectus, the Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed time of filing
or use thereof, a copy of such proposed amended or supplemented Free Writing Prospectus and the Company shall not file, use or refer
to any such amended or supplemented Free Writing Prospectus without the Agent&rsquo;s consent, which shall not be unreasonably withheld,
conditioned or delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Filing
of Agent Free Writing Prospectuses</U>. The Company shall not take any action that would result in the Agent or the Company being required
to file with the Commission pursuant to Rule&nbsp;433(d)&nbsp;under the Securities Act a Free Writing Prospectus prepared by or on behalf
of the Agent that the Agent otherwise would not have been required to file thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Copies
of Registration Statement and Prospectus</U>. After the date of this Agreement through the last time that a prospectus is required by
the Securities Act (including, without limitation, pursuant to Rule&nbsp;173(d)) to be delivered in connection with sales of the Shares,
the Company agrees to furnish the Agent with copies (which may be electronic copies) of the Registration Statement and each amendment
thereto, and with copies (which may be electronic copies) of the Prospectus and each amendment or supplement thereto in the form in which
it is filed with the Commission pursuant to the Securities Act or Rule&nbsp;424(b)&nbsp;under the Securities Act, both in such quantities
as the Agent may reasonably request from time to time; and, if the delivery of a prospectus is required under the Securities Act or under
the blue sky or securities laws of any jurisdiction at any time on or prior to the applicable Settlement Date for any period set forth
in an Issuance Notice in connection with the offering or sale of the Shares and if at such time any event has occurred as a result of
which the Prospectus as then amended or supplemented would include an untrue statement of a material fact or omit to state any material
fact necessary in order to make the statements therein, in the light of the circumstances under which they were made when such Prospectus
is delivered, not misleading, or, if for any other reason it is necessary during such same period to amend or supplement the Prospectus
or to file under the Exchange Act any document incorporated by reference in the Prospectus in order to comply with the Securities Act
or the Exchange Act, to notify the Agent and to request that the Agent suspend offers to sell Shares (and, if so notified, the Agent
shall cease such offers as soon as practicable); and if the Company decides to amend or supplement the Registration Statement or the
Prospectus as then amended or supplemented, to advise the Agent promptly by telephone (with confirmation in writing) and to prepare and
cause to be filed promptly with the Commission an amendment or supplement to the Registration Statement or the Prospectus as then amended
or supplemented that will correct such statement or omission or effect such compliance, including filing a document incorporated by reference
therein (it being acknowledged that the Company may delay the filing of any amendment or supplement if, in the judgment of the Company,
it is in the best interest of the Company); provided, however, that if during such same period the Agent is required to deliver a prospectus
in respect of transactions in the Shares, the Company shall promptly prepare and file with the Commission such an amendment or supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Blue
Sky Compliance</U>. The Company shall cooperate with the Agent and counsel for the Agent to qualify or register the Shares for sale under
(or obtain exemptions from the application of) the state securities or blue sky laws or Canadian provincial securities laws of those
jurisdictions designated by the Agent, shall comply with such laws and shall continue such qualifications, registrations and exemptions
in effect so long as required for the distribution of the Shares. The Company shall not be required to qualify as a foreign corporation
or to take any action that would subject it to general service of process in any such jurisdiction where it is not presently qualified
or where it would be subject to taxation as a foreign corporation. The Company will advise the Agent promptly of the suspension of the
qualification or registration of (or any such exemption relating to) the Shares for offering, sale or trading in any jurisdiction or
any initiation or threat of any proceeding for any such purpose, and in the event of the issuance of any order suspending such qualification,
registration or exemption, the Company shall use its best efforts to obtain the withdrawal thereof as soon as practicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Earnings
Statement</U>. As soon as practicable, the Company will make generally available to its security holders and to the Agent an earnings
statement (which need not be audited) covering a period of at least twelve months beginning with the first fiscal quarter of the Company
occurring after the date of this Agreement which shall satisfy the provisions of Section&nbsp;11(a)&nbsp;of the Securities Act and Rule&nbsp;158
under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Listing;
Reservation of Shares</U>. (a)&nbsp; The Company will use its best efforts to maintain the listing of the Shares on the Principal Market;
and (b)&nbsp;the Company will reserve and keep available at all times, free of preemptive rights, Shares for the purpose of enabling
the Company to satisfy its obligations under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Transfer
Agent</U>. The Company shall engage and maintain, at its expense, a registrar and transfer agent for the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Due
Diligence</U>. During the term of this Agreement, the Company will reasonably cooperate with any reasonable due diligence review conducted
by the Agent in connection with the transactions contemplated hereby, including, without limitation, providing information and making
available documents and senior corporate officers, during normal business hours and at the Company&rsquo;s principal offices or virtually,
as the Agent may reasonably request from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Representations
and Warranties</U>. The Company acknowledges that each delivery of an Issuance Notice and each delivery of Shares on a Settlement Date
shall be deemed to be (i)&nbsp;an affirmation to the Agent that the representations and warranties of the Company contained in or made
pursuant to this Agreement are true and correct as of the date of such Issuance Notice or of such Settlement Date, as the case may be,
as though made at and as of each such date, except as may be disclosed in the Prospectus (including any documents incorporated by reference
therein and any supplements thereto); and (ii)&nbsp;an undertaking that the Company will advise the Agent if any of such representations
and warranties will not be true and correct as of the Settlement Date for the Shares relating to such Issuance Notice, as though made
at and as of each such date (except that such representations and warranties shall be deemed to relate to the Registration Statement
and the Prospectus as amended and supplemented relating to such Shares).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Deliverables
at Triggering Event Dates; Certificates</U>. The Company agrees that on or prior to the date of the first Issuance Notice and, during
the term of this Agreement after the date of the first Issuance Notice, upon:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(A)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
filing of the Prospectus or the amendment or supplement of any Registration Statement or Prospectus (other than a prospectus supplement
relating solely to an offering of securities other than the Shares or a prospectus filed pursuant to <U>Section&nbsp;4(a)(ii)(B)</U>),
by means of a post-effective amendment, sticker or supplement, but not by means of incorporation of documents by reference into the Registration
Statement or Prospectus;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(B)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
filing with the Commission of an annual report on Form&nbsp;10-K or a quarterly report on Form&nbsp;10-Q (including any Form&nbsp;10-K/A
or Form&nbsp;10-Q/A containing amended financial information or a material amendment to the previously filed annual report on Form&nbsp;10-K
or quarterly report on Form&nbsp;10-Q), in each case, of the Company; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(C)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
filing with the Commission of a current report on Form&nbsp;8-K of the Company containing amended financial information (other than information
 &ldquo;furnished&rdquo; pursuant to Item 2.02 or 7.01 of Form&nbsp;8-K or to provide disclosure pursuant to Item 8.01 of Form&nbsp;8-K
relating to reclassification of certain properties as discontinued operations in accordance with Statement of Financial Accounting Standards
No.&nbsp;144) that is material to the offering of securities of the Company in the Agent&rsquo;s reasonable discretion;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">(any
such event, a &ldquo;<B>Triggering Event Date</B>&rdquo;), the Company shall furnish the Agent (but in the case of clause (C)&nbsp;above
only if the Agent reasonably determines that the information contained in such current report on Form&nbsp;8-K of the Company is material)
with a certificate as of the Triggering Event Date, in the form and substance satisfactory to the Agent and its counsel, substantially
similar to the form previously provided to the Agent and its counsel, modified, as necessary, to relate to the Registration Statement
and the Prospectus as amended or supplemented, (A)&nbsp;confirming that the representations and warranties of the Company contained in
this Agreement are true and correct, (B)&nbsp;confirming that the Company has performed all of its obligations hereunder to be performed
on or prior to the date of such certificate and as to the matters set forth in <U>Section&nbsp;5(a)(iii)</U>&nbsp;hereof, and (C)&nbsp;containing
any other certification that the Agent shall reasonably request. The requirement to provide a certificate under this <U>Section&nbsp;4(o)</U>&nbsp;shall
be waived for any Triggering Event Date occurring at a time when no Issuance Notice is pending or a suspension is in effect, which waiver
shall continue until the earlier to occur of the date the Company delivers instructions for the sale of Shares hereunder (which for such
calendar quarter shall be considered a Triggering Event Date) and the next occurring Triggering Event Date. Notwithstanding the foregoing,
if the Company subsequently decides to sell Shares following a Triggering Event Date when a suspension was in effect and did not provide
the Agent with a certificate under this <U>Section&nbsp;4(o)</U>, then before the Company delivers the instructions for the sale of Shares
or the Agent sells any Shares pursuant to such instructions, the Company shall provide the Agent with a certificate in conformity with
this <U>Section&nbsp;4(o)</U>&nbsp;dated as of the date that the instructions for the sale of Shares are issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(p)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Legal
Opinions</U>. On or prior to the date of the first Issuance Notice and on or prior to each Triggering Event Date with respect to which
the Company is obligated to deliver a certificate pursuant to <U>Section&nbsp;4(o)</U>&nbsp;for which no waiver is applicable and excluding
the date of this Agreement, a negative assurances letter and the written legal opinion of Goodwin Procter LLP, counsel to the Company,
and DLA Piper LLP (US), intellectual property counsel to the Company, each dated the date of delivery, in form and substance reasonably
satisfactory to Agent and its counsel, substantially similar to the form previously provided to the Agent and its counsel, modified,
as necessary, to relate to the Registration Statement and the Prospectus as then amended or supplemented. In lieu of such opinions for
subsequent periodic filings, in the discretion of the Agent, the Company may furnish a reliance letter from such counsel to the Agent,
permitting the Agent to rely on a previously delivered opinion letter, modified as appropriate for any passage of time or Triggering
Event Date (except that statements in such prior opinion shall be deemed to relate to the Registration Statement and the Prospectus as
amended or supplemented as of such Triggering Event Date).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(q)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Comfort
Letter</U>. On or prior to the date of the first Issuance Notice and on or prior to each Triggering Event Date with respect to which
the Company is obligated to deliver a certificate pursuant to <U>Section&nbsp;4(o)</U>&nbsp;for which no waiver is applicable and excluding
the date of this Agreement, the Company shall cause Ernst&nbsp;&amp; Young LLP, the independent registered public accounting firm who
has audited the financial statements included or incorporated by reference in the Registration Statement, to furnish the Agent a comfort
letter, dated the date of delivery, in form and substance reasonably satisfactory to the Agent and its counsel, substantially similar
to the form previously provided to the Agent and its counsel; provided, however, that any such comfort letter will only be required on
the Triggering Event Date specified to the extent that it contains financial statements filed with the Commission under the Exchange
Act and incorporated or deemed to be incorporated by reference into a Prospectus. If requested by the Agent, the Company shall also cause
a comfort letter to be furnished to the Agent on the date of occurrence of any material transaction or event requiring the filing of
a current report on Form&nbsp;8-K containing material amended financial information of the Company, including the restatement of the
Company&rsquo;s financial statements. The Company shall be required to furnish no more than one comfort letter hereunder per each filing
of an annual report on Form&nbsp;10-K or a quarterly report on Form&nbsp;10-Q.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(r)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Secretary&rsquo;s
Certificate</U>. On or prior to the date of the first Issuance Notice and on or prior to each Triggering Event Date, the Company shall
furnish the Agent a certificate executed by the Secretary of the Company, signing in such capacity, dated the date of delivery (i)&nbsp;certifying
that attached thereto are true and complete copies of the resolutions duly adopted by the Board of Directors of the Company authorizing
the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby (including, without limitation,
the issuance of the Shares pursuant to this Agreement), which authorization shall be in full force and effect on and as of the date of
such certificate, (ii)&nbsp;certifying and attesting to the office, incumbency, due authority and specimen signatures of each Person
who executed this Agreement for or on behalf of the Company, and (iii)&nbsp;containing any other certification that the Agent shall reasonably
request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(s)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Agent&rsquo;s
Own Account; Clients&rsquo; Account</U>. The Company consents to the Agent trading, in compliance with applicable law, in the Common
Shares for the Agent&rsquo;s own account and for the account of its clients at the same time as sales of the Shares occur pursuant to
this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(t)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Investment
Limitation</U>. The Company shall not invest, or otherwise use the proceeds received by the Company from its sale of the Shares in such
a manner as would require the Company or any of its Subsidiaries to register as an investment company under the Investment Company Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(u)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Market
Activities</U>. The Company will not take, directly or indirectly, any action designed to or that might be reasonably expected to cause
or result in stabilization or manipulation of the price of the Shares or any other reference security, whether to facilitate the sale
or resale of the Shares or otherwise, and the Company will, and shall use commercially reasonable efforts to cause each of its Affiliates
to, comply with all applicable provisions of Regulation M. If the limitations of Rule&nbsp;102 of Regulation M (&ldquo;<B>Rule&nbsp;102</B>&rdquo;)
do not apply with respect to the Shares or any other reference security pursuant to any exception set forth in Section&nbsp;(d)&nbsp;of
Rule&nbsp;102, then promptly upon notice from the Agent (or, if later, at the time stated in the notice), the Company will, and shall
use commercially reasonable efforts to cause each of its Affiliates to, comply with Rule&nbsp;102 as though such exception were not available
but the other provisions of Rule&nbsp;102 (as interpreted by the Commission) did apply. The Company shall promptly notify the Agent if
it no longer meets the requirements set forth in Section&nbsp;(d)&nbsp;of Rule&nbsp;102.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Notice
of Other Sale</U>. Without the written consent of the Agent, the Company will not, directly or indirectly, offer to sell, sell, contract
to sell, grant any option to sell or otherwise dispose of any Common Shares or securities convertible into or exchangeable for Common
Shares (other than Shares hereunder), warrants or any rights to purchase or acquire Common Shares, or effect a reverse stock split, recapitalization,
share consolidation, reclassification or similar transaction affecting the outstanding Common Shares, during the period beginning on
the third Trading Day immediately prior to the date on which any Issuance Notice is delivered to the Agent hereunder and ending on the
third Trading Day immediately following the Settlement Date with respect to Shares sold pursuant to such Issuance Notice; and will not
directly or indirectly enter into any other &ldquo;at the market&rdquo; or continuous equity transaction offer after the date hereof
to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common Shares (other than the Shares offered pursuant
to this Agreement) or securities convertible into or exchangeable for Common Shares, warrants or any rights to purchase or acquire, Common
Shares prior to the termination of this Agreement; provided, however, that such restrictions will not be required in connection with
the Company&rsquo;s (i)&nbsp;issuance or sale of Common Shares, options to purchase Common Shares or Common Shares issuable upon the
exercise of options or vesting and settlement of restricted stock units or vesting and settlement of performance stock units or other
equity awards pursuant to any employee or director share option, incentive or benefit plan, share purchase or ownership plan, long-term
incentive plan, dividend reinvestment plan, inducement award under Nasdaq rules&nbsp;or other compensation plan of the Company or its
Subsidiaries, as in effect on the date of this Agreement, (ii)&nbsp;issuance or sale of Common Shares issuable upon exchange, conversion
or redemption of securities or the exercise or vesting of warrants, options or other equity awards outstanding at the date of this Agreement,
(iii)&nbsp;issuance, grant or sale of Common Shares or securities convertible into or exchangeable for Common Shares as consideration
for mergers, acquisitions, other business combinations, joint ventures, strategic alliances and other business transactions (including,
without limitation, collaborations or arrangements involving research, development and/or commercialization activities) occurring after
the date of this Agreement which are not used primarily for capital raising purposes; provided that in the case of this clause (iii),
such issuances shall not be greater than 5% of the total outstanding shares of the Company immediately following the issuance of such
shares and (iv)&nbsp;modification of any outstanding options, warrants or any rights to purchase or acquire Common Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(w)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Emerging
Growth Company Status</U>. During the Agency Period, the Company agrees to notify the Agent as soon as practicable upon the Company ceasing
to be an Emerging Growth Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;CONDITIONS
TO DELIVERY OF ISSUANCE NOTICES AND TO SETTLEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Conditions
<U>Precedent to the Right of the Company to Deliver an Issuance Notice and the Obligation of the Agent to Sell Shares</U>. The right
of the Company to deliver an Issuance Notice hereunder is subject to the satisfaction, on the date of delivery of such Issuance Notice,
and the obligation of the Agent to use its commercially reasonable efforts to place Shares during the applicable period set forth in
the Issuance Notice is subject to the satisfaction, on each Trading Day during the applicable period set forth in the Issuance Notice,
of each of the following conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Accuracy
of the Company&rsquo;s Representations and Warranties; Performance by the Company</U>. The Company shall have delivered the certificate
required to be delivered pursuant to <U>Section&nbsp;4(o)</U>&nbsp;on or before the date on which delivery of such certificate is required
pursuant to <U>Section&nbsp;4(o)</U>. The Company shall have performed, satisfied and complied with all covenants, agreements and conditions
required by this Agreement to be performed, satisfied or complied with by the Company at or prior to such date, including, but not limited
to, the covenants contained in <U>&lrm;Section&nbsp;4(p)</U>, <U>Section&nbsp;4(q)</U>&nbsp;and <U>Section&nbsp;4(r)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Injunction</U>. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over
the matters contemplated hereby that prohibits or directly and materially adversely affects any of the transactions contemplated by this
Agreement, and no proceeding shall have been commenced that may have the effect of prohibiting or materially adversely affecting any
of the transactions contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Material
Adverse Effects</U>. Except as disclosed in the Prospectus and the Time of Sale Information, (a)&nbsp;in the judgment of the Agent there
shall not have occurred any Material Adverse Effect; and (b)&nbsp;there shall not have occurred any downgrading, nor shall any notice
have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction
of the possible change, in the rating accorded any securities of the Company or any of its Subsidiaries by any &ldquo;nationally recognized
statistical rating organization&rdquo; as such term is defined for purposes of Section&nbsp;3(a)(62) of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Suspension of Trading in or Delisting of Common Shares; Other Events</U>. The trading of the Common Shares (including without limitation
the Shares) shall not have been suspended by the Commission, the Principal Market or FINRA and the Common Shares (including without limitation
the Shares) shall have been approved for listing or quotation on and shall not have been delisted from the Principal Market or any of
their constituent markets. There shall not have occurred (and be continuing in the case of occurrences under clauses (i)&nbsp;and (ii)&nbsp;below)
any of the following: (i)&nbsp;trading or quotation in any of the Company&rsquo;s securities shall have been suspended or limited by
the Commission or by the Principal Market or trading in securities generally on the Principal Market shall have been suspended or limited,
or minimum or maximum prices shall have been generally established on any of such stock exchanges by the Commission or FINRA; (ii)&nbsp;a
general banking moratorium shall have been declared by any of federal or New York, authorities; or (iii)&nbsp;there shall have occurred
any outbreak or escalation of national or international hostilities or any crisis or calamity, or any change in the United States or
international financial markets, or any substantial change or development involving a prospective substantial change in United States&rsquo;
or international political, financial or economic conditions, as in the judgment of the Agent is material and adverse and makes it impracticable
to market the Shares in the manner and on the terms described in the Prospectus or to enforce contracts for the sale of securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Documents
Required to be Delivered on each Issuance Notice Date</U>. The Agent&rsquo;s obligation to use its commercially reasonable efforts to
place Shares hereunder shall additionally be conditioned upon the delivery to the Agent on or before the Issuance Notice Date of a certificate
in form and substance reasonably satisfactory to the Agent, executed by the Chief Executive Officer, President or Chief Financial Officer
of the Company, to the effect that all conditions to the delivery of such Issuance Notice shall have been satisfied as at the date of
such certificate as required to be delivered pursuant to Section&nbsp;4(o)&nbsp;(which certificate shall not be required if the foregoing
representations shall be set forth in the Issuance Notice).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Misstatement or Material Omission</U>. Agent shall not have advised the Company that the Registration Statement, the Prospectus or the
Time of Sale Information, or any amendment or supplement thereto, contains an untrue statement of fact that in the Agent&rsquo;s reasonable
opinion is material, or omits to state a fact that in the Agent&rsquo;s reasonable opinion is material and is required to be stated therein
or is necessary to make the statements therein not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Agent
Counsel Legal Opinion</U>. Agent shall have received from Duane Morris LLP, counsel for Agent, a negative assurance letter and such opinion
or opinions, on or before the date on which the delivery of the Company counsel legal opinion is required pursuant to <U>Section&nbsp;4(p)</U>,
with respect to such matters as Agent may reasonably require, and the Company shall have furnished to such counsel such documents as
they request for enabling them to pass upon such matters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;INDEMNIFICATION
AND CONTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Indemnification
of the Agent</U>. The Company agrees to indemnify and hold harmless the Agent, its officers and employees, and each person, if any, who
controls the Agent within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or expense,
as incurred, to which the Agent or such officer, employee or controlling person may become subject, under the Securities Act, the Exchange
Act, other federal or state statutory law or regulation, or the laws or regulations of foreign jurisdictions where Shares have been offered
or sold or at common law or otherwise (including in settlement of any litigation), insofar as such loss, claim, damage, liability or
expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i)&nbsp;any untrue statement or alleged
untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, including any information deemed
to be a part thereof pursuant to Rule&nbsp;430B under the Securities Act, or the omission or alleged omission therefrom of a material
fact required to be stated therein or necessary to make the statements therein not misleading; or (ii)&nbsp;any untrue statement or alleged
untrue statement of a material fact contained in any Free Writing Prospectus that the Company has used, referred to or filed, or is required
to file, pursuant to Rule&nbsp;433(d)&nbsp;of the Securities Act or the Prospectus (or any amendment or supplement thereto), or the omission
or alleged omission therefrom of a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading and to reimburse the Agent and each such officer, employee and controlling person for any
and all expenses (including the reasonable and documented fees and disbursements of counsel chosen by the Agent) as such documented expenses
are reasonably incurred by the Agent or such officer, employee or controlling person in connection with investigating, defending, settling,
compromising or paying any such loss, claim, damage, liability, expense or action; provided, however, that the foregoing indemnity agreement
shall not apply to any loss, claim, damage, liability or expense to the extent, but only to the extent, arising out of or based upon
any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with written
information furnished to the Company by the Agent expressly for use in the Registration Statement, any such Free Writing Prospectus or
the Prospectus (or any amendment or supplement thereto), it being understood and agreed that the only such information furnished by the
Agent to the Company consists of the information described in subsection (b)&nbsp;below. The indemnity agreement set forth in this &lrm;<U>Section&nbsp;6(a)</U>&nbsp;shall
be in addition to any liabilities that the Company may otherwise have.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Indemnification
of the Company, its Directors and Officers</U>. The Agent agrees to indemnify and hold harmless the Company, each of its directors, each
of its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of the Securities
Act or the Exchange Act against any loss, claim, damage, liability or expense, as incurred, to which the Company or any such director,
officer or controlling person may become subject, under the Securities Act, the Exchange Act, or other federal or state statutory law
or regulation, or the laws or regulations of foreign jurisdictions where Shares have been offered or sold or at common law or otherwise
(including in settlement of any litigation), arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue statement
of a material fact contained in the Registration Statement, or any amendment thereto, including any information deemed to be a part thereof
pursuant to Rule&nbsp;430B under the Securities Act, or the omission or alleged omission therefrom of a material fact required to be
stated therein or necessary to make the statements therein not misleading; or (ii)&nbsp;any untrue statement or alleged untrue statement
of a material fact contained in any Free Writing Prospectus that the Company has used, referred to or filed, or is required to file,
pursuant to Rule&nbsp;433(d)&nbsp;of the Securities Act or the Prospectus (or any amendment or supplement thereto), or the omission or
alleged omission therefrom of a material fact necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading; but, for each of (i)&nbsp;and (ii)&nbsp;above, only to the extent arising out of or based upon
any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with written
information furnished to the Company by the Agent expressly for use in the Registration Statement, any such Free Writing Prospectus or
the Prospectus (or any amendment or supplement thereto), it being understood and agreed that the only such information furnished by the
Agent to the Company consists of the information set forth in the first sentence of the ninth paragraph under the caption &ldquo;Plan
of Distribution&rdquo; in the Prospectus (the &ldquo;<B>Agent Information</B>&rdquo;), and to reimburse the Company and each such director,
officer and controlling person for any and all expenses (including the fees and disbursements of one counsel chosen by the Company) as
such expenses are reasonably incurred by the Company or such officer, director or controlling person in connection with investigating,
defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action. The indemnity agreement set forth
in this <U>Section&nbsp;6(b)</U>&nbsp;shall be in addition to any liabilities that the Agent or the Company may otherwise have.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Notifications
and Other Indemnification Procedures</U>. Promptly after receipt by an indemnified party under this &lrm;<U>Section&nbsp;6</U> of notice
of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party
under this &lrm;<U>Section&nbsp;6</U>, notify the indemnifying party in writing of the commencement thereof, but the omission so to notify
the indemnifying party will not relieve it from any liability which it may have to any indemnified party for contribution or otherwise
than under the indemnity agreement contained in this &lrm;<U>Section&nbsp;6</U> or to the extent it is not prejudiced as a proximate
result of such failure. In case any such action is brought against any indemnified party and such indemnified party seeks or intends
to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and, to the extent that it shall
elect, jointly with all other indemnifying parties similarly notified, by written notice delivered to the indemnified party promptly
after receiving the aforesaid notice from such indemnified party, to assume the defense thereof with counsel reasonably satisfactory
to such indemnified party; provided, however, if the defendants in any such action include both the indemnified party and the indemnifying
party and the indemnified party shall have reasonably concluded that a conflict may arise between the positions of the indemnifying party
and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it and/or other
indemnified parties which are different from or additional to those available to the indemnifying party, the indemnified party or parties
shall have the right to select separate counsel to assume such legal defenses and to otherwise participate in the defense of such action
on behalf of such indemnified party or parties. Upon receipt of notice from the indemnifying party to such indemnified party of such
indemnifying party&rsquo;s election so to assume the defense of such action and approval by the indemnified party of counsel, the indemnifying
party will not be liable to such indemnified party under this <U>Section&nbsp;6</U> for any legal or other expenses subsequently incurred
by such indemnified party in connection with the defense thereof unless (i)&nbsp;the indemnified party shall have employed separate counsel
in accordance with the proviso to the preceding sentence (it being understood, however, that the indemnifying party shall not be liable
for the fees and expenses of more than one separate counsel (together with local counsel), representing the indemnified parties who are
parties to such action), which counsel (together with any local counsel) for the indemnified parties shall be selected by the indemnified
party (in the case of counsel for the indemnified parties referred to in &lrm;<U>Section&nbsp;6(a)</U>&nbsp;and <U>Section&nbsp;6(b)</U>&nbsp;above),
(ii)&nbsp;the indemnifying party shall not have employed counsel satisfactory to the indemnified party to represent the indemnified party
within a reasonable time after notice of commencement of the action or (iii)&nbsp;the indemnifying party has authorized in writing the
employment of counsel for the indemnified party at the expense of the indemnifying party, in each of which cases the fees and expenses
of counsel shall be at the expense of the indemnifying party and shall be paid as they are incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Settlements</U>.
The indemnifying party under this &lrm;<U>Section&nbsp;6</U> shall not be liable for any settlement of any proceeding effected without
its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees
to indemnify the indemnified party against any loss, claim, damage, liability or expense by reason of such settlement or judgment. Notwithstanding
the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party
for fees and expenses of counsel as contemplated by <U>Section&nbsp;6(c)</U>&nbsp;hereof, the indemnifying party agrees that it shall
be liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more
than 30 days after receipt by such indemnifying party of the aforesaid request; and (ii)&nbsp;such indemnifying party shall not have
reimbursed the indemnified party in accordance with such request prior to the date of such settlement. No indemnifying party shall, without
the prior written consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending
or threatened action, suit or proceeding in respect of which any indemnified party is or could have been a party and indemnity was or
could have been sought hereunder by such indemnified party, unless such settlement, compromise or consent includes an unconditional release
of such indemnified party from all liability on claims that are the subject matter of such action, suit or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Contribution</U>.
If the indemnification provided for in this &lrm;<U>Section&nbsp;6</U> is for any reason held to be unavailable to or otherwise insufficient
to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each
indemnifying party shall contribute to the aggregate amount paid or payable by such indemnified party, as incurred, as a result of any
losses, claims, damages, liabilities or expenses referred to therein (i)&nbsp;in such proportion as is appropriate to reflect the relative
benefits received by the Company, on the one hand, and the Agent, on the other hand, from the offering of the Shares pursuant to this
Agreement; or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;above is not permitted by applicable law, in such proportion as
is appropriate to reflect not only the relative benefits referred to in clause (i)&nbsp;above but also the relative fault of the Company,
on the one hand, and the Agent, on the other hand, in connection with the statements or omissions which resulted in such losses, claims,
damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative benefits received by the Company,
on the one hand, and the Agent, on the other hand, in connection with the offering of the Shares pursuant to this Agreement shall be
deemed to be in the same respective proportions as the total gross proceeds from the offering of the Shares (before deducting expenses)
received by the Company bear to the total commissions received by the Agent. The relative fault of the Company, on the one hand, and
the Agent, on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement
of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company, on the one
hand, or the Agent, on the other hand, and the parties&rsquo; relative intent, knowledge, access to information and opportunity to correct
or prevent such statement or omission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be deemed
to include, subject to the limitations set forth in &lrm;<U>Section&nbsp;6(c)</U>, any reasonable and documented legal or other fees
or expenses reasonably incurred by such party in connection with investigating or defending any action or claim. The provisions set forth
in &lrm;<U>Section&nbsp;6(c)</U>&nbsp;with respect to notice of commencement of any action shall apply if a claim for contribution is
to be made under this <U>&lrm;Section&nbsp;6(e)</U>; provided, however, that no additional notice shall be required with respect to any
action for which notice has been given under &lrm;<U>Section&nbsp;6(c)</U>&nbsp;for purposes of indemnification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company and the Agent agree that it would not be just and equitable if contribution pursuant to this <U>&lrm;Section&nbsp;6(e)</U>&nbsp;were
determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred
to in this &lrm;<U>&lrm;Section&nbsp;6(e)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Notwithstanding
the provisions of this &lrm;<U>&lrm;Section&nbsp;6(e)</U>, the Agent shall not be required to contribute any amount in excess of the
Selling Commission received by the Agent in connection with the offering contemplated hereby. No person guilty of fraudulent misrepresentation
(within the meaning of Section&nbsp;11(f)&nbsp;of the Securities Act) shall be entitled to contribution from any person who was not guilty
of such fraudulent misrepresentation. For purposes of this &lrm;<U>&lrm;Section&nbsp;6(e)</U>, each officer and employee of the Agent
and each person, if any, who controls the Agent within the meaning of the Securities Act or the Exchange Act shall have the same rights
to contribution as the Agent, and each director of the Company, each officer of the Company who signed the Registration Statement, and
each person, if any, who controls the Company within the meaning of the Securities Act and the Exchange Act shall have the same rights
to contribution as the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;TERMINATION&nbsp;&amp;
SURVIVAL</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Term</U>.
Subject to the provisions of this &lrm;<U>Section&nbsp;7</U>, the term of this Agreement shall continue from the date of this Agreement
until the end of the Agency Period, unless earlier terminated by the parties to this Agreement pursuant to this &lrm;<U>Section&nbsp;7</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Termination;
Survival Following Termination</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Either
party may terminate this Agreement prior to the end of the Agency Period, by giving written notice as required by this Agreement, upon
ten (10)&nbsp;Trading Days&rsquo; notice to the other party; provided that, (A)&nbsp;if the Company terminates this Agreement after the
Agent confirms to the Company any sale of Shares, the Company shall remain obligated to comply with &lrm;<U>Section&nbsp;3(b)(v)</U>&nbsp;with
respect to such Shares and (B)&nbsp;&lrm;<U>Section&nbsp;2</U>, &lrm;<U>Section&nbsp;3(d)</U>, <U>Section&nbsp;6</U>, <U>Section&nbsp;7</U>
and <U>Section&nbsp;8</U> shall survive termination of this Agreement. If termination shall occur prior to the Settlement Date for any
sale of Shares, such sale shall nevertheless settle in accordance with the terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
addition to the survival provision of <U>&lrm;Section&nbsp;7(b)(i)</U>, the respective indemnities, agreements, representations, warranties
and other statements of the Company, of its officers and of the Agent set forth in or made pursuant to this Agreement will remain in
full force and effect, regardless of any investigation made by or on behalf of the Agent or the Company or any of its or their partners,
officers or directors or any controlling person, as the case may be, and, anything herein to the contrary notwithstanding, will survive
delivery of and payment for the Shares sold hereunder and any termination of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;MISCELLANEOUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Press
Releases and Disclosure</U>. The Company may issue a press release describing the material terms of the transactions contemplated hereby
as soon as practicable following the date of this Agreement, and may file with the Commission a Current Report on Form&nbsp;8 K, with
this Agreement attached as an exhibit thereto, describing the material terms of the transactions contemplated hereby, and the Company
shall consult with the Agent prior to making such disclosures, and the parties hereto shall use all commercially reasonable efforts,
acting in good faith, to agree upon a text for such disclosures that is reasonably satisfactory to all parties hereto. No party hereto
shall issue thereafter any press release or like public statement (including, without limitation, any disclosure required in reports
filed with the Commission pursuant to the Exchange Act) related to this Agreement or any of the transactions contemplated hereby without
the prior written approval of the other party hereto, except as may be necessary or appropriate in the reasonable opinion of the party
seeking to make disclosure to comply with the requirements of applicable law or stock exchange rules. If any such press release or like
public statement is so required, the party making such disclosure shall consult with the other party prior to making such disclosure,
and the parties shall use all commercially reasonable efforts, acting in good faith, to agree upon a text for such disclosure that is
reasonably satisfactory to all parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Advisory or Fiduciary Relationship</U>. The Company acknowledges and agrees that (i)&nbsp;the transactions contemplated by this Agreement,
including the determination of any fees, are arm&rsquo;s-length commercial transactions between the Company and the Agent, (ii)&nbsp;when
acting as a principal under this Agreement, the Agent is and has been acting solely as a principal and is not the agent or fiduciary
of the Company, or its stockholders, creditors, employees or any other party, (iii)&nbsp;the Agent has not assumed nor will assume an
advisory or fiduciary responsibility in favor of the Company with respect to the transactions contemplated hereby or the process leading
thereto (irrespective of whether the Agent has advised or is currently advising the Company on other matters) and the Agent does not
have any obligation to the Company with respect to the transactions contemplated hereby except the obligations expressly set forth in
this Agreement, (iv)&nbsp;the Agent and its Affiliates may be engaged in a broad range of transactions that involve interests that differ
from those of the Company, and (v)&nbsp;the Agent has not provided any legal, accounting, regulatory or tax advice with respect to the
transactions contemplated hereby and the Company has consulted its own legal, accounting, regulatory and tax advisors to the extent it
deemed appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Research
Analyst Independence</U>. The Company acknowledges that the Agent&rsquo;s research analysts and research departments are required to
and should be independent from their respective investment banking divisions and are subject to certain regulations and internal policies,
and as such the Agent&rsquo;s research analysts may hold views and make statements or investment recommendations and/or publish research
reports with respect to the Company or the offering that differ from the views of their respective investment banking divisions. The
Company understands that the Agent is a full service securities firm and as such from time to time, subject to applicable securities
laws, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity
securities of the companies that may be the subject of the transactions contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Notices</U>.
All communications hereunder shall be in writing and shall be mailed, hand delivered, sent via electronic mail (if applicable) or telecopied
and confirmed to the parties hereto as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">If to the Agent:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Jefferies LLC&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">520 Madison Avenue&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">New York, NY 10022&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Facsimile: (646)
786-5719&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Attention: General
Counsel</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">with a copy (which
shall not constitute notice) to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Duane Morris LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">22 Vanderbilt&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">335 Madison Avenue,
23<SUP>rd</SUP> Floor&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">New York, NY 10017&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Attention: Dean
M. Colucci&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">E-mail: dmcolucci@duanemorris.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">If to the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Attention: Lisa
Ricciardi, Chief Executive Officer&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">E-mail: lricciardi@cogrx.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">with a copy (which
shall not constitute notice) to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">Goodwin
Procter LLP&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">620
8<SUP>th</SUP> Avenue&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">New
York, NY 10018&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">Attention:
Rachael Bushey; Justin Platt&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">E-mail:
rbushey@goodwinlaw.com; jplatt@goodwinlaw.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Any party hereto
may change the address for receipt of communications by giving written notice to the others in accordance with this <U>Section&nbsp;8(d)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Successors</U>.
This Agreement will inure to the benefit of and be binding upon the parties hereto, and to the benefit of the employees, officers and
directors and controlling persons referred to in <U>Section&nbsp;6</U>, and in each case their respective successors, and no other person
will have any right or obligation hereunder. The term &ldquo;successors&rdquo; shall not include any purchaser of the Shares as such
from the Agent merely by reason of such purchase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Partial
Unenforceability</U>. The invalidity or unenforceability of any Article, Section, paragraph or provision of this Agreement shall not
affect the validity or enforceability of any other Article, Section, paragraph or provision hereof. If any Article, Section, paragraph
or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor
changes (and only such minor changes) as are necessary to make it valid and enforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Governing
Law Provisions</U>. This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York applicable
to agreements made and to be performed in such state. Any legal suit, action or proceeding arising out of or based upon this Agreement
or the transactions contemplated hereby may be instituted in the federal courts of the United States of America located in the Borough
of Manhattan in the City of New York or the courts of the State of New York in each case located in the Borough of Manhattan in the City
of New York (collectively, the &ldquo;<B>Specified Courts</B>&rdquo;), and each party irrevocably submits to the exclusive jurisdiction
(except for proceedings instituted in regard to the enforcement of a judgment of any such court, as to which such jurisdiction is non-exclusive)
of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail to such party&rsquo;s
address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The
parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified
Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other
proceeding brought in any such court has been brought in an inconvenient forum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Recognition
of the U.S. Special Resolution Regimes</U>. (i)&nbsp;In the event that the Agent is a Covered Entity and becomes subject to a proceeding
under a U.S. Special Resolution Regime, the transfer from the Agent of this Agreement, and any interest and obligation in or under this
Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement,
and any such interest and obligation, were governed by the laws of the United States or a state of the United States. (ii)&nbsp;In the
event that the Agent is a Covered Entity and the Agent or a BHC Act Affiliate of such Agent becomes subject to a proceeding under a U.S.
Special Resolution Regime, Default Rights under this Agreement that may be exercised against the Agent are permitted to be exercised
to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed
by the laws of the United States or a state of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">As used
in this Section&nbsp;8(h):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>BHC
Act Affiliate</B>&rdquo; has the meaning assigned to the term &ldquo;affiliate&rdquo; in, and shall be interpreted in accordance with,
12 U.S.C. &sect; 1841(k).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Covered
Entity</B>&rdquo; means any of the following: (i)&nbsp;a &ldquo;covered entity&rdquo; as that term is defined in, and interpreted in
accordance with, 12 C.F.R. &sect; 252.82(b); (ii)&nbsp;a &ldquo;covered bank&rdquo; as that term is defined in, and interpreted in accordance
with, 12 C.F.R. &sect; 47.3(b); or (iii)&nbsp;a &ldquo;covered FSI&rdquo; as that term is defined in, and interpreted in accordance with,
12 C.F.R. &sect; 382.2(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Default
Right</B>&rdquo; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &sect;&sect; 252.81,
47.2 or 382.1, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>U.S.
Special Resolution Regime</B>&rdquo; means each of (i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder
and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>General
Provisions</U>. This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or
oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This Agreement
may be executed in two or more counterparts, each one of which shall be an original, with the same effect as if the signatures thereto
and hereto were upon the same instrument, and may be delivered by facsimile transmission or by electronic delivery of a portable document
format (PDF) file (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions
Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com). This Agreement may not be amended or
modified unless in writing by all of the parties hereto, and no condition herein (express or implied) may be waived unless waived in
writing by each party whom the condition is meant to benefit. The Article&nbsp;and Section&nbsp;headings herein are for the convenience
of the parties only and shall not affect the construction or interpretation of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">[<I>Signature Page&nbsp;Immediately
Follows</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">If
the foregoing is in accordance with your understanding of our agreement, kindly sign and return to the Company the enclosed copies hereof,
whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COGNITION THERAPEUTICS,&nbsp;INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;/s/
    Lisa Ricciardi&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Lisa Ricciardi</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
foregoing Agreement is hereby confirmed and accepted by the Agent in New York, New York as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>JEFFERIES LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 47%">/s/ Michael Magarro</TD>
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Name: Michael Magarro</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Title: Managing Director</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">[<I>Signature Page&nbsp;to
Open Market Sale Agreement<SUP>SM</SUP></I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>EXHIBIT&nbsp;A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">ISSUANCE NOTICE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">[Date]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Jefferies LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">520 Madison Avenue</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">New York, New York 10022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Attn: [__________]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Reference is made
to the Open Market Sale Agreement<SUP>SM</SUP> (the &ldquo;<B>Sales Agreement</B>&rdquo;) between Cognition Therapeutics,&nbsp;Inc. (the
 &ldquo;<B>Company</B>&rdquo;) and Jefferies LLC (the &ldquo;<B>Agent</B>&rdquo;) dated as of December&nbsp;18, 2025. The Company confirms
that all conditions to the delivery of this Issuance Notice are satisfied as of the date hereof. Capitalized terms used herein and not
defined shall have the respective meanings ascribed to such terms in the Sales Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Date of Delivery of Issuance Notice
(determined pursuant to <U>Section&nbsp;3(b)(i)</U>):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">_______________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Issuance Amount (equal to the total
Sales Price for such Shares):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 48%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of days in selling period:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First date of selling period:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Last date of selling period:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement Date(s)&nbsp;if other than standard T+1
    settlement:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Floor Price Limitation (in no event
less than $1.00 without the prior written consent of the Agent, which consent may be withheld in the Agent&rsquo;s sole discretion):
$ ____ per share</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top"><TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">Comments:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 90%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Schedule A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Notice Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><U>The Company</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Lisa Ricciardi (lriccidari@cogrx.com)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">John Doyle (jdoyle@cogrx.com)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><U>The Agent</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Donald Lynaugh (mmagarro@jefferies.com)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Michael Magarro (dlynaugh@jefferies.com)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>3
<FILENAME>tm2533585d2_ex4-4.htm
<DESCRIPTION>EXHIBIT 4.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;4.4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COGNITION THERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDENTURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated
as of [ </FONT><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">],
20[ </FONT><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[
</B></FONT><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Trustee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0.25pt 0.5pt 1.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; padding: 0.25pt 0.5pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE&nbsp;I. DEFINITIONS AND INCORPORATION BY REFERENCE</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; width: 80%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitions</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.2.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Definitions</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.3.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporation by Reference of Trust Indenture Act</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.4.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rules&nbsp;of Construction</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE&nbsp;II. THE SECURITIES</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.1.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuable in Series</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.2.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Establishment of Terms of Series&nbsp;of Securities</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.3.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Execution and Authentication</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.4.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrar, Paying Agent and Notice Agent</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.5.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paying Agent to Hold Money in Trust</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.6.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder Lists</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.7.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer and Exchange</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.8.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mutilated, Destroyed, Lost and Stolen Securities</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.9.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding Securities</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.10.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treasury Securities</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.11.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Temporary Securities</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.12.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancellation</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.13.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defaulted Interest</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.14.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global Securities</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.15.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CUSIP Numbers</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE&nbsp;III. REDEMPTION</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.1.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice to Trustee</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.2.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selection of Securities to be Redeemed</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.3.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice of Redemption</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.4.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect of Notice of Redemption</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.5.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deposit of Redemption Price</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.6.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Redeemed in Part</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE&nbsp;IV. COVENANTS</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.1.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment of Principal and Interest</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.2.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC Reports</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.3.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance Certificate</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.4.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stay, Extension and Usury Laws</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE&nbsp;V. SUCCESSORS</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.1.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When Company May&nbsp;Merge, Etc.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.2.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successor Corporation Substituted</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE&nbsp;VI. DEFAULTS AND REMEDIES</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.1.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Events of Default</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.2.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acceleration of Maturity; Rescission and Annulment</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.3.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collection of Indebtedness and Suits for Enforcement by Trustee</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.4.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trustee May&nbsp;File Proofs of Claim</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.5.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trustee May&nbsp;Enforce Claims Without Possession of Securities</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.6.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Application of Money Collected</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.7.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Limitation on Suits</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.8.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; width: 80%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unconditional Right of Holders to Receive Principal and Interest</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.9.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restoration of Rights and Remedies</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.10.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights and Remedies Cumulative</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.11.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delay or Omission Not Waiver</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.12.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Control by Holders</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.13.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Waiver of Past Defaults</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.14.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Undertaking for Costs</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE&nbsp;VII. TRUSTEE</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.1.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Duties of Trustee</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.2.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights of Trustee</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.3.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual Rights of Trustee</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.4.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trustee&rsquo;s Disclaimer</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.5.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice of Defaults</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.6.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reports by Trustee to Holders</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.7.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation and Indemnity</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.8.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Replacement of Trustee</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.9.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successor Trustee by Merger, Etc.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.10.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eligibility; Disqualification</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.11.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferential Collection of Claims Against Company</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE&nbsp;VIII. SATISFACTION AND DISCHARGE; DEFEASANCE</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.1.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Satisfaction and Discharge of Indenture</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.2.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Application of Trust Funds; Indemnification</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.3.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Defeasance of Securities of any Series</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.4.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Covenant Defeasance</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.5.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repayment to Company</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.6.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reinstatement</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE&nbsp;IX. AMENDMENTS AND WAIVERS</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;9.1.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without Consent of Holders</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;9.2.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With Consent of Holders</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;9.3.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Limitations</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;9.4.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance with Trust Indenture Act</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;9.5.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revocation and Effect of Consents</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;9.6.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notation on or Exchange of Securities</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;9.7.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trustee Protected</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE&nbsp;X. MISCELLANEOUS</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.1.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trust Indenture Act Controls</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.2.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.3.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Communication by Holders with Other Holders</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.4.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate and Opinion as to Conditions Precedent</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.5.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements Required in Certificate or Opinion</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.6.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rules&nbsp;by Trustee and Agents</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.7.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Holidays</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.8.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Recourse Against Others</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.9.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Counterparts</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.10.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governing Law; Waiver of Jury Trial; Consent to Jurisdiction</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.11.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Adverse Interpretation of Other Agreements</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.12.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successors</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.13.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severability</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.14.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Table of Contents, Headings, Etc.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.15.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities in a Foreign Currency</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.16.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Judgment Currency</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.17.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Force Majeure</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.18.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.A. Patriot Act</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE&nbsp;XI. SINKING FUNDS</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;11.1.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; width: 80%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applicability of Article</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;11.2.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Satisfaction of Sinking Fund Payments with Securities</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;11.3.</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Redemption of Securities for Sinking Fund</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COGNITION THERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Reconciliation and tie between Trust Indenture
Act of 1939 and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indenture,
dated as of [</FONT><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">],
20[</FONT><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 0.5pt 0.75pt; text-align: right; width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&sect; 310(a)(1)</FONT></TD>
    <TD STYLE="text-align: center; padding: 0.5pt 0.75pt; width: 4%">&nbsp;</TD>
    <TD STYLE="padding: 0.5pt 0.75pt; width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.10</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 0.5pt 0.75pt 0.5pt 23.45pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)(2)</FONT></TD>
    <TD STYLE="text-align: center; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.10</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 0.5pt 0.75pt 0.5pt 23.45pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)(3)</FONT></TD>
    <TD STYLE="text-align: center; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not Applicable</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 0.5pt 0.75pt 0.5pt 23.45pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)(4)</FONT></TD>
    <TD STYLE="text-align: center; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not Applicable</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 0.5pt 0.75pt 0.5pt 23.45pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)(5)</FONT></TD>
    <TD STYLE="text-align: center; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.10</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 0.5pt 0.75pt 0.5pt 31pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: center; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.10</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 0.5pt 0.75pt 0.5pt 10.45pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&sect; 311(a)</FONT></TD>
    <TD STYLE="text-align: center; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.11</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 0.5pt 0.75pt 0.5pt 31pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: center; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.11</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 0.5pt 0.75pt 0.5pt 31pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: center; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not Applicable</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 0.5pt 0.75pt 0.5pt 10.45pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&sect; 312(a)</FONT></TD>
    <TD STYLE="text-align: center; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 0.5pt 0.75pt 0.5pt 31pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: center; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 0.5pt 0.75pt 0.5pt 31pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: center; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 0.5pt 0.75pt 0.5pt 10.45pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&sect; 313(a)</FONT></TD>
    <TD STYLE="text-align: center; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 0.5pt 0.75pt 0.5pt 22.45pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)(1)</FONT></TD>
    <TD STYLE="text-align: center; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 0.5pt 0.75pt 0.5pt 22.45pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)(2)</FONT></TD>
    <TD STYLE="text-align: center; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 0.5pt 0.75pt 0.5pt 23.45pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)(1)</FONT></TD>
    <TD STYLE="text-align: center; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 0.5pt 0.75pt 0.5pt 31pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: center; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 0.5pt 0.75pt 0.5pt 10.45pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&sect; 314(a)</FONT></TD>
    <TD STYLE="text-align: center; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2, 10.5</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 0.5pt 0.75pt 0.5pt 31pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: center; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not Applicable</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 0.5pt 0.75pt 0.5pt 23.45pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)(1)</FONT></TD>
    <TD STYLE="text-align: center; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 0.5pt 0.75pt 0.5pt 23.45pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)(2)</FONT></TD>
    <TD STYLE="text-align: center; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 0.5pt 0.75pt 0.5pt 23.45pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)(3)</FONT></TD>
    <TD STYLE="text-align: center; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not Applicable</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 0.5pt 0.75pt 0.5pt 31pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: center; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not Applicable</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 0.5pt 0.75pt 0.5pt 31pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="text-align: center; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 0.5pt 0.75pt 0.5pt 31pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="text-align: center; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not Applicable</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; padding: 0.5pt 0.75pt 0.5pt 10.45pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&sect; 315(a)</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; padding: 0.5pt 0.75pt 0.5pt 31pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; padding: 0.5pt 0.75pt 0.5pt 31pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; padding: 0.5pt 0.75pt 0.5pt 31pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; padding: 0.5pt 0.75pt 0.5pt 31pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.14</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; padding: 0.5pt 0.75pt 0.5pt 10.45pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&sect; 316(a)</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.10</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; padding: 0.5pt 0.75pt 0.5pt 7.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)(1)(A)</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.12</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; padding: 0.5pt 0.75pt 0.5pt 8.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)(1)(B)</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.13</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; padding: 0.5pt 0.75pt 0.5pt 31pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.8</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; padding: 0.5pt 0.75pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&sect; 317(a)(1)</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; padding: 0.5pt 0.75pt 0.5pt 23.45pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)(2)</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; padding: 0.5pt 0.75pt 0.5pt 31pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; padding: 0.5pt 0.75pt 0.5pt 10.45pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&sect; 318(a)</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom; padding: 0.5pt 0.75pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.5pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note: This reconciliation and tie shall not, for any purpose, be deemed
to be part of the Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indenture
dated as of [</FONT><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">],
20[</FONT><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">]
between Cognition Therapeutics,&nbsp;Inc., a company incorporated under the laws of the State of Delaware (&ldquo;<I>Company</I>&rdquo;),
and [</FONT><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">]
(&ldquo;<I>Trustee</I>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each party agrees as follows for the benefit of
the other party and for the equal and ratable benefit of the Holders of the Securities issued under this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE&nbsp;I.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">DEFINITIONS AND INCORPORATION BY REFERENCE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;1.1. <U>Definitions.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>Additional Amounts</I>&rdquo; means any
additional amounts which are required hereby or by any Security, under circumstances specified herein or therein, to be paid by the Company
in respect of certain taxes imposed on Holders specified herein or therein and which are owing to such Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>Affiliate</I>&rdquo; of any specified
person means any other person directly or indirectly controlling or controlled by or under common control with such specified person.
For the purposes of this definition, &ldquo;control&rdquo; (including, with correlative meanings, the terms &ldquo;controlled by&rdquo;
and &ldquo;under common control with&rdquo;), as used with respect to any person, shall mean the possession, directly or indirectly, of
the power to direct or cause the direction of the management or policies of such person, whether through the ownership of voting securities
or by agreement or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>Agent</I>&rdquo; means any Registrar,
Paying Agent or Notice Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>Board of Directors</I>&rdquo; means the
board of directors of the Company or any duly authorized committee thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>Board Resolution</I>&rdquo; means a copy
of a resolution certified by the Secretary or an Assistant Secretary of the Company to have been adopted by the Board of Directors or
pursuant to authorization by the Board of Directors and to be in full force and effect on the date of the certificate and delivered to
the Trustee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>Business Day</I>&rdquo; means any day
except a Saturday, Sunday or a legal holiday in the City of New York, New York (or in connection with any payment, the place of payment)
on which banking institutions are authorized or required by law, regulation or executive order to close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>Capital Stock</I>&rdquo; means any and
all shares, interests, participations, rights or other equivalents (however designated) of corporate stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>Company</I>&rdquo; means the party named
as such above until a successor replaces it and thereafter means the successor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>Company Order</I>&rdquo; means a written
order signed in the name of the Company by an Officer and delivered to the Trustee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>Corporate Trust Office</I>&rdquo; means
the office of the Trustee at which at any particular time its corporate trust business related to this Indenture shall be principally
administered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>Default</I>&rdquo; means any event which
is, or after notice, passage of time or both would be, an Event of Default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>Depositary</I>&rdquo; means, with respect
to the Securities of any Series&nbsp;issuable or issued in whole or in part in the form of one or more Global Securities, the person designated
as Depositary for such Series&nbsp;by the Company, which Depositary shall be a clearing agency registered under the Exchange Act; and
if at any time there is more than one such person, &ldquo;Depositary&rdquo; as used with respect to the Securities of any Series&nbsp;shall
mean the Depositary with respect to the Securities of such Series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>Discount Security</I>&rdquo; means any
Security that provides for an amount less than the stated principal amount thereof to be due and payable upon declaration of acceleration
of the maturity thereof pursuant to Section&nbsp;6.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>Dollars</I>&rdquo; and &ldquo;<I>$</I>&rdquo;
means the currency of the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>Exchange Act</I>&rdquo; means the Securities
Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>Foreign Currency</I>&rdquo; means any
currency or currency unit issued by a government other than the government of the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>Foreign Government Obligations</I>&rdquo;
means, with respect to Securities of any Series&nbsp;that are denominated in a Foreign Currency, direct obligations of, or obligations
guaranteed by, the government that issued or caused to be issued such currency for the payment of which obligations its full faith and
credit is pledged and which are not callable or redeemable at the option of the issuer thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><I>&ldquo;GAAP&rdquo;</I></FONT>
means generally accepted accounting principles in the United States of America set forth in the opinions and pronouncements of the Accounting
Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting
Standards Board or in such other statements by such other entity as have been approved by a significant segment of the accounting profession,
which are in effect as of the date of determination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>Global Security</I>&rdquo; or &ldquo;<I>Global
Securities</I>&rdquo; means a Security or Securities, as the case may be, in the form established pursuant to Section&nbsp;2.2 evidencing
all or part of a Series&nbsp;of Securities, issued to the Depositary for such Series&nbsp;or its nominee, and registered in the name of
such Depositary or nominee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>Holder</I>&rdquo; means a person in whose
name a Security is registered on the Registrar&rsquo;s books.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>Indenture</I>&rdquo; means this Indenture
as amended or supplemented from time to time and shall include the form and terms of particular Series&nbsp;of Securities established
as contemplated hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>interest</I>&rdquo; with respect to any
Discount Security which by its terms bears interest only after Maturity, means interest payable after Maturity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>Maturity</I>&rdquo; when used with respect
to any Security, means the date on which the principal of such Security becomes due and payable as therein or herein provided, whether
at the Stated Maturity or by declaration of acceleration, call for redemption or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>Officer</I>&rdquo; means the Chief Executive
Officer, President, the Chief Financial Officer, the Treasurer or any Assistant Treasurer, the Secretary or any Assistant Secretary and
any Vice President of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>Officer&rsquo;s Certificate</I>&rdquo;
means a certificate signed by any Officer that meets the requirements of this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>Opinion of Counsel</I>&rdquo; means a
written opinion of legal counsel who is acceptable to the Trustee. The counsel may be an employee of or counsel to the Company. The opinion
may contain customary limitations, conditions and exceptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>person</I>&rdquo; means any individual,
corporation, partnership, joint venture, association, limited liability company, joint-stock company, trust, unincorporated organization
or government or any agency or political subdivision thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>principal</I>&rdquo; of a Security means
the principal of the Security plus, when appropriate, the premium, if any, on, [and any Additional Amounts in respect of,] the Security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>Responsible Officer</I>&rdquo; means
any officer of the Trustee in its Corporate Trust Office having responsibility for administration of this Indenture and also means, with
respect to a particular corporate trust matter, any other officer to whom any corporate trust matter is referred because of his or her
knowledge of and familiarity with a particular subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>SEC</I>&rdquo; means the Securities and
Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>Security</I>&rdquo; or &ldquo;<I>Securities</I>&rdquo;
means the debentures, notes or other debt instruments of the Company of any Series&nbsp;authenticated and delivered under this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>Series</I>&rdquo; or &ldquo;<I>Series&nbsp;of
Securities</I>&rdquo; means each series of debentures, notes or other debt instruments of the Company created pursuant to Sections 2.1
and 2.2 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>Stated Maturity</I>&rdquo; when used
with respect to any Security, means the date specified in such Security as the fixed date on which the principal of such Security or interest
is due and payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>Subsidiary</I>&rdquo; of any specified
person means any corporation, association or other business entity of which more than 50% of the total voting power of shares of Capital
Stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers or trustees thereof
is at the time owned or controlled, directly or indirectly, by such person or one or more of the other Subsidiaries of that person or
a combination thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>TIA</I>&rdquo; means the Trust Indenture
Act of 1939 (15 U.S. Code &sect;&sect; 77aaa-77bbbb) as in effect on the date of this Indenture; <U>provided</U>, <U>however</U>, that
in the event the Trust Indenture Act of 1939 is amended after such date, &ldquo;TIA&rdquo; means, to the extent required by any such amendment,
the Trust Indenture Act as so amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>Trustee</I>&rdquo; means the person named
as the &ldquo;Trustee&rdquo; in the first paragraph of this instrument until a successor Trustee shall have become such pursuant to the
applicable provisions of this Indenture, and thereafter &ldquo;Trustee&rdquo; shall mean or include each person who is then a Trustee
hereunder, and if at any time there is more than one such person, &ldquo;Trustee&rdquo; as used with respect to the Securities of any
Series&nbsp;shall mean the Trustee with respect to Securities of that Series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>U.S. Government Obligations</I>&rdquo;
means securities which are direct obligations of, or guaranteed by, the United States of America for the payment of which its full faith
and credit is pledged and which are not callable or redeemable at the option of the issuer thereof, and shall also include a depositary
receipt issued by a bank or trust company as custodian with respect to any such U.S. Government Obligation or a specific payment of interest
on or principal of any such U.S. Government Obligation held by such custodian for the account of the holder of a depositary receipt, <I>provided</I>
that (except as required by law) such custodian is not authorized to make any deduction from the amount payable to the holder of such
depositary receipt from any amount received by the custodian in respect of the U.S. Government Obligation evidenced by such depositary
receipt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;1.2. <U>Other Definitions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; padding-left: 36.25pt; width: 80%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 18%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEFINED IN</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TERM</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; padding-left: 36.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<I>Agent Member</I>&rdquo;</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.14.6</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; padding-left: 36.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<I>Bankruptcy Law</I>&rdquo;</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; padding-left: 36.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<I>Custodian</I>&rdquo;</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; padding-left: 36.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<I>Event of Default</I>&rdquo;</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; padding-left: 36.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<I>Judgment Currency</I>&rdquo;</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; padding-left: 36.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<I>mandatory sinking fund payment</I>&rdquo;</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; padding-left: 36.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<I>New York Banking Day</I>&rdquo;</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; padding-left: 36.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<I>Notice Agent</I>&rdquo;</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; padding-left: 36.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<I>optional sinking fund payment</I>&rdquo;</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; padding-left: 36.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<I>Paying Agent</I>&rdquo;</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; padding-left: 36.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<I>Registrar</I>&rdquo;</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; padding-left: 36.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<I>Required Currency</I>&rdquo;</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; padding-left: 36.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<I>Specified Courts</I>&rdquo;</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; padding-left: 36.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<I>successor person</I>&rdquo;</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;1.3. <U>Incorporation by Reference
of Trust Indenture Act</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Whenever this Indenture refers to a provision of
the TIA, the provision is incorporated by reference in and made a part of this Indenture. The following TIA terms used in this Indenture
have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>Commission</I>&rdquo; means the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>indenture securities</I>&rdquo; means
the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>indenture security holder</I>&rdquo;
means a Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>indenture to be qualified</I>&rdquo;
means this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>indenture trustee</I>&rdquo; or &ldquo;<I>institutional
trustee</I>&rdquo; means the Trustee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>obligor</I>&rdquo; on the indenture securities
means the Company and any successor obligor upon the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All other terms used in this Indenture that are
defined by the TIA, defined by TIA reference to another statute or defined by SEC rule&nbsp;under the TIA and not otherwise defined herein
are used herein as so defined.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;1.4. <U>Rules&nbsp;of Construction</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unless the context otherwise requires:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;a term
has the meaning assigned to it;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;an accounting
term not otherwise defined has the meaning assigned to it in accordance with GAAP;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;&ldquo;<I>or</I>&rdquo;
is not exclusive;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)&nbsp;words in
the singular include the plural, and in the plural include the singular;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)&nbsp;provisions
apply to successive events and transactions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(f)&nbsp;in the
computation of periods of time from a specified date to a later specified date, the word &ldquo;from&rdquo; means &ldquo;from and including,&rdquo;
and the words &ldquo;to&rdquo; and &ldquo;until&rdquo; each mean &ldquo;to but excluding&rdquo;; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(g)&nbsp;the phrase
 &ldquo;in writing&rdquo; as used herein shall be deemed to include PDFs, e-mails and other electronic means of transmission, unless otherwise
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE&nbsp;II.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">THE SECURITIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;2.1. <U>Issuable in Series</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The aggregate principal amount of Securities that
may be authenticated and delivered under this Indenture is unlimited. The Securities may be issued in one or more Series. All Securities
of a Series&nbsp;shall be identical except as may be set forth or determined in the manner provided in a Board Resolution, a supplemental
indenture or an Officer&rsquo;s Certificate detailing the adoption of the terms thereof pursuant to authority granted under a Board Resolution.
In the case of Securities of a Series&nbsp;to be issued from time to time, the Board Resolution, Officer&rsquo;s Certificate or supplemental
indenture detailing the adoption of the terms thereof pursuant to authority granted under a Board Resolution may provide for the method
by which specified terms (such as interest rate, maturity date, record date or date from which interest shall accrue) are to be determined.
Securities may differ between Series&nbsp;in respect of any matters, provided that all Series&nbsp;of Securities shall be equally and
ratably entitled to the benefits of the Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;2.2. <U>Establishment of Terms of
Series&nbsp;of Securities</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in">At or prior to the issuance of any Securities within
a Series, the following shall be established (as to the Series&nbsp;generally, in the case of Subsection 2.2.1 and either as to such Securities
within the Series&nbsp;or as to the Series&nbsp;generally in the case of Subsections 2.2.2 through 2.2.23) by or pursuant to a Board Resolution,
and set forth or determined in the manner provided in a Board Resolution, supplemental indenture hereto or Officer&rsquo;s Certificate:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">2.2.1. the title (which shall
distinguish the Securities of that particular Series&nbsp;from the Securities of any other Series) and ranking (including the terms of
any subordination provisions) of the Series;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.2.2. the price or prices (expressed
as a percentage of the principal amount thereof) at which the Securities of the Series&nbsp;will be issued;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">2.2.3. any limit upon the aggregate
principal amount of the Securities of the Series&nbsp;which may be authenticated and delivered under this Indenture (except for Securities
authenticated and delivered upon registration of transfer of, or in exchange for, or in lieu of, other Securities of the Series&nbsp;pursuant
to Section&nbsp;2.7, 2.8, 2.11, 3.6 or 9.6);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.2.4. the date or dates on
which the principal of the Securities of the Series&nbsp;is payable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">2.2.5. the rate or rates (which
may be fixed or variable) per annum or, if applicable, the method used to determine such rate or rates (including, but not limited to,
any commodity, commodity index, stock exchange index or financial index) at which the Securities of the Series&nbsp;shall bear interest,
if any, the date or dates from which such interest, if any, shall accrue, the date or dates on which such interest, if any, shall commence
and be payable and any regular record date for the interest payable on any interest payment date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">2.2.6. the place or places where
the principal of and interest, if any, on the Securities of the Series&nbsp;shall be payable, where the Securities of such Series&nbsp;may
be surrendered for registration of transfer or exchange and where notices and demands to or upon the Company in respect of the Securities
of such Series&nbsp;and this Indenture may be delivered, and the method of such payment, if by wire transfer, mail or other means;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">2.2.7. if applicable, the period
or periods within which, the price or prices at which and the terms and conditions upon which the Securities of the Series&nbsp;may be
redeemed, in whole or in part, at the option of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">2.2.8. the obligation, if any,
of the Company to redeem or purchase the Securities of the Series&nbsp;pursuant to any sinking fund or analogous provisions or at the
option of a Holder thereof and the period or periods within which, the price or prices at which and the terms and conditions upon which
Securities of the Series&nbsp;shall be redeemed or purchased, in whole or in part, pursuant to such obligation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">2.2.9. the dates, if any, on
which and the price or prices at which the Securities of the Series&nbsp;will be repurchased by the Company at the option of the Holders
thereof and other detailed terms and provisions of such repurchase obligations;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">2.2.10. if other than denominations
of $1,000 and any integral multiple thereof, the denominations in which the Securities of the Series&nbsp;shall be issuable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.2.11. the forms of the Securities
of the Series&nbsp;and whether the Securities will be issuable as Global Securities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">2.2.12. if other than the principal
amount thereof, the portion of the principal amount of the Securities of the Series&nbsp;that shall be payable upon declaration of acceleration
of the maturity thereof pursuant to Section&nbsp;6.2;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">2.2.13. the currency of denomination
of the Securities of the Series, which may be Dollars or any Foreign Currency, and if such currency of denomination is a composite currency,
the agency or organization, if any, responsible for overseeing such composite currency;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">2.2.14. the designation of the
currency, currencies or currency units in which payment of the principal of and interest, if any, on the Securities of the Series&nbsp;will
be made;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">2.2.15. if payments of principal
of or interest, if any, on the Securities of the Series&nbsp;are to be made in one or more currencies or currency units other than that
or those in which such Securities are denominated, the manner in which the exchange rate with respect to such payments will be determined;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">2.2.16. the manner in which
the amounts of payment of principal of or interest, if any, on the Securities of the Series&nbsp;will be determined, if such amounts may
be determined by reference to an index based on a currency or currencies or by reference to a commodity, commodity index, stock exchange
index or financial index;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.2.17. the provisions, if any,
relating to any security provided for the Securities of the Series;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">2.2.18. any addition to, deletion
of or change in the Events of Default which applies to any Securities of the Series&nbsp;and any change in the right of the Trustee or
the requisite Holders of such Securities to declare the principal amount thereof due and payable pursuant to Section&nbsp;6.2;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.2.19. any addition to, deletion
of or change in the covenants applicable to Securities of the Series;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">2.2.20. any Depositaries, interest
rate calculation agents, exchange rate calculation agents or other agents with respect to Securities of such Series&nbsp;if other than
those appointed herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">2.2.21. the provisions, if any,
relating to conversion or exchange of any Securities of such Series, including if applicable, the conversion or exchange price, the conversion
or exchange period, provisions as to whether conversion or exchange will be mandatory, at the option of the Holders thereof or at the
option of the Company, the events requiring an adjustment of the conversion price or exchange price and provisions affecting conversion
or exchange if such Series&nbsp;of Securities are redeemed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">2.2.22. any other terms of the
Series&nbsp;(which may supplement, modify or delete any provision of this Indenture insofar as it applies to such Series), including any
terms that may be required under applicable law or regulations or advisable in connection with the marketing of Securities of that Series;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">2.2.23. whether any of the Company&rsquo;s
direct or indirect Subsidiaries will guarantee the Securities of that Series, including the terms of subordination, if any, of such guarantees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All Securities of any one Series&nbsp;need not
be issued at the same time and may be issued from time to time, consistent with the terms of this Indenture, if so provided by or pursuant
to the Board Resolution, supplemental indenture hereto or Officer&rsquo;s Certificate referred to above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;2.3. <U>Execution and Authentication</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">An Officer shall sign the Securities for the Company
by manual, facsimile or electronic signature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If an Officer whose signature is on a Security
no longer holds that office at the time the Security is authenticated, the Security shall nevertheless be valid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A Security shall not be valid until authenticated
by the manual signature of the Trustee or an authenticating agent. The signature shall be conclusive evidence that the Security has been
authenticated under this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Trustee shall at any time, and from time to
time, authenticate Securities for original issue in the principal amount provided in the Board Resolution, supplemental indenture hereto
or Officer&rsquo;s Certificate, upon receipt by the Trustee of a Company Order. Each Security shall be dated the date of its authentication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The aggregate principal amount of Securities of
any Series&nbsp;outstanding at any time may not exceed any limit upon the maximum principal amount for such Series&nbsp;set forth in the
Board Resolution, supplemental indenture hereto or Officer&rsquo;s Certificate delivered pursuant to Section&nbsp;2.2, except as provided
in Section&nbsp;2.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Prior to the issuance of Securities of any Series,
the Trustee shall have received and (subject to Section&nbsp;7.2) shall be fully protected in relying on: (a)&nbsp;the Board Resolution,
supplemental indenture hereto or Officer&rsquo;s Certificate establishing the form of the Securities of that Series&nbsp;or of Securities
within that Series&nbsp;and the terms of the Securities of that Series&nbsp;or of Securities within that Series, (b)&nbsp;an Officer&rsquo;s
Certificate complying with Sections 10.4 and 10.5, and (c)&nbsp;an Opinion of Counsel complying with Sections 10.4 and 10.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Trustee shall have the right to decline to
authenticate and deliver any Securities of such Series: (a)&nbsp;if the Trustee, being advised by counsel, determines that such action
may not be taken lawfully; or (b)&nbsp;if the Trustee in good faith determines that such action may expose the Trustee to personal liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Trustee may appoint an authenticating agent
acceptable to the Company to authenticate Securities. An authenticating agent may authenticate Securities whenever the Trustee may do
so. Each reference in this Indenture to authentication by the Trustee includes authentication by such agent. An authenticating agent has
the same rights as an Agent to deal with the Company or an Affiliate of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;2.4. <U>Registrar, Paying Agent and
Notice Agent</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company shall maintain, with respect to each
Series&nbsp;of Securities, at the place or places specified with respect to such Series&nbsp;pursuant to Section&nbsp;2.2, an office or
agency where Securities of such Series&nbsp;may be presented or surrendered for payment (&ldquo;<I>Paying Agent</I>&rdquo;), where Securities
of such Series&nbsp;may be surrendered for registration of transfer or exchange (&ldquo;<I>Registrar</I>&rdquo;) and where notices and
demands to or upon the Company in respect of the Securities of such Series&nbsp;and this Indenture may be delivered (&ldquo;<I>Notice
Agent</I>&rdquo;). The Registrar shall keep a register with respect to each Series&nbsp;of Securities and to their transfer and exchange.
The Company will give prompt written notice to the Trustee of the name and address, and any change in the name or address, of each Registrar,
Paying Agent or Notice Agent. If at any time the Company shall fail to maintain any such required Registrar, Paying Agent or Notice Agent
or shall fail to furnish the Trustee with the name and address thereof, such presentations, surrenders, notices and demands may be made
or served at the Corporate Trust Office of the Trustee, and the Company hereby appoints the Trustee as its agent to receive all such presentations,
surrenders, notices and demands; <U>provided</U>, <U>however</U>, that any appointment of the Trustee as the Notice Agent shall exclude
the appointment of the Trustee or any office of the Trustee as an agent to receive the service of legal process on the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company may also from time to time designate
one or more co-registrars, additional paying agents or additional notice agents and may from time to time rescind such designations; <U>provided</U>,
<U>however</U>, that no such designation or rescission shall in any manner relieve the Company of its obligations to maintain a Registrar,
Paying Agent and Notice Agent in each place so specified pursuant to Section&nbsp;2.2 for Securities of any Series&nbsp;for such purposes.
The Company will give prompt written notice to the Trustee of any such designation or rescission and of any change in the name or address
of any such co-registrar, additional paying agent or additional notice agent. The term &ldquo;<I>Registrar</I>&rdquo; includes any co-registrar;
the term &ldquo;<I>Paying Agent</I>&rdquo; includes any additional paying agent; and the term &ldquo;<I>Notice Agent</I>&rdquo; includes
any additional notice agent. The Company or any of its Affiliates may serve as Registrar or Paying Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company hereby appoints the Trustee the initial
Registrar, Paying Agent and Notice Agent for each Series&nbsp;unless another Registrar, Paying Agent or Notice Agent, as the case may
be, is appointed prior to the time Securities of that Series&nbsp;are first issued. The rights, powers, duties, obligations and actions
of each Agent under this Indenture are several and not joint or joint and several, and the Agents shall only be obliged to perform those
duties expressly set out in this Indenture and shall have no implied duties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;2.5. <U>Paying Agent to Hold Money
in Trust</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company shall require each Paying Agent other
than the Trustee to agree in writing that the Paying Agent will hold in trust, for the benefit of Holders of any Series&nbsp;of Securities,
or the Trustee, all money held by the Paying Agent for the payment of principal of or interest on the Series&nbsp;of Securities, and will
notify the Trustee in writing of any default by the Company in making any such payment. While any such default continues, the Trustee
may require a Paying Agent to pay all money held by it to the Trustee. The Company at any time may require a Paying Agent to pay all money
held by it to the Trustee. Upon payment over to the Trustee, the Paying Agent (if other than the Company or a Subsidiary of the Company)
shall have no further liability for the money. If the Company or a Subsidiary of the Company acts as Paying Agent, it shall segregate
and hold in a separate trust fund for the benefit of Holders of any Series&nbsp;of Securities all money held by it as Paying Agent. Upon
any bankruptcy, reorganization or similar proceeding with respect to the Company, the Trustee shall serve as Paying Agent for the Securities.
For the avoidance of doubt, a Paying Agent and the Trustee shall be held harmless and have no liability with respect to payments or disbursements
(including to the Holders) until they have confirmed receipt of funds sufficient to make the relevant payment. No money held by an Agent
needs to be segregated except as is required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;2.6. <U>Holder Lists</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If it is serving as Registrar, the Trustee shall
preserve in as current a form as is reasonably practicable the most recent list available to it of the names and addresses of Holders
of each Series&nbsp;of Securities and shall otherwise comply with TIA &sect; 312(a). If the Trustee is not the Registrar, the Company
shall furnish to the Trustee at least ten days before each interest payment date and at such other times as the Trustee may request in
writing a list, in such form and as of such date as the Trustee may reasonably require, of the names and addresses of Holders of each
Series&nbsp;of Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Every Holder, by receiving and holding Securities,
agrees with the Company and the Trustee that neither the Company nor the Trustee or any agent of either of them shall be held accountable
by reason of the disclosure of any such information as to the names and addresses of the Holders in accordance with TIA &sect; 312, regardless
of the source from which such information was derived, and that the Trustee shall not be held accountable by reason of mailing any material
pursuant to a request made under TIA &sect; 312(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;2.7. <U>Transfer and Exchange</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Where Securities of a Series&nbsp;are presented
to the Registrar or a co-registrar with a request to register a transfer or to exchange them for an equal principal amount of Securities
of the same Series, the Registrar shall register the transfer or make the exchange if its requirements for such transactions are met.
To permit registrations of transfers and exchanges, the Trustee shall authenticate Securities at the Registrar&rsquo;s request. No service
charge shall be made for any registration of transfer or exchange (except as otherwise expressly permitted herein), but the Company may
require payment of a sum sufficient to cover any transfer tax or similar governmental charge payable in connection therewith (other than
any such transfer tax or similar governmental charge payable upon exchanges pursuant to Sections 2.11, 3.6 or 9.6).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Neither the Company nor the Registrar shall be
required (a)&nbsp;to issue, register the transfer of or exchange Securities of any Series&nbsp;for the period beginning at the opening
of business 15 days immediately preceding the sending of a notice of redemption of Securities of that Series&nbsp;selected for redemption
and ending at the close of business on the day such notice is sent, (b)&nbsp;to register the transfer of or exchange Securities of any
Series&nbsp;selected, called or being called for redemption as a whole or the portion being redeemed of any such Securities selected,
called or being called for redemption in part or (c)&nbsp;to register the transfer of or exchange Securities of any Series&nbsp;between
a record date and payment date for such Series&nbsp;of Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;2.8. <U>Mutilated, Destroyed, Lost
and Stolen Securities</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If any mutilated Security is surrendered to the
Trustee, the Company shall execute and the Trustee shall authenticate and deliver in exchange therefor a new Security of the same Series&nbsp;and
of like tenor and principal amount and bearing a number not contemporaneously outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If there shall be delivered to the Company and
the Trustee (i)&nbsp;evidence to their satisfaction of the destruction, loss or theft of any Security and (ii)&nbsp;such security or indemnity
bond as may be required by each of them to hold itself and any of its agents harmless, then, in the absence of notice to the Company or
the Trustee that such Security has been acquired by a bona fide purchaser, the Company shall execute and upon receipt of a Company Order
the Trustee shall authenticate and make available for delivery, in lieu of any such destroyed, lost or stolen Security, a new Security
of the same Series&nbsp;and of like tenor and principal amount and bearing a number not contemporaneously outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In case any such mutilated, destroyed, lost or
stolen Security has become or is about to become due and payable, the Company in its discretion may, instead of issuing a new Security,
pay such Security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Upon the issuance of any new Security under this
Section, the Company may require the payment of a sum sufficient to cover any tax or other governmental charge that may be imposed in
relation thereto and any other expenses (including the fees and expenses of the Trustee) connected therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Every new Security of any Series&nbsp;issued pursuant
to this Section&nbsp;in lieu of any destroyed, lost or stolen Security shall constitute an original additional contractual obligation
of the Company, whether or not the destroyed, lost or stolen Security shall be at any time enforceable by anyone, and shall be entitled
to all the benefits of this Indenture equally and proportionately with any and all other Securities of that Series&nbsp;duly issued hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The provisions of this Section&nbsp;are exclusive
and shall preclude (to the extent lawful) all other rights and remedies with respect to the replacement or payment of mutilated, destroyed,
lost or stolen Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;2.9. <U>Outstanding Securities</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Securities outstanding at any time are all
the Securities authenticated by the Trustee except for those canceled by it, those delivered to it for cancellation, those reductions
in the interest on a Global Security effected by the Trustee in accordance with the provisions hereof and those described in this Section&nbsp;as
not outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If a Security is replaced pursuant to Section&nbsp;2.8,
it ceases to be outstanding until the Trustee receives proof satisfactory to it that the replaced Security is held by a bona fide purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the Paying Agent (other than the Company, a
Subsidiary of the Company or an Affiliate of the Company) holds on the Maturity of Securities of a Series&nbsp;money sufficient to pay
such Securities payable on that date, then on and after that date such Securities of the Series&nbsp;cease to be outstanding and interest
on them ceases to accrue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company may purchase or otherwise acquire the
Securities, whether by open market purchases, negotiated transactions or otherwise. A Security does not cease to be outstanding because
the Company or an Affiliate of the Company holds the Security (but see Section&nbsp;2.10 below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In determining whether the Holders of the requisite
principal amount of outstanding Securities have given any request, demand, authorization, direction, notice, consent or waiver hereunder,
the principal amount of a Discount Security that shall be deemed to be outstanding for such purposes shall be the amount of the principal
thereof that would be due and payable as of the date of such determination upon a declaration of acceleration of the Maturity thereof
pursuant to Section&nbsp;6.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;2.10. <U>Treasury Securities</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In determining whether the Holders of the required
principal amount of Securities of a Series&nbsp;have concurred in any request, demand, authorization, direction, notice, consent or waiver,
Securities of a Series&nbsp;owned by the Company or any Affiliate of the Company shall be disregarded, except that for the purposes of
determining whether the Trustee shall be protected in relying on any such request, demand, authorization, direction, notice, consent or
waiver only Securities of a Series&nbsp;that a Responsible Officer of the Trustee knows are so owned shall be so disregarded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;2.11. <U>Temporary Securities</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Until definitive Securities are ready for delivery,
the Company may prepare and the Trustee shall authenticate temporary Securities upon a Company Order. Temporary Securities shall be substantially
in the form of definitive Securities but may have variations that the Company considers appropriate for temporary Securities. Without
unreasonable delay, the Company shall prepare and the Trustee upon receipt of a Company Order shall authenticate definitive Securities
of the same Series&nbsp;and date of maturity in exchange for temporary Securities. Until so exchanged, temporary securities shall have
the same rights under this Indenture as the definitive Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;2.12. <U>Cancellation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company at any time may deliver Securities
to the Trustee for cancellation. The Registrar and the Paying Agent shall forward to the Trustee any Securities surrendered to them for
registration of transfer, exchange or payment. The Trustee shall cancel all Securities surrendered for transfer, exchange, payment, replacement
or cancellation and shall destroy such canceled Securities (subject to the record retention requirements of the Exchange Act and the Trustee)
and deliver a certificate of such cancellation to the Company upon written request of the Company. The Company may not issue new Securities
to replace Securities that it has paid or delivered to the Trustee for cancellation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;2.13. <U>Defaulted Interest</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the Company defaults in a payment of interest
on a Series&nbsp;of Securities, it shall pay the defaulted interest, plus, to the extent permitted by law, any interest payable on the
defaulted interest, to the persons who are Holders of the Series&nbsp;on a subsequent special record date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company shall fix the record date and payment
date. At least ten days before the special record date, the Company shall send to the Trustee and to each Holder of the Series&nbsp;a
notice that states the special record date, the payment date and the amount of interest to be paid. The Company may pay defaulted interest
in any other lawful manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;2.14. <U>Global Securities</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">2.14.1. <U>Terms of Securities</U>. A Board Resolution,
a supplemental indenture hereto or an Officer&rsquo;s Certificate shall establish whether the Securities of a Series&nbsp;shall be issued
in whole or in part in the form of one or more Global Securities and the Depositary for such Global Security or Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">2.14.2. <U>Transfer and Exchange</U>. Notwithstanding
any provisions to the contrary contained in Section&nbsp;2.7 of the Indenture and in addition thereto, any Global Security shall be exchangeable
pursuant to Section&nbsp;2.7 of the Indenture for Securities registered in the names of Holders other than the Depositary for such Security
or its nominee only if (i)&nbsp;such Depositary notifies the Company that it is unwilling or unable to continue as Depositary for such
Global Security or if at any time such Depositary ceases to be a clearing agency registered under the Exchange Act, and, in either case,
the Company fails to appoint a successor Depositary registered as a clearing agency under the Exchange Act within 90 days of such event
or (ii)&nbsp;the Company executes and delivers to the Trustee an Officer&rsquo;s Certificate to the effect that such Global Security shall
be so exchangeable. Any Global Security that is exchangeable pursuant to the preceding sentence shall be exchangeable for Securities registered
in such names as the Depositary shall direct in writing in an aggregate principal amount equal to the principal amount of the Global Security
with like tenor and terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Except as provided in this Section&nbsp;2.14.2,
a Global Security may not be transferred except as a whole by the Depositary with respect to such Global Security to a nominee of such
Depositary, by a nominee of such Depositary to such Depositary or another nominee of such Depositary or by the Depositary or any such
nominee to a successor Depositary or a nominee of such a successor Depositary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">None of the Trustee or any Agent shall have any
obligation or duty to monitor, determine or inquire as to compliance with any restrictions on transfer imposed under this Indenture or
under applicable law with respect to any transfer of any interest in any Security (including any transfers between or among Depositary
participants, members or beneficial owners in any Global Security) other than to require delivery of such certificates and other documentation
or evidence as are expressly required by, and to do so if and when expressly required by the terms of, this Indenture, and to examine
the same to determine substantial compliance as to form with the express requirements hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">None of the Trustee or any Agent shall have any
responsibility or obligation to any beneficial owner of a Global Security, a member of, or a participant in the Depositary or other Person
with respect to the accuracy of the records of the Depositary or its nominee or of any participant or member thereof, with respect to
any ownership interest in any Security or with respect to the delivery to any participant, member, beneficial owner or other Person (other
than the Depositary) of any notice (including any notice of optional redemption) or the payment of any amount, under or with respect to
such Security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.14.3. <U>Legends</U>. Any
Global Security issued hereunder shall bear a legend in substantially the following form:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;THIS SECURITY IS A GLOBAL SECURITY WITHIN
THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF THE DEPOSITARY OR A NOMINEE OF THE DEPOSITARY. THIS
SECURITY IS EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE ONLY IN THE LIMITED
CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND MAY&nbsp;NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY,
BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A SUCCESSOR
DEPOSITARY OR A NOMINEE OF SUCH A SUCCESSOR DEPOSITARY.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, so long as the Depository Trust Company
(&ldquo;DTC&rdquo;) is the Depositary, each Global Security registered in the name of DTC or its nominee shall bear a legend in substantially
the following form:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;UNLESS THIS GLOBAL SECURITY IS PRESENTED
BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (&ldquo;DTC&rdquo;), TO THE COMPANY OR ITS AGENT
FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY GLOBAL SECURITY ISSUED IS REGISTERED IN THE NAME OF CEDE&nbsp;&amp; CO. OR
IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE&nbsp;&amp; CO. OR TO SUCH OTHER
ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR
TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE&nbsp;&amp; CO., HAS AN INTEREST HEREIN.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">2.14.4. <U>Acts of Holders</U>. The Depositary, as
a Holder, may appoint agents and otherwise authorize participants to give or take any request, demand, authorization, direction, notice,
consent, waiver or other action which a Holder is entitled to give or take under the Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">2.14.5. <U>Payments</U>. Notwithstanding the other
provisions of this Indenture, unless otherwise specified as contemplated by Section&nbsp;2.2, payment of the principal of and interest,
if any, on any Global Security shall be made to the Holder thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">2.14.6. <U>Agent Members</U>. The registered Holder
of a Security will be treated as the owner of such Security for all purposes and only registered Holders shall have rights under this
Indenture and the Securities. Members of, or participants in, the Depositary (&ldquo;<I>Agent Members</I>&rdquo;) and persons who hold
beneficial interests in a Global Security through an Agent Member shall have no rights under this Indenture with respect to any Global
Security held on their behalf by the Depositary. The Depositary may be treated by the Company, the Trustee, the Paying Agent, the Registrar
and any agent of the foregoing as the absolute owner of the Global Securities for all purposes whatsoever. Notwithstanding the foregoing,
nothing herein shall prevent the Company, the Trustee, the Paying Agent, the Registrar or any agent of the foregoing from giving effect
to any written certification, proxy or other authorization furnished by the Depositary or impair, as between the Depositary and its Agent
Members, the operation of customary practices of such Depositary governing the exercise of the rights of a Holder of a beneficial interest
in any Global Security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;2.15. <U>CUSIP Numbers</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company in issuing the Securities may use &ldquo;CUSIP&rdquo;
numbers (if then generally in use), and, if so, the Trustee shall use &ldquo;CUSIP&rdquo; numbers in notices of redemption as a convenience
to Holders; <U>provided</U> that any such notice may state that no representation is made as to the correctness of such numbers either
as printed on the Securities or as contained in any notice of a redemption and that reliance may be placed only on the other elements
of identification printed on the Securities, and any such redemption shall not be affected by any defect in or omission of such numbers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE&nbsp;III.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">REDEMPTION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;3.1. <U>Notice to Trustee</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company may, with respect to any Series&nbsp;of
Securities, reserve the right to redeem and pay the Series&nbsp;of Securities or may covenant to redeem and pay the Series&nbsp;of Securities
or any part thereof prior to the Stated Maturity thereof at such time and on such terms as provided for in such Securities. If a Series&nbsp;of
Securities is redeemable and the Company wants or is obligated to redeem prior to the Stated Maturity thereof all or part of the Series&nbsp;of
Securities pursuant to the terms of such Securities, it shall notify the Trustee in writing of the redemption date and the principal amount
of the Series&nbsp;of Securities to be redeemed. The Company shall give the notice at least 15 days before the redemption date (or such
shorter period as may be acceptable to the Trustee).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;3.2. <U>Selection of Securities to
be Redeemed</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unless otherwise indicated for a particular Series&nbsp;by
a Board Resolution, a supplemental indenture hereto or an Officer&rsquo;s Certificate, if less than all the Securities of a Series&nbsp;are
to be redeemed, the Securities of the Series&nbsp;to be redeemed will be selected as follows: (a)&nbsp;if the Securities are in the form
of Global Securities, in accordance with the procedures of the Depositary, (b)&nbsp;if the Securities are listed on any national securities
exchange, in compliance with the requirements of the principal national securities exchange, if any, on which the Securities are listed
or (c)&nbsp;if not otherwise provided for under clause (a)&nbsp;or (b)&nbsp;in the manner that the Trustee deems fair and appropriate,
including by lot or other method, unless otherwise required by law or applicable stock exchange requirements, subject, in the case of
Global Securities, to the applicable rules&nbsp;and procedures of the Depositary. The Securities to be redeemed shall be selected from
Securities of the Series&nbsp;outstanding not previously called for redemption. Portions of the principal of Securities of the Series&nbsp;that
have denominations larger than $1,000 may be selected for redemption. Securities of the Series&nbsp;and portions of them it selected for
redemption shall be in amounts of $1,000 or whole multiples of $1,000 or, with respect to Securities of any Series&nbsp;issuable in other
denominations pursuant to Section&nbsp;2.2.10, the minimum principal denomination for each Series&nbsp;and the authorized integral multiples
thereof. Provisions of this Indenture that apply to Securities of a Series&nbsp;called for redemption also apply to portions of Securities
of that Series&nbsp;called for redemption. Neither the Trustee nor the Paying Agent shall be liable for any selection made by it in accordance
with this paragraph (including the procedures of the Depositary).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;3.3. <U>Notice of Redemption</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unless otherwise indicated for a particular Series&nbsp;by
Board Resolution, a supplemental indenture hereto or an Officer&rsquo;s Certificate, at least 15 days but not more than 60 days before
a redemption date, the Company shall send or cause to be sent by first-class mail or electronically, in accordance with the procedures
of the Depositary, a notice of redemption to each Holder whose Securities are to be redeemed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The notice shall identify the Securities of the
Series&nbsp;to be redeemed and shall state:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;the redemption
date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;the redemption
price;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;the name
and address of the Paying Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(d)&nbsp;if any Securities are being
redeemed in part, the portion of the principal amount of such Securities to be redeemed and that, after the redemption date and upon surrender
of such Security, a new Security or Securities in principal amount equal to the unredeemed portion of the original Security shall be issued
in the name of the Holder thereof upon cancellation of the original Security;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)&nbsp;that Securities
of the Series&nbsp;called for redemption must be surrendered to the Paying Agent to collect the redemption price;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(f)&nbsp;that interest on Securities
of the Series&nbsp;called for redemption ceases to accrue on and after the redemption date unless the Company defaults in the deposit
of the redemption price;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g)&nbsp;the &ldquo;CUSIP&rdquo;
number, if any; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h)&nbsp;any other
information as may be required by the terms of the particular Series&nbsp;or the Securities of a Series&nbsp;being redeemed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At the Company&rsquo;s request, the Trustee shall
give the notice of redemption in the Company&rsquo;s name and at its expense, provided, however, that the Company has delivered to the
Trustee, at least 10 days (unless a shorter time shall be acceptable to the Trustee) prior to the notice date, an Officer&rsquo;s Certificate
requesting that the Trustee give such notice and setting forth the information to be stated in such notice and the form of such notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;3.4. <U>Effect of Notice of Redemption</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Once notice of redemption is sent as provided in
Section&nbsp;3.3, Securities of a Series&nbsp;called for redemption become due and payable on the redemption date and at the redemption
price. Except as otherwise provided in the supplemental indenture, Board Resolution or Officer&rsquo;s Certificate for a Series, a notice
of redemption may not be conditional. Upon surrender to the Paying Agent, such Securities shall be paid at the redemption price plus accrued
interest to the redemption date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;3.5. <U>Deposit of Redemption Price</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On or before 11:00 a.m., New York City time, on
the redemption date, the Company shall deposit with the Paying Agent money sufficient to pay the redemption price of and accrued interest,
if any, on all Securities to be redeemed on that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;3.6. <U>Securities Redeemed in Part</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Upon surrender of a Security that is redeemed in
part, the Trustee shall authenticate for the Holder a new Security of the same Series&nbsp;and the same maturity equal in principal amount
to the unredeemed portion of the Security surrendered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE&nbsp;IV.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">COVENANTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;4.1. <U>Payment of Principal and Interest</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company covenants and agrees for the benefit
of the Holders of each Series&nbsp;of Securities that it will duly and punctually pay the principal of and interest, if any, on the Securities
of that Series&nbsp;in accordance with the terms of such Securities and this Indenture. On or before 11:00 a.m., New York City time, on
the applicable payment date, the Company shall deposit with the Paying Agent money sufficient to pay the principal of and interest, if
any, on the Securities of each Series&nbsp;in accordance with the terms of such Securities and this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;4.2. <U>SEC Reports</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To the extent any Securities of a Series&nbsp;are
outstanding, the Company shall deliver to the Trustee within 15 days after it files them with the SEC copies of the annual reports and
of the information, documents, and other reports (or copies of such portions of any of the foregoing as the SEC may by rules&nbsp;and
regulations prescribe) which the Company is required to file with the SEC pursuant to Section&nbsp;13 or 15(d)&nbsp;of the Exchange Act.
The Company also shall comply with the other provisions of TIA &sect; 314(a). Reports, information and documents filed with the SEC via
the EDGAR system will be deemed to be delivered to the Trustee as of the time of such filing via EDGAR for purposes of this Section&nbsp;4.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Delivery of reports, information and documents
to the Trustee under this Section&nbsp;4.2 is for informational purposes only and the Trustee&rsquo;s receipt of the foregoing shall not
constitute constructive or actual notice of any information contained therein or determinable from information contained therein, including
the Company&rsquo;s compliance with any of the covenants hereunder (as to which the Trustee is entitled to rely exclusively on Officer&rsquo;s
Certificates). All such reports, information or documents referred to in this Section&nbsp;4.2 that the Company files with the SEC via
the SEC&rsquo;s EDGAR system shall be deemed to be filed with the Trustee and transmitted to Holders at the time such reports, information
or documents are filed via the EDGAR system (or any successor system).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;4.3. <U>Compliance Certificate</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To the extent any Securities of a Series&nbsp;are
outstanding, the Company shall deliver to the Trustee, within 120 days after the end of each fiscal year of the Company, an Officer&rsquo;s
Certificate stating that a review of the activities of the Company and its Subsidiaries during the preceding fiscal year has been made
under the supervision of the signing Officer with a view to determining whether the Company has kept, observed, performed and fulfilled
its obligations under this Indenture, and further stating, as to such Officer signing such certificate, that to the best of his/her knowledge
the Company has kept, observed, performed and fulfilled each and every covenant contained in this Indenture and is not in default in the
performance or observance of any of the terms, provisions and conditions hereof (or, if a Default or Event of Default shall have occurred,
describing all such Defaults or Events of Default of which the Officer may have knowledge).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;4.4. <U>Stay, Extension and Usury
Laws</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company covenants (to the extent that it may
lawfully do so) that it will not at any time insist upon, plead or in any manner whatsoever claim or take the benefit or advantage of,
any stay, extension or usury law wherever enacted, now or at any time hereafter in force, which may affect the covenants or the performance
of this Indenture or the Securities; and the Company (to the extent it may lawfully do so) hereby expressly waives all benefit or advantage
of any such law and covenants that it will not, by resort to any such law, hinder, delay or impede the execution of any power herein granted
to the Trustee, but will suffer and permit the execution of every such power as though no such law has been enacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE&nbsp;V.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SUCCESSORS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;5.1. <U>When Company May&nbsp;Merge,
Etc</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company shall not consolidate with or merge
with or into, or convey, transfer or lease all or substantially all of its properties and assets to, any person (a &ldquo;<I>successor
person</I>&rdquo;) unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)&nbsp;the Company is the surviving
corporation or the successor person (if other than the Company) is a corporation organized and validly existing under the laws of any
U.S. domestic jurisdiction and expressly assumes by supplemental indenture the Company&rsquo;s obligations on the Securities and under
this Indenture; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)&nbsp;immediately after giving effect
to the transaction, no Default or Event of Default, shall have occurred and be continuing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company shall deliver to the Trustee prior
to the consummation of the proposed transaction an Officer&rsquo;s Certificate to the foregoing effect and an Opinion of Counsel stating
that the proposed transaction and any supplemental indenture comply with this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Notwithstanding the above, any Subsidiary of the
Company may consolidate with, merge into or transfer all or part of its properties to the Company. Neither an Officer&rsquo;s Certificate
nor an Opinion of Counsel shall be required to be delivered in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;5.2. <U>Successor Corporation Substituted</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Upon any consolidation or merger, or any sale,
lease, conveyance or other disposition of all or substantially all of the assets of the Company in accordance with Section&nbsp;5.1, the
successor corporation formed by such consolidation or into or with which the Company is merged or to which such sale, lease, conveyance
or other disposition is made shall succeed to, and be substituted for, and may exercise every right and power of, the Company under this
Indenture with the same effect as if such successor person has been named as the Company herein; <U>provided</U>, <U>however</U>, that
the predecessor Company in the case of a sale, conveyance or other disposition (other than a lease) shall be released from all obligations
and covenants under this Indenture and the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE&nbsp;VI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">DEFAULTS AND REMEDIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;6.1. <U>Events of Default</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<I>Event of Default</I>,&rdquo; wherever
used herein with respect to Securities of any Series, means any one of the following events, unless in the establishing Board Resolution,
supplemental indenture or Officer&rsquo;s Certificate it is provided that such Series&nbsp;shall not have the benefit of said Event of
Default:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)&nbsp;default in the payment of any
interest on any Security of that Series&nbsp;when it becomes due and payable, and continuance of such default for a period of 30 days
(unless the entire amount of such payment is deposited by the Company with the Trustee or with a Paying Agent prior to 11:00 a.m., New
York City time, on the 30th day of such period);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;default
in the payment of principal of any Security of that Series&nbsp;at its Maturity;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)&nbsp;default in the performance or
breach of any covenant or warranty of the Company in this Indenture (other than defaults pursuant to paragraph (a)&nbsp;or (b)&nbsp;above
or pursuant to a covenant or warranty that has been included in this Indenture solely for the benefit of a Series&nbsp;of Securities other
than that Series), which default continues uncured for a period of 60 days after there has been given, by registered or certified mail,
to the Company by the Trustee or to the Company and the Trustee by the Holders of at least 25% in principal amount of the outstanding
Securities of that Series&nbsp;a written notice specifying such default or breach and requiring it to be remedied and stating that such
notice is a &ldquo;Notice of Default&rdquo; hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)&nbsp;the Company
pursuant to or within the meaning of any Bankruptcy Law:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)&nbsp;commences
a voluntary case,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;consents
to the entry of an order for relief against it in an involuntary case,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)&nbsp;consents
to the appointment of a Custodian of it or for all or substantially all of its property,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iv)&nbsp;makes a
general assignment for the benefit of its creditors, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(v)&nbsp;generally
is unable to pay its debts as the same become due;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)&nbsp;a court
of competent jurisdiction enters an order or decree under any Bankruptcy Law that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)&nbsp;is for relief
against the Company in an involuntary case,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;appoints
a Custodian of the Company or for all or substantially all of its property, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)&nbsp;orders
the liquidation of the Company,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">and the order or decree remains
unstayed and in effect for 60 days; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(f)&nbsp;any other Event of Default provided
with respect to Securities of that Series, which is specified in a Board Resolution, a supplemental indenture hereto or an Officer&rsquo;s
Certificate, in accordance with Section&nbsp;2.2.18.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The term &ldquo;<I>Bankruptcy Law</I>&rdquo; means
title 11, U.S. Code or any similar Federal or State law for the relief of debtors. The term &ldquo;<I>Custodian</I>&rdquo; means any receiver,
trustee, assignee, liquidator or similar official under any Bankruptcy Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company will provide the Trustee written notice
of any Default or Event of Default within 30 days of becoming aware of the occurrence of such Default or Event of Default, which notice
will describe in reasonable detail the status of such Default or Event of Default and what action the Company is taking or proposes to
take in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;6.2. <U>Acceleration of Maturity;
Rescission and Annulment</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If an Event of Default with respect to Securities
of any Series&nbsp;at the time outstanding occurs and is continuing (other than an Event of Default referred to in Section&nbsp;6.1(d)&nbsp;or
(e)) then in every such case the Trustee or the Holders of not less than 25% in principal amount of the outstanding Securities of that
Series&nbsp;may declare the principal amount (or, if any Securities of that Series&nbsp;are Discount Securities, such portion of the principal
amount as may be specified in the terms of such Securities) of and accrued and unpaid interest, if any, on all of the Securities of that
Series&nbsp;to be due and payable immediately, by a notice in writing to the Company (and to the Trustee if given by Holders), and upon
any such declaration such principal amount (or specified amount) and accrued and unpaid interest, if any, shall become immediately due
and payable. If an Event of Default specified in Section&nbsp;6.1(d)&nbsp;or (e)&nbsp;shall occur, the principal amount (or specified
amount) of and accrued and unpaid interest, if any, on all outstanding Securities shall <I>ipso facto</I> become and be immediately due
and payable without any declaration or other act on the part of the Trustee or any Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At any time after such a declaration of acceleration
with respect to any Series&nbsp;has been made and before a judgment or decree for payment of the money due has been obtained by the Trustee
as hereinafter in this Article&nbsp;provided, the Holders of a majority in principal amount of the outstanding Securities of that Series,
by written notice to the Company and the Trustee, may rescind and annul such declaration and its consequences if all Events of Default
with respect to Securities of that Series, other than the non-payment of the principal and interest, if any, of Securities of that Series&nbsp;which
have become due solely by such declaration of acceleration, have been cured or waived as provided in Section&nbsp;6.13.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No such rescission shall affect any subsequent
Default or impair any right consequent thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;6.3. <U>Collection of Indebtedness
and Suits for Enforcement by Trustee</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company covenants that if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)&nbsp;default is made in the payment
of any interest on any Security when such interest becomes due and payable and such default continues for a period of 30 days,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;default
is made in the payment of principal of any Security at the Maturity thereof, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)&nbsp;default is made in the deposit
of any sinking fund payment, if any, when and as due by the terms of a Security,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><I>then,</I></FONT> the Company will,
upon demand of the Trustee, pay to it, for the benefit of the Holders of such Securities, the whole amount then due and payable on such
Securities for principal and interest and, to the extent that payment of such interest shall be legally enforceable, interest on any overdue
principal and any overdue interest at the rate or rates prescribed therefor in such Securities, and, in addition thereto, such further
amount as shall be sufficient to cover the costs and expenses of collection, including the compensation, reasonable expenses, disbursements
and advances of the Trustee, its agents and counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the Company fails to pay such amounts forthwith
upon such demand, the Trustee, in its own name and as trustee of an express trust, may institute a judicial proceeding for the collection
of the sums so due and unpaid, may prosecute such proceeding to judgment or final decree and may enforce the same against the Company
or any other obligor upon such Securities and collect the moneys adjudged or deemed to be payable in the manner provided by law out of
the property of the Company or any other obligor upon such Securities, wherever situated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If an Event of Default with respect to any Securities
of any Series&nbsp;occurs and is continuing, the Trustee, subject to Article&nbsp;VII hereof, may in its discretion proceed to protect
and enforce its rights and the rights of the Holders of Securities of such Series&nbsp;by such appropriate judicial proceedings as the
Trustee shall deem most effectual to protect and enforce any such rights, whether for the specific enforcement of any covenant or agreement
in this Indenture or in aid of the exercise of any power granted herein, or to enforce any other proper remedy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;6.4. <U>Trustee May&nbsp;File Proofs
of Claim</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In case of the pendency of any receivership, insolvency,
liquidation, bankruptcy, reorganization, arrangement, adjustment, composition or other judicial proceeding relative to the Company or
any other obligor upon the Securities or the property of the Company or of such other obligor or their creditors, the Trustee (irrespective
of whether the principal of the Securities shall then be due and payable as therein expressed or by declaration or otherwise and irrespective
of whether the Trustee shall have made any demand on the Company for the payment of overdue principal or interest) shall be entitled and
empowered, by intervention in such proceeding or otherwise,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)&nbsp;to file and prove a claim for
the whole amount of principal and interest owing and unpaid in respect of the Securities and to file such other papers or documents as
may be necessary or advisable in order to have the claims of the Trustee (including any claim for the compensation, reasonable expenses,
disbursements and advances of the Trustee, its agents and counsel) and of the Holders allowed in such judicial proceeding, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)&nbsp;to collect and receive any moneys
or other property payable or deliverable on any such claims and to distribute the same, and any custodian, receiver, assignee, trustee,
liquidator, sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Holder to make such payments
to the Trustee and, in the event that the Trustee shall consent to the making of such payments directly to the Holders, to pay to the
Trustee any amount due it for the compensation, reasonable expenses, disbursements and advances of the Trustee, its agents and counsel
and any other amounts due the Trustee under Section&nbsp;7.7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Nothing herein contained shall be deemed to authorize
the Trustee to authorize or consent to or accept or adopt on behalf of any Holder any plan of reorganization, arrangement, adjustment
or composition affecting the Securities or the rights of any Holder thereof or to authorize the Trustee to vote in respect of the claim
of any Holder in any such proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;6.5. <U>Trustee May&nbsp;Enforce Claims
Without Possession of Securities</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All rights of action and claims under this Indenture
or the Securities may be prosecuted and enforced by the Trustee without the possession of any of the Securities or the production thereof
in any proceeding relating thereto, and any such proceeding instituted by the Trustee shall be brought in its own name as trustee of an
express trust, and any recovery of judgment shall, after provision for the payment of the compensation, reasonable expenses, disbursements
and advances of the Trustee, its agents and counsel, be for the ratable benefit of the Holders of the Securities in respect of which such
judgment has been recovered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;6.6. <U>Application of Money Collected</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any money or property collected by the Trustee
pursuant to this Article&nbsp;shall be applied in the following order, at the date or dates fixed by the Trustee and, in case of the distribution
of such money or property on account of principal or interest, upon presentation of the Securities and the notation thereon of the payment
if only partially paid and upon surrender thereof if fully paid:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">First: To the payment of all amounts due to the
Trustee under Section&nbsp;7.7; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Second: To the payment of the amounts then due
and unpaid for principal of and interest on the Securities in respect of which or for the benefit of which such money has been collected,
ratably, without preference or priority of any kind, according to the amounts due and payable on such Securities for principal and interest,
respectively; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Third: To the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;6.7. <U>Limitation on Suits</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No Holder of any Security of any Series&nbsp;shall
have any right to institute any proceeding, judicial or otherwise, with respect to this Indenture, or for the appointment of a receiver
or trustee, or for any other remedy hereunder, unless</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)&nbsp;such Holder has previously given
written notice to the Trustee of a continuing Event of Default with respect to the Securities of that Series;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)&nbsp;the Holders of not less than
25% in principal amount of the outstanding Securities of that Series&nbsp;shall have made written request to the Trustee to institute
proceedings in respect of such Event of Default in its own name as Trustee hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)&nbsp;such Holder or Holders have
offered to the Trustee indemnity or security satisfactory to the Trustee against the costs, expenses and liabilities which might be incurred
by the Trustee in compliance with such request;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(d)&nbsp;the Trustee for 60 days after
its receipt of such notice, request and offer of indemnity has failed to institute any such proceeding; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(e)&nbsp;no direction inconsistent with
such written request has been given to the Trustee during such 60-day period by the Holders of a majority in principal amount of the outstanding
Securities of that Series;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">it being understood, intended and expressly covenanted by the Holder
of every Security with every other Holder and the Trustee that no one or more of such Holders shall have any right in any manner whatever
by virtue of, or by availing of, any provision of this Indenture to affect, disturb or prejudice the rights of any other of such Holders,
or to obtain or to seek to obtain priority or preference over any other of such Holders or to enforce any right under this Indenture,
except in the manner herein provided and for the equal and ratable benefit of all such Holders of the applicable Series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;6.8. <U>Unconditional Right of Holders
to Receive Principal and Interest</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Notwithstanding any other provision in this Indenture,
the Holder of any Security shall have the right, which is absolute and unconditional, to receive payment of the principal of and interest,
if any, on such Security on the Maturity of such Security, including the Stated Maturity expressed in such Security (or, in the case of
redemption, on the redemption date) and to institute suit for the enforcement of any such payment, and such rights shall not be impaired
without the consent of such Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;6.9. <U>Restoration of Rights and
Remedies</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the Trustee or any Holder has instituted any
proceeding to enforce any right or remedy under this Indenture and such proceeding has been discontinued or abandoned for any reason or
has been determined adversely to the Trustee or to such Holder, then and in every such case, subject to any determination in such proceeding,
the Company, the Trustee and the Holders shall be restored severally and respectively to their former positions hereunder and thereafter
all rights and remedies of the Trustee and the Holders shall continue as though no such proceeding had been instituted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;6.10. <U>Rights and Remedies Cumulative</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Except as otherwise provided with respect to the
replacement or payment of mutilated, destroyed, lost or stolen Securities in Section&nbsp;2.8, no right or remedy herein conferred upon
or reserved to the Trustee or to the Holders is intended to be exclusive of any other right or remedy, and every right and remedy shall,
to the extent permitted by law, be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing
at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not, to the extent
permitted by law, prevent the concurrent assertion or employment of any other appropriate right or remedy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;6.11. <U>Delay or Omission Not Waiver</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No delay or omission of the Trustee or of any Holder
of any Securities to exercise any right or remedy accruing upon any Event of Default shall impair any such right or remedy or constitute
a waiver of any such Event of Default or an acquiescence therein. Every right and remedy given by this Article&nbsp;or by law to the Trustee
or to the Holders may be exercised from time to time, and as often as may be deemed expedient, by the Trustee or by the Holders, as the
case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;6.12. <U>Control by Holders</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Holders of a majority in principal amount of
the outstanding Securities of any Series&nbsp;shall have the right to direct the time, method and place of conducting any proceeding for
any remedy available to the Trustee, or exercising any trust or power conferred on the Trustee, with respect to the Securities of such
Series, provided that</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;such direction
shall not be in conflict with any rule&nbsp;of law or with this Indenture,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;the Trustee
may take any other action deemed proper by the Trustee which is not inconsistent with such direction,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;subject
to the provisions of Section&nbsp;7.1, the Trustee shall have the right to decline to follow any such direction if the Trustee in good
faith shall, by a Responsible Officer of the Trustee, determine that the proceeding so directed would involve the Trustee in personal
liability, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)&nbsp;prior to
taking any action as directed under this Section&nbsp;6.12, the Trustee shall be entitled to indemnity satisfactory to it against the
costs, expenses and liabilities which might be incurred by it in compliance with such request or direction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;6.13. <U>Waiver of Past Defaults</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Holders of not less than a majority in principal
amount of the outstanding Securities of any Series&nbsp;may on behalf of the Holders of all the Securities of such Series, by written
notice to the Trustee and the Company, waive any past Default hereunder with respect to such Series&nbsp;and its consequences, except
a Default in the payment of the principal of or interest on any Security of such Series&nbsp;(provided, however, that the Holders of a
majority in principal amount of the outstanding Securities of any Series&nbsp;may rescind an acceleration and its consequences, including
any related payment default that resulted from such acceleration). Upon any such waiver, such Default shall cease to exist, and any Event
of Default arising therefrom shall be deemed to have been cured, for every purpose of this Indenture; but no such waiver shall extend
to any subsequent or other Default or impair any right consequent thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;6.14. <U>Undertaking for Costs</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All parties to this Indenture agree, and each Holder
of any Security by his, her or its acceptance thereof shall be deemed to have agreed, that any court may in its discretion require, in
any suit for the enforcement of any right or remedy under this Indenture, or in any suit against the Trustee for any action taken, suffered
or omitted by it as Trustee, the filing by any party litigant in such suit of an undertaking to pay the costs of such suit, and that such
court may in its discretion assess reasonable costs, including reasonable attorneys&rsquo; fees, against any party litigant in such suit,
having due regard to the merits and good faith of the claims or defenses made by such party litigant; but the provisions of this Section&nbsp;shall
not apply to any suit instituted by the Company, to any suit instituted by the Trustee, to any suit instituted by any Holder or group
of Holders, holding in the aggregate more than 10% in principal amount of the outstanding Securities of any Series, or to any suit instituted
by any Holder for the enforcement of the payment of the principal of or interest on any Security on or after the Maturity of such Security,
including the Stated Maturity expressed in such Security (or, in the case of redemption, on the redemption date).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE&nbsp;VII.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TRUSTEE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;7.1. <U>Duties of Trustee</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)&nbsp;If an Event of Default has occurred
and is continuing, the Trustee shall exercise the rights and powers vested in it by this Indenture and use the same degree of care and
skill in their exercise as a prudent person would exercise or use under the circumstances in the conduct of such person&rsquo;s own affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;Except
during the continuance of an Event of Default:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">(i)&nbsp;The Trustee need perform only
those duties that are specifically set forth in this Indenture and no others, and no implied covenants or obligations will be read into
this Indenture against the Trustee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">(ii)&nbsp;In the absence of bad faith on
its part, the Trustee may conclusively rely, as to the truth of the statements and the correctness of the opinions expressed therein,
upon Officer&rsquo;s Certificates or Opinions of Counsel furnished to the Trustee and conforming to the requirements of this Indenture;
<U>however</U>, in the case of any such Officer&rsquo;s Certificates or Opinions of Counsel which by any provisions hereof are specifically
required to be furnished to the Trustee, the Trustee shall examine such Officer&rsquo;s Certificates and Opinions of Counsel to determine
whether or not they conform to the form requirements of this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)&nbsp;The Trustee may not be relieved
from liability for its own negligent action, its own negligent failure to act or its own willful misconduct, except that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">(i)&nbsp;This paragraph does not limit
the effect of paragraph (b)&nbsp;of this Section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">(ii)&nbsp;The Trustee shall not be liable
for any error of judgment made in good faith by a Responsible Officer, unless it is proved that the Trustee was negligent in ascertaining
the pertinent facts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">(iii)&nbsp;The Trustee shall not be liable
with respect to any action taken, suffered or omitted to be taken by it with respect to Securities of any Series&nbsp;in good faith in
accordance with the direction of the Holders of a majority in principal amount of the outstanding Securities of such Series&nbsp;relating
to the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred
upon the Trustee, under this Indenture with respect to the Securities of such Series&nbsp;in accordance with Section&nbsp;6.12.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(d)&nbsp;Every provision of this Indenture that in any way
relates to the Trustee is subject to paragraph (a), (b)&nbsp;and (c)&nbsp;of this Section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(e)&nbsp;The Trustee may refuse to perform
any duty or exercise any right or power unless it receives indemnity satisfactory to it against the costs, expenses and liabilities which
might be incurred by it in performing such duty or exercising such right or power.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(f)&nbsp;The Trustee shall not be liable
for interest on any money received by it except as the Trustee may agree in writing with the Company. Money held in trust by the Trustee
need not be segregated from other funds except to the extent required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(g)&nbsp;No provision of this Indenture
shall require the Trustee to risk its own funds or otherwise incur any financial liability in the performance of any of its duties or
in the exercise of any of its rights or powers, if adequate indemnity against such risk is not assured to the Trustee in its satisfaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(h)&nbsp;The Paying Agent, the Notice
Agent, the Registrar, any authenticating agent and the Trustee when acting in any other capacity hereunder shall be entitled to the protections
and immunities as are set forth in this Article&nbsp;VII.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(i)&nbsp;The rights, privileges, protections,
immunities and benefits given to the Trustee, including its right to be indemnified, are extended to, and will be enforceable by, the
Trustee in each of its capacities under this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;7.2. <U>Rights of Trustee</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)&nbsp;The Trustee may rely on and
shall be protected in acting or refraining from acting upon any document (whether in its original or facsimile form) believed by it to
be genuine and to have been signed or presented by the proper person. The Trustee need not investigate any fact or matter stated in the
document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)&nbsp;Before the Trustee acts or refrains
from acting, it may require an Officer&rsquo;s Certificate or an Opinion of Counsel or both. The Trustee shall not be liable for any action
it takes or omits to take in good faith in reliance on such Officer&rsquo;s Certificate or Opinion of Counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)&nbsp;The Trustee may act through
agents and shall not be responsible for the misconduct or negligence of any agent appointed with due care. No Depositary shall be deemed
an agent of the Trustee, and the Trustee shall not be responsible for any act or omission by any Depositary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(d)&nbsp;The Trustee shall not be liable
for any action it takes or omits to take in good faith which it believes to be authorized or within its rights or powers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(e)&nbsp;The Trustee may consult with
counsel and the advice of such counsel or any Opinion of Counsel shall be full and complete authorization and protection in respect of
any action taken, suffered or omitted by it hereunder in good faith and in reliance thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(f)&nbsp;The Trustee shall be under no
obligation to exercise any of the rights or powers vested in it by this Indenture at the request or direction of any of the Holders of
Securities unless such Holders shall have offered to the Trustee security or indemnity satisfactory to it against the costs, expenses
and liabilities which might be incurred by it in compliance with such request or direction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(g)&nbsp;The Trustee shall not be bound
to make any investigation into the facts or matters stated in any resolution, certificate, statement, instrument, opinion, report, notice,
request, direction, consent, order, bond, debenture, note, other evidence of indebtedness or other paper or document, but the Trustee,
in its discretion, may make such further inquiry or investigation into such facts or matters as it may see fit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(h)&nbsp;The Trustee shall not be deemed
to have notice of any Default or Event of Default unless a Responsible Officer of the Trustee has actual knowledge thereof or unless written
notice of any event which is in fact such a default is received by a Responsible Officer at the Corporate Trust Office of the Trustee,
and such notice references the Securities generally or the Securities of a particular Series&nbsp;and this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(i)&nbsp;In no event shall the Trustee
be liable to any person for special, punitive, indirect, consequential or incidental loss or damage of any kind whatsoever (including
but not limited to lost profits), even if the Trustee has been advised of the likelihood of such loss or damage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(j)&nbsp;The permissive right of the
Trustee to take the actions permitted by this Indenture shall not be construed as an obligation or duty to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(k)&nbsp;The Trustee will not be required
to give any bond or surety in respect of the execution of this Indenture or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;7.3. <U>Individual Rights of Trustee</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Trustee in its individual or any other capacity
may become the owner or pledgee of Securities and may otherwise deal with the Company or an Affiliate of the Company with the same rights
it would have if it were not Trustee. Any Agent may do the same with like rights. The Trustee is also subject to Sections 7.10 and 7.11.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;7.4. <U>Trustee&rsquo;s Disclaimer</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Trustee makes no representation as to the validity
or adequacy of this Indenture or the Securities. The Trustee shall not be accountable for the Company&rsquo;s use of the proceeds from
the Securities and shall not be responsible for any statement in the Securities other than its certificate of authentication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;7.5. <U>Notice of Defaults</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If a Default or Event of Default occurs and is
continuing with respect to the Securities of any Series&nbsp;and if it is known to a Responsible Officer of the Trustee, the Trustee shall
send to each Holder of the Securities of that Series&nbsp;notice of a Default or Event of Default within 90 days after it occurs or, if
later, after a Responsible Officer of the Trustee has knowledge of such Default or Event of Default. Except in the case of a Default or
Event of Default in payment of principal of or interest on any Security of any Series, the Trustee may withhold the notice if and so long
as its corporate trust committee or a committee of its Responsible Officers in good faith determines that withholding the notice is in
the interests of Holders of that Series. The Trustee will not be deemed to have notice or be charged with knowledge of any Default or
Event of Default unless written notice thereof has been received by a Responsible Officer, and such notice references the applicable Series&nbsp;of
Securities and this Indenture and states on its face that a Default or Event of Default has occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;7.6. <U>Reports by Trustee to Holders</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Within 60 days after each [[&#9679;] commencing
[&#9679;], [&#9679;]], the Trustee shall transmit by mail to all Holders, as their names and addresses appear on the register kept by
the Registrar, a brief report dated as of such anniversary date, in accordance with, and to the extent required under, TIA &sect; 313.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A copy of each report at the time of its mailing
to Holders of any Series&nbsp;shall be filed with the SEC and each national securities exchange on which the Securities of that Series&nbsp;are
listed. The Company shall promptly notify the Trustee in writing when Securities of any Series&nbsp;are listed on any national securities
exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;7.7. <U>Compensation and Indemnity</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company shall pay to the Trustee from time
to time compensation for its services as the Company and the Trustee shall from time to time agree upon in writing. The Trustee&rsquo;s
compensation shall not be limited by any law on compensation of a trustee of an express trust. The Company shall reimburse the Trustee
upon request for all reasonable out-of-pocket expenses incurred by it. Such expenses shall include the reasonable compensation and expenses
of the Trustee&rsquo;s agents and counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company shall indemnify each of the Trustee
and any predecessor Trustee (including for the cost of defending itself) against any cost, expense or liability, including taxes (other
than taxes based upon, measured by or determined by the income of the Trustee) incurred by it except as set forth in the next paragraph
in the performance of its duties under this Indenture as Trustee or Agent. The Trustee shall notify the Company promptly of any claim
for which it may seek indemnity. Failure by the Trustee to so notify the Company shall not relieve the Company of its obligations hereunder,
unless and to the extent that the Company is materially prejudiced thereby. The Company shall defend the claim and the Trustee shall cooperate
in the defense. The Trustee may have separate counsel, and the Company shall pay the reasonable fees and expenses of such counsel. The
Company need not pay for any settlement made without its consent, which consent will not be unreasonably withheld. This indemnification
shall apply to officers, directors, employees, shareholders and agents of the Trustee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company need not reimburse any expense or indemnify
against any loss or liability incurred by the Trustee or by any officer, director, employee, shareholder or agent of the Trustee through
willful misconduct or negligence, as determined by a final decision of a court of competent jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To secure the Company&rsquo;s payment obligations
in this Section, the Trustee shall have a lien prior to the Securities of any Series&nbsp;on all money or property held or collected by
the Trustee, except that held in trust to pay principal of and interest on particular Securities of that Series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">When the Trustee incurs expenses or renders services
after an Event of Default specified in Section&nbsp;6.1(d)&nbsp;or (e)&nbsp;occurs, the expenses and the compensation for the services
are intended to constitute expenses of administration under any Bankruptcy Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The provisions of this Section&nbsp;shall survive
the termination of this Indenture and the resignation or removal of the Trustee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;7.8. <U>Replacement of Trustee</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A resignation or removal of the Trustee and appointment
of a successor Trustee shall become effective only upon the successor Trustee&rsquo;s acceptance of appointment as provided in this Section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Trustee may resign with respect to the Securities
of one or more Series&nbsp;by so notifying the Company at least 30 days prior to the date of the proposed resignation. The Holders of
a majority in principal amount of the Securities of any Series&nbsp;may remove the Trustee with respect to that Series&nbsp;by so notifying
the Trustee and the Company. The Company may remove the Trustee with respect to Securities of one or more Series&nbsp;if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;the Trustee
fails to comply with Section&nbsp;7.10;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)&nbsp;the Trustee is adjudged a bankrupt
or an insolvent or an order for relief is entered with respect to the Trustee under any Bankruptcy Law;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;a Custodian
or public officer takes charge of the Trustee or its property; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)&nbsp;the Trustee
becomes incapable of acting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the Trustee resigns or is removed or if a vacancy
exists in the office of Trustee for any reason, the Company shall promptly appoint a successor Trustee. Within one year after the successor
Trustee takes office, the Holders of a majority in principal amount of the then outstanding Securities may appoint a successor Trustee
to replace the successor Trustee appointed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If a successor Trustee with respect to the Securities
of any one or more Series&nbsp;does not take office within 60 days after the retiring Trustee resigns or is removed, the retiring Trustee,
the Company or the Holders of at least a majority in principal amount of the Securities of the applicable Series&nbsp;may petition any
court of competent jurisdiction for the appointment of a successor Trustee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A successor Trustee shall deliver a written acceptance
of its appointment to the retiring Trustee and to the Company. Immediately after that, the retiring Trustee shall transfer all property
held by it as Trustee to the successor Trustee subject to the lien provided for in Section&nbsp;7.7, the resignation or removal of the
retiring Trustee shall become effective, and the successor Trustee shall have all the rights, powers and duties of the Trustee with respect
to each Series&nbsp;of Securities for which it is acting as Trustee under this Indenture. A successor Trustee shall send a notice of its
succession to each Holder of each such Series. Notwithstanding replacement of the Trustee pursuant to this Section&nbsp;7.8, the Company&rsquo;s
obligations under Section&nbsp;7.7 hereof shall continue for the benefit of the retiring Trustee with respect to expenses and liabilities
incurred by it for actions taken or omitted to be taken in accordance with its rights, powers and duties under this Indenture prior to
such replacement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;7.9. <U>Successor Trustee by Merger,
Etc</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any organization or entity into which the Trustee
may be merged or converted or with which it may be consolidated, or any organization or entity resulting from any merger, conversion or
consolidation to which the Trustee shall be a party, or any organization or entity succeeding to all or substantially all of the corporate
trust business of the Trustee, shall be the successor of the Trustee hereunder, provided such organization or entity shall be otherwise
qualified and eligible under Section&nbsp;7.10, without the execution or filing of any paper or any further act on the part of any of
the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;7.10. <U>Eligibility; Disqualification</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Indenture shall always have a Trustee who
satisfies the requirements of TIA &sect; 310(a)(1), (2)&nbsp;and (5). The Trustee shall always have a combined capital and surplus of
at least $25,000,000 as set forth in its most recent published annual report of condition. The Trustee shall comply with TIA &sect; 310(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;7.11. <U>Preferential Collection of
Claims Against Company</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Trustee is subject to TIA &sect; 311(a), excluding
any creditor relationship listed in TIA &sect; 311(b). A Trustee who has resigned or been removed shall be subject to TIA &sect; 311(a)&nbsp;to
the extent indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE&nbsp;VIII.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SATISFACTION AND DISCHARGE; DEFEASANCE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;8.1. <U>Satisfaction and Discharge
of Indenture</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Indenture shall upon Company Order be discharged
with respect to the Securities of any Series&nbsp;and cease to be of further effect as to all Securities of such Series&nbsp;(except as
hereinafter provided in this Section&nbsp;8.1), and the Trustee, at the expense of the Company, shall execute instruments acknowledging
satisfaction and discharge of this Indenture, when</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;either</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">(i)&nbsp;all Securities of such Series&nbsp;theretofore
authenticated and delivered (other than Securities that have been destroyed, lost or stolen and that have been replaced or paid) have
been delivered to the Trustee for cancellation; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">(ii)&nbsp;all such Securities of such Series&nbsp;not
theretofore delivered to the Trustee for cancellation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">(1)&nbsp;have become
due and payable by reason of sending a notice of redemption or otherwise,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">(2)&nbsp;will become
due and payable at their Stated Maturity within one year,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0.5in">(3)&nbsp;have been called for redemption
or are to be called for redemption within one year under arrangements satisfactory to the Trustee for the giving of notice of redemption
by the Trustee in the name, and at the expense, of the Company, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">(4)&nbsp;are deemed
paid and discharged pursuant to Section&nbsp;8.3, as applicable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">and the Company, in the case of (1), (2)&nbsp;or
(3)&nbsp;above, has irrevocably deposited or caused to be deposited with the Trustee as trust funds in trust an amount of money or U.S.
Government Obligations, which amount shall be sufficient for the purpose of paying and discharging each installment of principal (including
mandatory sinking fund payments or analogous payments) of and interest on all the Securities of such Series&nbsp;on the dates such installments
of principal or interest are due;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;the Company
has paid or caused to be paid all other sums payable hereunder by the Company; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)&nbsp;the Company has delivered to
the Trustee an Officer&rsquo;s Certificate and an Opinion of Counsel, each stating that all conditions precedent provided for relating
to the satisfaction and discharge contemplated by this Section&nbsp;have been complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Notwithstanding the satisfaction and discharge
of this Indenture, (x)&nbsp;the obligations of the Company to the Trustee under Section&nbsp;7.7, (y)&nbsp;if money shall have been deposited
with the Trustee pursuant to clause (a)&nbsp;of this Section, the provisions of Sections 2.4, 2.7, 2.8, 8.2 and 8.5, and (z)&nbsp;the
rights, powers, trusts and immunities of the Trustee hereunder and the Company&rsquo;s obligations in connection therewith shall survive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;8.2. <U>Application of Trust Funds;
Indemnification</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)&nbsp;Subject to the provisions of
Section&nbsp;8.5, all money and U.S. Government Obligations or Foreign Government Obligations deposited with the Trustee pursuant to Section&nbsp;8.1,
8.3 or 8.4 and all money received by the Trustee in respect of U.S. Government Obligations or Foreign Government Obligations deposited
with the Trustee pursuant to Section&nbsp;8.1, 8.3 or 8.4, shall be held in trust and applied by it, in accordance with the provisions
of the Securities and this Indenture, to the payment, either directly or through any Paying Agent (including the Company acting as its
own Paying Agent) as the Trustee may determine, to the persons entitled thereto, of the principal and interest for whose payment such
money has been deposited with or received by the Trustee or to make mandatory sinking fund payments or analogous payments as contemplated
by Sections 8.1, 8.3 or 8.4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)&nbsp;The Company shall pay and shall
indemnify the Trustee (which indemnity shall survive termination of this Indenture) against any tax, fee or other charge imposed on or
assessed against U.S. Government Obligations or Foreign Government Obligations deposited pursuant to Sections 8.1, 8.3 or 8.4 or the interest
and principal received in respect of such obligations other than any payable by or on behalf of Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)&nbsp;The Trustee shall deliver or
pay to the Company from time to time upon Company Order any U.S. Government Obligations or Foreign Government Obligations or money held
by it as provided in Sections 8.3 or 8.4 which, in the opinion of a nationally recognized firm of independent certified public accountants
or investment bank expressed in a written certification thereof delivered to the Trustee, are then in excess of the amount thereof which
then would have been required to be deposited for the purpose for which such U.S. Government Obligations or Foreign Government Obligations
or money were deposited or received. This provision shall not authorize the sale by the Trustee of any U.S. Government Obligations or
Foreign Government Obligations held under this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;8.3. <U>Legal Defeasance of Securities
of any Series</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unless this Section&nbsp;8.3 is otherwise specified,
pursuant to Section&nbsp;2.2, to be inapplicable to Securities of any Series, the Company shall be deemed to have paid and discharged
the entire indebtedness on all the outstanding Securities of any Series&nbsp;on the 91st day after the date of the deposit referred to
in subparagraph (d)&nbsp;hereof, and the provisions of this Indenture, as it relates to such outstanding Securities of such Series, shall
no longer be in effect (and the Trustee, at the expense of the Company, shall, upon receipt of a Company Order, execute instruments acknowledging
the same), except as to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)&nbsp;the rights of Holders of Securities
of such Series&nbsp;to receive, from the trust funds described in subparagraph (d)&nbsp;hereof, (i)&nbsp;payment of the principal of and
each installment of principal of and interest on the outstanding Securities of such Series&nbsp;on the Maturity of such principal or installment
of principal or interest and (ii)&nbsp;the benefit of any mandatory sinking fund payments applicable to the Securities of such Series&nbsp;on
the day on which such payments are due and payable in accordance with the terms of this Indenture and the Securities of such Series;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)&nbsp;the provisions of Sections 2.4,
2.5, 2.7, 2.8, 7.7, 8.2, 8.3, 8.5 and 8.6; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)&nbsp;the rights, powers, trusts and
immunities of the Trustee hereunder and the Company&rsquo;s obligations in connection therewith;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">provided that, the following conditions shall have been satisfied:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(d)&nbsp;the Company shall have irrevocably
deposited or caused to be deposited (except as provided in Section&nbsp;8.2(c)) with the Trustee as trust funds specifically pledged as
security for and dedicated solely to the benefit of the Holders of such Securities (i)&nbsp;in the case of Securities of such Series&nbsp;denominated
in Dollars, cash in Dollars and/or U.S. Government Obligations or (ii)&nbsp;in the case of Securities of such Series&nbsp;denominated
in a Foreign Currency (other than a composite currency), money and/or Foreign Government Obligations, which through the payment of interest
and principal in respect thereof in accordance with their terms, will provide (and without reinvestment and assuming no tax liability
will be imposed on such Trustee), not later than one day before the due date of any payment of money, an amount in cash, sufficient, in
the opinion of a nationally recognized firm of independent public accountants or investment bank expressed in a written certification
thereof delivered to the Trustee, to pay and discharge each installment of principal of and interest, on and any mandatory sinking fund
payments in respect of all the Securities of such Series&nbsp;on the dates such installments of principal or interest and such sinking
fund payments are due;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(e)&nbsp;such deposit will not result
in a breach or violation of, or constitute a default under, this Indenture or any other agreement or instrument to which the Company is
a party or by which it is bound;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(f)&nbsp;no Default or Event of Default
with respect to the Securities of such Series&nbsp;shall have occurred and be continuing on the date of such deposit or during the period
ending on the 91st day after such date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(g)&nbsp;the Company shall have delivered
to the Trustee an Officer&rsquo;s Certificate and an Opinion of Counsel to the effect that (i)&nbsp;the Company has received from, or
there has been published by, the Internal Revenue Service a ruling or (ii)&nbsp;since the date of execution of this Indenture, there has
been a change in the applicable Federal income tax law, in either case to the effect that, and based thereon such Opinion of Counsel shall
confirm that, the Holders of the Securities of such Series&nbsp;will not recognize income, gain or loss for Federal income tax purposes
as a result of such deposit, defeasance and discharge and will be subject to Federal income tax on the same amount and in the same manner
and at the same times as would have been the case if such deposit, defeasance and discharge had not occurred;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(h)&nbsp;the Company shall have delivered
to the Trustee an Officer&rsquo;s Certificate stating that the deposit was not made by the Company with the intent of defeating, hindering,
delaying or defrauding any other creditors of the Company; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(i)&nbsp;the Company shall have delivered
to the Trustee an Officer&rsquo;s Certificate and an Opinion of Counsel, each stating that all conditions precedent provided for relating
to the defeasance contemplated by this Section&nbsp;have been complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;8.4. <U>Covenant Defeasance</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unless this Section&nbsp;8.4 is otherwise specified
pursuant to Section&nbsp;2.2 to be inapplicable to Securities of any Series, the Company may omit to comply with respect to the Securities
of any Series&nbsp;with any term, provision or condition set forth under Sections 4.2, 4.3, 4.4 and 5.1 and, unless otherwise specified
therein, any additional covenants specified in a supplemental indenture for such Series&nbsp;of Securities or a Board Resolution or an
Officer&rsquo;s Certificate delivered pursuant to Section&nbsp;2.2 (and the failure to comply with any such covenants shall not constitute
a Default or Event of Default with respect to such Series&nbsp;under Section&nbsp;6.1) and the occurrence of any event specified in a
supplemental indenture for such Series&nbsp;of Securities or a Board Resolution or an Officer&rsquo;s Certificate delivered pursuant to
Section&nbsp;2.2 and designated as an Event of Default shall not constitute a Default or Event of Default hereunder, with respect to the
Securities of such Series, but, except as specified above, the remainder of this Indenture and such Securities will be unaffected thereby;
provided that the following conditions shall have been satisfied:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)&nbsp;with reference to this Section&nbsp;8.4,
the Company has irrevocably deposited or caused to be irrevocably deposited (except as provided in Section&nbsp;8.2(c)) with the Trustee
as trust funds in trust for the purpose of making the following payments specifically pledged as security for, and dedicated solely to,
the benefit of the Holders of such Securities (i)&nbsp;in the case of Securities of such Series&nbsp;denominated in Dollars, cash in Dollars
and/or U.S. Government Obligations or (ii)&nbsp;in the case of Securities of such Series&nbsp;denominated in a Foreign Currency (other
than a composite currency), money and/or Foreign Government Obligations, which through the payment of interest and principal in respect
thereof in accordance with their terms, will provide (and without reinvestment and assuming no tax liability will be imposed on such Trustee),
not later than one day before the due date of any payment of money, an amount in cash, sufficient, in the opinion of a nationally recognized
firm of independent certified public accountants or investment bank expressed in a written certification thereof delivered to the Trustee,
to pay and discharge each installment of principal (including mandatory sinking fund payments or analogous payments) of and interest on
all the Securities of such Series&nbsp;on the dates such installments of principal or interest are due;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)&nbsp;such deposit will not result
in a breach or violation of, or constitute a default under, this Indenture or any other agreement or instrument to which the Company is
a party or by which it is bound;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)&nbsp;no Default or Event of Default
with respect to the Securities of such Series&nbsp;shall have occurred and be continuing on the date of such deposit;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(d)&nbsp;the Company shall have delivered
to the Trustee an Officers&rsquo; Certificate and an Opinion of Counsel to the effect that the Holders of the Securities of such Series&nbsp;will
not recognize income, gain or loss for Federal income tax purposes as a result of such deposit and covenant defeasance and will be subject
to Federal income tax on the same amount and in the same manner and at the same times as would have been the case if such deposit and
covenant defeasance had not occurred;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(e)&nbsp;The Company shall have delivered
to the Trustee an Officer&rsquo;s Certificate stating the deposit was not made by the Company with the intent of defeating, hindering,
delaying or defrauding any other creditors of the Company; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(f)&nbsp;The Company shall have delivered
to the Trustee an Officer&rsquo;s Certificate and an Opinion of Counsel, each stating that all conditions precedent herein provided for
relating to the covenant defeasance contemplated by this Section&nbsp;have been complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;8.5. <U>Repayment to Company</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to applicable abandoned property law, the
Trustee and the Paying Agent shall pay to the Company upon request any money held by them for the payment of principal and interest that
remains unclaimed for two years. After that, Holders entitled to the money must look to the Company for payment as general creditors unless
an applicable abandoned property law designates another person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;8.6. <U>Reinstatement</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the Trustee or the Paying Agent is unable to
apply any money deposited with respect to Securities of any Series&nbsp;in accordance with Section&nbsp;8.1 by reason of any legal proceeding
or by reason of any order or judgment of any court or governmental authority enjoining, restraining or otherwise prohibiting such application,
the obligations of the Company under this Indenture with respect to the Securities of such Series&nbsp;and under the Securities of such
Series&nbsp;shall be revived and reinstated as though no deposit had occurred pursuant to Section&nbsp;8.1 until such time as the Trustee
or the Paying Agent is permitted to apply all such money in accordance with Section&nbsp;8.1; <U>provided</U>, <U>however</U>, that if
the Company has made any payment of principal of or interest on [or any Additional Amounts with respect to] any Securities because of
the reinstatement of its obligations, the Company shall be subrogated to the rights of the Holders of such Securities to receive such
payment from the money or U.S. Government Obligations held by the Trustee or Paying Agent after payment in full to the Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE&nbsp;IX.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AMENDMENTS AND WAIVERS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;9.1. <U>Without Consent of Holders</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company and the Trustee may amend or supplement
this Indenture or the Securities of one or more Series&nbsp;without the consent of any Holder:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)&nbsp;to cure any ambiguity, defect
or inconsistency;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)&nbsp;to comply with Article&nbsp;V;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)&nbsp;to provide for uncertificated
Securities in addition to or in place of certificated Securities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(d)&nbsp;to add guarantees with respect
to Securities of any Series&nbsp;or secure Securities of any Series;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(e)&nbsp;to surrender any of the Company&rsquo;s
rights or powers under this Indenture;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(f)&nbsp;to add covenants or events of
default for the benefit of the holders of Securities of any Series;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(g)&nbsp;to comply with the applicable
procedures of the applicable depositary;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h)&nbsp;to make
any change that does not adversely affect the rights of any Holder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(i)&nbsp;to provide for the issuance
of and establish the form and terms and conditions of Securities of any Series&nbsp;as permitted by this Indenture;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(j)&nbsp;to evidence and provide for
the acceptance of appointment hereunder by a successor Trustee with respect to the Securities of one or more Series&nbsp;and to add to
or change any of the provisions of this Indenture as shall be necessary to provide for or facilitate the administration of the trusts
hereunder by more than one Trustee; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(k)&nbsp;to comply with requirements
of the SEC in order to effect or maintain the qualification of this Indenture under the TIA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;9.2. <U>With Consent of Holders</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to Section&nbsp;9.3, the Company and the
Trustee may enter into a supplemental indenture with the written consent of the Holders of at least a majority in principal amount of
the outstanding Securities of each Series&nbsp;affected by such supplemental indenture (including consents obtained in connection with
a tender offer or exchange offer for the Securities of such Series), for the purpose of adding any provisions to or changing in any manner
or eliminating any of the provisions of this Indenture or of any supplemental indenture or of modifying in any manner the rights of the
Holders of each such Series. Except as provided in Section&nbsp;6.13, and subject to Section&nbsp;9.3, the Holders of at least a majority
in principal amount of the outstanding Securities of any Series&nbsp;by notice to the Trustee (including consents obtained in connection
with a tender offer or exchange offer for the Securities of such Series) may waive compliance by the Company with any provision of this
Indenture or the Securities with respect to such Series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">It shall not be necessary for the consent of the
Holders of Securities under this Section&nbsp;9.2 to approve the particular form of any proposed supplemental indenture or waiver, but
it shall be sufficient if such consent approves the substance thereof. After a supplemental indenture or waiver under this section becomes
effective, the Company shall send to the Holders of Securities affected thereby, a notice briefly describing the supplemental indenture
or waiver. Any failure by the Company to send such notice, or any defect therein, shall not, however, in any way impair or affect the
validity of any such supplemental indenture or waiver.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;9.3. <U>Limitations</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Without the consent of each Holder affected, an
amendment or waiver may not:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;reduce
the principal amount of Securities whose Holders must consent to an amendment, supplement or waiver;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)&nbsp;reduce the rate of or extend
the time for payment of interest (including default interest) on any Security;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)&nbsp;reduce the principal or change
the Stated Maturity of any Security or reduce the amount of, or postpone the date fixed for, the payment of any sinking fund or analogous
obligation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(d)&nbsp;reduce the principal amount
of Discount Securities payable upon acceleration of the maturity thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(e)&nbsp;waive a Default or Event of
Default in the payment of the principal of or interest, if any, on any Security (except a rescission of acceleration of the Securities
of any Series&nbsp;by the Holders of at least a majority in principal amount of the outstanding Securities of such Series&nbsp;and a waiver
of the payment default that resulted from such acceleration);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(f)&nbsp;make the principal of or interest,
if any, on any Security payable in any currency other than that stated in the Security;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(g)&nbsp;make any change in Sections
6.8, 6.13 or 9.3 (this sentence); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(h)&nbsp;waive a redemption payment with
respect to any Security, provided that such redemption is made at the Company&rsquo;s option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;9.4. <U>Compliance with Trust Indenture
Act</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Every amendment to this Indenture or the Securities
of one or more Series&nbsp;shall be set forth in a supplemental indenture hereto that complies with the TIA as then in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;9.5. <U>Revocation and Effect of Consents</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Until an amendment is set forth in a supplemental
indenture or a waiver becomes effective, a consent to it by a Holder of a Security is a continuing consent by the Holder and every subsequent
Holder of a Security or portion of a Security that evidences the same debt as the consenting Holder&rsquo;s Security, even if notation
of the consent is not made on any Security. However, any such Holder or subsequent Holder may revoke the consent as to his, her or its
Security or portion of a Security if the Trustee receives the notice of revocation before the date of the supplemental indenture or the
date the waiver becomes effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any amendment or waiver once effective shall bind
every Holder of each Series&nbsp;affected by such amendment or waiver unless it is of the type described in any of clauses (a)&nbsp;through
(h)&nbsp;of Section&nbsp;9.3. In that case, the amendment or waiver shall bind each Holder of a Security who has consented to it and every
subsequent Holder of a Security or portion of a Security that evidences the same debt as the consenting Holder&rsquo;s Security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company may, but shall not be obligated to,
fix a record date for the purpose of determining the Holders entitled to give their consent or take any other action described above or
required or permitted to be taken pursuant to this Indenture. If a record date is fixed, then notwithstanding the second immediately preceding
paragraph, those Persons who were Holders at such record date (or their duly designated proxies), and only those Persons, shall be entitled
to give such consent or to revoke any consent previously given or take any such action, whether or not such Persons continue to be Holders
after such record date. No such consent shall be valid or effective for more than 120 days after such record date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;9.6. <U>Notation on or Exchange of
Securities</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company or the Trustee may, but shall not be
obligated to, place an appropriate notation about an amendment or waiver on any Security of any Series&nbsp;thereafter authenticated.
The Company in exchange for Securities of that Series&nbsp;may issue and the Trustee shall authenticate upon receipt of a Company Order
in accordance with Section&nbsp;2.3 new Securities of that Series&nbsp;that reflect the amendment or waiver.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;9.7. <U>Trustee Protected</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In executing, or accepting the additional trusts
created by, any supplemental indenture permitted by this Article&nbsp;or the modifications thereby of the trusts created by this Indenture,
the Trustee shall be entitled to receive, upon request, an Officer&rsquo;s Certificate and/or an Opinion of Counsel complying with Sections
10.4 and 10.5 and (subject to Section&nbsp;7.1) shall be fully protected in relying upon such Officer&rsquo;s Certificate and/or Opinion
of Counsel. The Trustee shall sign all supplemental indentures upon delivery of such an Officer&rsquo;s Certificate or Opinion of Counsel
or both, except that the Trustee need not sign any supplemental indenture that adversely affects its rights, duties, liabilities or immunities
under this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE&nbsp;X.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">MISCELLANEOUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;10.1. <U>Trust Indenture Act Controls</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If any provision of this Indenture limits, qualifies,
or conflicts with another provision which is required or deemed to be included in this Indenture by the TIA, such required or deemed provision
shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;10.2. <U>Notices</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any notice or communication by the Company or the
Trustee to the other, or by a Holder to the Company or the Trustee, is duly given if in writing and delivered in person or mailed by first-class
mail (registered or certified, return receipt requested), email or overnight air courier guaranteeing next day delivery, to the others&rsquo;
address:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if to the Company:</FONT></TD>
    <TD STYLE="width: 80%">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cognition Therapeutics,&nbsp;Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2500 Westchester Avenue</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase, NY 10577</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention: Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone: (412) 481-2210&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with a copy to: &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></TD>
    <TD>Goodwin Procter LLP</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3025 John F Kennedy Blvd</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Philadelphia, PA 19104</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention: Rachael M. Bushey,&nbsp;Esq. and Justin Platt,&nbsp;Esq.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone: (445) 207-7800</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if to the Trustee:</FONT></TD>
    <TD></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[</FONT><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention: [</FONT><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone: [</FONT><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with a copy to:</FONT></TD>
    <TD></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[</FONT><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention: [</FONT><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone: [</FONT><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">]</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company or the Trustee by notice to the other
may designate additional or different addresses for subsequent notices or communications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any notice or communication to a Holder shall be
sent electronically or by first-class mail or overnight air courier to his, her or its address shown on the register kept by the Registrar,
in accordance with the procedures of the Depositary. Failure to send a notice or communication to a Holder of any Series&nbsp;or any defect
in it shall not affect its sufficiency with respect to other Holders of that or any other Series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If a notice or communication is sent or published
in the manner provided above, within the time prescribed, it is duly given, whether or not the Holder receives it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the Company sends a notice or communication
to Holders, it shall send a copy to the Trustee and each Agent at the same time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Trustee shall not have any duty to confirm
that the person sending any notice, instruction or other communication by electronic transmission (including by e-mail, facsimile transmission,
web portal or other electronic methods) is, in fact, a person authorized to do so. Electronic signatures believed by the Trustee to comply
with the ESIGN Act of 2000 or other applicable law (including electronic images of handwritten signatures and digital signatures provided
by DocuSign, Orbit, Adobe Sign or any other digital signature provider acceptable to the Trustee) shall be deemed original signatures
for all purposes. The Company assumes all risks arising out of the use of electronic signatures and electronic methods to send communications
to the Trustee, including without limitation the risk of the Trustee acting on an unauthorized communication, and the risk of interception
or misuse by third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Notwithstanding any other provision of this Indenture
or any Security, where this Indenture or any Security provides for notice of any event (including any notice of redemption) to a Holder
of a Global Security (whether by mail or otherwise), such notice shall be sufficiently given to the Depositary for such Security (or its
designee) pursuant to the customary procedures of such Depositary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;10.3. <U>Communication by Holders
with Other Holders</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Holders of any Series&nbsp;may communicate pursuant
to TIA &sect; 312(b)&nbsp;with other Holders of that Series&nbsp;or any other Series&nbsp;with respect to their rights under this Indenture
or the Securities of that Series&nbsp;or all Series. The Company, the Trustee, the Registrar and anyone else shall have the protection
of TIA &sect; 312(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;10.4. <U>Certificate and Opinion as
to Conditions Precedent</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Upon any request or application by the Company
to the Trustee to take any action under this Indenture, the Company shall furnish to the Trustee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)&nbsp;an Officer&rsquo;s Certificate
stating that, in the opinion of the signers, all conditions precedent, if any, provided for in this Indenture relating to the proposed
action have been complied with; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)&nbsp;an Opinion of Counsel stating
that, in the opinion of such counsel, all such conditions precedent have been complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;10.5. <U>Statements Required in Certificate
or Opinion</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each certificate or opinion with respect to compliance
with a condition or covenant provided for in this Indenture (other than a certificate provided pursuant to TIA &sect; 314(a)(4)) shall
comply with the provisions of TIA &sect; 314(e)&nbsp;and shall include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)&nbsp;a statement that the person
making such certificate or opinion has read such covenant or condition;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)&nbsp;a brief statement as to the
nature and scope of the examination or investigation upon which the statements or opinions contained in such certificate or opinion are
based;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)&nbsp;a statement that, in the opinion
of such person, such person has made such examination or investigation as is necessary to enable such person to express an informed opinion
as to whether or not such covenant or condition has been complied with; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(d)&nbsp;a statement as to whether or
not, in the opinion of such person, such condition or covenant has been complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;10.6. <U>Rules&nbsp;by Trustee and
Agents</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Trustee may make reasonable rules&nbsp;for
action by or a meeting of Holders of one or more Series. Any Agent may make reasonable rules&nbsp;and set reasonable requirements for
its functions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;10.7. <U>Legal Holidays</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If a payment date for any payment made under this
Indenture is not a Business Day, payment may be made on the next succeeding Business Day, and no interest shall accrue for the intervening
period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;10.8. <U>No Recourse Against Others</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A director, officer, employee or stockholder (past
or present), as such, of the Company shall not have any liability for any obligations of the Company under the Securities or the Indenture
or for any claim based on, in respect of or by reason of such obligations or their creation. Each Holder by accepting a Security waives
and releases all such liability. The waiver and release are part of the consideration for the issue of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;10.9. <U>Counterparts</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Indenture may be executed in any number of
counterparts and by the parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and
all of which taken together shall constitute one and the same agreement. The exchange of copies of this Indenture and of signature pages&nbsp;by
facsimile or electronic format (e.g., &ldquo;.pdf&rdquo; or &ldquo;.tif&rdquo;) transmission shall constitute effective execution and
delivery of this Indenture as to the parties hereto and may be used in lieu of the original Indenture for all purposes. Signatures of
the parties hereto transmitted by facsimile or electronic format (e.g., &ldquo;.pdf&rdquo; or &ldquo;.tif&rdquo;) shall be deemed to be
their original signatures for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unless otherwise provided herein or in any other
Securities, the words &ldquo;execute&rdquo;, &ldquo;execution&rdquo;, &ldquo;signed&rdquo; and &ldquo;signature&rdquo; and words of similar
import used in or related to any document to be signed in connection with this Indenture, any Securities or any of the transactions contemplated
hereby (including amendments, waivers, consents and other modifications) shall be deemed to include electronic signatures and the keeping
of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature
in ink or the use of a paper-based recordkeeping system, as applicable, to the fullest extent and as provided for in any applicable law,
including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records
Act and any other similar state laws based on the Uniform Electronic Transactions Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;10.10. <U>Governing Law; Waiver of
Jury Trial; Consent to Jurisdiction</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>THIS INDENTURE AND THE SECURITIES,&nbsp;INCLUDING
ANY CLAIM OR CONTROVERSY ARISING OUT OF OR RELATING TO THE INDENTURE OR THE SECURITIES, SHALL BE GOVERNED BY THE LAWS OF THE STATE OF
NEW YORK.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>THE COMPANY, THE TRUSTEE AND THE HOLDERS (BY THEIR
ACCEPTANCE OF THE SECURITIES) EACH HEREBY IRREVOCABLY WAIVE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL
BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS INDENTURE, THE SECURITIES OR THE TRANSACTIONS CONTEMPLATED HEREBY OR
THEREBY.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any legal suit, action or proceeding arising out
of or based upon this Indenture or the transactions contemplated hereby may be instituted in the federal courts of the United States of
America located in the City of New York or the courts of the State of New York in each case located in the City of New York (collectively,
the &ldquo;<I>Specified Courts</I>&rdquo;), and each party irrevocably submits to the non-exclusive jurisdiction of such courts in any
such suit, action or proceeding. Service of any process, summons, notice or document by mail (to the extent allowed under any applicable
statute or rule&nbsp;of court) to such party&rsquo;s address set forth above shall be effective service of process for any suit, action
or other proceeding brought in any such court. The Company, the Trustee and the Holders (by their acceptance of the Securities) each hereby
irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts
and irrevocably and unconditionally waive and agree not to plead or claim any such suit, action or other proceeding has been brought in
an inconvenient forum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;10.11. <U>No Adverse Interpretation
of Other Agreements</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Indenture may not be used to interpret another
indenture, loan or debt agreement of the Company or a Subsidiary of the Company. Any such indenture, loan or debt agreement may not be
used to interpret this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;10.12. <U>Successors</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All agreements of the Company in this Indenture
and the Securities shall bind its successor. All agreements of the Trustee in this Indenture shall bind its successor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;10.13. <U>Severability</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In case any provision in this Indenture or in the
Securities shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not
in any way be affected or impaired thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;10.14. <U>Table of Contents, Headings,
Etc.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Table of Contents, Cross Reference Table, and
headings of the Articles and Sections of this Indenture have been inserted for convenience of reference only, are not to be considered
a part hereof, and shall in no way modify or restrict any of the terms or provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;10.15. <U>Securities in a Foreign
Currency</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unless otherwise specified in a Board Resolution,
a supplemental indenture hereto or an Officer&rsquo;s Certificate delivered pursuant to Section&nbsp;2.2 of this Indenture with respect
to a particular Series&nbsp;of Securities, whenever for purposes of this Indenture any action may be taken by the Holders of a specified
percentage in aggregate principal amount of Securities of all Series&nbsp;or all Series&nbsp;affected by a particular action at the time
outstanding and, at such time, there are outstanding Securities of any Series&nbsp;which are denominated in more than one currency, then
the principal amount of Securities of such Series&nbsp;which shall be deemed to be outstanding for the purpose of taking such action shall
be determined by converting any such other currency into a currency that is designated upon issuance of any particular Series&nbsp;of
Securities. Unless otherwise specified in a Board Resolution, a supplemental indenture hereto or an Officer&rsquo;s Certificate delivered
pursuant to Section&nbsp;2.2 of this Indenture with respect to a particular Series&nbsp;of Securities, such conversion shall be at the
spot rate for the purchase of the designated currency as published in The Financial Times in the &ldquo;Currency Rates&rdquo; section
(or, if The Financial Times is no longer published, or if such information is no longer available in The Financial Times, such source
as may be selected in good faith by the Company) on any date of determination. The provisions of this paragraph shall apply in determining
the equivalent principal amount in respect of Securities of a Series&nbsp;denominated in currency other than Dollars in connection with
any action taken by Holders of Securities pursuant to the terms of this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All decisions and determinations provided for in
the preceding paragraph shall, in the absence of manifest error, to the extent permitted by law, be conclusive for all purposes and irrevocably
binding upon the Trustee and all Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;10.16. <U>Judgment Currency</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company agrees, to the fullest extent that
it may effectively do so under applicable law, that (a)&nbsp;if for the purpose of obtaining judgment in any court it is necessary to
convert the sum due in respect of the principal of or interest or other amount on the Securities of any Series&nbsp;(the &ldquo;<I>Required
Currency</I>&rdquo;) into a currency in which a judgment will be rendered (the &ldquo;<I>Judgment Currency</I>&rdquo;), the rate of exchange
used shall be the rate at which in accordance with normal banking procedures the Trustee could purchase in the City of New York the Required
Currency with the Judgment Currency on the day on which final unappealable judgment is entered, unless such day is not a New York Banking
Day, then the rate of exchange used shall be the rate at which in accordance with normal banking procedures the Trustee could purchase
in the City of New York the Required Currency with the Judgment Currency on the New York Banking Day preceding the day on which final
unappealable judgment is entered and (b)&nbsp;its obligations under this Indenture to make payments in the Required Currency (i)&nbsp;shall
not be discharged or satisfied by any tender, any recovery pursuant to any judgment (whether or not entered in accordance with subsection
(a)), in any currency other than the Required Currency, except to the extent that such tender or recovery shall result in the actual receipt,
by the payee, of the full amount of the Required Currency expressed to be payable in respect of such payments, (ii)&nbsp;shall be enforceable
as an alternative or additional cause of action for the purpose of recovering in the Required Currency the amount, if any, by which such
actual receipt shall fall short of the full amount of the Required Currency so expressed to be payable, and (iii)&nbsp;shall not be affected
by judgment being obtained for any other sum due under this Indenture. For purposes of the foregoing, &ldquo;<I>New York Banking Day</I>&rdquo;
means any day except a Saturday, Sunday or a legal holiday in the City of New York on which banking institutions are authorized or required
by law, regulation or executive order to close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;10.17. <U>Force Majeure</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In no event shall the Trustee be responsible or
liable for any failure or delay in the performance of its obligations hereunder arising out of or caused by, directly or indirectly, forces
beyond its control, including, without limitation, strikes, work stoppages, accidents, acts of war or terrorism, civil or military disturbances,
nuclear or natural catastrophes, pandemics, epidemics or other public health emergencies, or acts of God, and interruptions, loss or malfunctions
of utilities, communications or computer (software and hardware) services, it being understood that the Trustee shall use reasonable best
efforts which are consistent with accepted practices in the banking industry to resume performance as soon as practicable under the circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;10.18. <U>U.S.A. Patriot Act</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The parties hereto acknowledge that in accordance
with Section&nbsp;326 of the U.S.A. Patriot Act, the Trustee is required to obtain, verify and record information that identifies each
person or legal entity that establishes a relationship or opens an account with the Trustee. The parties to this Indenture agree that
they will provide the Trustee with such information as it may request in order for the Trustee to satisfy the requirements of the U.S.A.
Patriot Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE&nbsp;XI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SINKING FUNDS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;11.1. <U>Applicability of Article</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The provisions of this Article&nbsp;shall be applicable
to any sinking fund for the retirement of the Securities of a Series&nbsp;if so provided by the terms of such Securities pursuant to Section&nbsp;2.2,
except as otherwise permitted or required by any form of Security of such Series&nbsp;issued pursuant to this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The minimum amount of any sinking fund payment
provided for by the terms of the Securities of any Series&nbsp;is herein referred to as a &ldquo;<I>mandatory sinking fund payment</I>&rdquo;
and any other amount provided for by the terms of Securities of such Series&nbsp;is herein referred to as an &ldquo;<I>optional sinking
fund payment</I>.&rdquo; If provided for by the terms of Securities of any Series, the cash amount of any sinking fund payment may be
subject to reduction as provided in Section&nbsp;11.2. Each sinking fund payment shall be applied to the redemption of Securities of any
Series&nbsp;as provided for by the terms of the Securities of such Series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;11.2. <U>Satisfaction of Sinking Fund
Payments with Securities</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company may, in satisfaction of all or any
part of any sinking fund payment with respect to the Securities of any Series&nbsp;to be made pursuant to the terms of such Securities
(1)&nbsp;deliver outstanding Securities of such Series&nbsp;to which such sinking fund payment is applicable (other than any of such Securities
previously called for mandatory sinking fund redemption) and (2)&nbsp;apply as credit Securities of such Series&nbsp;to which such sinking
fund payment is applicable and which have been repurchased by the Company or redeemed either at the election of the Company pursuant to
the terms of such Series&nbsp;of Securities (except pursuant to any mandatory sinking fund) or through the application of permitted optional
sinking fund payments or other optional redemptions pursuant to the terms of such Securities, provided that such Securities have not been
previously so credited. Such Securities shall be received by the Trustee, together with an Officer&rsquo;s Certificate with respect thereto,
not later than 15 days prior to the date on which the Trustee begins the process of selecting Securities for redemption and shall be credited
for such purpose by the Trustee at the price specified in such Securities for redemption through operation of the sinking fund and the
amount of such sinking fund payment shall be reduced accordingly. If as a result of the delivery or credit of Securities in lieu of cash
payments pursuant to this Section&nbsp;11.2, the principal amount of Securities of such Series&nbsp;to be redeemed in order to exhaust
the aforesaid cash payment shall be less than $100,000, the Trustee need not call Securities of such Series&nbsp;for redemption, except
upon receipt of a Company Order that such action be taken, and such cash payment shall be held by the Trustee or a Paying Agent and applied
to the next succeeding sinking fund payment, <U>provided</U>, <U>however</U>, that the Trustee or such Paying Agent shall from time to
time upon receipt of a Company Order pay over and deliver to the Company any cash payment so being held by the Trustee or such Paying
Agent upon delivery by the Company to the Trustee of Securities of that Series&nbsp;purchased by the Company having an unpaid principal
amount equal to the cash payment required to be released to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;11.3. <U>Redemption of Securities
for Sinking Fund</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not less than 45 days (unless otherwise indicated
in the Board Resolution, supplemental indenture hereto or Officer&rsquo;s Certificate in respect of a particular Series&nbsp;of Securities)
prior to each sinking fund payment date for any Series&nbsp;of Securities, the Company will deliver to the Trustee an Officer&rsquo;s
Certificate specifying the amount of the next ensuing mandatory sinking fund payment for that Series&nbsp;pursuant to the terms of that
Series, the portion thereof, if any, which is to be satisfied by payment of cash and the portion thereof, if any, which is to be satisfied
by delivering and crediting of Securities of that Series&nbsp;pursuant to Section&nbsp;11.2, and the optional amount, if any, to be added
in cash to the next ensuing mandatory sinking fund payment, and the Company shall thereupon be obligated to pay the amount therein specified.
Not less than 30 days (unless otherwise indicated in the Board Resolution, Officer&rsquo;s Certificate or supplemental indenture in respect
of a particular Series&nbsp;of Securities) before each such sinking fund payment date the Securities to be redeemed upon such sinking
fund payment date will be selected in the manner specified in Section&nbsp;3.2, and the Company shall send or cause to be sent a notice
of the redemption thereof to be given in the name of and at the expense of the Company in the manner provided in and in accordance with
Section&nbsp;3.3. Such notice having been duly given, the redemption of such Securities shall be made upon the terms and in the manner
stated in Sections 3.4, 3.5 and 3.6.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the parties hereto have caused
this Indenture to be duly executed as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COGNITION THERAPEUTICS,&nbsp;INC.</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; width: 47%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Its:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&mdash;], as Trustee</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 47%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Its:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 42; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>tm2533585d2_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&#8239;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 5.1</B></P>

<P STYLE="margin: 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%; text-align: left"><IMG SRC="tm2533585d2_ex5-1img001.jpg" ALT="">&#8239;</TD><TD STYLE="text-align: right; width: 50%">Goodwin Procter&#8239;LLP<BR>
3025 John F Kennedy Blvd<BR>
Philadelphia, PA 19104<BR>
goodwinlaw.com<BR>
+1 (445) 207-7800</TD>
</TR></TABLE>

<P STYLE="margin: 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">December&#8239;18, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cognition Therapeutics,&#8239;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2500 Westchester Ave.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Purchase, NY 10577</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Re:&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Securities
Being Registered under Registration Statement on Form&#8239;S-3</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have acted as counsel to you in connection with your filing of a
Registration Statement on Form&#8239;S-3 (as amended or supplemented, the &ldquo;Registration Statement&rdquo;) pursuant to the Securities
Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), relating to the offering by Cognition Therapeutics,&#8239;Inc. a Delaware corporation
(the &ldquo;Company&rdquo;), of up to $300,000,000 of any combination of (i)&#8239;the Company&rsquo;s common stock, par value $0.001 per
share (&ldquo;Common Stock&rdquo;), (ii)&#8239;the Company&rsquo;s preferred stock, par value $0.001 per share (&ldquo;Preferred Stock&rdquo;),
(iii)&#8239;the Company&rsquo;s debt securities (&ldquo;Debt Securities&rdquo;), (iv)&#8239;warrants to purchase Common Stock, Preferred
Stock or Debt Securities (&ldquo;Warrants&rdquo;), (v)&#8239; units comprised of Common Stock, Preferred Stock, Debt Securities, Warrants,
Subscription Rights (as defined below) and other securities in any combination (&ldquo;Units&rdquo;), and (vi)&#8239;subscription rights
to purchase Common Stock, Preferred Stock or Debt Securities or any combination of such securities (&ldquo;Subscription Rights&rdquo;).
The Common Stock, Preferred Stock, Debt Securities, Warrants, Units and Subscription Rights are sometimes referred to collectively herein
as the &ldquo;Securities.&rdquo; Securities may be issued in an unspecified number (with respect to Common Stock, Preferred Stock, Warrants,
Units and Subscription Rights) or in an unspecified principal amount (with respect to Debt Securities). The Registration Statement provides
that the Securities may be offered separately or together, in separate series, in amounts, at prices and on terms to be set forth in one
or more prospectus supplements (each a &ldquo;Prospectus Supplement&rdquo;) to the prospectus contained in the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have reviewed such documents and made such examination of law as
we have deemed appropriate to give the opinions set forth below. We have relied, without independent verification, on certificates of
public officials and, as to matters of fact material to the opinions set forth below, on certificates of officers of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The opinions set forth below are limited to the Delaware General Corporation
Law and the law of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For purposes of the opinions set forth below, without limiting any
other exceptions or qualifications set forth herein, we have assumed that (i)&#8239;each of the Debt Securities, Warrants and Units and
Subscription Rights, and the indentures, warrant agreements, unit agreements, subscription rights agreements, and other agreements governing
Securities offered pursuant to the Registration Statement will be governed by the internal law of New York and (ii)&#8239;after the issuance
of any Securities offered pursuant to the Registration Statement, the total number of issued shares of Common Stock or Preferred Stock,
as applicable, together with the total number of shares of such stock issuable upon the exercise, exchange, conversion or settlement,
as the case may be, of any exercisable, exchangeable or convertible security (including without limitation any Unit or Subscription Right),
as the case may be, then outstanding, will not exceed the total number of authorized shares of Common Stock or Preferred Stock, as applicable,
then available for issuance under the Company&rsquo;s certificate of incorporation as then in effect (the &ldquo;Charter&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cognition Therapeutics, Inc.<BR>
 December 18, 2025 <BR>
Page 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For purposes of the opinions set forth below, we refer to the following
as the &ldquo;Future Approval and Issuance&rdquo; of Securities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">with respect to any of the Securities, (a)&#8239;the approval by the Company
of the amount, terms and issuance of such Securities (the &ldquo;Approval&rdquo;) and (b)&#8239;the issuance of such Securities in accordance
with the Approval upon the receipt by the Company of the consideration (which, in the case of shares of Common Stock or Preferred Stock,
is not less than the par value of such shares) to be paid in accordance with the Approval;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">with respect to Preferred Stock, (a)&#8239;the establishment of the terms
of such Preferred Stock by the Company in conformity with the Charter and applicable law and (b)&#8239;the execution, acknowledgement and
filing with the Delaware Secretary of State, and the effectiveness of, a certificate of designations to the Charter setting forth the
terms of such Preferred Stock in accordance with the Charter and applicable law;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">with respect to Debt Securities, (a)&#8239;the approval, execution and delivery
of the indenture or a supplemental indenture relating to such Securities by the Company and the trustee and/or (b)&#8239;the establishment
of the terms of such Securities by the Company in conformity with the indenture or supplemental indenture and applicable law, and (c)&#8239;the
execution, authentication and issuance of such Securities in accordance with the indenture or supplemental indenture and applicable law;
and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">with respect to Warrants, Units or Subscription Rights, (a)&#8239;the approval,
execution and delivery by the Company and any other parties thereto of any agreement under which such Securities are to be issued, and
(b)&#8239;the establishment of the terms of such Securities and the issuance of such Securities in conformity with those terms, the terms
of any applicable agreement and applicable law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based upon the foregoing, and subject to the additional qualifications
set forth below, we are of the opinion that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Upon
the Future Approval and Issuance of shares of Common Stock, such shares of Common Stock will be validly issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cognition Therapeutics, Inc.<BR>
 December 18, 2025<BR>
 Page 3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Upon
the Future Approval and Issuance of shares of Preferred Stock, such shares of Preferred Stock will be validly issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Upon
the Future Approval and Issuance of Debt Securities, such Debt Securities will be valid and binding obligations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Upon
the Future Approval and Issuance of Warrants, such Warrants will be valid and binding obligations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Upon
the Future Approval and Issuance of Units, such Units will be valid and binding obligations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Upon
the Future Approval and Issuance of Subscription Rights, such Subscription Rights will be valid and binding obligations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The opinions expressed above are subject to bankruptcy, insolvency,
fraudulent transfer, reorganization, moratorium and other similar laws of general application affecting the rights and remedies of creditors
and to general principles of equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This opinion letter and the opinions it contains shall be interpreted
in accordance with the Core Opinion Principles as published in 74 <I>Business Lawyer</I> 815 (Summer 2019).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We hereby consent to the inclusion of this opinion as Exhibit&#8239;5.1
to the Registration Statement and to the references to our firm under the caption &ldquo;Legal Matters&rdquo; in the Registration Statement.
In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section&#8239;7 of the Securities
Act or the rules&#8239;and regulations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Goodwin Procter LLP</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">GOODWIN PROCTER LLP</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="margin: 0">&#8239;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.2
<SEQUENCE>5
<FILENAME>tm2533585d2_ex5-2.htm
<DESCRIPTION>EXHIBIT 5.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit&nbsp;5.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%; text-align: left"><IMG SRC="tm2533585d2_ex5-2img001.jpg" ALT="">&nbsp;</TD><TD STYLE="text-align: right; width: 50%">Goodwin Procter&nbsp;LLP<BR>
3025 John F Kennedy Blvd<BR>
Philadelphia, PA 19104<BR>
goodwinlaw.com<BR>
+1 (445) 207-7800</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 30pt 0pt 0; text-align: right">December&nbsp;18, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cognition Therapeutics,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2500 Westchester Ave.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Purchase, NY 10577</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Re:&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Securities
Registered under Registration Statement on Form&nbsp;S-3</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have acted as counsel to
you in connection with your filing of a Registration Statement on Form&nbsp;S-3 (as amended or supplemented, the &ldquo;Registration Statement&rdquo;)
filed on December&nbsp;18, 2025 with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) pursuant to the Securities
Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), relating to the registration of the offering by Cognition Therapeutics,&nbsp;Inc.,
a Delaware corporation (the &ldquo;Company&rdquo;) of up to $300,000,000 of any combination of securities of the types specified therein.
Reference is made to our opinion letter dated December&nbsp;18, 2025 and included as Exhibit&nbsp;5.1 to the Registration Statement. We
are delivering this supplemental opinion letter in connection with the prospectus supplement (the &ldquo;Prospectus Supplement&rdquo;)
included in the Registration Statement. The Prospectus Supplement relates to the offering by the Company of up to $75,000,000 in shares
(the &ldquo;Shares&rdquo;) of the Company&rsquo;s common stock, par value $0.001 per share (&ldquo;Common Stock&rdquo;) covered by the
Registration Statement. The Shares are being offered and sold by the sales agent(s)&nbsp;named in, and pursuant to, a sales agreement
among the Company and such sales agent(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have reviewed such documents
and made such examination of law as we have deemed appropriate to give the opinion set forth below. We have relied, without independent
verification, on certificates of public officials and, as to matters of fact material to the opinion set forth below, on certificates
of officers of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of the opinion
set forth below, we have assumed that the Shares are issued for a price per share equal to or greater than the minimum price authorized
by the Company&rsquo;s board of directors (or a duly authorized committee of the board of directors) prior to the date hereof (the &ldquo;Minimum
Price&rdquo;) and that no event occurs that causes the number of authorized shares of Common Stock available for issuance by the Company
to be less than the number of then unissued Shares that may be issued for the Minimum Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of the opinion
set forth below, we refer to the following as &ldquo;Future Approval and Issuance&rdquo;: (a)&nbsp;the approval by the Company&rsquo;s
board of directors (or a duly authorized committee of the board of directors) of the issuance of the Shares (the &ldquo;Approval&rdquo;)
and (b)&nbsp;the issuance of the Shares in accordance with the Approval and the receipt by the Company of the consideration (which shall
not be less than the par value of such Shares) to be paid in accordance with the Approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cognition Therapeutics, Inc.<BR>
 December 18, 2025<BR>
 Page 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The opinion set forth below
is limited to the Delaware General Corporation Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the foregoing, we
are of the opinion that the Shares have been duly authorized and, upon Future Approval and Issuance, will be validly issued, fully paid
and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This opinion letter and the
opinions it contains shall be interpreted in accordance with the Core Opinion Principles as published in 74 <I>Business Lawyer </I>815
(Summer 2019).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This opinion is being furnished
to you for submission to the Commission as Exhibit&nbsp;5.2 to the Registration Statement. We hereby consent to the filing of this opinion
letter as an exhibit to the Registration Statement and its incorporation by reference and the reference to our firm in therein. In giving
our consent, we do not admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act
or the rules&nbsp;and regulations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Goodwin Procter LLP</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">GOODWIN PROCTER LLP</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>tm2533585d2_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Consent of Independent Registered Public Accounting
Firm</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We&nbsp;consent&nbsp;to the reference to our firm under the caption
&quot;Experts&quot; in the Registration Statement (Form&nbsp;S-3) and related Prospectus of Cognition Therapeutics,&nbsp;Inc. for the
registration of its common stock,&nbsp;preferred stock, debt securities, warrants, units and subscription rights and to the incorporation
by reference therein of our report dated March&nbsp;20, 2025, with respect to the consolidated financial statements of Cognition Therapeutics,&nbsp;Inc.
included in its Annual Report (Form&nbsp;10-K) for the year ended December&nbsp;31, 2024, filed with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Ernst&nbsp;&amp; Young LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Philadelphia, Pennsylvania</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">December&nbsp;18, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>7
<FILENAME>tm2533585d1_ex-filingfees.htm
<DESCRIPTION>FILING FEE IXBRL
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ffd="http://xbrl.sec.gov/ffd/2025">
  <head>
    <title>EX-FILING FEES</title>
  </head>
  <body>
    <div style="display: none">
      <ix:header>
        <ix:hidden>
          <ix:nonNumeric name="ffd:FormTp" contextRef="rc" id="ixv-426">S-3</ix:nonNumeric>
          <ix:nonNumeric name="ffd:SubmissnTp" contextRef="rc" id="ixv-427">S-3</ix:nonNumeric>
          <ix:nonNumeric name="ffd:FeeExhibitTp" contextRef="rc" id="ixv-428">EX-FILING FEES</ix:nonNumeric>
          <ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="rc" id="ixv-429">0001455365</ix:nonNumeric>
          <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="rc" id="ixv-430">COGNITION THERAPEUTICS INC</ix:nonNumeric>
          <ix:nonNumeric name="ffd:OfferingTableNa" contextRef="rc" id="hiddenrcOfferingTableNa" xsi:nil="true"></ix:nonNumeric>
          <ix:nonNumeric name="ffd:OffsetTableNa" contextRef="rc" id="hiddenrcOffsetTableNa">N/A</ix:nonNumeric>
          <ix:nonNumeric name="ffd:CombinedProspectusTableNa" contextRef="rc" id="hiddenrcCombinedProspectusTableNa">N/A</ix:nonNumeric>
          <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-434">0.0001381</ix:nonFraction>
          <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_2" id="ixv-435">0.0001381</ix:nonFraction>
          <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_3" id="ixv-436">0.0001381</ix:nonFraction>
          <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_4" id="ixv-437">0.0001381</ix:nonFraction>
          <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_5" id="ixv-438">0.0001381</ix:nonFraction>
          <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_6" id="ixv-439">0.0001381</ix:nonFraction>
        </ix:hidden>
        <ix:references>
          <link:schemaRef xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd" xlink:type="simple"/>
        </ix:references>
        <ix:resources>
          <xbrli:context id="rc">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-12-15</xbrli:startDate>
              <xbrli:endDate>2025-12-15</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="offrl_1">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                  <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-12-15</xbrli:startDate>
              <xbrli:endDate>2025-12-15</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="offrl_2">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                  <dei:lineNo>2</dei:lineNo>
                </xbrldi:typedMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-12-15</xbrli:startDate>
              <xbrli:endDate>2025-12-15</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="offrl_3">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                  <dei:lineNo>3</dei:lineNo>
                </xbrldi:typedMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-12-15</xbrli:startDate>
              <xbrli:endDate>2025-12-15</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="offrl_4">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                  <dei:lineNo>4</dei:lineNo>
                </xbrldi:typedMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-12-15</xbrli:startDate>
              <xbrli:endDate>2025-12-15</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="offrl_5">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                  <dei:lineNo>5</dei:lineNo>
                </xbrldi:typedMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-12-15</xbrli:startDate>
              <xbrli:endDate>2025-12-15</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="offrl_6">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                  <dei:lineNo>6</dei:lineNo>
                </xbrldi:typedMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-12-15</xbrli:startDate>
              <xbrli:endDate>2025-12-15</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="offrl_7">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                  <dei:lineNo>7</dei:lineNo>
                </xbrldi:typedMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-12-15</xbrli:startDate>
              <xbrli:endDate>2025-12-15</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:unit id="USD">
            <xbrli:measure>iso4217:USD</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="pure">
            <xbrli:measure>xbrli:pure</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="Shares">
            <xbrli:measure>xbrli:shares</xbrli:measure>
          </xbrli:unit>
        </ix:resources>
      </ix:header>
    </div>
    <div>
      <table style="width: 99%; font-family: Arial, Helvetica, sans-serif; font-size: 20pt; text-align: center;">
        <tr>
          <td colspan="4" style="padding-bottom: .5em">
            <p>
              <b>Calculation of Filing Fee Tables</b>
            </p>
          </td>
        </tr>
        <tr>
          <td style="padding-bottom: .25em">
            <p>
              <b>
                <ix:nonNumeric name="ffd:FormTp" contextRef="rc" id="ixv-518">S-3</ix:nonNumeric>
              </b>
            </p>
          </td>
        </tr>
        <tr>
          <td style="padding-bottom: .25em">
            <p>
              <b>
                <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="rc" id="ixv-519">COGNITION THERAPEUTICS INC</ix:nonNumeric>
              </b>
            </p>
          </td>
        </tr>
      </table>
    </div>
    <div style="padding-bottom: 20px;">
      <table style="float: center; width: 100%; text-align: left;  ">
        <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
          <th style="vertical-align: bottom; text-align: left; word-wrap: break-word">
            <b>Table 1: Newly Registered and Carry Forward Securities</b>
          </th>
          <th style="vertical-align: bottom; word-wrap: break-word; text-align: right;">
            <span style="-sec-ix-hidden: hiddenrcOfferingTableNa">&#9744;Not Applicable</span>
          </th>
        </tr>
      </table>
      <table style="font-family: Arial, Helvetica, sans-serif; float: center; width: 100%; text-align: center; border: 1px solid black; font-size: 16px;">
        <tr style="background-color:#9ADAF6">
          <th style="width: 12%;">
            <!-- BLANK -->
          </th>
          <th style="width: 2%;">
            <!-- BLANK -->
          </th>
          <th style="width: 12%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Security Type</b>
            </p>
          </th>
          <th style="width: 14%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Security Class Title </b>
            </p>
          </th>
          <th style="width: 2%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Fee Calculation or Carry Forward Rule</b>
            </p>
          </th>
          <th style="width: 5%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Amount Registered</b>
            </p>
          </th>
          <th style="width: 15%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Proposed Maximum Offering Price Per Unit</b>
            </p>
          </th>
          <th style="width: 10%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Maximum Aggregate Offering Price</b>
            </p>
          </th>
          <th style="width: 5%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Fee Rate</b>
            </p>
          </th>
          <th style="width: 6%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Amount of Registration Fee</b>
            </p>
          </th>
          <th style="width: 1%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Carry Forward Form Type</b>
            </p>
          </th>
          <th style="width: 7%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Carry Forward File Number</b>
            </p>
          </th>
          <th style="width: 6%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Carry Forward Initial Effective Date</b>
            </p>
          </th>
          <th style="width: 7%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward</b>
            </p>
          </th>
        </tr>
        <tr>
          <td colspan="14" style="text-align: center">
            <b>Newly Registered Securities</b>
          </td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: left;">
            <span style="text-indent: 0px; display:inline-block; padding-left: 20px;">
              <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_1" id="ixv-520">Equity</ix:nonNumeric>
            </span>
          </td>
          <td style="text-align: left;">
            <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_1" id="ixv-521">Common Stock, par value $0.0001 per share </ix:nonNumeric>
          </td>
          <td style="text-align: center;">
            <ix:nonNumeric name="ffd:Rule457oFlg" contextRef="offrl_1" format="ixt:booleantrue" id="ixv-522">457(o)</ix:nonNumeric>
          </td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: left;">
            <span style="text-indent: 0px; display:inline-block; padding-left: 20px;">
              <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_2" id="ixv-523">Equity</ix:nonNumeric>
            </span>
          </td>
          <td style="text-align: left;">
            <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_2" id="ixv-524">Preferred Stock </ix:nonNumeric>
          </td>
          <td style="text-align: center;">
            <ix:nonNumeric name="ffd:Rule457oFlg" contextRef="offrl_2" format="ixt:booleantrue" id="ixv-525">457(o)</ix:nonNumeric>
          </td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: left;">
            <span style="text-indent: 0px; display:inline-block; padding-left: 20px;">
              <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_3" id="ixv-526">Debt</ix:nonNumeric>
            </span>
          </td>
          <td style="text-align: left;">
            <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_3" id="ixv-527">Debt Securities </ix:nonNumeric>
          </td>
          <td style="text-align: center;">
            <ix:nonNumeric name="ffd:Rule457oFlg" contextRef="offrl_3" format="ixt:booleantrue" id="ixv-528">457(o)</ix:nonNumeric>
          </td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: left;">
            <span style="text-indent: 0px; display:inline-block; padding-left: 20px;">
              <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_4" id="ixv-529">Equity</ix:nonNumeric>
            </span>
          </td>
          <td style="text-align: left;">
            <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_4" id="ixv-530">Warrants</ix:nonNumeric>
          </td>
          <td style="text-align: center;">
            <ix:nonNumeric name="ffd:Rule457oFlg" contextRef="offrl_4" format="ixt:booleantrue" id="ixv-531">457(o)</ix:nonNumeric>
          </td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: left;">
            <span style="text-indent: 0px; display:inline-block; padding-left: 20px;">
              <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_5" id="ixv-532">Equity</ix:nonNumeric>
            </span>
          </td>
          <td style="text-align: left;">
            <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_5" id="ixv-533">Units</ix:nonNumeric>
          </td>
          <td style="text-align: center;">
            <ix:nonNumeric name="ffd:Rule457oFlg" contextRef="offrl_5" format="ixt:booleantrue" id="ixv-534">457(o)</ix:nonNumeric>
          </td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: left;">
            <span style="text-indent: 0px; display:inline-block; padding-left: 20px;">
              <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_6" id="ixv-535">Equity</ix:nonNumeric>
            </span>
          </td>
          <td style="text-align: left;">
            <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_6" id="ixv-536">Subscription rights</ix:nonNumeric>
          </td>
          <td style="text-align: center;">
            <ix:nonNumeric name="ffd:Rule457oFlg" contextRef="offrl_6" format="ixt:booleantrue" id="ixv-537">457(o)</ix:nonNumeric>
          </td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
            <ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="offrl_7" format="ixt:booleanfalse" id="ixv-538">Fees to be Paid</ix:nonNumeric>
          </td>
          <td style="text-align: center;">
		1
	</td>
          <td style="text-align: left;">
            <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_7" id="ixv-539">Unallocated (Universal) Shelf</ix:nonNumeric>
          </td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: center;">
            <ix:nonNumeric name="ffd:Rule457oFlg" contextRef="offrl_7" format="ixt:booleantrue" id="ixv-540">457(o)</ix:nonNumeric>
          </td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">
            <span>$</span>
            <ix:nonFraction name="ffd:MaxAggtOfferingPric" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_7" id="ixv-541">300,000,000.00</ix:nonFraction>
          </td>
          <td style="text-align: right;">
            <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_7" id="ixv-542">0.0001381</ix:nonFraction>
          </td>
          <td style="text-align: right;">
            <span>$</span>
            <ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_7" id="ixv-543">41,430.00</ix:nonFraction>
          </td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Fees Previously Paid
	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr>
          <td colspan="14" style="text-align: center">
            <b>Carry Forward Securities</b>
          </td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Carry Forward Securities
	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td colspan="3" style="vertical-align: top">
            <p style="margin: 0pt; text-align: right">Total Offering Amounts:</p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td style="vertical-align: top; width: 16%;">
            <p id="MaxAggtOfferingPrice" style="margin: 0pt; text-align: right">
              <span>$</span>
              <ix:nonFraction name="ffd:TtlOfferingAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-544">300,000,000.00</ix:nonFraction>
            </p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td style="vertical-align: top; border-bottom: 1px black; width: 16%;">
            <p id="TotalFeeAmt" style="margin: 0pt; text-align: right">
              <span>$</span>
              <ix:nonFraction name="ffd:TtlFeeAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-545">41,430.00</ix:nonFraction>
            </p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
        </tr>
        <tr>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td colspan="3" style="vertical-align: top">
            <p style="margin: 0pt; text-align: right">
					Total Fees Previously Paid:
				</p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td style="vertical-align: top">
            <p id="TotalPreviouslyPaidAmt" style="margin: 0pt; text-align: right">
              <span>$</span>
              <ix:nonFraction name="ffd:TtlPrevslyPdAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-546">0.00</ix:nonFraction>
            </p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
        </tr>
        <tr>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td colspan="3" style="vertical-align: top">
            <p style="margin: 0pt; text-align: right">
					Total Fee Offsets:
				</p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td style="vertical-align: top">
            <p id="TotalOffsetAmt" style="margin: 0pt; text-align: right">
              <span>$</span>
              <ix:nonFraction name="ffd:TtlOffsetAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-547">0.00</ix:nonFraction>
            </p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
        </tr>
        <tr>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td colspan="3" style="vertical-align: top">
            <p style="margin: 0pt; text-align: right">
					Net Fee Due:
				</p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td style="vertical-align: top">
            <p id="NetFeeAmt" style="margin: 0pt; text-align: right">
              <span>$</span>
              <ix:nonFraction name="ffd:NetFeeAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-548">41,430.00</ix:nonFraction>
            </p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
        </tr>
      </table>
    </div>
    <div>
      <table style="width: 100%; text-indent: 0px;">
        <tbody>
          <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; vertical-align: top;">
            <td>
              <p style="margin:0pt;text-align:left; margin-bottom: 5px;">
                <b>Offering Note</b>
              </p>
            </td>
            <td/>
          </tr>
        </tbody>
      </table>
    </div>
    <div style="padding-bottom: 20px;">
      <table style="width: 100%; text-indent: 0px;">
        <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; vertical-align: top;">
          <td style="width:10pt;">
            <p style="margin:0pt;text-align:left;">
              <sup style="vertical-align:top;line-height:120%;font-size:10px">1</sup>
            </p>
          </td>
          <td colspan="7" style="white-space: pre-line;">
            <ix:nonNumeric name="ffd:OfferingNote" escape="1" contextRef="offrl_7" id="ixv-549">(a) The amount to be registered consists of up to $300,000,000 of an indeterminate amount of common stock, preferred stock, debt securities, warrants, units and/or subscription rights. There is also being registered hereunder such currently indeterminate number of (i) shares of common stock or other securities of the registrant as may be issued upon conversion of, or in exchange for, convertible or exchangeable debt securities and/or preferred stock registered hereby, or (ii) shares of debt securities, common stock, preferred stock or units as may be issued upon exercise of warrants registered hereby, as the case may be, including under any applicable antidilution provisions. Any securities registered hereunder may be sold separately or together with other securities registered hereunder. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement also covers any additional securities that may be offered or issued in connection with any stock split, stock dividend or pursuant to anti-dilution provisions of any of the securities. Separate consideration may or may not be received for securities that are issuable upon conversion, exercise or exchange of other securities.

(b) The proposed maximum offering price per security will be determined from time to time by the registrant in connection with the issuance by the registrant of the securities registered hereunder and is not specified as to each class of security pursuant to General Instruction II.D. of Form S-3 under the Securities Act.

(c) Including such indeterminate amount of common stock as may be issued from time to time at indeterminate prices or upon conversion of debt securities and/or preferred stock registered hereby, or upon exercise of warrants registered hereby, as the case may be.

(d) Including such indeterminate amount of preferred stock as may be issued from time to time at indeterminate prices or upon conversion of debt securities and/or preferred stock registered hereby, or upon exercise of warrants registered hereby, as the case may be.

(e) Including such indeterminate principal amount of debt securities as may be issued from time to time at indeterminate prices or upon exercise of warrants registered hereby, as the case may be.

(f) Warrants may be sold separately or together with any of the securities registered hereby and may be exercisable for shares of common stock, preferred stock, debt securities, or units registered hereby. Because the warrants will provide a right only to purchase such securities offered hereunder, no additional registration fee is required.

(g) Each unit will be issued under a unit agreement and will represent an interest in two or more securities registered pursuant to this registration statement, which may or may not be separable from one another. Because the units will provide a right only to purchase such securities offered hereunder, no additional registration fee is required.

(h) Subscription rights will be issued under a subscription agreement and will represent rights to purchase securities registered pursuant to this registration statement. Because the subscription rights will provide a right only to purchase such securities offered hereunder, no additional registration fee is required.
</ix:nonNumeric>
          </td>
        </tr>
        <tr>
          <td colspan="7">
            <hr style="width:100%;text-align:left;margin-left:0"/>
          </td>
        </tr>
      </table>
    </div>
    <div style="padding-bottom: 20px;">
      <table style="float: center; width: 100%; text-align: left;  ">
        <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
          <th style="vertical-align: bottom; text-align: left; word-wrap: break-word">
            <b>Table 2: Fee Offset Claims and Sources</b>
          </th>
          <th style="vertical-align: bottom; word-wrap: break-word; text-align: right;">
            <span style="-sec-ix-hidden: hiddenrcOffsetTableNa">&#9745;Not Applicable</span>
          </th>
        </tr>
      </table>
      <table style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; float: center; width: 100%; text-align: center;  border: 1px solid black;">
        <tr style="background-color:#9ADAF6">
          <th style="width: 10%; text-align: left;">
            <!-- BLANK -->
          </th>
          <th style="width: 8%; text-align: left;">
            <!-- BLANK -->
          </th>
          <th style="width: 16%;">
				Registrant or Filer Name
			</th>
          <th style="width: 6%;">
				Form or Filing Type
			</th>
          <th style="width: 7%;">
				File Number
			</th>
          <th style="width: 6%;">
				Initial Filing Date
			</th>
          <th style="width: 6%;">
				Filing Date
			</th>
          <th style="width: 6%;">
				Fee Offset Claimed
			</th>
          <th style="width: 6%;">
				Security Type Associated with Fee Offset Claimed
			</th>
          <th style="width: 8%;">
				Security Title Associated with Fee Offset Claimed
			</th>
          <th style="width: 6%;">
				Unsold Securities Associated with Fee Offset Claimed
			</th>
          <th style="width: 9%;">
				Unsold Aggregate Offering Amount Associated with Fee Offset Claimed
			</th>
          <th style="width: 6%;">
				Fee Paid with Fee Offset Source
			</th>
        </tr>
        <tr>
          <td colspan="14" style="text-align: center">
            <b>Rules 457(b) and 0-11(a)(2)</b>
          </td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Fee Offset Claims
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Fee Offset Sources
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
        </tr>
        <tr>
          <td colspan="14" style="text-align: center">
            <b>Rule 457(p)</b>
          </td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Fee Offset Claims
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Fee Offset Sources
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
        </tr>
      </table>
    </div>
    <div style="padding-bottom: 20px;">
      <table style="float: center; width: 100%; text-align: left;  ">
        <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
          <th style="vertical-align: bottom; text-align: left; word-wrap: break-word">
            <b>Table 3: Combined Prospectuses</b>
          </th>
          <th style="vertical-align: bottom; word-wrap: break-word; text-align: right;">
            <span style="-sec-ix-hidden: hiddenrcCombinedProspectusTableNa">&#9745;Not Applicable</span>
          </th>
        </tr>
      </table>
      <table style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; float: center; width: 100%; border: 1px solid black;">
        <tr style="background-color:#9ADAF6">
          <th style="width: 4%">
            <!-- Note column -->
          </th>
          <th style="width: 14%">
            <p style="margin: 0pt; text-align: center;">
              <b>Security Type</b>
            </p>
          </th>
          <th style="width: 25%">
            <p style="margin: 0pt; text-align: center;">
              <b>Security Class Title</b>
            </p>
          </th>
          <th style="width: 14%">
            <p style="margin: 0pt; text-align: center;">
              <b>Amount of Securities Previously Registered</b>
            </p>
          </th>
          <th style="width: 18%">
            <p style="margin: 0pt; text-align: center;">
              <b>Maximum Aggregate Offering Price of Securities Previously Registered</b>
            </p>
          </th>
          <th style="width: 6%">
            <p style="margin: 0pt; text-align: center;">
              <b>Form Type</b>
            </p>
          </th>
          <th style="width: 10%">
            <p style="margin: 0pt; text-align: center;">
              <b>File Number</b>
            </p>
          </th>
          <th style="width: 8%">
            <p style="margin: 0pt; text-align: center;">
              <b>Initial Effective Date</b>
            </p>
          </th>
        </tr>
        <tr style="background-color:#E7E7E2;">
          <td style="text-align: center;">
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: center;">
		N/A
	</td>
          <td style="text-align: center;">
		N/A
	</td>
          <td style="text-align: center;">
		N/A
	</td>
        </tr>
      </table>
    </div>
  </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>lg_cognition-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_cognition-4c.jpg
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MYK< >3,B;BP6BN"\VBVW[I'Z-:21'>5ZE!7A$]AZ?302)Y?-U8V9XVSCEU?
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MIMCJ )6H>VZ="1W1HG74J::",O,*0G9K+">0C-$GT 2&J")O)TXVXO-"VH+
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/*!0*!0*!0*!0*!0*#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tm2533585d2_ex5-2img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2533585d2_ex5-2img001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !+ 34# 2(  A$! Q$!_\0
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M-\,M)=).X7R8^#^=% 'XS_\ !6"YDC_:ZO[>+?YC>!-"V>7US_:^N@9]N?\
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M'X3"K4S"K6Q->5ZD/?7KS)?^W"I#\H[?C_\ 6/X]O2G>7LYS[?YX'I5E_O\
MX'_V6DIR^%^G^1Z5/^&_0>?N+]?\:93TZGZ?U%2UB2%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 0NF]B/H?T'L?6F^1[_ *__ %JL44 1
<)'L).>V/U'L/2I:** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tm2533585d2_ex5-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2533585d2_ex5-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !- 3@# 2(  A$! Q$!_\0
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M2YI@8'\:4$9KI,!^:,TF:,BF N:6DXHS0 M%)FCB@ S1FC@T4 &:,T8Q29H
M7-+249Q0 &C-&<T<&@89HS29&:6@0M)FC-'% "TF:3.*,T +FC-)D49% "YH
MS29%*<4 &:,TW-+F@!U%)FC/%,!:*0'-% '(>-I72QM]K$$O@X/M7G$]D78R
M@DD^M>B>.CBR@_W_ .E<.'KY[&SFJMD?399%>Q4K:E*TL+JZF$<2$FNQT?P6
MSA'OCSG.#5GP?&CF0D FNT\O!'M77A*"G&[.3'8ZHI>S1AW/A6QEB$<: <=1
M7,:AX3N;7<\&64=J]"+%023CWK*U'7K*Q4F60$C^$5K6PU-(XZ.)K)V6IPEI
MHM[<#F,KSSFNKTG3;/3I$WW*^:>V>]<UJGC"28LEF@13W%<]#=7%QJMNTDS$
MEQGFN:FHPEH=]2E4K0N]#V\9QD>E&6JMI^XVL>6SQ5OOUKU(MM7/!?NR:'+G
M'--QS_\ 7I0>:\_^(GC3_A'XA:VS W,@/([5J/<[2ZU.RM,>?<QQ_5AS44&N
M:;<.%BO(F;T#"O"M(\'^(O&6Z\NKF1(R<@L<9S5^_P#AAK^CQ_:[&Z9WCY(1
MN30![L"#C!R/6D+8&21BN-^'YUHZ0'U@N"#A0W6J7Q"\:CP_;BUMG_TF0$X'
M84 =K<:G96?^NN8T^K5%#K=A<N$ANX78GLU>%:3X3\2>,,WES<2I$QR-S&KN
MI?#;7= @^V6-U(Y3YCM;F@1[PK$C.<TI/3G%>1_#[Q[<7%X-&U1R)3PK.><U
MZ/KFKQ:)I,U[*1A%^4>IH OSW<=LA::54'JQQ5+_ (2'2V;:+V+=_O5X3)JG
MB+QYJ;V]K)*(=WKP!6R_P@U80"1+YO- SRQZT >U1W"3Q^9$P<=L&G!S@GIC
MDY[5\_:5XCUSP5K"6>I22-"&P0Q/K7NUI>1:GH_VN(C9+&2,?2@")O$&EHVU
M[V$..""U.7Q!I98*M["2?]JOG<:7/KOC2XL$F=,RGG=[UUDOP@U6-"\5^Q<<
M@;J /:8;F.XCWQ2*X_V3FF7-[;V4?F7$R1IZL<5\_P!GK>O^!M:2VO)',!/(
M8]:].\3K%XL\!/=6^0Q3>,'GB@#L+74+>]0O;3)*HZE34SS+'&7<A0.2?:O&
M_@[JCI=W&F3.<YXW'K7<_$34_P"S?"\Y\PHS@J,4 =!;ZO97LIBM[F-W'.T&
MKC\<=Z^:_ &JRZ?XIMI9I'*S<?,>O/\ ]>OHG4;M+?3)KHD!5CW9_"@",ZQ8
M"Z^SM=Q^:#C9GO5BZO[:RC$D\Z1J>A8UX1X)MI?$'Q ENW=VBC=GY/'7BNK^
M,NY-*M-C%!NZ XH ].M[I;N 2PNLD9Z$&H)-:T^"X$$EW"DA_A+<USGPU+/X
M/MV)).#UKQOQ]-+%XWF,<C*4P5 /?- 'TFLBOAEY!YR.]17E];6D0DN)5B7U
M8X%<)\-_&*:Y8"QFEQ<Q <'O4/Q>=AX9# D$GH#0!Z!8W]K?AFM)XY51L-L.
M<45YG\$&W:9J67)(F4<GI\HHI@=%X_.VRMO^NG]#7!B2NX^(3;;.U/\ TU_]
ME->?ASQ7S^,5ZA]3EBO0L=YX'.YY/:NXQQFN"\!MF26N[4]NM>EA4_9GB8]6
MK,Y+QEJ=Q901QPMMWYZ&O/YY'E;>[EV/K7>^,K">ZDA\F,M@GM698>#))@9+
MLD*>@KDKTZDIV._"5Z5&G=[LXLJ0XS@YJ>P_Y"-OC@;Q6CK^G1Z=>"*/IC-9
M]@/^)A;?[]<R@X2U/:=15*+L>UV2XM(S["K&*KV7_'G%]*L@<5]!!>ZCXJ>L
MF)TZ>E?._BUSJ'Q*,=P3Y8D (;IBOHGIFO#_ (J:!=V>M#6;9"R<%L#I3$>Q
M6,,5I80+&H5%C'RJ..E<G=_$S0["^EMIB=\9(:LWPE\2M.OK&&VOI5BE1 I)
M.,UE>,O^$+:PN9[=HY+V4\%3T- '?>'?%-CXD$ILND?48KQOQBRWGQ*$-P<Q
M[PH![5U?P9C;[+?9+;688/M6=\4_#ES:ZLNMVZ$YQDKVQ0!Z]IMJEII]M##\
ML:H,8[\5;F17C(;D$8P>]>:^#_B3975G%:ZC*()8E #$]:U]<^(FBV%FSPW0
MGF (55- CRGQ1$FF?$='M0,K,K +[FNU^+EU*/#5F 2?,(##\*Y'PMI5[XQ\
M9KJ$R$1*^]SCIZ5ZIX_\.'6O#!BA7,L"Y3'?_.* ,WX3Z?;0^&8[I OF2DAC
MWXKT)@,<D@#I7@G@+QF_A6=]-U-2L>['S=C7JTOCG0$L_M"WZ=,[ >: .-^,
MFGV[:7;W04><K$9[D<5M?#"[DN/!.USG9N S]*\Y\9^*9?&^LP:?8JS1*2%*
M_A7L7A;11H?A6.VQ^\\LLWUQ0!X_X4/_ !=.4'IYIX_&OH( ?>'7%?.^@7<&
MG_$F:ZN'"()6R3VYKV6?QQX?AB+_ -HQ,<= >: .6^,-A!)H$5WM43J^W.!G
M_/%3?"EOM?A*6&3YE'R#/H17$>._%\GBZ]@TO2EWQ;^H&37JG@?1&T/PY#"R
M_O3\S#WH \D@+>%?B2N<B-IB#GT)KH_BSJ2WU[9:7"^2Q!*^N:9\7M(-O>6^
MJ0J 21G%<[X9>;Q9XVMI;E=QB !SSTXH M^,] 'A^'1;R!0F(U+$>M=?XL\2
MY^&MM,&^>X79FMGXCZ0FH^$Y5"@M /EXKP]-2N]6M-/T9RQ2*3 'XT >K?"'
M1S::/)?2##3M@9]*A^-)_P")7:G'\7%>@>'].33M$M;=5VA5!->??&@@Z7:C
MT:@#H_AD<>"K?/O7DWBJ"*Z^)1@E!*2NJ_SKU?X8Y_X0NW.20<UY=X@RWQ40
M@])5'\Z *^NZ3?>!/$$%[:[DA;# CH:ZGQQXAM_$/@&*XB<>80"_JI[UZ#X@
M\.6WB+PZUM,O/E_(>X.*^=M4M+W1KF73;@L(PWW2>",T >L? \@Z3J&%QF53
MGU^444GP.S_9>I\Y7SQCVX%%,#;^(YVV-I_UU_H:X"**24\<5[+J^DP:I$B3
MIN"-D5RM]X2DBW-;C*CL*\?&4)2ES1/?R[&0I0Y9&1X>U+^Q'8N,[J[JP\06
MMX1MD4$]C7G5Q:S6S%9(V7'K42.48,I(/J#7+3Q,Z.DC2OAX8B7-$]9GFB5-
M[.H4>]8&I>+;6TC*1G>W85Q4NH73)L-PQ7ZU0(+$DDL?3&:VECE/2)G3RWE^
M,EU?4)-2N1.XQQ@"JU@"=2MQC_EH.*O6>C7E](/*0\]\=*['1O!R6LB33G?)
MG/-%&C.4N9G57Q5.G#DB=79?\>L?TJUVJ.)-B 8X!J2O:CHK'S$G=W#&<55O
MK&*_@,,Z!XV!!!%7%Z48IDGENJ_!W3[J8RV<KV['G"]*@L?@Q:)-ON[EI!QQ
M7K)H_"@#*T;0;+0[8064(11W]:M7EE%?0O#<(KQMV(JWUHQ0!Y?K/P>TZ\G>
M:SD\@L<E>U5+#X+VB7"/>7+2JO\ #7K>*08!H S-)T.ST6U$%G$(QT)'4UH;
M <C'!'3L:EXHXH XGQ'\.-)\0'S6C$4W7<HZUR8^"B>:"UZVS/0&O8<4=* .
M3\-^!-*\.)F"$-,.=[#)S73.F]77!&Y<9J;\*.M 'E%]\'H[S4)[HWC*9&)X
M-5X_@JBL-U\Q'?WKU_%&* ./\/\ P]TC0#YD<(DG/\;#-=6L>U<8J6C% '/^
M*O#<7B32S9N=I['TK&\&_#^+PK<R3B7?(PQDUW/%% %2]M4O+26W<?*ZX->>
M:3\*8--UU;_SRRJVX+^->G<^E-- "!=HP.G05RWC3P<GBRUBB:8Q^6>W>NL%
M&* ,+PSH1\/:)'IZOO"9YKEK_P"&:7OBI=9-P05?=MS7HV*.* (DCV1*H_A
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38I:** "BBB@ HHHH ****8'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Submission<br></strong></div></th>
<th class="th"><div>Dec. 15, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissionLineItems', window );"><strong>Submission [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0001455365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">COGNITION THERAPEUTICS INC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FormTp', window );">Form Type</a></td>
<td class="text">S-3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissnTp', window );">Submission Type</a></td>
<td class="text">S-3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeExhibitTp', window );">Fee Exhibit Type</a></td>
<td class="text">EX-FILING FEES<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTableNa', window );">Offering Table N/A</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OffsetTableNa', window );">Offset Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CombinedProspectusTableNa', window );">Combined Prospectus Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_CombinedProspectusTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_CombinedProspectusTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeExhibitTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeExhibitTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:feeExhibitTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FormTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FormTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissnTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissnTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Offerings<br></strong></div></th>
<th class="th">
<div>Dec. 15, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=1', window );">Offering: 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock, par value $0.0001 per share <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=2', window );">Offering: 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Preferred Stock <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=3', window );">Offering: 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Debt<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Debt Securities <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=4', window );">Offering: 4</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Warrants<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=5', window );">Offering: 5</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Units<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=6', window );">Offering: 6</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Subscription rights<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=7', window );">Offering: 7</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Unallocated (Universal) Shelf<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 300,000,000.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 41,430.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">(a) The amount to be registered consists of up to $300,000,000 of an indeterminate amount of common stock, preferred stock, debt securities, warrants, units and/or subscription rights. There is also being registered hereunder such currently indeterminate number of (i) shares of common stock or other securities of the registrant as may be issued upon conversion of, or in exchange for, convertible or exchangeable debt securities and/or preferred stock registered hereby, or (ii) shares of debt securities, common stock, preferred stock or units as may be issued upon exercise of warrants registered hereby, as the case may be, including under any applicable antidilution provisions. Any securities registered hereunder may be sold separately or together with other securities registered hereunder. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement also covers any additional securities that may be offered or issued in connection with any stock split, stock dividend or pursuant to anti-dilution provisions of any of the securities. Separate consideration may or may not be received for securities that are issuable upon conversion, exercise or exchange of other securities.

(b) The proposed maximum offering price per security will be determined from time to time by the registrant in connection with the issuance by the registrant of the securities registered hereunder and is not specified as to each class of security pursuant to General Instruction II.D. of Form S-3 under the Securities Act.

(c) Including such indeterminate amount of common stock as may be issued from time to time at indeterminate prices or upon conversion of debt securities and/or preferred stock registered hereby, or upon exercise of warrants registered hereby, as the case may be.

(d) Including such indeterminate amount of preferred stock as may be issued from time to time at indeterminate prices or upon conversion of debt securities and/or preferred stock registered hereby, or upon exercise of warrants registered hereby, as the case may be.

(e) Including such indeterminate principal amount of debt securities as may be issued from time to time at indeterminate prices or upon exercise of warrants registered hereby, as the case may be.

(f) Warrants may be sold separately or together with any of the securities registered hereby and may be exercisable for shares of common stock, preferred stock, debt securities, or units registered hereby. Because the warrants will provide a right only to purchase such securities offered hereunder, no additional registration fee is required.

(g) Each unit will be issued under a unit agreement and will represent an interest in two or more securities registered pursuant to this registration statement, which may or may not be separable from one another. Because the units will provide a right only to purchase such securities offered hereunder, no additional registration fee is required.

(h) Subscription rights will be issued under a subscription agreement and will represent rights to purchase securities registered pursuant to this registration statement. Because the subscription rights will provide a right only to purchase such securities offered hereunder, no additional registration fee is required.
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of registration fee (amount due after offsets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxAggtOfferingPric">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate offering price for the offering that is being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxAggtOfferingPric</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative100TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTitl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The title of the class of securities being registered (for each class being registered).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTitl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Type of securities: "Asset-backed Securities", "ADRs/ADSs", "Debt", "Debt Convertible into Equity", "Equity", "Face Amount Certificates", "Limited Partnership Interests", "Mortgage Backed Securities", "Non-Convertible Debt", "Unallocated (Universal) Shelf", "Exchange Traded Vehicle Securities", "Other"</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_PrevslyPdFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_PrevslyPdFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_Rule457oFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 457<br> -Subsection o<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_Rule457oFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=5">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=5</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=6">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=6</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=7">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=7</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fees Summary<br></strong></div></th>
<th class="th">
<div>Dec. 15, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesSummaryLineItems', window );"><strong>Fees Summary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOfferingAmt', window );">Total Offering</a></td>
<td class="nump">$ 300,000,000.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlPrevslyPdAmt', window );">Previously Paid Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlFeeAmt', window );">Total Fee Amount</a></td>
<td class="nump">41,430.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOffsetAmt', window );">Total Offset Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_NetFeeAmt', window );">Net Fee</a></td>
<td class="nump">$ 41,430.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesSummaryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesSummaryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_NetFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_NetFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOfferingAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOfferingAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOffsetAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOffsetAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlPrevslyPdAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlPrevslyPdAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>8</ContextCount>
  <ElementCount>21</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>1</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2533585d1_ex-filingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995210 - Document - Submission</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/submissionTable</Role>
      <ShortName>Submission</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tm2533585d1_ex-filingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995211 - Document - Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesOfferingTable</Role>
      <ShortName>Offerings</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tm2533585d1_ex-filingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995215 - Document - Fees Summary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesSummaryTable</Role>
      <ShortName>Fees Summary</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="EX-FILING FEES" original="tm2533585d1_ex-filingfees.htm">tm2533585d1_ex-filingfees.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="3">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="43">http://xbrl.sec.gov/ffd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>20
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2533585d1_ex-filingfees.htm": {
   "dts": {
    "inline": {
     "local": [
      "tm2533585d1_ex-filingfees.htm"
     ]
    },
    "schema": {
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/deprecated-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
     ]
    }
   },
   "keyStandard": 21,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 14,
    "http://xbrl.sec.gov/ffd/2025": 12,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 8,
   "entityCount": 1,
   "segmentCount": 1,
   "elementCount": 107,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ffd/2025": 43,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/ffd/role/document/submissionTable",
     "longName": "995210 - Document - Submission",
     "shortName": "Submission",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
     "longName": "995211 - Document - Offerings",
     "shortName": "Offerings",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "offrl_1",
      "name": "ffd:Rule457oFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2533585d1_ex-filingfees.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "offrl_1",
      "name": "ffd:Rule457oFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2533585d1_ex-filingfees.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable",
     "longName": "995215 - Document - Fees Summary",
     "shortName": "Fees Summary",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "3",
     "firstAnchor": {
      "contextRef": "rc",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2533585d1_ex-filingfees.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "rc",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2533585d1_ex-filingfees.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ffd_AggtRedRpPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtRedRpPricPrrFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricPrrFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Prior Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, Prior FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtSalesPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtSalesPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Sales Price, Fiscal Year",
        "terseLabel": "Aggregate Sales Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtRedCdts": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtRedCdts",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Redemption Credits",
        "terseLabel": "Redemption Credits"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtSctiesRcvd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Received",
        "terseLabel": "Amount of Securities Received",
        "documentation": "Amount of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_AmtSctiesRegd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRegd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Registered",
        "terseLabel": "Amount Registered",
        "documentation": "The amount of securities being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CeasedOprsDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CeasedOprsDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ceased Operations Date",
        "terseLabel": "Ceased Operations Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CfwdFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Form Type",
        "terseLabel": "Carry Forward Form Type",
        "documentation": "The Form Type of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrevslyPdFee": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrevslyPdFee",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Previously Paid Fee",
        "terseLabel": "Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward",
        "documentation": "The fee previously paid in connection with the securities being brought forward from the prior shelf registration statement on which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Prior Effective Date",
        "terseLabel": "Carry Forward Initial Effective Date",
        "documentation": "The initial effective date of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward File Number",
        "terseLabel": "Carry Forward File Number",
        "documentation": "The EDGAR File Number of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). If the prior registration statement has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CmbndPrspctsItemAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsItemAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Item [Axis]",
        "terseLabel": "Combined Prospectus",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different references to earlier prospectuses on a single fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Line Items]",
        "terseLabel": "Combined Prospectus:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Table]",
        "terseLabel": "Combined Prospectus Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CombinedProspectusTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CombinedProspectusTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Table [N/A]",
        "terseLabel": "Combined Prospectus Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CshPdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshPdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid by Registrant in Transaction",
        "terseLabel": "Cash Consideration Paid",
        "documentation": "Amount of cash consideration paid by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ffd_CshRcvdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshRcvdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Received by Registrant in Transaction",
        "terseLabel": "Cash Consideration Received",
        "documentation": "Amount of cash consideration received by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "ffd_FeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Amount",
        "terseLabel": "Amount of Registration Fee",
        "documentation": "Total amount of registration fee (amount due after offsets)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeExhibitTp": {
     "xbrltype": "feeExhibitTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeExhibitTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Exhibit Type",
        "terseLabel": "Fee Exhibit Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeeIntrstAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Interest Amount",
        "terseLabel": "Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note",
        "terseLabel": "Fee Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNoteMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNoteMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note Maximum Aggregate Offering Price",
        "terseLabel": "Fee Note MAOP"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeRate",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Rate",
        "terseLabel": "Fee Rate",
        "documentation": "The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesOthrRuleFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesOthrRuleFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees, Other Rule [Flag]",
        "terseLabel": "Other Rule",
        "documentation": "Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesSummaryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesSummaryLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees Summary [Line Items]",
        "terseLabel": "Fees Summary:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FnlPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FnlPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final Prospectus [Flag]",
        "terseLabel": "Final Prospectus"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FormTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Form Type",
        "terseLabel": "Form Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_GnlInstrIIhiFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "GnlInstrIIhiFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Instruction II.H,I [Flag]",
        "terseLabel": "General Instruction II.H,I"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrCity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrCity",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, City",
        "terseLabel": "City"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStatOrCtryCd": {
     "xbrltype": "stateOrCountryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStatOrCtryCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, State or Country Code",
        "terseLabel": "State or Country Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt1",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 1",
        "terseLabel": "Street 1"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt2": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt2",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 2",
        "terseLabel": "Street 2"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrZipCd": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrZipCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Zip Code",
        "terseLabel": "Zip Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrNm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Name",
        "terseLabel": "Issuer Name"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_MaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum Aggregate Offering Price",
        "documentation": "The maximum aggregate offering price for the offering that is being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_MaxOfferingPricPerScty": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxOfferingPricPerScty",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Offering Price per Security",
        "terseLabel": "Proposed Maximum Offering Price per Unit",
        "documentation": "The maximum offering price per share/unit being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetFeeAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Fee Amount",
        "terseLabel": "Net Fee"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetSalesAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetSalesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Sales Amount",
        "terseLabel": "Net Sales"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvDsclsr": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvDsclsr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure",
        "terseLabel": "Narrative Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Amount",
        "terseLabel": "Narrative - Max Aggregate Offering Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Price",
        "terseLabel": "Narrative - Max Aggregate Offering Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Axis]",
        "terseLabel": "Offering",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different security offerings on a single fee bearing submission."
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Line Items]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Note",
        "terseLabel": "Offering Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Title",
        "terseLabel": "Security Class Title",
        "documentation": "The title of the class of securities being registered (for each class being registered)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Type",
        "terseLabel": "Security Type",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Table]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Table [N/A]",
        "terseLabel": "Offering Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset [Axis]",
        "terseLabel": "Offset",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different offsets as applied to a fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetClmInitlFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmInitlFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claim Initial Filing Date",
        "terseLabel": "Initial Filing Date",
        "documentation": "The initial filing date of the earlier registration statement with which the earlier (offsetting) fee was paid for a claimed offset. If the offset fee was paid with an amendment, do not provide the amendment date under this element; instead, provide the date of the initial filing (i.e. the \"parent\" filing) ."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Amount",
        "terseLabel": "Fee Offset Claimed",
        "documentation": "The amount of offsetting fees being claimed."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdInd": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdInd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Indicator",
        "terseLabel": "Offset Claimed"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetExpltnForClmdAmt": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetExpltnForClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Explanation for Claimed Amount",
        "terseLabel": "Explanation for Claimed Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetLineItems",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset:",
        "label": "Offset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Note",
        "terseLabel": "Offset Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetPrrFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Fee Amount",
        "terseLabel": "Fee Paid with Fee Offset Source",
        "documentation": "The fee previously paid from which an offset is being derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior File Number",
        "terseLabel": "File Number",
        "documentation": "The EDGAR File Number of the earlier registration statement with which the earlier (offsetting) fee was paid. If the offset filing for the offset has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFilerNm": {
     "xbrltype": "filerNameItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFilerNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Filer Name",
        "terseLabel": "Registrant or Filer Name",
        "documentation": "The name of the registrant that filed the earlier registration statement with which the earlier (offsetting) fee was paid."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Form Type",
        "terseLabel": "Form or Filing Type",
        "documentation": "The Form Type of the offset filing."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrNbOfUnsoldScties": {
     "xbrltype": "nonNegativeIntegerItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrNbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Number of Securities",
        "terseLabel": "Unsold Securities Associated with Fee Offset Claimed",
        "documentation": "The number of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Title",
        "terseLabel": "Security Title Associated with Fee Offset Claimed",
        "documentation": "The title of the class of securities from which offset fees were derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Type",
        "terseLabel": "Security Type Associated with Fee Offset Claimed",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrUnsoldOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrUnsoldOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Offering Amount",
        "terseLabel": "Unsold Aggregate Offering Amount Associated with Fee Offset Claimed",
        "documentation": "The aggregate offering amount of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetSrcFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetSrcFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Source Filing Date",
        "terseLabel": "Filing Date",
        "documentation": "The filing date of the earlier registration statement with which the earlier (offsetting) fee was paid in an offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset Payment:",
        "label": "Offset [Table]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Table [N/A]",
        "terseLabel": "Offset Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_PrevslyPdFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "PrevslyPdFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Previously Paid [Flag]",
        "terseLabel": "Fee Previously Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RegnFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RegnFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration File Number",
        "terseLabel": "Registration File Number"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RptgFsclYrEndDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RptgFsclYrEndDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting Fiscal Year End Date",
        "terseLabel": "Reporting FY End Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 0-11 [Flag]",
        "terseLabel": "Rule 0-11"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011a2OffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011a2OffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 0-11(a)(2) Offset",
        "label": "Rule 0-11(a)(2) Offset [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule415a6Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule415a6Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 415(a)(6) [Flag]",
        "terseLabel": "Rule 415(a)(6)",
        "documentation": "Checkbox indicating whether filer is claiming a 415(a)(6) carryforward."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_Rule429AggtOfferingAmt": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429AggtOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Aggregate Offering Amount",
        "terseLabel": "Maximum Aggregate Offering Price of Securities Previously Registered",
        "documentation": "The maximum aggregate offering amount of unsold securities registered on the prior registration statement that are carried forward under Rule 429. Only applicable if 457(o) was used in the fee calculation for the prior registration statement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429CmbndPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429CmbndPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Combined Prospectus [Flag]",
        "terseLabel": "Rule 429",
        "documentation": "Checkbox indicating whether filer is using a combined prospectus under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier File Number",
        "terseLabel": "File Number",
        "documentation": "The Securities Act File Number of the earlier effective registration statement(s) from which securities may be offered and sold using the combined prospectus pursuant to Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier Form Type",
        "terseLabel": "Form Type",
        "documentation": "The Form Type of the earlier registration statement from which unsold securities are carried forward under Rule 429. This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429InitlFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429InitlFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Initial Effective Date",
        "terseLabel": "Initial Effective Date",
        "documentation": "The filing date of the earlier registration statement from which unsold securities are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429NbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429NbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Number Of Unsold Securities",
        "terseLabel": "Amount of Securities Previously Registered",
        "documentation": "The number of securities registered on the prior registration statement that are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429PrspctsNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429PrspctsNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Prospectus Note",
        "terseLabel": "Combined Prospectus Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Title",
        "terseLabel": "Security Class Title"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Type",
        "terseLabel": "Security Type"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule457aFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457aFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(a) [Flag]",
        "terseLabel": "Rule 457(a)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ffd_Rule457bOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457bOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(b) Offset [Flag]",
        "terseLabel": "Rule 457(b) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(b) or 0-11(a)(2)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ffd_Rule457fFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457fFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(f) [Flag]",
        "terseLabel": "Rule 457(f)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_Rule457oFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457oFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(o) [Flag]",
        "terseLabel": "Rule 457(o)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ffd_Rule457pOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457pOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(p) Offset [Flag]",
        "terseLabel": "Rule 457(p) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(p)."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ffd_Rule457rFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457rFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(r) [Flag]",
        "terseLabel": "Rule 457(r)"
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ffd_Rule457sFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457sFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(s) Flag",
        "terseLabel": "Rule 457(s)"
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ffd_Rule457uFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457uFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(u) [Flag]",
        "terseLabel": "Rule 457(u)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(u) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ffd_Scties424iAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Axis]",
        "terseLabel": "Securities, 424I"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Line Items]",
        "terseLabel": "Securities, 424I:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Table]",
        "terseLabel": "Securities, 424I Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Securities424iTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Securities424iNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities 424I [N/A]",
        "terseLabel": "Securities 424I N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissionLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission [Line Items]",
        "terseLabel": "Items"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissnTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissnTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission Type",
        "terseLabel": "Submission Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TermntnCmpltnWdrwl": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TermntnCmpltnWdrwl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination / Completion / Withdrawal Statement",
        "terseLabel": "Termination / Withdrawal Statement"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TtlFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee Amount",
        "terseLabel": "Total Fee Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlFeeAndIntrstAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAndIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee and Interest Amount",
        "terseLabel": "Total Fee and Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offering Amount",
        "terseLabel": "Total Offering"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOffsetAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOffsetAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offset Amount",
        "terseLabel": "Total Offset Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlPrevslyPdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlPrevslyPdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Previously Paid Amount",
        "terseLabel": "Previously Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlTxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlTxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Transaction Valuation",
        "terseLabel": "Total Transaction Valuation"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Valuation",
        "terseLabel": "Transaction Valuation"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_ValSctiesRcvd": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received",
        "terseLabel": "Value of Securities Received",
        "documentation": "Value of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_ValSctiesRcvdPerShr": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvdPerShr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received, Per Share",
        "terseLabel": "Value of Securities Received, Per Share",
        "documentation": "Value per share of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form). This is included in the explanation of 457(f) fee calculation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "415",
   "Subsection": "a"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "429"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "f"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "o"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "p"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "r"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "s"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "u"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Subsection": "f",
   "Section": "457"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>21
<FILENAME>0001104659-25-122536-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-25-122536-xbrl.zip
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M_OYP>W5/;GM7F^CWS\$ KEC#!ZUOTIZ6WK;G:UQ/",,8;%O,_%22W 67W1"
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M     '1M,C4S,S4X-60Q7V5X+69I;&EN9V9E97,N:'1M4$L%!@     !  $
*2P   %P0      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>tm2533585d1_ex-filingfees_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
      xlink:type="simple"/>
    <context id="rc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
        </entity>
        <period>
            <startDate>2025-12-15</startDate>
            <endDate>2025-12-15</endDate>
        </period>
    </context>
    <context id="offrl_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-15</startDate>
            <endDate>2025-12-15</endDate>
        </period>
    </context>
    <context id="offrl_2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>2</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-15</startDate>
            <endDate>2025-12-15</endDate>
        </period>
    </context>
    <context id="offrl_3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>3</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-15</startDate>
            <endDate>2025-12-15</endDate>
        </period>
    </context>
    <context id="offrl_4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>4</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-15</startDate>
            <endDate>2025-12-15</endDate>
        </period>
    </context>
    <context id="offrl_5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>5</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-15</startDate>
            <endDate>2025-12-15</endDate>
        </period>
    </context>
    <context id="offrl_6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>6</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-15</startDate>
            <endDate>2025-12-15</endDate>
        </period>
    </context>
    <context id="offrl_7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>7</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-15</startDate>
            <endDate>2025-12-15</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <ffd:FormTp contextRef="rc" id="ixv-426">S-3</ffd:FormTp>
    <ffd:SubmissnTp contextRef="rc" id="ixv-427">S-3</ffd:SubmissnTp>
    <ffd:FeeExhibitTp contextRef="rc" id="ixv-428">EX-FILING FEES</ffd:FeeExhibitTp>
    <dei:EntityCentralIndexKey contextRef="rc" id="ixv-429">0001455365</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-430">COGNITION THERAPEUTICS INC</dei:EntityRegistrantName>
    <ffd:OfferingTableNa contextRef="rc" id="hiddenrcOfferingTableNa" xsi:nil="true"/>
    <ffd:OffsetTableNa contextRef="rc" id="hiddenrcOffsetTableNa">N/A</ffd:OffsetTableNa>
    <ffd:CombinedProspectusTableNa contextRef="rc" id="hiddenrcCombinedProspectusTableNa">N/A</ffd:CombinedProspectusTableNa>
    <ffd:FeeRate
      contextRef="offrl_1"
      decimals="INF"
      id="ixv-434"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeRate
      contextRef="offrl_2"
      decimals="INF"
      id="ixv-435"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeRate
      contextRef="offrl_3"
      decimals="INF"
      id="ixv-436"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeRate
      contextRef="offrl_4"
      decimals="INF"
      id="ixv-437"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeRate
      contextRef="offrl_5"
      decimals="INF"
      id="ixv-438"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeRate
      contextRef="offrl_6"
      decimals="INF"
      id="ixv-439"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FormTp contextRef="rc" id="ixv-518">S-3</ffd:FormTp>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-519">COGNITION THERAPEUTICS INC</dei:EntityRegistrantName>
    <ffd:OfferingSctyTp contextRef="offrl_1" id="ixv-520">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_1" id="ixv-521">Common Stock, par value $0.0001 per share </ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="offrl_1" id="ixv-522">true</ffd:Rule457oFlg>
    <ffd:OfferingSctyTp contextRef="offrl_2" id="ixv-523">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_2" id="ixv-524">Preferred Stock </ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="offrl_2" id="ixv-525">true</ffd:Rule457oFlg>
    <ffd:OfferingSctyTp contextRef="offrl_3" id="ixv-526">Debt</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_3" id="ixv-527">Debt Securities </ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="offrl_3" id="ixv-528">true</ffd:Rule457oFlg>
    <ffd:OfferingSctyTp contextRef="offrl_4" id="ixv-529">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_4" id="ixv-530">Warrants</ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="offrl_4" id="ixv-531">true</ffd:Rule457oFlg>
    <ffd:OfferingSctyTp contextRef="offrl_5" id="ixv-532">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_5" id="ixv-533">Units</ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="offrl_5" id="ixv-534">true</ffd:Rule457oFlg>
    <ffd:OfferingSctyTp contextRef="offrl_6" id="ixv-535">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_6" id="ixv-536">Subscription rights</ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="offrl_6" id="ixv-537">true</ffd:Rule457oFlg>
    <ffd:PrevslyPdFlg contextRef="offrl_7" id="ixv-538">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="offrl_7" id="ixv-539">Unallocated (Universal) Shelf</ffd:OfferingSctyTp>
    <ffd:Rule457oFlg contextRef="offrl_7" id="ixv-540">true</ffd:Rule457oFlg>
    <ffd:MaxAggtOfferingPric
      contextRef="offrl_7"
      decimals="INF"
      id="ixv-541"
      unitRef="USD">300000000.00</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="offrl_7"
      decimals="INF"
      id="ixv-542"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="offrl_7"
      decimals="INF"
      id="ixv-543"
      unitRef="USD">41430.00</ffd:FeeAmt>
    <ffd:TtlOfferingAmt contextRef="rc" decimals="INF" id="ixv-544" unitRef="USD">300000000.00</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt contextRef="rc" decimals="INF" id="ixv-545" unitRef="USD">41430.00</ffd:TtlFeeAmt>
    <ffd:TtlPrevslyPdAmt contextRef="rc" decimals="INF" id="ixv-546" unitRef="USD">0.00</ffd:TtlPrevslyPdAmt>
    <ffd:TtlOffsetAmt contextRef="rc" decimals="INF" id="ixv-547" unitRef="USD">0.00</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt contextRef="rc" decimals="INF" id="ixv-548" unitRef="USD">41430.00</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="offrl_7" id="ixv-549">(a) The amount to be registered consists of up to $300,000,000 of an indeterminate amount of common stock, preferred stock, debt securities, warrants, units and/or subscription rights. There is also being registered hereunder such currently indeterminate number of (i) shares of common stock or other securities of the registrant as may be issued upon conversion of, or in exchange for, convertible or exchangeable debt securities and/or preferred stock registered hereby, or (ii) shares of debt securities, common stock, preferred stock or units as may be issued upon exercise of warrants registered hereby, as the case may be, including under any applicable antidilution provisions. Any securities registered hereunder may be sold separately or together with other securities registered hereunder. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement also covers any additional securities that may be offered or issued in connection with any stock split, stock dividend or pursuant to anti-dilution provisions of any of the securities. Separate consideration may or may not be received for securities that are issuable upon conversion, exercise or exchange of other securities.

(b) The proposed maximum offering price per security will be determined from time to time by the registrant in connection with the issuance by the registrant of the securities registered hereunder and is not specified as to each class of security pursuant to General Instruction II.D. of Form S-3 under the Securities Act.

(c) Including such indeterminate amount of common stock as may be issued from time to time at indeterminate prices or upon conversion of debt securities and/or preferred stock registered hereby, or upon exercise of warrants registered hereby, as the case may be.

(d) Including such indeterminate amount of preferred stock as may be issued from time to time at indeterminate prices or upon conversion of debt securities and/or preferred stock registered hereby, or upon exercise of warrants registered hereby, as the case may be.

(e) Including such indeterminate principal amount of debt securities as may be issued from time to time at indeterminate prices or upon exercise of warrants registered hereby, as the case may be.

(f) Warrants may be sold separately or together with any of the securities registered hereby and may be exercisable for shares of common stock, preferred stock, debt securities, or units registered hereby. Because the warrants will provide a right only to purchase such securities offered hereunder, no additional registration fee is required.

(g) Each unit will be issued under a unit agreement and will represent an interest in two or more securities registered pursuant to this registration statement, which may or may not be separable from one another. Because the units will provide a right only to purchase such securities offered hereunder, no additional registration fee is required.

(h) Subscription rights will be issued under a subscription agreement and will represent rights to purchase securities registered pursuant to this registration statement. Because the subscription rights will provide a right only to purchase such securities offered hereunder, no additional registration fee is required.
</ffd:OfferingNote>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
